



US 20250257067A1

(19) United States

(12) Patent Application Publication (10) Pub. No.: US 2025/0257067 A1

LEI et al.

(43) Pub. Date: Aug. 14, 2025

(54) COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY

(71) Applicant: **Aconcagua Bio, Inc.**, South San Francisco, CA (US)

(72) Inventors: **Hui LEI**, Shanghai (CN); **Cui LI**, Shanghai (CN); **Chunliang LU**, Shanghai (CN); **Ding XUE**, Shanghai (CN); **Haizhen ZHANG**, Shanghai (CN); **Zhuming ZHANG**, Shanghai (CN); **Jian LIU**, New York, NY (US); **Zhe NIE**, New York, NY (US); **Anatoly RUVINSKY**, New York, NY (US); **Eric THERRIEN**, New York, NY (US); **Evelyne HOUANG**, New York, NY (US)

(21) Appl. No.: 19/074,260

(22) Filed: Mar. 7, 2025

Related U.S. Application Data

(63) Continuation of application No. PCT/US2025/015122, filed on Feb. 7, 2025.

Foreign Application Priority Data

Feb. 8, 2024 (WO) PCT/CN2024/076922
Jun. 6, 2024 (WO) PCT/CN2024/097824
Nov. 21, 2024 (WO) PCT/CN2024/133596
Dec. 24, 2024 (WO) PCT/CN2024/141875

Publication Classification

(51)	Int. Cl.		
	<i>C07D 471/14</i>	(2006.01)	
	<i>A61K 31/4365</i>	(2006.01)	
	<i>A61K 31/437</i>	(2006.01)	
	<i>A61K 31/444</i>	(2006.01)	
	<i>A61K 31/4709</i>	(2006.01)	
	<i>A61K 31/4725</i>	(2006.01)	
	<i>A61K 31/4985</i>	(2006.01)	
	<i>A61K 31/519</i>	(2006.01)	
	<i>A61K 31/5383</i>	(2006.01)	
	<i>C07D 495/04</i>	(2006.01)	
	<i>C07D 495/10</i>	(2006.01)	
	<i>C07D 513/14</i>	(2006.01)	
	<i>C07D 519/00</i>	(2006.01)	
(52)	U.S. Cl.		
	CPC	<i>C07D 471/14</i> (2013.01); <i>A61K 31/4365</i> (2013.01); <i>A61K 31/437</i> (2013.01); <i>A61K 31/444</i> (2013.01); <i>A61K 31/4709</i> (2013.01); <i>A61K 31/4725</i> (2013.01); <i>A61K 31/4985</i> (2013.01); <i>A61K 31/519</i> (2013.01); <i>A61K 31/5383</i> (2013.01); <i>C07D 495/04</i> (2013.01); <i>C07D 495/10</i> (2013.01); <i>C07D 513/14</i> (2013.01); <i>C07D 519/00</i> (2013.01)	

ABSTRACT

The present disclosure provides compounds for modulating calcitonin receptor and/or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and/or amylin receptor associated disease or disorder.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] The application claims the benefit of International Patent Application Number PCT/CN2024/076922, filed on Feb. 8, 2024, International Patent Application Number PCT/CN2024/097824, filed on Jun. 6, 2024, International Patent Application Number PCT/CN2024/133596, filed on Nov. 21, 2024, and International Patent Application Number PCT/CN2024/141875, filed Dec. 24, 2024, each of which is incorporated herein by reference in its entirety.

FIELD

[0002] The present disclosure provides compounds for modulating calcitonin receptor and/or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating calcitonin receptor and/or amylin receptor associated diseases, disorders, and conditions.

BACKGROUND

[0003] Calcitonin and amylin are hormones that interact with receptors within the same family to exert their effects on the human organism. Calcitonin, derived from thyroid C cells, is known for its inhibitory effect on osteoclasts. Calcitonin of mammalian origin promotes insulin sensitivity, while the more potent calcitonin extracted from salmon additionally inhibits gastric emptying, promotes gallbladder relaxation, increases energy expenditure and induces satiety as well as weight loss. Studies have also indicated that oral salmon calcitonin (sCT) exerts an insulin-sensitizing effect to improve glucose metabolism in obesity and type 2 diabetes. European Journal of Pharmacology, 2024, 737(7): 91-96.

[0004] Amylin receptors (AMYRs) are G protein-coupled receptors (GPCRs), which respond to the peptide hormones amylin and calcitonin. Amylin receptors are heterodimers comprising the calcitonin receptor, which is a G protein-coupled receptor, and one of three receptor-modifying proteins. Amylin, formed primarily in pancreatic islet β cells, is cosecreted with insulin in response to caloric intake. Patients with type 1 diabetes have lower baseline amylin serum concentrations, and amylin response to caloric intake is absent. Patients with type 2 diabetes requiring insulin also have a diminished amylin response to caloric intake, potentially related to the degree of β -cell impairment. Key physiologic functions of amylin in maintaining glucose homeostasis include suppressing glucagon release in response to caloric intake, delaying the rate of gastric emptying, and stimulating the satiety center in the brain to limit caloric intake.

[0005] The synthetic amylin analogue pramlintide is an approved treatment for diabetes mellitus as an adjunctive therapy to mealtime insulin which promotes better glycemic control and small but significant weight loss. AM833 (cagrilintide), an investigational novel long-acting acylated amylin analogue, acts as a non-selective amylin receptor agonist. This amylin receptor agonist can serve as an attractive novel treatment for obesity, resulting in reduction of

food intake and significant weight loss in a dose-dependent manner. *J Obes Metab Syndr*. 2021; 30(4): 320-325.

[0006] Accordingly, modulators of the amylin and/or calcitonin receptor could be useful in treating various metabolic disorders, as well as inducing weight loss.

SUMMARY

[0007] The present disclosure provides small molecule calcitonin and/or amylin receptor modulators (e.g., amylin-receptor agonists), as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating calcitonin receptor and/or amylin receptor associated diseases or disorders. It has been shown that calcitonin receptor activation is important for blood glucose regulation in diabetes; this is in addition to the known metabolic beneficial role of amylin receptor activation. *Journal of Pharmacology and Experimental Therapeutics*, 2020, 374 (1) 74-83.

[0008] This disclosure also provides pharmaceutical compositions comprising one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0009] Also provided herein are pharmaceutical compositions comprising one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0010] Also provided herein are methods for treating or preventing a calcitonin receptor and/or an amylin receptor associated disease or disorder in a subject in need thereof, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula I or subformula thereof, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition thereof. In some embodiments, the method further comprises administering to the subject, a therapeutically effective amount of one or more additional therapy or therapeutic agent to the patient, such as, but not limited to, an antidiabetic agent, an anti-obesity agent, a weight loss agent, a GLP-1 receptor agonist, an anti-emetic agent, an agent to treat non-alcoholic steatohepatitis (NASH), gastric electrical stimulation, dietary monitoring, physical activity, or a combination thereof.

[0011] In some embodiments, the calcitonin receptor and/or amylin receptor associated disease or disorder is a bone disorder, a metabolic disorder, pain, a neurodegenerative disease or disorder, a cardiovascular disease, or other disease or disorder.

[0012] In some embodiments, the calcitonin receptor and/or amylin receptor associated disease or disorder is a bone disorder, including, but not limited to, osteoporosis, Paget's disease, hypercalcemia, Sudeck's atrophy, polystatic fibrous dysplasia, intersemicostoclavicular ossification, osteogenesis imperfecta, osteopenia, periodontal disease or defect, osteolytic bone disease, metastatic bone disorder, or bone loss resulting from a malignancy, autoimmune arthritides, a breakage or fracture, or immobility or disuse.

[0013] In some embodiments, the calcitonin receptor and/or amylin receptor associated disease or disorder is pain, including, but not limited to, osteopathic pain, phantom limb pain, general pain, hyperalgesia, or pain associated with diabetic neuropathy.

[0014] In some embodiments, the calcitonin receptor and/or amylin receptor associated disease or disorder is a neurodegenerative disease or disorder, including, but not limited to, Alzheimer's disease.

[0015] In some embodiments, the calcitonin receptor and/or amylin receptor associated disease or disorder is a metabolic disorder, including, but not limited to, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), insulin dependent diabetes, non-insulin dependent diabetes, impaired glucose tolerance, obesity, syndrome X, or other diabetic complication.

[0016] In some embodiments, the calcitonin receptor and/or amylin receptor associated disease or disorder is include primary or secondary hyperthyroidism, endocrine disorder, conditions associated with inhibiting gastric secretion, gastrointestinal disorders, renal osteodystrophy, or male infertility.

DETAILED DESCRIPTION

Definitions

[0017] The following description sets forth exemplary embodiments of the present technology. It should be recognized, however, that such description is not intended as a limitation on the scope of the present disclosure but is instead provided as a description of exemplary embodiments.

[0018] As used in the present specification, the following words, phrases and symbols are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.

[0019] A dash ("‐") that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, —C(O)NH₂ is attached through the carbon atom. A dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning. A wavy line or a dashed line drawn through a line in a structure indicates a specified point of attachment of a group. Unless chemically or structurally required, no directionality or stereochemistry is indicated or implied by the order in which a chemical group is written or named.

[0020] The prefix "C_{u-v}" indicates that the following group has from u to v carbon atoms. For example, "C₁₋₆ alkyl" indicates that the alkyl group has from 1 to 6 carbon atoms.

[0021] Reference to "about" a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. In certain embodiments, the term "about" includes the indicated amount ±10%. In other embodiments, the term "about" includes the indicated amount ±5%. In certain other embodiments, the term "about" includes the indicated amount ±1%. Also, to the term "about x" includes description of "x". Also, the singular forms "a" and "the" include plural references unless the context clearly dictates otherwise. Thus, e.g., reference to "the compound" includes a plurality of such compounds and reference to "the assay" includes reference to one or more assays and equivalents thereof known to those skilled in the art.

[0022] "Alkyl" refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1 to 20 carbon atoms (i.e., C₁₋₂₀ alkyl), 1 to 12 carbon atoms (i.e., C₁₋₁₂ alkyl), 1 to 8 carbon atoms (i.e., C₁₋₈ alkyl), 1 to 6

carbon atoms (i.e., C₁₋₆ alkyl), or 1 to 4 carbon atoms (i.e., C₁₋₄ alkyl). Examples of alkyl groups include, e.g., methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl residue having a specific number of carbons is named by chemical name or identified by molecular formula, all positional isomers having that number of carbons may be encompassed; thus, for example, "butyl" includes n-butyl (i.e., —(CH₂)₃CH₃), sec-butyl (i.e., —CH(CH₃)CH₂CH₃), isobutyl (i.e., —CH₂CH(CH₃)₂), and tert-butyl (i.e., —C(CH₃)₃), and "propyl" includes n-propyl (i.e., —(CH₂)₂CH₃), and isopropyl (i.e., —CH(CH₃)₂).

[0023] "Alkenyl" refers to an alkyl group containing at least one (e.g., 1-3, or 1) carbon-carbon double bond and having from 2 to 20 carbon atoms (i.e., C₂₋₂₀ alkenyl), 2 to 12 carbon atoms (i.e., C₂₋₁₂ alkenyl), 2 to 8 carbon atoms (i.e., C₂₋₈ alkenyl), 2 to 6 carbon atoms (i.e., C₂₋₆ alkenyl), or 2 to 4 carbon atoms (i.e., C₂₋₄ alkenyl). Examples of alkenyl groups include, e.g., ethenyl, propenyl, butadienyl (including 1,2-butadienyl, and 1,3-butadienyl).

[0024] "Alkynyl" refers to an alkyl group containing at least one (e.g., 1-3, or 1) carbon-carbon triple bond and having from 2 to 20 carbon atoms (i.e., C₂₋₂₀ alkynyl), 2 to 12 carbon atoms (i.e., C₂₋₁₂ alkynyl), 2 to 8 carbon atoms (i.e., C₂₋₈ alkynyl), 2 to 6 carbon atoms (i.e., C₂₋₆ alkynyl), or 2 to 4 carbon atoms (i.e., C₂₋₄ alkynyl). The term "alkynyl" also includes those groups having one triple bond and one double bond.

[0025] Certain commonly used alternative chemical names may be used. For example, a divalent group such as a divalent "alkyl" group, a divalent "aryl" group, etc., may also be referred to as an "alkylene" group or an "alkylenyl" group, an "arylene" group or an "arylenyl" group, respectively.

[0026] "Alkoxy" refers to the group "alkyl-O—". Examples of alkoxy groups include, e.g., methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy.

[0027] "Alkoxyalkyl" refers to an alkyl group as defined above, wherein a hydrogen atom is replaced by an alkoxy group as defined herein.

[0028] "Haloalkyl" refers to an unbranched or branched alkyl group as defined above, wherein one or more (e.g., 1 to 6 or 1 to 3) hydrogen atoms are replaced by an independently selected halo group. For example, where a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached. Dihaloalkyl and trihaloalkyl refer to alkyl substituted with two ("di") or three ("tri") halo groups, which may be, but are not necessarily, the same halogen. Examples of haloalkyl include, e.g., trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like.

[0029] "Haloalkoxy" refers to an alkoxy group as defined above, wherein one or more (e.g., 1 to 6, or 1 to 3) hydrogen atoms are replaced by an independently selected halo group.

[0030] "Haloalkoxyalkyl" refers to an alkyl group as defined above, wherein a hydrogen atom is replaced by a haloalkoxy group as defined herein.

[0031] "Hydroxyalkyl" refers to an alkyl group as defined above, wherein one or more (e.g., 1 to 6, or 1 to 3) hydrogen atoms are replaced by a hydroxy group.

[0032] “Cyanoalkyl” refers to an alkyl group as defined above, wherein one, or one or more (e.g., 1 to 6, or 1 to 3) hydrogen atoms are replaced by cyano.

[0033] “Alkylthio” refers to the group “alkyl-S—”.

[0034] “Acyl” refers to a group —C(O)R, wherein R is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein. Examples of acyl include formyl, acetyl, cyclohexylcarbonyl, cyclohexylmethyl-carbonyl, and benzoyl.

[0035] “Amido” refers to both a “C-amido” group which refers to the group —C(O)NR^yR^z and an “N-amido” group which refers to the group —NR^yC(O)R^z, wherein R^y and R^z are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein, or R^y and R^z are taken together to form a cycloalkyl or heterocyclyl; each of which may be optionally substituted, as defined herein.

[0036] “Amino” refers to the group —NR^yR^z wherein R^y and R^z are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.

[0037] “Amidino” refers to —C(NR^y)(NR^z)₂, wherein R^y and R^z are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.

[0038] “Aryl” refers to an aromatic carbocyclic group having a single ring (e.g., monocyclic) or multiple rings (e.g., bicyclic or tricyclic) including fused systems. As used herein, aryl has 6 to 20 ring carbon atoms (i.e., C₆₋₂₀ aryl), 6 to 12 carbon ring atoms (i.e., C₆₋₁₂ aryl), or 6 to 10 carbon ring atoms (i.e., C₆₋₁₀ aryl). Examples of aryl groups include, e.g., phenyl, naphthyl, fluorenyl, and anthryl. Aryl, however, does not encompass or overlap in any way with heteroaryl defined below. If one or more aryl groups are fused with a heteroaryl, the resulting ring system is heteroaryl regardless of point of attachment. If one or more aryl groups are fused with a heterocyclyl, the resulting ring system is heterocyclyl regardless of point of attachment. If one or more aryl groups are fused with a cycloalkyl, the resulting ring system is cycloalkyl regardless of point of attachment.

[0039] “Carbamoyl” refers to both an “O-carbamoyl” group which refers to the group —O—C(O)NR^yR^z and an “N-carbamoyl” group which refers to the group —NR^yC(O)OR^z, wherein R^y and R^z are independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.

[0040] “Carboxyl ester” or “ester” refer to both —OC(O)R^x and —C(O)OR^x, wherein R^x is alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.

[0041] “Cycloalkyl” refers to a saturated or partially unsaturated cyclic alkyl group having a single ring or multiple rings including fused, bridged, and spiro ring systems. The term “cycloalkyl” includes cycloalkenyl groups (i.e., the cyclic group having at least one double bond) and carbocyclic fused ring systems having at least one sp³ carbon atom (i.e., at least one non-aromatic ring). As

used herein, cycloalkyl has from 3 to 20 ring carbon atoms (i.e., C₃₋₂₀ cycloalkyl), 3 to 14 ring carbon atoms (i.e., C₃₋₁₂ cycloalkyl), 3 to 12 ring carbon atoms (i.e., C₃₋₁₂ cycloalkyl), 3 to 10 ring carbon atoms (i.e., C₃₋₈ cycloalkyl), or 3 to 6 ring carbon atoms (i.e., C₃₋₆ cycloalkyl). Monocyclic groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic groups include, for example, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, adamantlyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Further, the term cycloalkyl is intended to encompass any non-aromatic ring which may be fused to an aryl ring, regardless of the attachment to the remainder of the molecule (e.g., 2,3-dihydro-1H-indenyl). Still further, cycloalkyl also includes “spirocycloalkyl” when there are two positions for substitution on the same carbon atom, for example spiro[2.5]octanyl, spiro[4.5]decanyl, or spiro[5.5]undecanyl.

[0042] “Cycloalkylalkyl” refers to an alkyl group as defined above, wherein a hydrogen atom is replaced by a cycloalkyl group as defined herein.

[0043] “Imino” refers to a group —C(NR^y)R^z, wherein R^y and R^z are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.

[0044] “Imido” refers to a group —C(O)NR^yC(O)R^z or —N(C(O)R^y)C(O)R^z, wherein R^y and R^z are each independently hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein, or R^y and R^z are taken together to form a heterocyclyl which may be optionally substituted, as defined herein.

[0045] “Halogen” or “halo” refers to atoms occupying group VIIA of the periodic table, such as fluoro, chloro, bromo, or iodo.

[0046] “Heteroalkyl” refers to an alkyl group in which one or more of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatomic group. The term “heteroalkyl” includes unbranched or branched saturated chain having carbon and heteroatoms. By way of example, 1, 2 or 3 carbon atoms may be independently replaced with the same or different heteroatomic group. Heteroatomic groups include, but are not limited to, —NR—, —O—, —S—, —S(O)—, —S(O)₂—, and the like, where R is H, alkyl, aryl, cycloalkyl, heteroalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted. Examples of heteroalkyl groups include —OCH₃, —CH₂OCH₃, —SCH₃, —CH₂SCH₃, —NRCH₃, and —CH₂NRCH₃, where R is hydrogen, alkyl, aryl, arylalkyl, heteroalkyl, or heteroaryl, each of which may be optionally substituted. As used herein, heteroalkyl include 1 to 10 carbon atoms, 1 to 8 carbon atoms, or 1 to 4 carbon atoms; and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom.

[0047] “Heteroalkylene” refers to a divalent heteroalkyl group. “Heteroalkylene” groups must have at least one carbon and at least one heteroatomic group within the chain. The term “heteroalkylene” includes unbranched or branched saturated chain having carbon and heteroatoms. By way of example, 1, 2, or 3 carbon atoms may be independently replaced with the same or different heteroatomic group. Heteroatomic groups include, but are not limited to, —NR—, —O—, —S—, —S(O)—, —S(O)₂—, and the

like, wherein R is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl or heteroaryl; each of which may be optionally substituted, as defined herein. Examples of heteroalkylene groups include, e.g., —CH₂OCH₂—, —CH(CH₃)OCH₂—, —CH₂CH₂OCH₂—, —OCH₂—, —CH(CH₃)O—, —CH₂CH₂O—, —CH₂CH₂OCH₂CH₂OCH₂—, —CH₂CH₂OCH₂CH₂O—, —CH₂SCH₂—, —CH(CH₃)SCH₂—, —CH₂CH₂SCH₂—, —SCH₂—, —CH(CH₃)S—, —CH₂CH₂S—, —CH₂CH₃SCH₂CH₃S—, —CH₂S(O)CH₂—, —CH(CH₃)S(O)CH₂—, —CH₂CH₃S(O)CH₂—, —CH₂CH₂S(O)₂CH₂OCH₂—, —CH₂NR^yCH₂—, —CH(CH₃)NR^yCH₂—, —CH₂CH₂NR^yCH₂—, —CH₂CH₂NR^yCH₂NR^yCH₂—, etc., where R^y is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein). As used herein, heteroalkylene includes 1 to 10 carbon atoms, 1 to 8 carbon atoms, or 1 to 4 carbon atoms; and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom. As used herein, the term “heteroalkylene” does not include groups such as amides or other functional groups having an oxo present on one or more carbon atoms.

[0048] “Heteroaryl” refers to an aromatic group having a single ring or multiple fused rings, with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. As used herein, heteroaryl includes 1 to 20 ring carbon atoms (i.e., C₁₋₂₀ heteroaryl), 3 to 12 ring carbon atoms (i.e., C₃₋₁₂ heteroaryl), or 3 to 8 carbon ring atoms (i.e., C₃₋₈ heteroaryl), and 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur. In certain instances, heteroaryl includes 5-10 membered ring systems, 5-7 membered ring systems, or 5-6 membered ring systems, each independently having 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, oxygen, and sulfur. Examples of heteroaryl groups include, e.g., acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzofuranyl, benzothiazolyl, benzothiadiazolyl, benzonaphthofuranyl, benzoxazolyl, benzothienyl, benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothienyl, furanyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, isoquinolyl, isoxazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, phenazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinoliny, quinuclidinyl, isoquinolinyl, thiazolyl, thiadiazolyl, thiienyl, triazolyl, tetrazolyl, and triazinyl. Examples of the fused-heteroaryl rings include, but are not limited to, benzo[d]thiazolyl, quinolinyl, isoquinolinyl, benzo[b]thienyl, indazolyl, benzo[d]imidazolyl, pyrazolo[1,5-a]pyridinyl, and imidazo[1,5-a]pyridinyl, where the heteroaryl can be bound via either ring of the fused system. Any aromatic ring, having a single or multiple fused rings, containing at least one heteroatom, is considered a heteroaryl regardless of the attachment to the remainder of the molecule (i.e., through any one of the fused rings). Heteroaryl does not encompass or overlap with aryl as defined above.

[0049] “Heterocyclyl” refers to a saturated or partially unsaturated cyclic alkyl group, with one or more ring

heteroatoms independently selected from nitrogen, oxygen, and sulfur. The term “heterocyclyl” includes heterocycloalkenyl groups (i.e., the heterocyclyl group having at least one double bond), bridged-heterocyclyl groups, fused-heterocyclyl groups, and spiro-heterocyclyl groups. A heterocyclyl may be a single ring or multiple rings wherein the multiple rings may be fused, bridged, or spiro, and may comprise one or more (e.g., 1 to 3) oxo (=O) (e.g., —C(O)—, —S(O)—, —S(O)₂—, or —P(O)—) or N-oxide (=O⁻) moieties. Any non-aromatic ring or fused ring system containing at least one heteroatom and one non-aromatic ring is considered a heterocyclyl, regardless of the attachment to the remainder of the molecule. For example, fused ring systems such as 6,7-dihydro-5H-cyclopenta[b]pyridinyl, decahydroquinazolinyl, 1,2,3,4-tetrahydroquinazolinyl, and 5,6,7,8-tetrahydroquinazolinyl are heterocyclyl, regardless of the attachment (i.e., can be bound through a carbon atom or a heteroatom). Further, the term heterocyclyl is intended to encompass any non-aromatic ring containing at least one heteroatom, which ring may be fused to a cycloalkyl, an aryl, or heteroaryl ring, regardless of the attachment to the remainder of the molecule. As used herein, heterocyclyl has 2 to 20 ring carbon atoms (i.e., C₂₋₂₀ heterocyclyl), 2 to 12 ring carbon atoms (i.e., C₂₋₁₂ heterocyclyl), 2 to 10 ring carbon atoms (i.e., C₂₋₁₀ heterocyclyl), 2 to 8 ring carbon atoms (i.e., C₂₋₈ heterocyclyl), 3 to 12 ring carbon atoms (i.e., C₃₋₁₂ heterocyclyl), 3 to 8 ring carbon atoms (i.e., C₃₋₈ heterocyclyl), or 3 to 6 ring carbon atoms (i.e., C₃₋₆ heterocyclyl); having 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, sulfur, or oxygen. Examples of heterocyclyl groups include, e.g., azetidinyl, azepinyl, benzodioxolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzopyranyl, benzodioxinyl, benzopyranonyl, benzofuranonyl, dioxolanyl, dihydropyranyl, hydropyranyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, furanonyl, imidazolinyl, imidazolidinyl, indolinyl, indolizinyl, isoindolinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, oxiranyl, oxetanyl, phenothiazinyl, phenoxazinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, tetrahydropyranyl, trithianyl, tetrahydroquinolinyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. The term “heterocyclyl” also includes “spiroheterocyclyl” when there are two positions for substitution on the same carbon atom. Examples of the spiro-heterocyclyl rings include, e.g., bicyclic and tricyclic ring systems, such as oxabicyclo[2.2.2]octanyl, 2-oxa-7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.4]octanyl, and 6-oxa-1-azaspiro[3.3]heptanyl. Examples of the fused-heterocyclyl rings include, but are not limited to, 1,2,3,4-tetrahydroisoquinolinyl, 4,5,6,7-tetrahydrothieno[2,3-c]pyridinyl, indolinyl, and isoindolinyl, where the heterocyclyl can be bound via either ring of the fused system.

[0050] “Sulfonyl” refers to the group —S(O)₂R^y, where R^y is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein. Examples of sulfonyl are methylsulfonyl, ethylsulfonyl, phenylsulfonyl, and toluenesulfonyl.

[0051] “Sulfinyl” refers to the group —S(O)R’, where R’ is hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein.

[0052] The terms “optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. Also, the term “optionally substituted” refers to any one or more (e.g., 1 to 5, or 1 to 3) hydrogen atoms on the designated atom or group may or may not be replaced by a moiety other than hydrogen.

[0053] As used herein, the term “compound,” is meant to include any or all stereoisomers, geometric isomers, tautomers, and isotopically enriched analogs (e.g., deuterated analogs) of the structures depicted. Compounds herein identified by name or structure as one particular tautomeric form are intended to include other tautomeric forms unless otherwise specified.

[0054] Some of the compounds exist as tautomers. Tautomers are in equilibrium with one another. For example, amide containing compounds may exist in equilibrium with imidic acid tautomers. Regardless of which tautomer is shown, and regardless of the nature of the equilibrium among tautomers, the compounds are understood by one of ordinary skill in the art to comprise both amide and imidic acid tautomers. Thus, the amide containing compounds are understood to include their imidic acid tautomers. Likewise, the imidic acid containing compounds are understood to include their amide tautomers.

[0055] Any compound or structure given herein, is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. These forms of compounds may also be referred to as “isotopically enriched analogs.” Isotopically labeled compounds have structures depicted herein, except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as ^2H , ^3H , ^{11}C , ^{13}C , ^{14}C , ^{13}N , ^{15}N , ^{15}O , ^{17}O , ^{18}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F , ^{36}Cl , ^{123}I , and ^{125}I , respectively. Various isotopically labeled compounds of the present disclosure, for example those into which radioactive isotopes such as ^3H and ^{14}C are incorporated. Such isotopically labelled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays or in radioactive treatment of patients.

[0056] The term “isotopically enriched analogs” includes “deuterated analogs” of compounds described herein in which one or more hydrogens is/are replaced by deuterium, such as a hydrogen on a carbon atom. Such compounds exhibit increased resistance to metabolism and are thus useful for increasing the half-life of any compound when administered to a mammal, particularly a human. See, for example, Foster, “Deuterium Isotope Effects in Studies of Drug Metabolism,” Trends Pharmacol. Sci. 5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogens have been replaced by deuterium.

[0057] Deuterium labelled or substituted therapeutic compounds of the disclosure may have improved DMPK (drug metabolism and pharmacokinetics) properties, relating to distribution, metabolism, and excretion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life, reduced dosage requirements, and/or an improvement in therapeutic index. An ^{18}F , ^3H , ^{11}C labeled compound may be useful for PET or SPECT or other imaging studies. Isotopically labeled compounds of this disclosure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent. It is understood that deuterium in this context is regarded as a substituent in a compound described herein.

[0058] The concentration of such a heavier isotope, specifically deuterium, may be defined by an isotopic enrichment factor. In the compounds of this disclosure any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise stated, when a position is designated specifically as “H” or “hydrogen,” the position is understood to have hydrogen at its natural abundance isotopic composition. Accordingly, in the compounds of this disclosure any atom specifically designated as a deuterium (D) is meant to represent deuterium.

[0059] In many cases, the compounds of this disclosure are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.

[0060] Provided are also pharmaceutically acceptable salts, hydrates, solvates, tautomeric forms, polymorphs, and prodrugs of the compounds described herein. “Pharmaceutically acceptable” or “physiologically acceptable” refer to compounds, salts, compositions, dosage forms and other materials which are useful in preparing a pharmaceutical composition that is suitable for veterinary or human pharmaceutical use.

[0061] The term “pharmaceutically acceptable salt” of a given compound refers to salts that retain the biological effectiveness and properties of the given compound and which are not biologically or otherwise undesirable. “Pharmaceutically acceptable salts” or “physiologically acceptable salts” include, for example, salts with inorganic acids and salts with an organic acid. In addition, if the compounds described herein are obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic methodologies that may be used to prepare nontoxic pharmaceutically acceptable addition salts. Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids. Salts derived from inorganic acids include, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like. Salts derived from organic acids include, e.g., acetic acid, propionic acid, gluconic acid, glycolic acid,

pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like. Likewise, pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, aluminum, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of NH₃, or primary, secondary, tertiary amines, such as salts derived from a N-containing heterocycle, a N-containing heteroaryl, or derived from an amine of formula N(R^N)₃ (e.g., HN⁺(R^N)₃ or (alkyl)N⁺(R^N)₃) where each R^N is independently hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, heterocycl, aryl, or heteroaryl, wherein each is optionally substituted, such as by one or more (e.g., 1-5 or 1-3) substituents (e.g., halo, cyano, hydroxy, amino, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, or haloalkoxy). Specific examples of suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.

[0062] The term “substituted” means that any one or more hydrogen atoms on the designated atom or group is replaced with one or more substituents other than hydrogen, provided that the designated atom’s normal valence is not exceeded. The one or more substituents include, but are not limited to, acyl, alkenyl, alkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, amidino, amido, amino, aryl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, cyanoalkyl, cycloalkyl, cycloalkylalkyl, guanidino, halo, haloalkoxy, haloalkoxyalkyl, haloalkyl, heteroalkyl, heteroaryl, heterocycl, hydrazino, hydroxy, hydroxylalkyl, imido, imino, nitro, oxo, sulfinyl, sulfonic acid, sulfonyl, thiocyanate, thiol, thione, or combinations thereof.

[0063] Polymers or similar indefinite structures arrived at by defining substituents with further substituents appended ad infinitum (e.g., a substituted aryl having a substituted alkyl which is itself substituted with a substituted aryl group, which is further substituted by a substituted heteroalkyl group, etc.) are not intended for inclusion herein. Unless otherwise noted, the maximum number of serial substitutions in compounds described herein is three. For example, serial substitutions of substituted aryl groups with two other substituted aryl groups are limited to ((substituted aryl) substituted aryl) substituted aryl. Similarly, the above definitions are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluorines or heteroaryl groups having two adjacent oxygen ring atoms). Such impermissible substitution patterns are well known to the skilled artisan. When used to modify a chemical group, the term “substituted” may describe other chemical groups defined herein. Unless specified otherwise, where a group is described as optionally substituted, any substituents of the group are themselves unsubstituted. For example, in some embodiments, the term “substituted alkyl” refers to an alkyl group having one or more substituents including hydroxy, halo, alkoxy, cycloalkyl, heterocycl, aryl, and heteroaryl. In other embodiments, the one or more substituents may be further substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, cycloalkyl, heterocycl, aryl, or heteroaryl, each of which is substituted. In other embodiments, the substituents

may be further substituted with halo, alkyl, haloalkyl, alkoxy, hydroxy, cycloalkyl, heterocycl, aryl, or heteroaryl, each of which is unsubstituted.

[0064] As used herein, “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

[0065] A “solvate” is formed by the interaction of a solvent and a compound. Solvates of salts of the compounds described herein are also provided. Hydrates of the compounds described herein are also provided.

[0066] The term “pharmaceutically acceptable” as used herein indicates that the compound, or salt or composition thereof is compatible chemically and/or toxicologically with the other ingredients comprising a formulation and/or the subject being treated therewith.

[0067] The term “administration” or “administering” refers to a method of giving a dosage of a compound or pharmaceutical composition to a vertebrate or invertebrate, including a mammal, a bird, a fish, or an amphibian. The method of administration can vary depending on various factors, e.g., the components of the pharmaceutical composition, the site of the disease, and the severity of the disease.

[0068] The terms “effective amount” or “effective dosage” or “pharmaceutically effective amount” or “therapeutically effective amount,” as used herein, refer to a sufficient amount of a chemical entity (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof) being administered which will relieve to some extent one or more of the symptoms of the disease or condition being treated, and can include curing the disease. “Curing” means that the symptoms of active disease are eliminated. The result includes reduction and/or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an “effective amount” for therapeutic uses is the amount of the composition comprising a compound as disclosed herein required to provide a clinically significant decrease in disease symptoms. An appropriate “effective” amount in any individual case is determined using any suitable technique, such as a dose escalation study. In some embodiments, a “therapeutically effective amount” of a compound as provided herein refers to an amount of the compound that is effective as a monotherapy or combination therapy.

[0069] The term “excipient” or “pharmaceutically acceptable excipient” means a pharmaceutically-acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, carrier, solvent, or encapsulating material. In some embodiments, each component is “pharmaceutically acceptable” in the sense of being compatible with the other ingredients of a pharmaceutical formulation, and suitable for use in contact with the tissue or organ of humans and animals without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications, commensurate with a reasonable benefit/risk ratio. See, e.g., Remington: The Science and Practice of Pharmacy, 21st ed.; Lippincott Williams & Wilkins: Philadelphia.

phia, PA, 2005; Handbook of Pharmaceutical Excipients, 6th ed.; Rowe et al., Eds.; The Pharmaceutical Press and the American Pharmaceutical Association: 2009; Handbook of Pharmaceutical Additives, 3rd ed.; Ash and Ash Eds.; Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, 2nd ed.; Gibson Ed.; CRC Press LLC: Boca Raton, FL, 2009.

[0070] The term “pharmaceutical composition” refers to a mixture of a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof as provided herein with other chemical components (referred to collectively herein as “excipients”), such as carriers, stabilizers, diluents, dispersing agents, suspending agents, and/or thickening agents. The pharmaceutical composition facilitates administration of the compound to an organism. Multiple techniques of administering a compound exist in the art including, but not limited to, rectal, oral, intravenous, aerosol, parenteral, ophthalmic, pulmonary, and topical administration.

[0071] The term “calcitonin receptor and/or amylin receptor associated disease or disorder” as used herein is meant to include, without limitation, those diseases, disorders, or conditions in which activation of at least one calcitonin receptor (CTR) and/or amylin receptor (AMY) by calcitonin and/or amylin contributes to the symptomology or progression of the disease or disorder. These diseases or disorders may arise from one or more of a genetic, iatrogenic, immunological, infectious, metabolic, oncological, toxic, surgical, and/or traumatic etiology.

[0072] The terms “treat,” “treating,” and “treatment,” in the context of treating a disease, disorder, or condition, are meant to include alleviating or abrogating a disorder, disease, or condition, or one or more of the symptoms associated with the disorder, disease, or condition; or to slowing the progression, spread or worsening of a disease, disorder or condition or of one or more symptoms thereof.

[0073] The term “preventing”, as used herein, is the prevention of the onset, recurrence or spread, in whole or in part, of the disease or condition as described herein, or a symptom thereof.

[0074] The terms “subject,” “patient,” or “individual,” as used herein, are used interchangeably and refers to any animal, including mammals such as mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, primates, and humans. In some embodiments, the term refers to a subject, particularly a mammalian subject, for whom diagnosis, prognosis, or therapy is desired or needed. In some embodiments, the subject is a human. In some embodiments, the subject has experienced and/or exhibited at least one symptom of the disease, disorder, or condition to be treated and/or prevented.

[0075] The terms “treatment regimen” and “dosing regimen” are used interchangeably to refer to the dose and timing of administration of each therapeutic agent in a combination.

[0076] The term “pharmaceutical combination,” as used herein, refers to a pharmaceutical treatment resulting from the mixing or combining of more than one active ingredient and includes both fixed and non-fixed combinations of the active ingredients.


[0077] The term “combination therapy” as used herein refers to a dosing regimen of two different therapeutically active agents (i.e., the components or combination partners of the combination), wherein the therapeutically active

agents are administered together or separately in a manner prescribed by a medical care taker or according to a regulatory agency as defined herein.

[0078] The term “modulate,” “modulating,” or “modulation,” as used herein, refers to a regulation or an adjustment (e.g., increase or decrease) and can include, for example agonism, partial agonism or antagonism.

Compounds


[0079] Provided herein are compounds that are amylin modulators. In some embodiments, provided is a compound of Formula I:



I

[0080] or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof, wherein X¹, X², X³, X⁴, A, Y¹, Y², Y³, L¹, L², R⁴, and R⁵, are each independently as defined herein.

[0081] In some embodiments, provided is a compound of Formula I:



I

[0082] or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof, wherein:

[0083] A is C₁₋₆ alkylene, C₂₋₆ alkenylene, C₂₋₆ alkynylene, C₃₋₁₀ cycloalkylene, heterocyclylene, arylene, or heteroarylene; wherein the C₁₋₆ alkylene, C₂₋₆ alkenylene, C₂₋₆ alkynylene, C₃₋₁₀ cycloalkylene, heterocyclylene, arylene, or heteroaryl of A is independently optionally substituted with one to five Z^A;

[0084] X¹ is O, S, NH, NR^A, CH, or CR^B;

[0085] one of X² and X³ is C(O); and the other of X² and X³ is O, S, NH, NR^A, CH, or CR^B;

[0086] X⁴ is N, CH, or CR^B;

[0087] provided that at least one of X¹, X², X³, and X⁴ is a heteroatom;

[0088] each R^A is independently selected from cyano, C₁₋₃ alkyl, and C₁₋₃ haloalkyl; wherein each C₁₋₃ alkyl of R^A is independently optionally substituted with —NH₂, —NHC₁₋₃ alkyl, —N(C₁₋₃ alkyl)₂, hydroxy, or C₁₋₃ alkoxy;

- [0089] each R^B is independently selected from halo, hydroxy, —NH₂, cyano, C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkoxy, and C₁₋₃ haloalkoxy; wherein each C₁₋₃ alkyl of R^B is independently optionally substituted with —NH₂, —NHC₁₋₃ alkyl, —N(C₁₋₃ alkyl)₂, hydroxy, or C₁₋₃ alkoxy;
- [0090] Y¹ is —C(O)—, —C(S)—, —S(O)₂—, —S(O)(NR⁶)—, or —P(O)(R⁷)—;
- [0091] Y² is —O—, —S—, —NR²—, or —C(R²)₂—; wherein the bond between Y¹ and Y² is a single bond; and
- [0092] Y³ is —NR⁸—, —O—, —S—, —C(R³)₂—, —NR⁸—C(R³)₂—, —O—C(R³)₂—, —S—C(R³)₂—, —C(R^{3a})₂—C(R^{3a})₂—, —C(R^{3a})₂—C(R^{3a})₂—C(R^{3a})₂—, or —CR³—CR³—; or
- [0093] Y¹ is —C(O)—, —C(S)—, —S(O)₂—, —S(O)(NR⁶)—, or —P(O)(R⁷)—;
- [0094] Y² is —N— or —CR²—, and
- [0095] Y³ is —N— or —CR³—; wherein the bond between Y² and Y³ is a double bond; or
- [0096] Y¹ is —N— or —CR¹—;
- [0097] Y² is —N— or —CR²—; wherein the bond between Y¹ and Y² is a double bond; and
- [0098] Y³ is —NR⁸—, —O—, or —S—;
- [0099] provided that the ring comprising Y¹, Y², and Y³ contains at least one heteroatom;
- [0100] L¹ is C₁₋₃ alkylene, C₂₋₃ alkenylene, C₂₋₃ alkynylene, C₁₋₃ heteroalkylene, C₃₋₆ cycloalkylene, or 4-6 membered heterocyclene; wherein the C₁₋₃ alkylene, C₂₋₃ alkenylene, C₂₋₃ alkynylene, C₁₋₃ heteroalkylene, C₃₋₆ cycloalkylene, or 4-6 membered heterocyclene of L¹ is independently optionally substituted with one to five substituents independently selected from halo, oxo, hydroxy, cyano, C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkoxy, and C₁₋₃ haloalkoxy;
- [0101] L² is a bond, —O—, —S—, —NR^{2a}—, —C(O)—, —C(O)O—, —OC(O)—, —OC(O)O—, —C(O)NR^{2a}—, —NR^{2a}C(O)—, —OC(O)NR^{2a}—, —NR^{2a}C(O)O—, —NR^{2a}C(O)NR^{2b}—, —S(O)—, —S(O)₂—, —S(O)NR^{2a}—, —S(O)₂NR^{2a}—, —NR^{2a}S(O)—, —NR^{2a}S(O)₂—, —NR^{2a}S(O)NR^{2b}—, —NR^{2a}S(O)₂NR^{2b}—, C₁₋₆ alkylene, C₂₋₆ alkenylene, C₁₋₆ alkynylene, C₁₋₆ heteroalkylene, C₃₋₆ cycloalkylene, 4-6 membered heterocyclene, or 5 membered heteroarylene; wherein the C₁₋₃ alkylene, C₂₋₃ alkenylene, C₂₋₃ alkynylene, C₁₋₃ heteroalkylene, C₃₋₆ cycloalkylene, 4-6 membered heterocyclene, or 5 membered heteroarylene of L² is independently optionally substituted with one to five substituents independently selected from halo, oxo, hydroxy, cyano, —NH₂, —NHC₁₋₃ alkyl, —N(C₁₋₃ alkyl)₂, C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkoxy, and C₁₋₃ haloalkoxy;
- [0102] R¹ is hydrogen, halo, hydroxy, cyano, C₁₋₃ alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl, C₁₋₃ haloalkyl, C₁₋₃ alkoxy, or C₁₋₃ haloalkoxy;
- [0103] each R² is independently hydrogen, C₁₋₃ alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl, C₁₋₃ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4 to 6-membered heterocycl, or 5 to 6-membered heteroaryl; wherein each C₁₋₃ alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl, C₁₋₃ haloalkyl, C₃₋₆ cycloalkyl, phenyl, 4 to 6-membered heterocycl, or 5 to 6-membered heteroaryl of R² is independently optionally substituted with one to five substituents independently selected from halo, hydroxy, cyano, C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkoxy, and C₁₋₃ haloalkoxy;
- [0104] or R² and any one or two of R¹, R³, R^{3a}, R⁶, R⁷, and R⁸, together with the atoms to which they are attached, form a C₃₋₁₀ cycloalkyl, heterocycl, or heteroaryl; wherein the C₃₋₁₀ cycloalkyl, heterocycl, or heteroaryl is optionally substituted with one to five Z²;
- [0105] each R^{2a} and R^{2b} is independently hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, heterocycl, aryl, or heteroaryl; wherein each C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, heterocycl, aryl, or heteroaryl of R^{2a} and R^{2b} is independently optionally substituted with one to five Z^{2a};
- [0106] or R^{2a} and R^{2b} are taken together with the atoms to which they are attached to form heterocycl independently optionally substituted by one to five Z^{2a};
- [0107] each R³ is independently hydrogen, hydroxy, —NR^{3b}R^{3c}, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy, C₁₋₆ heteroalkyl, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₃₋₁₀ cycloalkyl, heterocycl, aryl, or heteroaryl; wherein each C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy, C₁₋₆ heteroalkyl, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₃₋₁₀ cycloalkyl, heterocycl, aryl, or heteroaryl of R³ is independently optionally substituted with one to five Z³;
- [0108] or two R³, together with the atom(s) to which they are attached, form a C₃₋₁₀ cycloalkyl, heterocycl, aryl, or heteroaryl; wherein the C₃₋₁₀ cycloalkyl, heterocycl, aryl, or heteroaryl is optionally substituted with one to five Z³;
- [0109] or two R³, together with the carbon atom to which both are attached, form an oxo;
- [0110] each R^{3a} is independently hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₃₋₁₀ cycloalkyl, heterocycl, aryl, or heteroaryl; wherein each C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₁₋₆ haloalkoxy, C₃₋₁₀ cycloalkyl, heterocycl, aryl, or heteroaryl of R^{3a} is independently optionally substituted with one to five Z^{3a};
- [0111] or two R^{3a}, together with the atom(s) to which they are attached, form a C₃₋₁₀ cycloalkyl, heterocycl, or heteroaryl; wherein the C₃₋₁₀ cycloalkyl, heterocycl, or heteroaryl is optionally substituted with one to five Z^{3a};
- [0112] or two R^{3a}, together with the carbon atom to which both are attached, form an oxo;
- [0113] R^{3b} and R^{3c} are each independently hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, heterocycl, aryl, or heteroaryl; wherein each C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, heterocycl, aryl, or heteroaryl of R^{3b} and R^{3c} is independently optionally substituted with one to five substituents independently selected from halo, hydroxy, cyano, C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkoxy, and C₁₋₃ haloalkoxy;
- [0114] or R^{3b} and R^{3c} are taken together with the nitrogen atom to which they are attached to form a heterocycl optionally substituted with one to five Z^{3b};
- [0115] R⁴ is C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, heterocycl, aryl, or heteroaryl; wherein the C₁₋₆ alkyl, C₃₋₁₀

cycloalkyl, heterocyclyl, aryl, or heteroaryl of R⁴ is independently optionally substituted with one to five Z⁴;

[0116] R⁵ is hydrogen, halo, hydroxy, amino, cyano, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein the C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, heterocyclyl, aryl, or heteroaryl of R⁵ is independently optionally substituted with one to five Z⁵;

[0117] R⁶ is hydrogen, C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₃₋₆ cycloalkyl, or 4 to 6-membered heterocyclyl; wherein the C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₃₋₆ cycloalkyl, or 4 to 6-membered heterocyclyl is optionally substituted with one to five substituents independently selected from halo, oxo, hydroxy, cyano, C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkoxy, and C₁₋₃ haloalkoxy;

[0118] R⁷ is hydroxy, C₁₋₃ alkoxy, C₁₋₃ haloalkoxy, C₁₋₃ alkyl, or C₁₋₃ haloalkyl;

[0119] R⁸ is hydrogen, —S(O)₂—C₁₋₃ alkyl, —S(O)₂—C₁₋₃ haloalkyl, C₁₋₃ alkyl, C₁₋₃ haloalkyl C₃₋₆ cycloalkyl, or 4 to 6-membered heterocyclyl; wherein the —S(O)₂—C₁₋₃ alkyl, —S(O)₂—C₁₋₃ haloalkyl, C₁₋₃ alkyl, C₁₋₃ haloalkyl C₃₋₆ cycloalkyl, or 4 to 6-membered heterocyclyl of R⁸ is optionally substituted with one to five substituents independently selected from halo, oxo, hydroxy, cyano, C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkoxy, and C₁₋₃ haloalkoxy;

[0120] each Z⁴, Z², Z^{2a}, Z³, Z^{3a}, Z^{3b}, Z⁴, and Z⁵; is independently halo, cyano, nitro, oxo, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, heterocyclyl, aryl, heteroaryl, -L-H, -L-C₁₋₆ alkyl, -L-C₂₋₆ alkenyl, -L-C₂₋₆ alkynyl, -L-C₁₋₆ haloalkyl, -L-C₃₋₁₀ cycloalkyl, -L-heterocyclyl, -L-aryl, or -L-heteroaryl; wherein each C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z⁴, Z², Z^{2a}, Z³, Z^{3a}, Z^{3b}, Z⁴, and Z⁵ are each independently optionally substituted with one to five Z^{1a};


[0121] each L is independently —O—, —S—, —NR²⁰—, —C(O)—, —C(O)O—, —OC(O)—, —OC(O)O—, —C(O)NR²⁰—, —NR²⁰C(O)—, —OC(O)NR²⁰—, —NR²⁰C(O)O—, —NR²⁰C(O)NR²¹—, —S(O)—, —S(O)₂—, —S(O)NR²⁰—, —S(O)NR²⁰S—, —NR²⁰S(O)—, —NR²⁰S(O)₂—, —NR²⁰S(O)NR²¹—, or —NR²⁰S(O)₂NR²¹—;

[0122] each R²⁰ and R²¹ is independently hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein each C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, heterocyclyl, aryl, or heteroaryl of R²⁰ and R²¹ is independently optionally substituted with one to five Z^{1a}; or an R²⁰ and R²¹ are taken together with the atoms to which they are attached to form heterocyclyl independently optionally substituted by one to five Z^{1a}; and

[0123] each Z^{1a} is independently halo, hydroxy, cyano, nitro, oxo, —SH, —NH₂, —NH—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —S—C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein each —NH—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —S—C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z¹ is independently optionally substituted

with one to five substituents independently selected from C₁₋₆ alkyl, oxo, halo, hydroxy, and cyano.

[0124] In some embodiments, provided is a compound of Formula I:



[0125] or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof, wherein:

[0126] A is C₁₋₆ alkylene, C₂₋₆ alkenylene, C₂₋₆ alkynylene, C₃₋₁₀ cycloalkylene, heterocyclylene, arylene, or heteroarylene; wherein the C₁₋₆ alkylene, C₂₋₆ alkenylene, C₂₋₆ alkynylene, C₃₋₁₀ cycloalkylene, heterocyclylene, arylene, or heteroaryl of A is independently optionally substituted with one to five Z⁴;

[0127] X¹ is O, S, NH, NR⁴, CH, or CR^B;

[0128] one of X² and X³ is C(O); and the other of X² and X³ is O, S, NH, NR⁴, CH, or CR^B;

[0129] X⁴ is N, CH, or CR^B;

[0130] provided that at least one of X¹, X², X³, and X⁴ is a heteroatom;

[0131] each R⁴ is independently selected from cyano, C₁₋₃ alkyl, and C₁₋₃ haloalkyl; wherein each C₁₋₃ alkyl of R⁴ is independently optionally substituted with —NH₂, —NHC₁₋₃ alkyl, —N(C₁₋₃ alkyl)₂, hydroxy, or C₁₋₃ alkoxy;

[0132] each R^B is independently selected from halo, hydroxy, cyano, C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkoxy, and C₁₋₃ haloalkoxy; wherein each C₁₋₃ alkyl of R^B is independently optionally substituted with —NH₂, —NHC₁₋₃ alkyl, —N(C₁₋₃ alkyl)₂, hydroxy, or C₁₋₃ alkoxy;

[0133] Y¹ is —C(O)—, —C(S)—, —S(O)₂—, —S(O)(NR⁶)—, or —P(O)(R⁷)—;

[0134] Y² is —O—, —S—, —NR²— or —C(R²)₂—; wherein the bond between Y¹ and Y² is a single bond; and

[0135] Y³ is —NR⁸—, —O—, —S—, —C(R³)₂—, —NR⁸—C(R³)₂—, —O—C(R³)₂—, —S—C(R³)₂—, —C(R^{3a})₂—C(R^{3a})₂—, —C(R^{3a})₂—C(R^{3a})₂—C(R^{3a})₂—, or —CR³—CR³—; or

[0136] Y¹ is —C(O)—, —C(S)—, —S(O)₂—, —S(O)(NR⁶)—, or —P(O)(R⁷)—;

[0137] Y² is —N— or —CR²—, and

[0138] Y³ is —N— or —CR³—; wherein the bond between Y² and Y³ is a double bond; or

[0139] Y¹ is —N— or —CR¹—;

[0140] Y² is —N— or —CR²—; wherein the bond between Y¹ and Y² is a double bond; and

[0141] Y³ is —NR⁸—, —O—, or —S—;

[0142] provided that the ring comprising Y¹, Y², and Y³ contains at least one heteroatom;

[0143] L¹ is C₁₋₃ alkylene, C₂₋₃ alkenylene, C₂₋₃ alkynylene, C₁₋₃ heteroalkylene, C₃₋₆ cycloalkylene, or 4-

membered heterocyclylene; wherein the C_{1-3} alkylene, C_{2-3} alkenylene, C_{2-3} alkynylene, C_{1-3} heteroalkylene, C_{3-6} cycloalkylene, or 4-6 membered heterocyclylene of L^1 is independently optionally substituted with one to five substituents independently selected from halo, oxo, hydroxy, cyano, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkoxy, and C_{1-3} haloalkoxy;

[0144] L^2 is a bond, $—O—$, $—S—$, $—NR^{2a}—$, $—C(O)—$, $—C(O)O—$, $—OC(O)—$, $—OC(O)O—$, $—C(O)NR^{2a}—$, $—NR^{2a}C(O)—$, $—OC(O)NR^{2a}—$, $—NR^{2a}C(O)O—$, $—NR^{2a}C(O)NR^{2b}—$, $—S(O)—$, $—S(O)_2—$, $—S(O)NR^{2a}—$, $—S(O)_2NR^{2a}—$, $—NR^{2a}S(O)—$, $—NR^{2a}S(O)_2—$, $—NR^{2a}S(O)$
 $NR^{2b}—$, $—NR^{2a}S(O)NR^{2b}—$, C_{1-6} alkylene, C_{2-6} alkenylene, C_{2-6} alkynylene, C_{1-6} heteroalkylene, C_{3-6} cycloalkylene, 4-6 membered heterocyclylene, or 5 membered heteroarylene; wherein the C_{1-3} alkylene, C_{2-3} alkenylene, C_{2-3} alkynylene, C_{1-3} heteroalkylene, C_{3-6} cycloalkylene, 4-6 membered heterocyclylene, or 5 membered heteroarylene of L^2 is independently optionally substituted with one to five substituents independently selected from halo, oxo, hydroxy, cyano, $—NH_2$, $—NHC_{1-3}$ alkyl, $—N(C_{1-3}$ alkyl)₂, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkoxy, and C_{1-3} haloalkoxy;

[0145] R^1 is hydrogen, halo, hydroxy, cyano, C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, C_{1-3} haloalkyl, C_{1-3} alkoxy, or C_{1-3} haloalkoxy;

[0146] each R^2 is independently hydrogen, C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, phenyl, 4 to 6-membered heterocycl, or 5 to 6-membered heteroaryl; wherein each C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, phenyl, 4 to 6-membered heterocycl, or 5 to 6-membered heteroaryl of R^2 is independently optionally substituted with one to five substituents independently selected from halo, hydroxy, cyano, C_{1-3} alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl, C_{1-3} haloalkyl, C_{1-3} alkoxy, or C_{1-3} haloalkoxy;

[0147] or R^2 and any one of R^1 , R^3 , R^{3a} , R^6 , R^7 , and R^8 , together with the atoms to which they are attached, form a C_{3-10} cycloalkyl, heterocycl, or heteroaryl; wherein the C_{3-10} cycloalkyl, heterocycl, or heteroaryl is optionally substituted with one to five Z^2 ;

[0148] each R^{2a} and R^{2b} is independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, heterocycl, aryl, or heteroaryl; wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, heterocycl, aryl, or heteroaryl of R^{2a} and R^{2b} is independently optionally substituted with one to five Z^2a ;

[0149] or R^{2a} and R^{2b} are taken together with the atoms to which they are attached to form heterocycl independently optionally substituted by one to five Z^2a ;

[0150] each R^3 is independently hydroxy, $—NR^{3b}R^{3c}—$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} heteroalkyl, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-10} cycloalkyl, heterocycl, aryl, or heteroaryl; wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} heteroalkyl, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, C_{3-10} cycloalkyl, heterocycl, aryl, or heteroaryl of R^3 is independently optionally substituted with one to five Z^3 ;

[0151] or two R^3 , together with the atom(s) to which they are attached, form a C_{3-10} cycloalkyl, heterocycl,

aryl, or heteroaryl; wherein the C_{3-10} cycloalkyl, heterocycl, aryl, or heteroaryl is optionally substituted with one to five Z^3 ;

[0152] or two R^3 , together with the carbon atom to which both are attached, form an oxo;

[0153] each R^{3a} is independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-10} cycloalkyl, heterocycl, aryl, or heteroaryl; wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-10} cycloalkyl, heterocycl, aryl, or heteroaryl of R^{3a} is independently optionally substituted with one to five Z^3a ;

[0154] or two R^{3a} , together with the atom(s) to which they are attached, form a C_{3-10} cycloalkyl, heterocycl, or heteroaryl; wherein the C_{3-10} cycloalkyl, heterocycl, or heteroaryl is optionally substituted with one to five Z^{3a} ;

[0155] or two R^{3a} , together with the carbon atom to which both are attached, form an oxo;

[0156] R^{3b} and R^{3c} are each independently hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, heterocycl, aryl, or heteroaryl; wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, heterocycl, aryl, or heteroaryl of R^{3b} and R^{3c} is independently optionally substituted with one to five substituents independently selected from halo, hydroxy, cyano, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkoxy, and C_{1-3} haloalkoxy;

[0157] or R^{3b} and R^{3c} are taken together with the nitrogen atom to which they are attached to form a heterocycl optionally substituted with one to five Z^{3b} ;

[0158] R^4 is C_{1-6} alkyl, C_{3-10} cycloalkyl, heterocycl, aryl, or heteroaryl; wherein the C_{1-6} alkyl, C_{3-10} cycloalkyl, heterocycl, aryl, or heteroaryl of R^4 is independently optionally substituted with one to five Z^4 ;

[0159] R^5 is hydrogen, halo, hydroxy, amino, cyano, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, heterocycl, aryl, or heteroaryl; wherein the C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} haloalkyl, C_{3-10} cycloalkyl, heterocycl, aryl, or heteroaryl of R^5 is independently optionally substituted with one to five Z^5 ;

[0160] R^6 is hydrogen, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, or 4 to 6-membered heterocycl; wherein the C_{1-3} alkyl, C_{1-3} haloalkyl, C_{3-6} cycloalkyl, or 4 to 6-membered heterocycl is optionally substituted with one to five substituents independently selected from halo, oxo, hydroxy, cyano, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkoxy, and C_{1-3} haloalkoxy;

[0161] R^7 is hydroxy, C_{1-3} alkoxy, C_{1-3} haloalkoxy, C_{1-3} alkyl, or C_{1-3} haloalkyl;

[0162] R^8 is hydrogen, $—S(O)_2—C_{1-3}$ alkyl, $—S(O)_2—C_{1-3}$ haloalkyl, C_{1-3} alkyl, C_{1-3} haloalkyl C_{3-6} cycloalkyl, or 4 to 6-membered heterocycl; wherein the $—S(O)_2—C_{1-3}$ alkyl, $—S(O)_2—C_{1-3}$ haloalkyl, C_{1-3} alkyl, C_{1-3} haloalkyl C_{3-6} cycloalkyl, or 4 to 6-membered heterocycl of R^8 is optionally substituted with one to five substituents independently selected from halo, oxo, hydroxy, cyano, C_{1-3} alkyl, C_{1-3} haloalkyl, C_{1-3} alkoxy, and C_{1-3} haloalkoxy;

[0163] each Z^4 , Z^2 , Z^2a , Z^3 , Z^3a , Z^{3b} , Z^4 , and Z^5 ; is independently halo, cyano, nitro, oxo, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} haloalkyl, C_{3-10} cycloalkyl,

heterocyclyl, aryl, heteroaryl, -L-H, -L-C₁₋₆ alkyl, -L-C₂₋₆ alkenyl, -L-C₂₋₆ alkynyl, -L-C₁₋₆ haloalkyl, -L-C₃₋₁₀ cycloalkyl, -L-heterocyclyl, -L-aryl, or -L-heteroaryl; wherein each C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z⁴, Z², Z^{2a}, Z³, Z^{3a}, Z^{4b}, Z⁴, and Z⁵ are each independently optionally substituted with one to five Z^{1a};

[0164] each L is independently —O—, —S—, —NR²⁰—, —C(O)—, —C(O)O—, —OC(O)—, —OC(O)O—, —C(O)NR²⁰—, —NR²⁰C(O)—, —OC(O)NR²⁰—, —NR²⁰C(O)O—, —NR²⁰C(O)NR²¹—, —S(O)—, —S(O)₂—, —S(O)NR²⁰—, —S(O)NR²⁰—, —NR²⁰S(O)—, —NR²⁰S(O)₂—, —NR²⁰S(O)₂NR²¹—, or —NR²⁰S(O)₂NR²¹—;

[0165] each R²⁰ and R²¹ is independently hydrogen, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein each C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, heterocyclyl, aryl, or heteroaryl of R²⁰ and R²¹ is independently optionally substituted with one to five Z^{1a}; or an R²⁰ and R²¹ are taken together with the atoms to which they are attached to form heterocyclyl independently optionally substituted by one to five Z^{1a}; and

[0166] each Z^{1a} is independently halo, hydroxy, cyano, nitro, oxo, —SH, —NH₂, —NH—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —S—C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein each —NH—C₁₋₆ alkyl, —N(C₁₋₆ alkyl)₂, —S—C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ haloalkyl, C₃₋₁₀ cycloalkyl, heterocyclyl, aryl, or heteroaryl of Z^{1a} is independently optionally substituted with one to five substituents independently selected from C₁₋₆ alkyl, oxo, halo, hydroxy, and cyano.

[0167] In some embodiments, when A is C₁₋₆ alkylene; then R⁵ is C₃₋₁₀ cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein the C₃₋₁₀ cycloalkyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted.

[0168] In some embodiments, Y¹ is —C(O)—, —S(O)₂—, —S(O)(NR⁶)—, or —P(O)(R⁷)—; Y² is —O—, —S—, —NR²— or —C(R²)₂—; and the bond between Y¹ and Y² is a single bond; and Y³ is —NR⁸—, —C(R³)₂—, —C(R^{3a})₂—, or —C(R^{3a})₂—C(R^{3a})₂—C(R^{3a})₂—.

[0169] In some embodiments, Y¹ is —C(O)—, —S(O)₂—, —S(O)(NR⁶)—, or —P(O)(R⁷)—; Y² is —O—, —S—, —NR²—, or —C(R²)₂—; and the bond between Y¹ and Y² is a single bond; and Y³ is —NR⁸—.

[0170] In some embodiments, R⁶ is C₁₋₃ alkyl.

[0171] In some embodiments, R⁷ is C₁₋₃ alkyl.

[0172] In some embodiments, Y¹ is —C(O)— or —S(O)₂—.

[0173] In some embodiments, Y¹ is —C(O)— or —S(O)₂—; and the bond between Y¹ and Y² is a single bond.

[0174] In some embodiments, Y¹ is —C(O)—.

[0175] In some embodiments, Y¹ is —C(O)—; and the bond between Y¹ and Y² is a single bond.

[0176] In some embodiments, Y¹ is —S(O)₂—; and the bond between Y¹ and Y² is a single bond.

[0177] In some embodiments, Y² is —NR²— or —C(R²)₂—; and the bond between Y¹ and Y² is a single bond.

[0178] In some embodiments, Y² is —NR²— or —C(R²)₂—; and the bond between Y¹ and Y² is a single bond.

[0179] In some embodiments, Y² is —NR₂—.

[0180] In some embodiments, Y² is —NR²—; and the bond between Y¹ and Y² is a single bond.

[0181] In some embodiments, Y¹ is —C(O)—; and Y² is —NR²—; and the bond between Y¹ and Y² is a single bond.


[0182] In some embodiments, Y³ is —N— or —C(R³)₂—.

[0183] In some embodiments, Y³ is —C(R³)₂—.

[0184] In some embodiments, Y¹ is —C(O)— or —S(O)₂—; Y² is —NR²— or —C(R²)₂—; and the bond between Y¹ and Y² is a single bond; and Y³ is —N— or —C(R³)₂—.

[0185] In some embodiments, provided is a compound of Formula IA:

IA



[0186] or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof, wherein each X¹, X², X³, X⁴, A, L¹, L², R², R³, R⁴, and R⁵ are independently as defined herein.

[0187] In some embodiments, R² and R³, together with the atoms to which they are attached, form a heterocyclyl optionally substituted with one to five Z².


[0188] In some embodiments, R² and R³, together with the atoms to which they are attached, form an unsubstituted heterocyclyl.

[0189] In some embodiments, R² is hydrogen.

[0190] In some embodiments, each R³ is independently hydrogen or C₁₋₃ alkyl.


[0191] In some embodiments, provided is a compound of Formula IB:

IB



[0192] or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof, wherein each X¹, X², X³, X⁴, A, L¹, L², R², R³, R⁴, and R⁵ are independently as defined herein.


[0193] In some embodiments, provided is a compound of Formula IC:



IC

[0194] or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof, wherein each X¹, X², X³, X⁴, A, L¹, L², R³, R⁴, and R⁵ are independently as defined herein.


[0195] In some embodiments, provided is a compound of Formula ID:



ID

[0196] or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof, wherein each X¹, X², X³, X⁴, A, L¹, L², R⁴, and R⁵ are independently as defined herein.


[0197] In some embodiments, provided is a compound of Formula IE:



IE

[0198] or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof, wherein each X¹, X², X³, X⁴, A, L¹, L², R⁴, and R⁵ are independently as defined herein.


[0199] In some embodiments, provided is a compound of Formula IF:



IF

[0200] or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof, wherein each X¹, X², X³, X⁴, A, L¹, L², R⁴, and R⁵ are independently as defined herein.

[0201] In some embodiments, provided is a compound of Formula IG:



IG

[0202] or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof, wherein each A, L¹, L², R², R³, R⁴, and R⁵ are independently as defined herein.


[0203] In some embodiments, R² and R³, together with the atoms to which they are attached, form a heterocyclyl optionally substituted with one to five Z².

[0204] In some embodiments, R² and R³, together with the atoms to which they are attached, form an unsubstituted heterocyclyl.

[0205] In some embodiments, R² is hydrogen.

[0206] In some embodiments, each R³ is independently hydrogen or C₁₋₃ alkyl.


[0207] In some embodiments, provided is a compound of Formula IH:



IH

[0208] or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof, wherein each A, L¹, L², R³, R⁴, and R⁵ are independently as defined herein.


[0209] In some embodiments, provided is a compound of Formula IJ:



IJ

[0210] or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof, wherein each A, L¹, L², R³, R⁴, and R⁵ are independently as defined herein.


[0211] In some embodiments, provided is a compound of Formula IK:



IK

[0212] or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof, wherein each A, L¹, L², R⁴, and R⁵ are independently as defined herein.

[0213] In some embodiments, provided is a compound of Formula IL:




IL

[0214] or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof, wherein each X¹, X², X³, X⁴, A, L¹, L², R⁴, and R⁵ are independently as defined herein.

[0215] In some embodiments, provided is a compound of Formula IM:

IM



[0216] or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof, wherein each A, L¹, L², R⁴, and R⁵ are independently as defined herein.

[0217] In some embodiments, A is C₁₋₆ alkylene, C₃₋₁₀ cycloalkylene, heterocyclylene, arylene, or heteroarylene; wherein the C₁₋₆ alkylene, C₃₋₁₀ cycloalkylene, heterocyclylene, arylene, or heteroarylene of A is independently optionally substituted with one to five Z⁴.

[0218] In some embodiments, A is C₁₋₆ alkylene, C₃₋₁₀ cycloalkylene, 3 to 10-membered heterocyclylene, C₆₋₁₀ arylene, or 5 to 10-membered heteroarylene; wherein each is independently optionally substituted with one to five Z⁴.

[0219] In some embodiments, A is C₃₋₁₀ cycloalkylene, 3 to 10-membered heterocyclylene, C₆₋₁₀ arylene, or 5 to 10-membered heteroarylene; wherein each is independently optionally substituted with one to five Z⁴.

[0220] In some embodiments, A is C₃₋₁₀ cycloalkylene or 3 to 10-membered heterocyclylene; wherein the cycloalkylene or heterocyclylene is optionally substituted with one to five Z⁴.

[0221] In some embodiments, A is arylene or heteroarylene; wherein the arylene or heteroarylene is optionally substituted with one to five Z⁴.

[0222] In some embodiments, A is arylene optionally substituted with one to five Z⁴.

[0223] In some embodiments, A is heteroarylene optionally substituted with one to five Z⁴.

[0224] In some embodiments, A is C₃₋₁₀ cycloalkylene optionally substituted with one to five Z⁴.

[0225] In some embodiments, A is 3 to 10-membered heterocyclylene optionally substituted with one to five Z⁴.

[0226] In some embodiments, A is unsubstituted C₃₋₁₀ cycloalkylene, unsubstituted 3 to 10-membered heterocyclylene, unsubstituted C₆₋₁₀ arylene, or unsubstituted 5 to 10-membered heteroarylene.

[0227] In some embodiments, A is unsubstituted arylene.



[0228] In some embodiments, A is unsubstituted heteroarylene.

[0229] In some embodiments, A is unsubstituted C₃₋₁₀ cycloalkylene.

[0230] In some embodiments, A is unsubstituted 3 to 10-membered heterocyclylene.


[0231] In some embodiments, A is methylene, ethylene, n-propylene,

-continued




wherein bond a is bonded to L².


[0232] In some embodiments, A is



-continued




-continued




wherein each is independently optionally substituted with one to five Z^A ; and wherein bond a is bonded to L^2 .




[0233] In some embodiments, A is




wherein each is independently optionally substituted with one to three substituents independently selected from halo, C_{1-6} alkyl and C_{1-6} haloalkyl; and wherein bond a is bonded to L^2 .

[0234] In some embodiments A is









-continued

and wherein bond a is bonded to L².


[0237] In some embodiments, A is


wherein bond a is bonded to L².

[0238] In some embodiments, A is


wherein bond a is bonded to L².[0239] In some embodiments, at least one of X¹, X², X³, and X⁴ is other than CH or CR^B.[0240] In some embodiments, at least one of X¹, X², X³, and X⁴ is O, S, N, NH, or NR^A.[0241] In some embodiments, X¹ is O, NH, or NR^A. In some embodiments, X¹ is O. In some embodiments, X¹ is NH or NR^A. In some embodiments, X¹ is NH. In some embodiments, X¹ is NR^A. In some embodiments, R^A is methyl. In some embodiments, X¹ is O, NH, or NCH₃.[0242] In some embodiments, X² is C(O). In some embodiments, the moiety[0243] In some embodiments, X³ is O, NH, or NR^A. In some embodiments, X³ is O. In some embodiments, X³ is NH or NR^A. In some embodiments, X³ is NH. In some embodiments, X³ is NR^A. In some embodiments, R^A is methyl.[0244] In some embodiments, X³ is C(O). In some embodiments, the moiety[0245] In some embodiments, X² is O, NH, or NR^A. In some embodiments, X² is O. In some embodiments, X² is NH or NR^A. In some embodiments, X² is NH. In some embodiments, X² is NR^A. In some embodiments, R^A is methyl.[0246] In some embodiments, X⁴ is N, CH, or CR^B. In some embodiments, X⁴ is N or CH. In some embodiments, X⁴ is N. In some embodiments, X⁴ is CH.

[0247] In some embodiments, the moiety






[0248] In some embodiments, the moiety



wherein each is optionally substituted with R^B.


[0249] In some embodiments, the moiety



wherein each is optionally substituted with R^B.

[0250] In some embodiments, each R^B is independently C₁₋₃ alkyl.

[0251] In some embodiments, the moiety



[0252] In some embodiments, L¹ is C₁₋₃ alkylene or C₁₋₃ heteroalkylene; wherein each is optionally substituted with one to five independently selected halo. In some embodiments, L¹ is C₁₋₃ alkylene or C₁₋₃ heteroalkylene. In some embodiments, L¹ is C₁₋₃ alkylene.

[0253] In some embodiments, R⁴ is C₁₋₆ alkyl optionally substituted with one to five Z⁴.

[0254] In some embodiments, R⁴ is aryl or heteroaryl; wherein the aryl or heteroaryl is optionally substituted with one to five Z⁴.

[0255] In some embodiments, R⁴ is C₃₋₁₀ cycloalkyl or aryl; wherein the C₃₋₁₀ cycloalkyl or heteroaryl is optionally substituted with one to five Z⁴.

[0256] In some embodiments, R⁴ is C₃₋₁₀ cycloalkyl or aryl; wherein the C₃₋₁₀ cycloalkyl or heteroaryl is optionally substituted with halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, or C₃₋₁₀ cycloalkyl.

[0257] In some embodiments, R⁴ is cyclohexyl or phenyl; wherein the cyclohexyl or phenyl is optionally substituted with one to five Z⁴.


[0258] In some embodiments, R⁴ is cyclohexyl or phenyl; wherein the cyclohexyl or phenyl is independently optionally substituted with halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, or C₃₋₁₀ cycloalkyl.

[0259] In some embodiments, R⁴ is C₃₋₁₀ cycloalkyl, heterocycl, aryl, or heteroaryl; wherein the C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, heterocycl, aryl, or heteroaryl of R⁴ is independently optionally substituted with one to five Z⁴.

[0260] In some embodiments, R⁴ is C₃₋₁₀ cycloalkyl, heterocycl, aryl, or heteroaryl; wherein the C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, heterocycl, aryl, or heteroaryl of R⁴ is independently optionally substituted with halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, or C₃₋₁₀ cycloalkyl.


[0261] In some embodiments, R⁴ is C₃₋₁₀ cycloalkyl, heterocycl, aryl, or heteroaryl; wherein the C₁₋₆ alkyl, C₃₋₁₀ cycloalkyl, heterocycl, aryl, or heteroaryl of R⁴ is independently optionally substituted with one to three substituents independently selected from halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, heteroaryl, and C₃₋₁₀ cycloalkyl.



[0262] In some embodiments, R⁴ is phenyl,



wherein each is independently optionally substituted with one to three Z⁴.


[0263] In some embodiments, R⁴ is phenyl,





wherein each is independently optionally substituted with one to three substituents independently selected from halo, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₁₋₆ alkoxy, pyrazolyl, and C₃₋₆ cycloalkyl.

[0264] In some embodiments, L¹-R⁴ is



[0265] In some embodiments, L² is a bond, —NR^{2a}—, —C(O)—, —C(O)NR^{2a}—, —NR^{2a}C(O)—, C₁₋₆ alkylene, C₂₋₆ alkenylene, C₂₋₆ alkynylene, C₁₋₆ heteroalkylene, 4-6 membered heterocyclene, or 5 membered heteroarylene; wherein the C₁₋₆ alkylene, C₂₋₆ alkenylene, C₂₋₆ alkynylene, C₁₋₆ heteroalkylene, 4-6 membered heterocyclene, or 5 membered heteroarylene is independently optionally substituted with one to five substituents independently selected from halo, oxo, hydroxy, cyano, C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkoxy, and C₁₋₃ haloalkoxy.

[0266] In some embodiments, L² is a bond, —C(O)—, —NR^{2a}—, —C(O)NR^{2a}—, —NR^{2a}C(O)—, C₁₋₆ alkylene, C₁₋₆ heteroalkylene, 4-6 membered heterocyclene, or 5 membered heteroarylene; wherein the C₁₋₆ alkylene, C₁₋₆ heteroalkylene, 4-6 membered heterocyclene, or 5 membered heteroarylene is independently optionally substituted with one to five substituents independently selected from halo, oxo, hydroxy, cyano, C₁₋₃ alkyl, C₁₋₃ haloalkyl, C₁₋₃ alkoxy, and C₁₋₃ haloalkoxy.

[0267] In some embodiments, L² is a bond, —NR^{2a}—, —C(O)—, —C(O)NR^{2a}—, C₁₋₆ alkylene, C₁₋₆ heteroal-

kylene, or 4-6 membered heterocyclylene; wherein the C₁₋₆ alkylene or C₁₋₆ heteroalkylene is optionally substituted with one to three substituents independently selected from methyl and oxo.

[0268] In some embodiments, L² is a bond, —NR^{2a}—, —C(O)—, —C(O)NR^{2a}—, C₁₋₆ alkylene, C₁₋₆ heteroalkylene, or 4-6 membered heterocyclylene; wherein the C₁₋₆ alkylene or C₁₋₆ heteroalkylene is optionally substituted with methyl.

[0269] In some embodiments, R^{2a} is hydrogen or methyl. In some embodiments, R^{2a} is hydrogen.

[0270] In some embodiments, L² is a bond, —NR^{2a}—, —C(O)—, —C(O)NR^{2a}—, C₁₋₆ alkylene, C₁₋₆ heteroalkylene, or 4-6 membered heterocyclylene; wherein R^{2a} is hydrogen or methyl; and wherein the C₁₋₆ alkylene or C₁₋₆ heteroalkylene is optionally substituted with methyl.

[0271] In some embodiments, L² is a bond, —NR^{2a}—, —C(O)—, —C(O)NR^{2a}—, C₁₋₆ alkylene, C₁₋₆ heteroalkylene, or 4-6 membered heterocyclylene; wherein R^{2a} is hydrogen or methyl; and wherein the C₁₋₆ alkylene or C₁₋₆ heteroalkylene is optionally substituted with one to three substituents independently selected from methyl and oxo.

[0272] In some embodiments, L² is a bond, —NH—, —NHCH₂—, —NH—CH(CH₃)—, —N(CH₃)—CH₂—, —OCH₂—, —CH₂—, —CH₂CH₂—, —C(O)—, —C(O)NH—CH₂—, —C(O)N(CH₃)—CH₂—.

[0273] In some embodiments, L² is a bond, —NH—, —NHCH₂—, —NH—CH(CH₃)—, —N(CH₃)—CH₂—, —OCH₂—, —CH₂—, —CH(CH₃)—, —CH₂CH₂—, —C(O)—, —C(O)NH—CH₂—, —C(O)N(CH₃)—CH₂—.

[0274] In some embodiments, R⁵ is hydrogen, halo, amino, cyano, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₁₀ cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein the C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₁₀ cycloalkyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with one to five Z⁵.

[0275] In some embodiments, R⁵ is C₃₋₁₀ cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein the cycloalkyl, heterocyclyl, aryl, or heteroaryl of R⁵ is independently optionally substituted with one to five Z⁵.

[0276] In some embodiments, R⁵ is C₃₋₁₀ cycloalkyl, heterocyclyl, or aryl; wherein the cycloalkyl, heterocyclyl, or aryl of R⁵ is independently optionally substituted with one to five Z⁵.

[0277] In some embodiments, R⁵ is C₁₋₆ alkyl optionally substituted with C₃₋₁₀ cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein the C₃₋₁₀ cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with one to five Z^{1a}.


[0278] In some embodiments, R⁵ is C₁₋₆ alkyl, aryl, or heteroaryl; wherein the aryl or heteroaryl is optionally substituted with one to five Z⁵.

[0279] In some embodiments, R⁵ is aryl or heteroaryl; wherein the aryl or heteroaryl is optionally substituted with one to five Z⁵.

[0280] In some embodiments, R⁵ is hydrogen, halo, amino, cyano, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₁₀ cycloalkyl, heterocyclyl, or aryl; wherein the C₁₋₆ alkyl, C₁₋₆ alkoxy, C₃₋₁₀ cycloalkyl, heterocyclyl, aryl, or heteroaryl is independently optionally substituted with one to five Z⁵.


[0281] In some embodiments, R⁵ is C₃₋₁₀ cycloalkyl, heterocyclyl, aryl, or heteroaryl; wherein the cycloalkyl, heterocyclyl, aryl, or heteroaryl of R⁵ is independently optionally substituted with one to five Z⁵, and wherein at least one Z⁵ group is fluorine.

[0282] In some embodiments, R⁵ is




wherein each is independently optionally substituted with one to five Z⁵.


[0283] In some embodiments, R⁵ is



-continued





-continued



or wherein each is independently optionally substituted with one to five substituents independently selected from halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₁₋₆ haloalkyl, cyano, and halo substituted phenyl.

[0284] In some embodiments, L²-R⁵ is



wherein the ring moiety of each is independently optionally substituted with one to five substituents independently selected from halo, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₁₋₆ haloalkyl, cyano, and halo substituted phenyl.

[0285] In some embodiments, R⁶ is C₁₋₃ alkyl or cyclopropyl. In some embodiments, R⁶ is C₁₋₃ alkyl.

[0286] In some embodiments, R⁷ is C₁₋₃ alkyl or cyclopropyl. In some embodiments, R⁷ is C₁₋₃ alkyl.

[0287] In some embodiments, provided is compound selected from Table 1, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof:

TABLE 1

Compound No.	Structure
101	
102	
103	

TABLE 1-continued

Compound No.	Structure
104	
107	
108	

TABLE 1-continued

Compound No.	Structure
109	
110	
111	

TABLE 1-continued

Compound No.	Structure
112	
113	
114	

TABLE 1-continued




Compound No.	Structure
115	
116	
117	

TABLE 1-continued




Compound No.	Structure
118	
119	
120	

TABLE 1-continued




Compound No.	Structure
121	
122	
123	

TABLE 1-continued




Compound No.	Structure
124	
125	
126	

TABLE 1-continued




Compound No.	Structure
127	
128	
129	

TABLE 1-continued

Compound No.	Structure
130	
133	
137	

TABLE 1-continued

Compound No.	Structure
138	
139	
140	

TABLE 1-continued

Compound No.	Structure
141	
146	
147	

TABLE 1-continued

Compound No.	Structure
148	
149	
150	

TABLE 1-continued




Compound No.	Structure
151	
152	
153	

TABLE 1-continued

Compound No.	Structure
154	
155	
156	

TABLE 1-continued




Compound No.	Structure
157	
158	
159	

TABLE 1-continued




Compound No.	Structure
160	
161	
162	

TABLE 1-continued




Compound No.	Structure
163	
164	
165	

TABLE 1-continued




Compound No.	Structure
166	
167	
168	

TABLE 1-continued

Compound No.	Structure
169	
170	
171	

TABLE 1-continued




Compound No.	Structure
172	
173	
174	

TABLE 1-continued

Compound No.	Structure
175	
176	
177	

TABLE 1-continued

Compound No.	Structure
178	
179	
180	

TABLE 1-continued




Compound No.	Structure
181	
182	
183	

TABLE 1-continued

Compound No.	Structure
184	
185	
186	

TABLE 1-continued

Compound No.	Structure
187	
188	
189	

TABLE 1-continued




Compound No.	Structure
190	
191	
192	

TABLE 1-continued

Compound No.	Structure
193	
194	
195	

TABLE 1-continued




Compound No.	Structure
196	
197	
198	

TABLE 1-continued




Compound No.	Structure
199	
200	
201	

TABLE 1-continued

Compound No.	Structure
202	
203	
204	

TABLE 1-continued

Compound No.	Structure
205	
206	
207	

TABLE 1-continued

Compound No.	Structure
208	
209	
210	

TABLE 1-continued

Compound No.	Structure
211	
212	
213	

TABLE 1-continued

Compound No.	Structure
214	
215	
216	

TABLE 1-continued

Compound No.	Structure
217	
218	
219	

TABLE 1-continued




Compound No.	Structure
220	
221	
222	

TABLE 1-continued




Compound No.	Structure
223	
224	
225	

TABLE 1-continued




Compound No.	Structure
226	
227	
228	

TABLE 1-continued

Compound No.	Structure
229	
230	
231	

TABLE 1-continued




Compound No.	Structure
232	
233	
234	

TABLE 1-continued

Compound No.	Structure
235	
236	
237	

TABLE 1-continued

Compound No.	Structure
238	
239	
240	

TABLE 1-continued

Compound No.	Structure
241	
242	
243	

TABLE 1-continued




Compound No.	Structure
244	
245	
246	

TABLE 1-continued




Compound No.	Structure
247	
248	
249	

TABLE 1-continued

Compound No.	Structure
250	
251	
252	

TABLE 1-continued

Compound No.	Structure
253	
254	
255	

TABLE 1-continued

Compound No.	Structure
256	
257	
258	

TABLE 1-continued

Compound No.	Structure
259	
260	
261	

TABLE 1-continued

Compound No.	Structure
262	
263	
264	

TABLE 1-continued

Compound No.	Structure
265	
266	
267	

TABLE 1-continued

Compound No.	Structure
268	
269	
270	

TABLE 1-continued




Compound No.	Structure
271	
272	
273	

TABLE 1-continued




Compound No.	Structure
274	
275	
276	

TABLE 1-continued




Compound No.	Structure
277	
278	
279	

TABLE 1-continued




Compound No.	Structure
280	
281	
282	

TABLE 1-continued




Compound No.	Structure
283	
284	
285	

TABLE 1-continued

Compound No.	Structure
286	
287	
288	

TABLE 1-continued

Compound No.	Structure
289	
290	
291	

TABLE 1-continued




Compound No.	Structure
292	
293	
294	

TABLE 1-continued

Compound No.	Structure
295	
296	
297	

TABLE 1-continued




Compound No.	Structure
298	
299	
300	

TABLE 1-continued



Compound No.	Structure
301	 The chemical structure of compound 301 is a complex molecule featuring a tricyclic core. It includes a 2-methoxy-3-fluorophenyl group attached to a cyclopentane ring, which is further substituted with a 2-(4-fluorophenyl)ethyl group. The core also contains a 2-methyl-4-pyridyl group, a 2-thienyl group, and a 2-oxo-3-oxazolidinyl group.
302	 The chemical structure of compound 302 is similar to compound 301 but with a different substituent on the cyclopentane ring. Instead of a 2-(4-fluorophenyl)ethyl group, it has a 2-methoxy-3-fluorophenyl group attached to the cyclopentane ring.

TABLE 1-continued

Compound No.	Structure
303	

[0288] The compounds of Formula I provided herein encompass stereochemical forms of the compounds, for example, optical isomers, such as enantiomers, diastereomers, as well as mixtures thereof, e.g., mixtures of enantiomers and/or diastereomers, including racemic mixtures, as well as equal or non-equal mixtures of individual enantiomers and/or diastereomers. All stereochemical forms are contemplated in this disclosure. Unless otherwise indicated, when a disclosed compound is named or depicted by a structure without specifying the stereochemistry and has one or more chiral centers, it is understood to represent all possible stereoisomers of the compound. Representative stereochemical forms are provided throughout the specification, including but not limited to those delineated in Table 2. In some embodiments, provided is compound selected from Table 2, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof:

TABLE 2	Structure

TABLE 2-continued

Structure




TABLE 2-continued






TABLE 2-continued






TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued




TABLE 2-continued








TABLE 2-continued






TABLE 2-continued






TABLE 2-continued






TABLE 2-continued






TABLE 2-continued






TABLE 2-continued






TABLE 2-continued




TABLE 2-continued




TABLE 2-continued

Structure






TABLE 2-continued

Structure






TABLE 2-continued




TABLE 2-continued








TABLE 2-continued






TABLE 2-continued






TABLE 2-continued




TABLE 2-continued




TABLE 2-continued






TABLE 2-continued






TABLE 2-continued

Structure






TABLE 2-continued

Structure






TABLE 2-continued






TABLE 2-continued





TABLE 2-continued

Structure




TABLE 2-continued

Structure






TABLE 2-continued




TABLE 2-continued




TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued




TABLE 2-continued








TABLE 2-continued




TABLE 2-continued








TABLE 2-continued




TABLE 2-continued








TABLE 2-continued






TABLE 2-continued






TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued




TABLE 2-continued








TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued

Structure






TABLE 2-continued

Structure





TABLE 2-continued




TABLE 2-continued




TABLE 2-continued




TABLE 2-continued








TABLE 2-continued




TABLE 2-continued








TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued




TABLE 2-continued








TABLE 2-continued






TABLE 2-continued






TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued




TABLE 2-continued








TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued






TABLE 2-continued






TABLE 2-continued

Structure






TABLE 2-continued

Structure






TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued




TABLE 2-continued




TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued




TABLE 2-continued




TABLE 2-continued

Structure






TABLE 2-continued

Structure






TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued






TABLE 2-continued






TABLE 2-continued




TABLE 2-continued








TABLE 2-continued




TABLE 2-continued




TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued




TABLE 2-continued








TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued




TABLE 2-continued








TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued




TABLE 2-continued








TABLE 2-continued




TABLE 2-continued








TABLE 2-continued




TABLE 2-continued






TABLE 2-continued




TABLE 2-continued






TABLE 2-continued



Structure




Structure



Structure



Structure



Structure




TABLE 2-continued

Structure






TABLE 2-continued

Structure





TABLE 2-continued

Structure




TABLE 2-continued

Structure






TABLE 2-continued




TABLE 2-continued




TABLE 2-continued




TABLE 2-continued








TABLE 2-continued




TABLE 2-continued








TABLE 2-continued






TABLE 2-continued






TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued




TABLE 2-continued




TABLE 2-continued




TABLE 2-continued




TABLE 2-continued

Structure






TABLE 2-continued

Structure






TABLE 2-continued

Structure




TABLE 2-continued

Structure




TABLE 2-continued

Structure






TABLE 2-continued

Structure






TABLE 2-continued




TABLE 2-continued








TABLE 2-continued




TABLE 2-continued








TABLE 2-continued

Structure




TABLE 2-continued

Structure






TABLE 2-continued

Structure




TABLE 2-continued

Structure






TABLE 2-continued






TABLE 2-continued






TABLE 2-continued




TABLE 2-continued




TABLE 2-continued




TABLE 2-continued








TABLE 2-continued




TABLE 2-continued








TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued

Structure






TABLE 2-continued

Structure






TABLE 2-continued




TABLE 2-continued








TABLE 2-continued

Structure






TABLE 2-continued

Structure






TABLE 2-continued




TABLE 2-continued




TABLE 2-continued

Structure






TABLE 2-continued

Structure






TABLE 2-continued




TABLE 2-continued




TABLE 2-continued

Structure




TABLE 2-continued

Structure








TABLE 2-continued

Structure






TABLE 2-continued

Structure






TABLE 2-continued

Structure






TABLE 2-continued

Structure






TABLE 2-continued






TABLE 2-continued






TABLE 2-continued




TABLE 2-continued








TABLE 2-continued




TABLE 2-continued




TABLE 2-continued




TABLE 2-continued








TABLE 2-continued






TABLE 2-continued






TABLE 2-continued

Structure






TABLE 2-continued

Structure






TABLE 2-continued






TABLE 2-continued






TABLE 2-continued




TABLE 2-continued




TABLE 2-continued




TABLE 2-continued








TABLE 2-continued




TABLE 2-continued








TABLE 2-continued




TABLE 2-continued







TABLE 2-continued




TABLE 2-continued






TABLE 2-continued

Structure







TABLE 2-continued

Structure



[0289] The compounds of Formula I and subformulas thereof include pharmaceutically acceptable salts thereof. In addition, the compounds of Formula I and subformulas thereof also include other salts of such compounds which are not necessarily pharmaceutically acceptable salts, and which may be useful as intermediates for preparing and/or purifying compounds of Formula I and subformulas thereof and/or for separating enantiomers of compounds of Formula I and subformulas thereof.

[0290] It will further be appreciated that the compounds of Formula I and subformulas or their salts may be isolated in the form of solvates, and accordingly that any such solvate is included within the scope of the present disclosure. For example, compounds of Formula I and subformulas thereof

and salts of each thereof can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.

Pharmaceutical Compositions and Administration

[0291] When employed as pharmaceuticals, compounds as described herein (e.g., one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof) can be administered in the form of a pharmaceutical compositions. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration can be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral or parenteral. Oral administration can include a dosage form formulated for once-daily or twice-daily (BID) administration. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or can be, for example, by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration can include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.

[0292] Also provided herein are pharmaceutical compositions which contain, as the active ingredient, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof, in combination with one or more pharmaceutically acceptable excipients (carriers). For example, a pharmaceutical composition prepared using one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof.

[0293] In one embodiment, provided is a pharmaceutical composition comprising a compound, or a stereoisomer or mixture of stereoisomers thereof, or pharmaceutically acceptable salt thereof, as disclosed herein, and a pharmaceutically acceptable excipient. In one embodiment, provided is a pharmaceutical composition comprising a compound, or a stereoisomer or mixture of stereoisomers thereof, or pharmaceutically acceptable salt thereof, as disclosed herein, and a pharmaceutically acceptable excipient, wherein a compound, or a stereoisomer or mixture of stereoisomers thereof, or pharmaceutically acceptable salt thereof, is present in the pharmaceutical composition in an amount greater than about 0.1%, greater than about 1%, greater than about 5%, greater than about 10%, greater than about 15%, greater than about 20%, greater than about 25%, greater than about 35%, or greater than about 40%, or greater than about 45%, or greater than about 50%, or greater than about 55%, or greater than about 60%, or greater than about 65%, or greater than about 70%, or greater than about 75%, or greater than about 80%, or greater than about 85%, or greater than about 90%, or greater than about 95% purity, or about 40%, or about 45%, or about 50%, or about 55%, or about 60%, or about 65%,

or about 70%, or about 75%, or about 80%, or about 85%, or about 90%, or about 95%, by weight.

[0294] In some embodiments, the composition is suitable for topical administration. In making the compositions provided herein, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, for example, a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders. In some embodiments, the composition is formulated for oral administration. In some embodiments, the composition is a solid oral formulation. In some embodiments, the composition is formulated as a tablet or capsule.

[0295] Further provided herein are pharmaceutical compositions containing one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof with a pharmaceutically acceptable excipient. Pharmaceutical compositions containing one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof as the active ingredient can be prepared by intimately mixing one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier can take a wide variety of forms depending upon the desired route of administration (e.g., oral, parenteral). In some embodiments, the composition is a solid oral composition.

[0296] Suitable pharmaceutically acceptable carriers are well known in the art. Descriptions of some of these pharmaceutically acceptable carriers can be found in The Handbook of Pharmaceutical Excipients, published by the American Pharmaceutical Association and the Pharmaceutical Society of Great Britain.

[0297] Methods of formulating pharmaceutical compositions have been described in numerous publications such as Pharmaceutical Dosage Forms: Tablets, Second Edition, Revised and Expanded, Volumes 1-3, edited by Lieberman et al; Pharmaceutical Dosage Forms: Parenteral Medications, Volumes 1-2, edited by Avis et al; and Pharmaceutical Dosage Forms: Disperse Systems, Volumes 1-2, edited by Lieberman et al; published by Marcel Dekker, Inc.

[0298] In some embodiments, the compound or pharmaceutical composition can be administered in combination with one or more conventional pharmaceutical excipients. Pharmaceutically acceptable excipients include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d- α -tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens, poloxamers or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, tris, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium-chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone,

cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, and wool fat. Cyclodextrins such as α -, β , and γ -cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl- β -cyclodextrins, or other solubilized derivatives can also be used to enhance delivery of compounds described herein. Dosage forms or compositions containing a chemical entity as described herein in the range of 0.005% to 100% with the balance made up from non-toxic excipient may be prepared. The contemplated compositions may contain 0.001%-100% of a chemical entity provided herein, in one embodiment 0.1-95%, in another embodiment 75-85%, in a further embodiment 20-80%. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington: The Science and Practice of Pharmacy, 22nd Edition (Pharmaceutical Press, London, U.K. 2012).

[0299] In some embodiments, the compounds and pharmaceutical compositions described herein or a pharmaceutical composition thereof can be administered to patient in need thereof by any accepted route of administration. Acceptable routes of administration include, but are not limited to, buccal, cutaneous, endocervical, endosinusial, endotracheal, enteral, epidural, interstitial, intra-abdominal, intra-arterial, intrabronchial, intrabursal, intracerebral, intracisternal, intracoronal, intradermal, intraductal, intraduodenal, intradural, intraepidermal, intraesophageal, intragastric, intralingual, intraileal, intralymphatic, intramedullary, intrameningeal, intramuscular, intraovarian, intraperitoneal, intraprostatic, intrapulmonary, intrasinal, intraspinal, intrasynovial, intratesticular, intrathecal, intratubular, intratumoral, intrauterine, intravascular, intravenous, nasal (e.g., intranasal), nasogastric, oral, parenteral, percutaneous, peridural, rectal, respiratory (inhalation), subcutaneous, sublingual, submucosal, topical, transdermal, transmucosal, tracheal, ureteral, urethral and vaginal. In some embodiments, a route of administration is parenteral (e.g., intratumoral).

[0300] In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof as described herein or pharmaceutical compositions thereof can be formulated for parenteral administration, e.g., formulated for injection via the intraarterial, intrasternal, intracranial, intravenous, intramuscular, subcutaneous, or intraperitoneal routes. For example, such compositions can be prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for use to prepare solutions or suspensions upon the addition of a liquid prior to injection can also be prepared; and the preparations can also be emulsified. The preparation of such formulations will be known to those of skill in the art in light of the present disclosure. In some embodiments, devices are used for parenteral administration. For example, such devices may include needle injectors, microneedle injectors, needle-free injectors, and infusion techniques.

[0301] In some embodiments, the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil, or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In some embodiments, the form must be sterile and must be fluid to the extent that it may be easily injected.

In some embodiments, the form should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.

[0302] In some embodiments, the carrier also can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. In some embodiments, the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion, and by the use of surfactants. In some embodiments, the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In some embodiments, isotonic agents, for example, sugars or sodium chloride are included. In some embodiments, prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

[0303] In some embodiments, sterile injectable solutions are prepared by incorporating one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. In some embodiments, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In some embodiments, sterile powders are used for the preparation of sterile injectable solutions. In some embodiments, the methods of preparation are vacuum-drying and freeze-drying techniques, which yield a powder of the active ingredient, plus any additional desired ingredient from a previously sterile-filtered solution thereof.

[0304] In some embodiments, pharmacologically acceptable excipients usable in a rectal composition as a gel, cream, enema, or rectal suppository, include, without limitation, any one or more of cocoa butter glycerides, synthetic polymers such as polyvinylpyrrolidone, PEG (like PEG ointments), glycerine, glycerinated gelatin, hydrogenated vegetable oils, poloxamers, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol, Vaseline, anhydrous lanolin, shark liver oil, sodium saccharinate, menthol, sweet almond oil, sorbitol, sodium benzoate, anoxid SBN, vanilla essential oil, aerosol, parabens in phenoxyethanol, sodium methyl p-oxybenzoate, sodium propyl p-oxybenzoate, diethylamine, carbomers, carbopol, methoxybenzoate, macrogol cetostearyl ether, cocoyl caprylocaprate, isopropyl alcohol, propylene glycol, liquid paraffin, xanthan gum, carboxy-metabisulfite, sodium edetate, sodium benzoate, potassium metabisulfite, grapefruit seed extract, methyl sulfonyl methane (MSM), lactic acid, glycine, vitamins, such as vitamin A and E and potassium acetate.

[0305] In some embodiments, suppositories can be prepared by mixing one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof, or pharmaceutical compositions as described herein with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax

which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum and release the active compound. In some embodiments, compositions for rectal administration are in the form of an enema.

[0306] In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof, as described herein or a pharmaceutical composition thereof is formulated for local delivery to the digestive or GI tract by way of oral administration (e.g., solid or liquid dosage forms).

[0307] In some embodiments, solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof, is mixed with one or more pharmaceutically acceptable excipients, such as sodium citrate or dicalcium phosphate and/or: a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. For example, in the case of capsules, tablets and pills, the dosage form may also comprise buffering agents. In some embodiments, solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

[0308] In some embodiments, the pharmaceutical compositions will take the form of a unit dosage form such as a pill or tablet and thus the composition may contain, along with one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof as provided herein, a diluent such as lactose, sucrose, dicalcium phosphate, or the like; a lubricant such as magnesium stearate or the like; and a binder such as starch, gum acacia, polyvinylpyrrolidine, gelatin, cellulose, cellulose derivatives or the like. In some embodiments, another solid dosage form, a powder, marume, solution or suspension (e.g., in propylene carbonate, vegetable oils, PEG's, poloxamer 124 or triglycerides) is encapsulated in a capsule (gelatin or cellulose base capsule). In some embodiments, unit dosage forms in which one or more compounds and pharmaceutical compositions as provided herein or additional active agents are physically separated are also contemplated; e.g., capsules with granules (or tablets in a capsule) of each drug; two-layer tablets; two-compartment gel caps, etc. In some embodiments, enteric coated or delayed release oral dosage forms are also contemplated.

[0309] In some embodiments, other physiologically acceptable compounds may include wetting agents, emulsifying agents, dispersing agents or preservatives that are particularly useful for preventing the growth or action of microorganisms. For example, various preservatives are well known and include, for example, phenol and ascorbic acid.

[0310] In some embodiments, the excipients are sterile and generally free of undesirable matter. For example, these compositions can be sterilized by conventional, well-known sterilization techniques. In some embodiments, for various oral dosage form excipients such as tablets and capsules, sterility is not required. For example, the United States Pharmacopeia/National Formulary (USP/NF) standard can be sufficient.

[0311] In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof as described herein or a pharmaceutical composition thereof is formulated for ocular administration. In some embodiments, ocular compositions can include, without limitation, one or more of any of the following: viscosagens (e.g., carboxymethylcellulose, glycerin, polyvinylpyrrolidinone, polyethylene glycol); stabilizers (e.g., Pluronic (triblock copolymers), cyclodextrins); preservatives (e.g., benzalkonium chloride, EDTA, SofZia (boric acid, propylene glycol, sorbitol, and zinc chloride; Alcon Laboratories, Inc.), Purite (stabilized oxychloro complex; Allergan, Inc.).

[0312] In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof as described herein or a pharmaceutical composition thereof is formulated for topical administration to the skin or mucosa (e.g., dermally or transdermally). In some embodiments, topical compositions can include ointments and creams. In some embodiments, ointments are semisolid preparations that are typically based on petrolatum or other petroleum derivatives. In some embodiments, creams containing the selected active agent are typically viscous liquid or semisolid emulsions, often either oil-in-water or water-in-oil. For example, cream bases are typically water-washable, and contain an oil phase, an emulsifier and an aqueous phase. For example, the oil phase, also sometimes called the "internal" phase, is generally comprised of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol; the aqueous phase usually, although not necessarily, exceeds the oil phase in volume, and generally contains a humectant. In some embodiments, the emulsifier in a cream formulation is generally a nonionic, anionic, cationic or amphoteric surfactant. In some embodiments, as with other carriers or vehicles, an ointment base should be inert, stable, nonirritating and non-sensitizing.

[0313] In any of the foregoing embodiments, pharmaceutical compositions as described herein can include one or more one or more of the following: lipids, interbilayer crosslinked multilamellar vesicles, biodegradable poly(D,L-lactic-co-glycolic acid) (PLGA)-based or poly anhydride-based nanoparticles or microparticles, and nanoporous particle-supported lipid bilayers.

[0314] The amount of the compound in a pharmaceutical composition or formulation can vary within the full range employed by those skilled in the art. Typically, the formulation will contain, on a weight percent (wt %) basis, from about 0.01-99.99 wt % of a compound of this disclosure based on the total formulation, with the balance being one or more suitable pharmaceutical excipients. In one embodiment, the compound is present at a level of about 1-80 wt %. Representative pharmaceutical formulations are described below.

Formulation Example 1—Tablet Formulation

[0315] The following ingredients are mixed intimately and pressed into single scored tablets.

Ingredient	Quantity per tablet, mg
compound of this disclosure	400
cornstarch	50
croscarmellose sodium	25
lactose	120
magnesium stearate	5

Formulation Example 2—Capsule Formulation

[0316] The following ingredients are mixed intimately and loaded into a hard-shell gelatin capsule

Ingredient	Quantity per capsule, mg
compound of this disclosure	200
lactose, spray-dried	148
magnesium stearate	2

Formulation Example 3—Suspension Formulation

[0317] The following ingredients are mixed to form a suspension for oral administration.

Ingredient	Amount
compound of this disclosure	1.0 g
fumaric acid	0.5 g
sodium chloride	2.0 g
methyl paraben	0.15 g
propyl paraben	0.05 g
granulated sugar	25.0 g
sorbitol (70% solution)	13.00 g
Veegum K (Vanderbilt Co.)	1.0 g
flavoring	0.035 mL
coloring	0.5 mg
distilled water	q.s. to 100 mL

Formulation Example 4—Injectable Formulation

[0318] The following ingredients are mixed to form an injectable formulation.

Ingredient	Amount
compound of this disclosure	0.2 mg-20 mg
sodium acetate buffer solution, 0.4M	2.0 mL
HCl (1N) or NaOH (1N)	q.s. to suitable pH
water (distilled, sterile)	q.s. to 20 mL

Formulation Example 5—Suppository Formulation

[0319] A suppository of total weight 2.5 g is prepared by mixing the compound of this disclosure with Witepsol® H-15 (triglycerides of saturated vegetable fatty acid; Riches-Nelson, Inc., New York), and has the following composition:

Ingredient	Amount
compound of this disclosure	500 mg
Witepsol ® H-15	balance

[0320] In some embodiments, the dosage for one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof, is determined based on a multiple factors including, but not limited to, type, age, weight, sex, medical condition of the patient, severity of the medical condition of the patient, route of administration, and activity of the compound or pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof. In some embodiments, proper dosage for a particular situation can be determined by one skilled in the medical arts. In some embodiments, the total daily dosage may be divided and administered in portions throughout the day or by means providing continuous delivery.

[0321] In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof, is administered at a dose from about 0.01 to about 1000 mg. For example, from about 0.1 to about 30 mg, about 10 to about 80 mg, about 0.5 to about 15 mg, about 50 mg to about 200 mg, about 100 mg to about 300 mg, about 200 to about 400 mg, about 300 mg to about 500 mg, about 400 mg to about 600 mg, about 500 mg to about 800 mg, about 600 mg to about 900 mg, or about 700 mg to about 1000 mg. In some embodiments, the dose is a therapeutically effective amount.

[0322] In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof as described herein is administered at a dosage of from about 0.0002 mg/Kg to about 100 mg/Kg (e.g., from about 0.0002 mg/Kg to about 50 mg/Kg; from about 0.0002 mg/Kg to about 25 mg/Kg; from about 0.0002 mg/Kg to about 10 mg/Kg; from about 0.0002 mg/Kg to about 5 mg/Kg; from about 0.0002 mg/Kg to about 1 mg/Kg; from about 0.0002 mg/Kg to about 0.5 mg/Kg; from about 0.0002 mg/Kg to about 0.1 mg/Kg; from about 0.001 mg/Kg to about 50 mg/Kg; from about 0.001 mg/Kg to about 25 mg/Kg; from about 0.001 mg/Kg to about 10 mg/Kg; from about 0.001 mg/Kg to about 5 mg/Kg; from about 0.001 mg/Kg to about 1 mg/Kg; from about 0.001 mg/Kg to about 0.5 mg/Kg; from about 0.001 mg/Kg to about 0.1 mg/Kg; from about 0.01 mg/Kg to about 50 mg/Kg; from about 0.01 mg/Kg to about 25 mg/Kg; from about 0.01 mg/Kg to about 10 mg/Kg; from about 0.01 mg/Kg to about 5 mg/Kg; from about 0.01 mg/Kg to about 1 mg/Kg; from about 0.01 mg/Kg to about 0.5 mg/Kg). In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof as described herein is administered as a dosage of about 100 mg/Kg.

[0323] In some embodiments, the foregoing dosages of one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof, can be administered on a daily basis (e.g., as a single dose or as two or more divided doses) or non-daily basis (e.g., every other day, every two days, every three days, once weekly, twice weeks, once every two weeks, once a month).

[0324] In some embodiments, the period of administration of one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof as described herein is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days,

14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more. In some embodiments, a period of during which administration is stopped is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more. In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof is administered to a patient for a period of time followed by a separate period of time where administration of one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof is stopped. In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof is administered for a first period and a second period following the first period, with administration stopped during the second period, followed by a third period where administration of one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof is started and then a fourth period following the third period where administration is stopped. For example, the period of administration of one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof followed by a period where administration is stopped is repeated for a determined or undetermined period of time. In some embodiments, a period of administration is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more. In some embodiments, a period of during which administration is stopped is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more.

[0325] In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof, is orally administered to the patient one or more times per day (e.g., one time per day, two times per day, three times per day, four times per day per day or a single daily dose).

[0326] In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof, is administered by parenteral administration to the patient one or more times per day (e.g., 1 to 4 times, one time per day, two times per day, three times per day, four times per day or a single daily dose).

[0327] In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof, is administered by parenteral administration to the patient weekly.

Methods of Treatment

[0328] In some embodiments, this disclosure provides methods for treating a subject (e.g., a human) having a disease, disorder, or condition in which inhibition of one or

more calcitonin receptor and/or amylin receptor is beneficial for the treatment of the underlying pathology and/or symptoms and/or progression of the disease, disorder, or condition. In some embodiments, the methods provided herein can include treating one or more conditions associated, co-morbid or sequela with any one or more of the conditions provided herein.

[0329] Provided herein is a method for treating a calcitonin receptor and/or an amylin receptor associated disease or disorder, the method comprising administering to a subject in need thereof an effective amount of a compound disclosed herein (e.g., a compound of Formula I, or any subformula thereof or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition as disclosed herein. Also provided herein are methods for treating or preventing a calcitonin receptor and/or an amylin receptor associated disease or disorder in a subject in need thereof, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula I or any subformula thereof, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition thereof.

[0330] In some embodiments, the calcitonin receptor and/or amylin receptor associated disease or disorder is a bone disorder, a metabolic disorder, pain, a neurodegenerative disease or disorder, a cardiovascular disease, or other disease or disorder as described herein.

[0331] In some embodiments, the disease or disorder includes, but is not limited to type 1 diabetes mellitus, type 2 diabetes mellitus, early onset type 2 diabetes mellitus, idiopathic type 1 diabetes mellitus (Type 1b), youth-onset atypical diabetes (YOAD), maturity onset diabetes of the young (MODY), latent autoimmune diabetes in adults (LADA), obesity, weight gain from use of other agents, gout, excessive sugar craving, hypertriglyceridemia, dyslipidemia, malnutrition-related diabetes, gestational diabetes, kidney disease, adipocyte dysfunction, sleep apnea, visceral adipose deposition, eating disorders, cardiovascular disease, congestive heart failure, myocardial infarction, left ventricular hypertrophy, peripheral arterial disease, stroke, hemorrhagic stroke, ischemic stroke, transient ischemic attacks, atherosclerotic cardiovascular disease, traumatic brain injury, peripheral vascular disease, endothelial dysfunction, impaired vascular compliance, vascular restenosis, thrombosis, hypertension, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, hyperglycemia, post-prandial lipemia, metabolic acidosis, ketosis, hyperinsulinemia, impaired glucose metabolism, insulin resistance, hepatic insulin resistance, alcohol use disorder, chronic renal failure, metabolic syndrome, syndrome X, smoking cessation, premenstrual syndrome, angina pectoris, diabetic nephropathy, impaired glucose tolerance, diabetic neuropathy, diabetic retinopathy, macular degeneration, cataract, glomerulosclerosis, arthritis, osteoporosis, treatment of addiction, cocaine dependence, bipolar disorder/major depressive disorder, skin and connective tissue disorders, foot ulcerations, psoriasis, primary polydipsia, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), ulcerative colitis, inflammatory bowel disease, colitis, irritable bowel syndrome, Crohn's disease, short bowel syndrome, Parkinson's, Alzheimer's disease, impaired cognition, schizophrenia, and Polycystic Ovary Syndrome (PCOS).

[0332] In some embodiments, the disease or disorder includes, but is not limited to type 2 diabetes mellitus, early onset type 2 diabetes mellitus, obesity, weight gain from use of other agents, gout, excessive sugar craving, hypertriglyceridemia, dyslipidemia, gestational diabetes, kidney disease, adipocyte dysfunction, sleep apnea, visceral adipose deposition, eating disorders, cardiovascular disease, congestive heart failure, myocardial infarction, left ventricular hypertrophy, peripheral arterial disease, stroke, hemorrhagic stroke, ischemic stroke, transient ischemic attacks, atherosclerotic cardiovascular disease, hyperglycemia, post-prandial lipemia, metabolic acidosis, ketosis, hyperinsulinemia, impaired glucose metabolism, insulin resistance, hepatic insulin resistance, alcohol use disorder, chronic renal failure, metabolic syndrome, syndrome X, smoking cessation, pre-menstrual syndrome, angina pectoris, diabetic nephropathy, impaired glucose tolerance, diabetic neuropathy, diabetic retinopathy, bipolar disorder/major depressive disorder, skin and connective tissue disorders, foot ulcerations, psoriasis, primary polydipsia, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), short bowel syndrome, Parkinson's disease, Polycystic Ovary Syndrome (PCOS), or any combination thereof.

[0333] In some embodiments, the disease or disorder includes, but is not limited to type 2 diabetes mellitus, early onset type 2 diabetes mellitus, obesity, weight gain from use of other agents, gout, excessive sugar craving, hypertriglyceridemia, dyslipidemia, gestational diabetes, adipocyte dysfunction, visceral adipose deposition, myocardial infarction, peripheral arterial disease, stroke, transient ischemic attacks, hyperglycemia, post-prandial lipemia, metabolic acidosis, ketosis, hyperinsulinemia, impaired glucose metabolism, insulin resistance, hepatic insulin resistance, chronic renal failure, syndrome X, angina pectoris, diabetic nephropathy, impaired glucose tolerance, diabetic neuropathy, diabetic retinopathy, skin and connective tissue disorders, foot ulcerations, or any combination thereof.

[0334] In some embodiments, the compounds and pharmaceutical compositions and methods for treating a patient described herein induce one or more of blood glucose reduction (e.g., reduce blood glucose levels), reduce blood hemoglobin A1c (HbA1c) levels, promote insulin synthesis, stimulate insulin secretion, increase the mass of β -cells, modulate gastric acid secretion, modulate gastric emptying, decrease the body mass index (BMI), and/or decrease glucagon production (e.g., level). In certain embodiments, the compounds and pharmaceutical compositions and methods for treating a patient described herein stabilize serum glucose and serum insulin levels (e.g., serum glucose and serum insulin concentrations). Also provided herein are methods for modulating glucose or insulin levels in a patient in need of such modulating, the method comprising administering to the patient an effective amount of one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof, or a pharmaceutical composition as disclosed herein.

[0335] In some embodiments, provided herein is a method for reducing the risk (e.g., by about at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, or at least 80%) of major adverse cardiovascular events (MACE) in a patient in need thereof, the method comprising administering to the patient an effective amount of one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof, or a pharmaceutical com-

position as disclosed herein. In certain of these embodiments, the patient is an adult that has been diagnosed with type 2 diabetes (T2D). In certain embodiments, the patient is an adult that has been diagnosed with a heart disease. In certain embodiments, the patient is an adult that has been diagnosed with type 2 diabetes (T2D) and a heart disease. In certain embodiments, the patient is an adult that has type 2 diabetes (T2D). In certain embodiments, the patient is an adult that has a heart disease. In certain embodiments, the patient has type 2 diabetes (T2D) and a heart disease.

[0336] In some embodiments, the calcitonin receptor and/or amylin receptor associated disease or disorder is a bone disorder, including, but not limited to, osteoporosis, Paget's disease, hypercalcemia, Sudeck's atrophy, polystatic fibrous dysplasia, intersemicostoclavicular ossification, osteogenesis imperfecta, osteopenia, periodontal disease or defect, osteolytic bone disease, metastatic bone disorder, or bone loss resulting from a malignancy, autoimmune arthritides, a breakage or fracture, or immobility or disuse.

[0337] In some embodiments, the calcitonin receptor and/or amylin receptor associated disease or disorder is pain, including, but not limited to, osteopathic pain, phantom limb pain, general pain, hyperalgesia, or pain associated with diabetic neuropathy.

[0338] In some embodiments, the calcitonin receptor and/or amylin receptor associated disease or disorder is a neurodegenerative disease or disorder, including, but not limited to, Alzheimer's disease.

[0339] In some embodiments, the calcitonin receptor and/or amylin receptor associated disease or disorder is a metabolic disorder, including, but not limited to, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), insulin dependent diabetes, non-insulin dependent diabetes, impaired glucose tolerance, obesity, syndrome X, or other diabetic complication.

[0340] In some embodiments, the calcitonin receptor and/or amylin receptor associated disease or disorder is include primary or secondary hyperthyroidism, endocrine disorder, conditions associated with inhibiting gastric secretion, gastrointestinal disorders, renal osteodystrophy, or male infertility.

[0341] In some embodiments, a compound disclosed herein (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition as provided herein is useful to alleviate insulin suppression in pancreatic tissue.

[0342] In some embodiments, a compound disclosed herein (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition as provided herein is useful to treat alleviate insulin resistance.

[0343] In some embodiments, a compound disclosed herein (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition as provided herein is useful to treat impaired glucose tolerance.

[0344] In some embodiments, a compound disclosed herein (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition as provided herein is useful to treat obesity and symptoms thereof.

[0345] In some embodiments, provided is a method for reducing body fat or body fat gain, comprising administer-

ing to a subject in need thereof a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition as provided herein.

[0346] In some embodiments, provided is a method of altering a body composition of a subject in need of treatment, wherein body fat is reduced and lean body mass is maintained or increased, comprising administering to the subject a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition as provided herein.

[0347] In some embodiments, provided is a method for reducing body weight in a subject in need of, comprising administering to the subject a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition as provided herein.

[0348] In some embodiments, provided is a method for reducing caloric intake in a subject in need of reduction thereof, comprising administering to the subject a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition as provided herein.

[0349] In some embodiments, provided is a method for reducing body fat or body fat gain in a subject in need of treatment while maintaining or increasing lean body mass, comprising administering to the subject a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition as provided herein.

[0350] In some embodiments, a compound disclosed herein (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition as provided herein is useful to treat hypertension.

[0351] In some embodiments, a compound disclosed herein (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition as provided herein is useful to treat essential hypertension.

[0352] In some embodiments, a compound disclosed herein (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition as provided herein is useful to treat a subject suffering from hypertension and hyperamylinemia.

[0353] In some embodiments, provided is a method for treating hyperinsulinemia, comprising administering to a subject in need thereof a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition as provided herein.

[0354] In some embodiments, provided is a method for treating a hypertensive, insulin-resistant subject suffering from coronary artery disease and having hyperamylinemia

or hyperinsulinemia, comprising administering to a subject in need thereof a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition as provided herein.

[0355] In some embodiments, provided is a method for decreasing basal and submaximally stimulated rates of glycogen synthesis in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition as provided herein.

[0356] In some embodiments, provided is a method for decreasing the rate of incorporation of glucose into glycogen in muscle tissue of a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition as provided herein.

[0357] In some embodiments, provided is a method for treating obesity and hypertension, and the lipid disorders and atherosclerosis associated therewith, in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition as provided herein.

[0358] In some embodiments, a compound disclosed herein (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition as provided herein is useful to modulate renin activity in a subject in need thereof.

[0359] In some embodiments, provided is a method for treating or preventing the development of cardiac failure, in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound disclosed herein (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition as provided herein.

[0360] In some embodiments, a compound disclosed herein (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition as provided herein is useful to beneficially regulate gastrointestinal motility in a subject in need thereof. In some embodiments, the beneficial regulation of gastrointestinal motility comprises delaying gastric emptying.

[0361] In some embodiments, a compound disclosed herein (e.g., a compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or solvate thereof), or a pharmaceutical composition as provided herein is useful to treat postprandial hyperglycemia in a subject in need thereof.

Obesity

[0362] In some embodiments, the condition, disease or disorder is obesity and conditions, diseases or disorders that are associated with or related to obesity. Non-limiting

examples of obesity and obesity related conditions include symptomatic obesity, simple obesity, childhood obesity, morbid obesity, and abdominal obesity (central obesity characterized by abdominal adiposity). Non-limiting examples of symptomatic obesity include endocrine obesity (e.g., Cushing syndrome, hypothyroidism, insulinoma, obese type II diabetes, pseudohypoparathyroidism, hypogonadism), hypothalamic obesity, hereditary obesity (e.g., Prader-Willi syndrome, Laurence-Moon-Biedl syndrome), and drug-induced obesity (e.g., steroid, phenothiazine, insulin, sulfonylurea agent, or β -blocker-induced obesity).

[0363] In some embodiments, the condition, disease or disorder is associated with obesity. Examples of such conditions, diseases or disorders include, without limitation, glucose tolerance disorders, diabetes (e.g., type 2 diabetes, obese diabetes), lipid metabolism abnormality, hyperlipidemia, hypertension, cardiac failure, hyperuricemia, gout, fatty liver (including non-alcoholic steatohepatitis (NASH)), coronary heart disease (e.g., myocardial infarction, angina pectoris), cerebral infarction (e.g., brain thrombosis, transient cerebral ischemic attack), bone or articular disease (e.g., knee osteoarthritis, hip osteoarthritis, spondylitis deformans, lumbago), sleep apnea syndrome, obesity hypoventilation syndrome (Pickwickian syndrome), menstrual disorder (e.g., abnormal menstrual cycle, abnormality of menstrual flow and cycle, amenorrhea, abnormal catamenial symptom), visceral obesity syndrome, and metabolic syndrome. In some embodiments, the chemical compound and pharmaceutical compositions described herein can be used to treat patients exhibiting symptoms of both obesity and insulin deficiency.

Diabetes

[0364] In some embodiments, the condition, disease or disorder is diabetes. Non-limiting examples of diabetes include type 1 diabetes mellitus, type 2 diabetes mellitus (e.g., diet-treated type 2-diabetes, sulfonylurea-treated type 2-diabetes, a far-advanced stage type 2-diabetes, long-term insulin-treated type 2-diabetes), diabetes mellitus (e.g., non-insulin-dependent diabetes mellitus, insulin-dependent diabetes mellitus), gestational diabetes, obese diabetes, autoimmune diabetes, and borderline type diabetes. In some embodiments, the condition, disease or disorder is type 2 diabetes mellitus (e.g., diet-treated type 2-diabetes, sulfonylurea-treated type 2-diabetes, a far-advanced stage type 2-diabetes, long-term insulin-treated type 2-diabetes).

[0365] Provided herein is a method of treating a diabetes mellitus in a patient, the method comprising (a) determining that the patient has type 2 diabetes mellitus, and (b) administering to the patient a therapeutically effective amount of one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof, or a pharmaceutical composition as disclosed herein.

[0366] Provided herein is a method for treating type 2 diabetes mellitus in a patient, the method comprising administering to a patient identified or diagnosed as having type 2 diabetes mellitus a therapeutically effective amount of one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof, or a pharmaceutical composition as disclosed herein.

[0367] Also provided herein is a method of treating type 2 diabetes mellitus in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of one or more compounds as disclosed

herein, or a stereoisomer or mixture of stereoisomers thereof, or a pharmaceutical composition as disclosed herein.

[0368] In some embodiments, the compounds and pharmaceutical compositions and methods for treating a patient with a condition, disease, or disorder (e.g., type 2 diabetes mellitus) described herein reduce fasting plasma glucose levels. In some embodiments, the compounds and pharmaceutical compositions and methods for treating a patient with a condition, disease, or disorder (e.g., type 2 diabetes mellitus) described herein reduce non-fasting plasma glucose levels. In some embodiments, the compounds and pharmaceutical compositions and methods for treating a patient with a condition, disease, or disorder (e.g., type 2 diabetes mellitus) described herein reduce HbA1c levels. In some embodiments, the compounds and pharmaceutical compositions and methods for treating a patient with a condition, disease, or disorder (e.g., type 2 diabetes mellitus) described herein reduce glucagon levels. In some embodiments, the compounds and pharmaceutical compositions and methods for treating a patient with a condition, disease, or disorder (e.g., type 2 diabetes mellitus) described herein increase insulin levels. In some embodiments, the compounds and pharmaceutical compositions and methods for treating a patient with a condition, disease, or disorder (e.g., type 2 diabetes mellitus) described herein reduce BMI.

[0369] In some embodiments, a reduction in fasting plasma glucose levels of about 5% to about 95% indicates treatment of type 2 diabetes mellitus. In some embodiments, a reduction in fasting plasma glucose levels of about 15% to about 80% indicates treatment of type 2 diabetes mellitus. In some embodiments, a reduction in fasting plasma glucose levels of about 25% to about 60% indicates treatment of type 2 diabetes mellitus. In some embodiments, a reduction in fasting plasma glucose levels to about or below 126 mg/dL, about or below 110 mg/dL, or about or below 90 mg/dL indicates treatment of the type 2 diabetes mellitus.

[0370] In some embodiments, a reduction in non-fasting plasma glucose levels of about 5% to about 95% indicates treatment of type 2 diabetes mellitus. In some embodiments, a reduction in non-fasting plasma glucose levels of about 15% to about 80% indicates treatment of type 2 diabetes mellitus. In some embodiments, a reduction in non-fasting plasma glucose levels of about 25% to about 60% indicates treatment of type 2 diabetes mellitus. In some embodiments, a reduction in non-fasting plasma glucose levels to about or below 200 mg/dL, about or below 150 mg/dL, or about or below 130 mg/dL indicates treatment of type 2 diabetes mellitus.

[0371] In some embodiments, a reduction in HbA1c levels of about 5% to about 95% indicates treatment of type 2 diabetes mellitus. In some embodiments, a reduction in HbA1c levels of about 15% to about 80% indicates treatment of type 2 diabetes mellitus. In some embodiments, a reduction in HbA1c levels of about 25% to about 60% indicates treatment of type 2 diabetes mellitus. In some embodiments, reduction in HbA1c levels to about or below 6.5%, about or below 6.0%, or about or below 5.0% indicates treatment of type 2 diabetes mellitus.

[0372] In some embodiments, a reduction in glucagon levels of about 5% to about 95% indicates treatment of type 2 diabetes mellitus. In some embodiments, a reduction in glucagon levels of about 15% to about 80% indicates treatment of type 2 diabetes mellitus. In some embodiments,

a reduction in glucagon levels of about 25% to about 60% indicates treatment of type 2 diabetes mellitus. In some embodiments, an increase in insulin levels of about 5% to about 95% indicates treatment of type 2 diabetes mellitus. In some embodiments, an increase in insulin levels of about 15% to about 80% indicates treatment of type 2 diabetes mellitus. In some embodiments, an increase in insulin levels of about 25% to about 60% indicates treatment of type 2 diabetes mellitus.

[0373] In some embodiments, a reduction in BMI of about 5% to about 95% indicates treatment of type 2 diabetes mellitus. In some embodiments, a reduction in BMI of about 15% to about 80% indicates treatment of the type 2 diabetes mellitus. In some embodiments, a reduction in BMI of about 25% to about 60% indicates treatment of type 2 diabetes mellitus. In some embodiments, a reduction in BMI of about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, or about 95% indicates treatment of type 2 diabetes mellitus. In some embodiments, a reduction in BMI to about or below 40, about or below 30, or about or below 20 indicates treatment of type 2 diabetes mellitus.

[0374] In some embodiments, the condition, disease or disorder is associated with diabetes (e.g., a complication of diabetes). Non-limiting examples of disorders associated with diabetes include obesity, obesity-related disorders, metabolic syndrome, neuropathy, nephropathy (e.g., diabetic nephropathy), retinopathy, diabetic cardiomyopathy, cataract, macroangiopathy, osteopenia, hyperosmolar diabetic coma, infectious disease (e.g., respiratory infection, urinary tract infection, gastrointestinal infection, dermal soft tissue infections, inferior limb infection), diabetic gangrene, xerostomia, hypacusis, cerebrovascular disorder, diabetic cachexia, delayed wound healing, diabetic dyslipidemia peripheral blood circulation disorder, cardiovascular risk factors. (e.g., coronary artery disease, peripheral artery disease, cerebrovascular disease, hypertension, and risk factors related to unmanaged cholesterol and/or lipid levels, and/or inflammation), NASH, bone fracture, and cognitive dysfunction

[0375] Other non-limiting examples of disorders related to diabetes include pre-diabetes, hyperlipidemia (e.g., hypertriglyceridemia, hypercholesterolemia, high LDL-cholesterolemia, low HDL-cholesterolemia, postprandial hyperlipemia), metabolic syndrome (e.g., metabolic disorder where activation of GLP-1R is beneficial, metabolic syndrome X), hypertension, impaired glucose tolerance (IGT), insulin resistance, and sarcopenia.

[0376] In some embodiments, the condition, disease or disorder is diabetes and obesity (diabesity). In some embodiments, the compounds described herein are also useful in improving the therapeutic effectiveness of metformin.

Disorders of Metabolically Important Tissues

[0377] In some embodiments, the condition, disease or disorder is a disorder of a metabolically important tissue. Non-limiting examples of metabolically important tissues include liver, fat, pancreas, kidney, and gut.

[0378] In some embodiments, the condition, disease or disorder is a fatty liver disease. Fatty liver diseases include, but are not limited to, non-alcoholic fatty acid liver disease (NAFLD), steatohepatitis, non-alcoholic steatohepatitis (NASH), fatty liver disease resulting from hepatitis, fatty

liver disease resulting from obesity, fatty liver disease resulting from diabetes, fatty liver disease resulting from insulin resistance, fatty liver disease resulting from hypertriglyceridemia, Abetalipoproteinemia, glycogen storage diseases, Weber-Christian disease, Wolman's disease, acute fatty liver of pregnancy, and lipodystrophy.

[0379] Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of disease occurring in the absence of alcohol abuse and is typically characterized by the presence of steatosis (fat in the liver). NAFLD is believed to be linked to a variety of conditions, e.g., metabolic syndrome (including obesity, diabetes and hypertriglyceridemia) and insulin resistance. It can cause liver disease in adults and children and may ultimately lead to cirrhosis (Skelly et al., J Hepatol 2001; 35: 195-9; Chitturi et al., Hepatology 2002; 35(2): 373-9). The severity of NAFLD ranges from the relatively benign isolated predominantly macrovesicular steatosis (i.e., nonalcoholic fatty liver or NAFL) to non-alcoholic steatohepatitis (NASH) (Angulo et al., J Gastroenterol Hepatol 2002; 17 Suppl:S186-90). In some embodiments, the patient is a pediatric patient. The term "pediatric patient" as used herein refers to a patient under the age of 21 years at the time of diagnosis or treatment. The term "pediatric" can be further be divided into various subpopulations including: neonates (from birth through the first month of life); infants (1 month up to two years of age); children (two years of age up to 12 years of age); and adolescents (12 years of age through 21 years of age (up to, but not including, the twenty-second birthday)). Berhman R E, Kliegman R, Arvin A M, Nelson W E. Nelson Textbook of Pediatrics, 15th Ed. Philadelphia: W.B. Saunders Company, 1996; Rudolph A M, et al. Rudolph's Pediatrics, 21st Ed. New York: McGraw-Hill, 2002; and Avery M D, First L R. Pediatric Medicine, 2nd Ed. Baltimore: Williams & Wilkins; 1994. In some embodiments, a pediatric patient is from birth through the first 28 days of life, from 29 days of age to less than two years of age, from two years of age to less than 12 years of age, or 12 years of age through 21 years of age (up to, but not including, the twenty-second birthday). In some embodiments, a pediatric patient is from birth through the first 28 days of life, from 29 days of age to less than 1 year of age, from one month of age to less than four months of age, from three months of age to less than seven months of age, from six months of age to less than 1 year of age, from 1 year of age to less than 2 years of age, from 2 years of age to less than 3 years of age, from 2 years of age to less than seven years of age, from 3 years of age to less than 5 years of age, from 5 years of age to less than 10 years of age, from 6 years of age to less than 13 years of age, from 10 years of age to less than 15 years of age, or from 15 years of age to less than 22 years of age. In some embodiments, the patient is an adult patient.

[0380] Other non-limiting examples of disorders in metabolically important tissues include joint disorders (e.g., osteoarthritis, secondary osteoarthritis), steatosis (e.g. in the liver); gall stones; gallbladder disorders; gastroesophageal reflux; sleep apnea; hepatitis; fatty liver; bone disorder characterized by altered bone metabolism, such as osteoporosis, including post-menopausal osteoporosis, poor bone strength, osteopenia, Paget's disease, osteolytic metastasis in cancer patients, osteodystrophy in liver disease and the altered bone metabolism caused by renal failure or hemodialysis, bone fracture, bone surgery, aging, pregnancy, protection against bone fractures, and malnutrition polycys-

tic ovary syndrome; renal disease (e.g., chronic renal failure, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, end-stage renal disease); muscular dystrophy, angina pectoris, acute or chronic diarrhea, testicular dysfunction, respiratory dysfunction, frailty, sexual dysfunction (e.g., erectile dysfunction), and geriatric syndrome. In some embodiments, the compounds and pharmaceutical compositions described herein can be used for treating surgical trauma by improving recovery after surgery and/or by preventing the catabolic reaction caused by surgical trauma.

Cardiovascular and Vascular Diseases

[0381] In some embodiments, the disease or disorder is a cardiovascular disease. Non-limiting examples of cardiovascular disease include congestive heart failure, atherosclerosis, arteriosclerosis, coronary heart disease, coronary artery disease, congestive heart failure, coronary heart disease, hypertension, cardiac failure, cerebrovascular disorder (e.g., cerebral infarction), vascular dysfunction, myocardial infarction, elevated blood pressure (e.g., 130/85 mm Hg or higher), and prothrombotic state (exemplified by high fibrinogen or plasminogen activator inhibitor in the blood).

[0382] In some embodiments, the disease or disorder is related to a vascular disease. Non-limiting examples of vascular diseases include peripheral vascular disease, macrovascular complications (e.g., stroke), vascular dysfunction, peripheral artery disease, abdominal aortic aneurysm, carotid artery disease, cerebrovascular disorder (e.g., cerebral infarction), pulmonary embolism, chronic venous insufficiency, critical limb ischemia, retinopathy, nephropathy, and neuropathy.

Neurological Diseases

[0383] In some embodiments, the disease or disorder is a neurological disorder (e.g., neurodegenerative disorder) or a psychiatric disorder. Non-limiting examples of neurological disorders include brain insulin resistance, mild cognitive impairment (MCI), Alzheimer's disease (AD), Parkinson's disease (PD), anxiety, dementia (e.g., senile dementia), traumatic brain injury, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania, Morbus Parkinson, Steele-Richardson syndrome, Down's syndrome, myasthenia gravis, nerve trauma, brain trauma, vascular amyloidosis, cerebral hemorrhage I with amyloidosis, brain inflammation, Friedrich's ataxia, acute confusion disorder, amyotrophic lateral sclerosis (ALS), glaucoma, and apoptosis-mediated degenerative diseases of the central nervous system (e.g., Creutzfeld-Jakob Disease, bovine spongiform encephalopathy (mad cow disease), and chronic wasting syndrome). See, e.g., US2006/0275288A1.

[0384] Non-limiting examples of psychiatric disorders include drug dependence/addiction (narcotics and amphetamines and attention deficit/hyperactivity disorder (ADHD). The compounds and pharmaceutical compositions described herein can be useful in improving behavioral response to addictive drugs, decreasing drug dependence, prevention drug abuse relapse, and relieving anxiety caused by the absence of a given addictive substance. See, e.g., US2012/0021979A1.

[0385] In some embodiments, the compounds and pharmaceutical compositions described herein are useful in improving learning and memory by enhancing neuronal

plasticity and facilitation of cellular differentiation, and also in preserving dopamine neurons and motor function in Morbus Parkinson.

Insulin-Related Conditions and Disorders

[0386] In some embodiments, the disease or disorder is impaired fasting glucose (IFG), impaired fasting glycemia (IFG), hyperglycemia, insulin resistance (impaired glucose homeostasis), hyperinsulinemia, elevated blood levels of fatty acids or glycerol, a hypoglycemic condition, insulin resistant syndrome, paresthesia caused by hyperinsulinemia, hyperlipidemia, hypercholesterolemia, impaired wound healing, leptin resistance, glucose intolerance, increased fasting glucose, dyslipidemia (e.g., hyperlipidemia, atherogenic dyslipidemia characterized by high triglycerides and low HDL cholesterol), glucagonoma, hyperprolactinemia, hypoglycemia (e.g., nighttime hypoglycemia), and concomitant comatose endpoint associated with insulin.

[0387] In some embodiments, the compounds and pharmaceutical compositions described herein can reduce or slow down the progression of borderline type, impaired fasting glucose or impaired fasting glycemia into diabetes.

Autoimmune Disorders

[0388] In some embodiments, the disease or disorder is an autoimmune disorder. Non-limiting examples of autoimmune disorders include multiple sclerosis, experimental autoimmune encephalomyelitis, autoimmune disorder is associated with immune rejection, graft versus host disease, uveitis, optic neuropathies, optic neuritis, transverse myelitis, inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, myasthenia gravis, and Graves' disease. See, e.g., US20120148586A1.

Stomach and Intestine-Related Disorders

[0389] In some embodiments, the disease or disorder is a stomach or intestine related disorder. Non-limiting examples of these disorders include ulcers of any etiology (e.g. peptic ulcers, Zollinger-Ellison syndrome, drug-induced ulcers, ulcers related to infections or other pathogens), digestion disorders, malabsorption, short bowel syndrome, cul-de-sac syndrome, inflammatory bowel diseases (Crohn's disease and ulcerative colitis), celiac sprue, hypogammaglobulinemic sprue, chemotherapy and/or radiation therapy-induced mucositis and diarrhea, gastrointestinal inflammation, short bowel syndrome, colitis ulcerosa, gastric mucosal injury (e.g., gastric mucosal injury caused by aspirin), small intestinal mucosal injury, and cachexia (e.g., cancerous cachexia, tuberculous cachexia, cachexia associated with blood disease, cachexia associated with endocrine disease, cachexia associated with infectious disease, and cachexia caused by acquired immunodeficiency syndrome).

Body Weight

[0390] In some embodiments, the compounds and pharmaceutical compositions described herein can be used to reduce body weight (e.g., excess body weight), prevent body weight gain, induce weight loss, decrease body fat, or reduce food intake in a patient (e.g., a patient in need thereof). In some embodiments, the weight increase in a patient may be attributed to excessive ingestion of food or unbalanced diets, or may be weight increase derived from a concomitant drug

(e.g., insulin sensitizers having a PPAR γ agonist-like action, such as troglitazone, rosiglitazone, englitazone, ciglitazone, pioglitazone and the like). In some embodiments, the weight increase may be weight increase before reaching obesity, or may be weight increase in an obese patient. In some embodiments, the weight increase may also be medication-induced weight gain or weight gain subsequent to cessation of smoking.

[0391] In some embodiments, the disease or disorder is an eating disorder, such as hyperphagia, binge eating, bulimia, or compulsive eating.

Inflammatory Diseases

[0392] In some embodiments, the disease or disorder is an inflammatory disorder. Non-limiting examples of inflammatory disorders include chronic rheumatoid arthritis, spondylitis deformans, arthritis deformans, lumbago, gout, post-operative or post-traumatic inflammation, bloating, neuralgia, laryngopharyngitis, cystitis, pneumonia, pancreatitis, enteritis, inflammatory bowel disease (including inflammatory large bowel disease), inflammation in metabolically important tissues including liver, fat, pancreas, kidney and gut, and a proinflammatory state (e.g., elevated levels of proinflammatory cytokines or markers of inflammation-like C-reactive protein in the blood).

Cancer

[0393] In some embodiments, the disease or disorder is cancer. Suitable examples of cancer include breast cancer (e.g., invasive ductal breast cancer, noninvasive ductal breast cancer, inflammatory breast cancer), prostate cancer (e.g., hormone-dependent prostate cancer, hormone-independent prostate cancer), pancreatic cancer (e.g., ductal pancreatic cancer), gastric cancer (e.g., papillary adenocarcinoma, mucous adenocarcinoma, adenosquamous carcinoma), lung cancer (e.g., non-small cell lung cancer, small-cell lung cancer, malignant mesothelioma), colon cancer (e.g., gastrointestinal stromal tumor), rectal cancer (e.g., gastrointestinal stromal tumor), colorectal cancer (e.g., familial colorectal cancer, hereditary non-polyposis colorectal cancer, gastrointestinal stromal tumor), small intestinal cancer (e.g., non-Hodgkin's lymphoma, gastrointestinal stromal tumor), esophageal cancer, duodenal cancer, tongue cancer, pharyngeal cancer (e.g., nasopharyngeal cancer, oropharynx cancer, hypopharyngeal cancer), salivary gland cancer, brain tumor (e.g., pineal astrocytoma, pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma), neurilemmoma, liver cancer (e.g., primary liver cancer, extrahepatic bile duct cancer), renal cancer (e.g., renal cell cancer, transitional cell cancer of the renal pelvis and ureter), bile duct cancer, endometrial cancer, uterine cervical cancer, ovarian cancer (e.g., epithelial ovarian cancer, extragonadal germ cell tumor, ovarian germ cell tumor, ovarian tumor of low malignant potential), bladder cancer, urethral cancer, skin cancer (e.g., intraocular (ocular) melanoma, Merkel cell carcinoma), hemangioma, malignant lymphoma, malignant melanoma, thyroid cancer (e.g., medullary thyroid cancer), parathyroid cancer, nasal cavity cancer, sinus cancer, bone tumor (e.g., osteosarcoma, Ewing tumor, uterine sarcoma, soft tissue sarcoma), angiomyxoma, sarcoma of the retina, penis cancer, testicular tumor, pediatric solid tumor (e.g., Wilms' tumor, childhood kidney tumor), Kaposi's sarcoma, Kaposi's sarcoma caused by AIDS, tumor of maxillary

sinus, fibrous histiocytoma, leiomyosarcoma, rhabdomyosarcoma, and leukemia (e.g., acute myeloid leukemia, acute lymphoblastic leukemia).

Hypothalamic-Pituitary Disorders

[0394] In some embodiments, the disease or disorder is related to the hypothalamic-pituitary-gonadal axis. For example, the condition, disease or disorder is related to the hypothalamus-pituitary-ovary axis. In another example, the condition, disease or disorder is related to the hypothalamus-pituitary-testis axis. Hypothalamic-pituitary-gonadal axis diseases include, but are not limited to, hypogonadism, polycystic ovary syndrome, hypothyroidism, hypopituitarism, sexual dysfunction, and Cushing's disease.

[0395] In some embodiments, the disease or disorder associated with diabetes is related to the hypothalamic-pituitary-gonadal axis.

Pulmonary Disease

[0396] In some embodiments, the disease or disorder is related to a pulmonary disease. Pulmonary diseases include, but are not limited to, asthma, idiopathic pulmonary fibrosis, pulmonary hypertension, obstructive sleep apnoea-hypopnoea syndrome, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis, and refractory (non-reversible) asthma).

[0397] In some embodiments, the disease or disorder associated with diabetes is a pulmonary disease.

Combination Therapy

[0398] In some embodiments, this disclosure contemplates both monotherapy regimens as well as combination therapy regimens.

[0399] In some embodiments, the methods described herein can further include administering one or more additional therapies (e.g., one or more additional therapeutic agents and/or one or more therapeutic regimens) in combination with administration of the compounds described herein.

[0400] In some embodiments, the methods described herein include administering a compound described herein in combination with one or more of a diet therapy (e.g., dietary monitoring, diet therapy for diabetes), an exercise therapy (e.g., physical activity), blood sugar monitoring, gastric electrical stimulation (e.g., TANTALUS®), and diet modifications.

[0401] In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof can be administered in combination with one or more additional therapeutic agents.

[0402] Representative additional therapeutic agents include, but are not limited to, anti-obesity agents, therapeutic agents for diabetes, therapeutic agents for diabetic complications, therapeutic agents for hyperlipidemia, anti-hypertensive agents, diuretics, chemotherapeutics, immunotherapeutics, anti-inflammatory drugs, antithrombotic agents, anti-oxidants, therapeutic agents for osteoporosis, vitamins, antidiamentia drugs, erectile dysfunction drugs, therapeutic drugs for urinary frequency or urinary incontinence, therapeutic agents for NAFLD, therapeutic agents for NASH, therapeutic agents for dysuria and anti-emetic agents.

[0403] In some embodiments, the one or more additional therapeutic agents include those useful, for example, as anti-obesity agents. Non-limiting examples include monoamine uptake inhibitors (e.g., tramadol, phentermine, sibutramine, mazindol, fluoxetine, tesofensine), serotonin 2C receptor agonists (e.g., lorcaserin), serotonin 6 receptor antagonists, histamine H3 receptor modulator, GABA modulator (e.g., topiramate), including GABA receptor agonists (e.g., gabapentin, pregabalin), neuropeptide Y antagonists (e.g., velnoperit), cannabinoid receptor antagonists (e.g., rimonabant, taranabant), ghrelin antagonists, ghrelin receptor antagonists, ghrelin acylation enzyme inhibitors, opioid receptor antagonists (e.g., GSK-1521498), orexin receptor antagonists, melanocortin 4 receptor agonists, 11 β -hydroxysteroid dehydrogenase inhibitors (e.g., AZD-4017, BVT-3498, INCB-13739), pancreatic lipase inhibitors (e.g., orlistat, cetilistat), β 3 agonists (e.g., N-5984), diacylglycerol acyltransferase 1 (DGAT1) inhibitors, acetylCoA carboxylase (ACC) inhibitors, stearoyl-CoA desaturated enzyme inhibitors, microsomal triglyceride transfer protein inhibitors (e.g., R-256918), sodium-glucose cotransporter 2 (SGLT-2) inhibitors (e.g., JNJ-28431754, dapagliflozin, AVE2268, TS-033, YM543, TA-7284, ASP1941, remoglipi- fizin), NFK inhibitors (e.g., HE-3286), PPAR agonists (e.g., GFT-505, DRF-11605, gemfibrozil and fenofibrate), phosphotyrosine phosphatase inhibitors (e.g., sodium vanadate, trodusquemine), GPR119 agonists (e.g., PSN-821, MBX-2982, APD597), glucokinase activators (e.g., piagliatin, AZD-1656, AZD6370, TTP-355, compounds described in WO006/112549, W0007/028135, W0008/047821, W0008/050821, W0008/136428 and W0008/156757), leptin, leptin derivatives (e.g., metreleptin), leptin resistance improving drugs, CNTF (ciliary neurotrophic factor), BDNF (brain-derived neurotrophic factor), cholecystokinin agonists, amylin preparations (e.g., pramlintide, AC-2307), neuropeptide Y agonists (e.g., PYY3-36, derivatives of PYY3-36, obin peptide, TM-30339, TM-30335), oxyntomodulin (OXM) preparations, appetite suppressants (e.g. ephedrine), FGF21 preparations (e.g., animal FGF21 preparations extracted from the pancreas of bovine or swine; human FGF21 preparations genetically synthesized using *Escherichia coli* or yeast; fragments or derivatives of FGF21), anorexigenic agents (e.g., P-57), human proislet peptide (HIP), farnesoid X receptor (FXR) agonist, phentermine, zonisamide, norepinephrine/dopamine reuptake inhibitor, GDF-15 analog, methionine aminopeptidase 2 (MetAP2) inhibitor, diethylpropion, phenidmetrazine, benzphetamine, fibroblast growth factor receptor (FGFR) modulator, and AMP-activated protein kinase (AMPK) activator.

[0404] In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof can be administered in combination with one or more additional therapeutic agents, wherein the additional therapeutic agent is a GLP-1 agonist or exhibits GLP-1 agonist activity.

[0405] In some embodiments, the additional therapeutic agent is TTP273, LY2944876 (pegapamodutide), HDM1002, K-757, K-833, retatrutide, IBI362 (mazdutide), cotadutide, AMG133, CT-868, HRS9531, HS-20094, dapi- glutide, efinepegdutide, efocipegtrutide, pemvidutide, survodutide, AP026, AZD9550, BGM0504, CT-388, DD01, DR10624, G3215, GMA106, HEC88473, HZ010, LY3493269, MWN101, NN9487, NN9541, RAY1225, SCO-094, SHR-1816, TB001, VK2735, ZP2929, ecno-

glutide, GX-G6, GZR18, HRS-7535, YH14617, avexitide, fronioglutide, pegsebrenatide, vurolenatide, JY09, NB1001, Byetalog, GW002, HL08, KN056, SAL0112, SHR2042, VCT220, ZT002, ZYOG1, or utreglutide.

[0406] In some embodiments, the additional therapeutic agent is endogenous GLP-1, endogenous glucagon, oxyntomodulin, exendin-4, exenatide, lixisenatide, albiglutide, beinaglutide, dulaglutide, espegeglatide, langlenatide, liraglutide, semaglutide, taspaglutide, tirzepatide, pegapamodutide, lithium chloride, PF-06882961 (danuglipron), LY3502970 (orforglipron), ECC-5004, GSBR-1290, AZD0186, PF-07081532 (lotiglipron), VCT220, TERN-601, RGT-075, CT-996, MDR-001, SAL0112, XW014, AVE-0010, S4P, or Boc5).

[0407] In some embodiments, one or more compounds as disclosed herein, or a stereoisomer or mixture of stereoisomers thereof can be administered in combination with one or more additional therapeutic agents, wherein the additional therapeutic agent is selected from a compound disclosed in WO2021/155841, WO/2018/109607, WO/2018/056453, WO/2019/239319, or WO/2019/239371.

[0408] In some embodiments, the one or more additional therapeutic agents include those useful, for example, as anti-diabetic agents. Non-limiting examples include insulin and insulin preparations (e.g., animal insulin preparations extracted from the pancreas of bovine or swine; human insulin preparations genetically synthesized using *Escherichia coli* or yeast; zinc insulin; protamine zinc insulin; fragment or derivative of insulin (e.g., INS-1), oral insulin preparation, synthetic human insulin), insulin sensitizers (e.g., pioglitazone or a salt thereof), biguanides (e.g., metformin, buformin or a salt thereof (e.g., hydrochloride, fumarate, succinate)), glucagon analogs (e.g., any of glucagon analogs described, e.g., in WO 2010/011439), agents which antagonize the actions of or reduce secretion of glucagon, sulfonylurea agents (e.g., chlorpropamide, tolazamide, gliclazide, glimepiride, tolbutamide, glibenclamide, gliclazide, acetohexamide, glycopryamide, glibuzole, glyburide), thiazolidinedione agents (e.g. rosiglitazone or pioglitazone), α -glucosidase inhibitors (e.g., voglibose, acarbose, miglitol, emiglitate), insulin secretagogues, such as prandial glucose regulators (sometimes called "short-acting secretagogues"), e.g., meglitinides (e.g. repaglinide and nateglinide), cholinesterase inhibitors (e.g., donepezil, galantamine, rivastigmine, tacrine), NMDA receptor antagonists, dual GLP-1/GIP receptor agonists (e.g., LBT-2000, ZPD1-70), GLP-1R agonists (e.g., exenatide, liraglutide, albiglutide, dulaglutide, abiglutide, taspaglutide, lixisenatide, semaglutide, AVE-0010, S4P and Boc5), and dipeptidyl peptidase IV (DPP-4) inhibitors (e.g., vildagliptin, dutoglipitin, gemigliptin, alogliptin, saxagliptin, sitagliptin, linagliptin, berberine, adogliptin, BI1356, GRC8200, MP-513, PF-00734200, PHX1149, SK-0403, ALS2-0426, TA-6666, TS-021, KRP-104, trelagliptin).

[0409] In some embodiments, the one or more additional therapeutic agents include those useful, for example, for treating NAFL and NASH. Non-limiting examples include FXR agonists, PF-05221304, a synthetic fatty acid-bile conjugate, an anti-lysyl oxidase homologue 2 (LOXL2) monoclonal antibody, a caspase inhibitor, a MAPK5 inhibitor, a galectin 3 inhibitor, a fibroblast growth factor 21 (FGF21), a niacin analogue, a leukotriene D4 (LTD4) receptor antagonist, an acetyl-CoA carboxylase (ACC) inhibitor, a ketohexokinase (KHK) inhibitor, an apoptosis signal-

regulating kinase 1 (ASK1) inhibitor, an ileal bile acid transporter (IBAT) inhibitor, glycyrrhizin, Schisandra extract, ascorbic acid, glutathione, silymarin, lipoic acid, and d-alpha-tocopherol, ascorbic acid, glutathione, vitamin B-complex, glitazones/thiazolidinediones (e.g., troglitazone, rosiglitazone, pioglitazone), metformin, cysteamine, sulfonylureas, alpha-glucosidase inhibitors, meglitinides, vitamin E, tetrahydrolipstatin, milk thistle protein, anti-virals, and anti-oxidants.

[0410] In some embodiments, the one or more additional therapeutic agents include those useful, for example, for treating diabetic complications. Non-limiting examples include aldose reductase inhibitors (e.g., tolrestat, epalrestat, zopolrestat, fidarestat, CT-112, ranirestat, lidorestat), neurotrophic factor and increasing agents thereof (e.g., NGF, NT-3, BDNF, neurotrophic production/secretion promoting agents described in WO01/14372 (e.g., 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl] oxazole), compounds described in WO2004/039365), PKC inhibitors (e.g., ruboxistaurin mesylate), AGE inhibitors (e.g., ALT946, N-phenacylthiazolium bromide (ALT766), EXO-226, pyridorin, pyridoxamine), serotonin and norepinephrine reuptake inhibitors (e.g., duloxetine), sodium channel inhibitors (e.g., lacosamide), active oxygen scavengers (e.g., thioctic acid), cerebral vasodilators (e.g., tiapride, mexiletine), somatostatin receptor agonists (e.g., BIM23190), and apoptosis signal regulating kinase-1 (ASK-1) inhibitors.

[0411] In some embodiments, the one or more additional therapeutic agents include those useful, for example, for treating hyperlipidemia. Non-limiting examples include HMG-CoA reductase inhibitors (e.g., pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin, rosuvastatin, pitavastatin or a salt thereof (e.g., sodium salt, calcium salt)), squalene synthase inhibitors (e.g., compounds described in WO97/10224, e.g., N-[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidin-4-acetic acid), fibrate compounds (e.g., bezafibrate, clofibrate, simfibrate, clinofibrate), anion exchange resin (e.g., colestyramine), nicotinic acid drugs (e.g., nicomol, niacetrol, niaspan), phytosterols (e.g., soysterol, gamma oryzanol (γ -oryzanol)), cholesterol absorption inhibitors (e.g., zechia), CETP inhibitors (e.g., dalcetrapib, anacetrapib) and ω -3 fatty acid preparations (e.g., ω -3-fatty acid ethyl esters 90).

[0412] In some embodiments, the one or more additional therapeutic agents include those useful, for example, as anti-hypertensive agents. Non-limiting examples include angiotensin converting enzyme inhibitors (e.g., captopril, enalapril, delapril), angiotensin II antagonists (e.g., candesartan cilexetil, candesartan, losartan, losartan potassium, eprosartan, valsartan, telmisartan, irbesartan, tasosartan, olmesartan, olmesartan medoxomil, azilsartan, azilsartan medoxomil), calcium antagonists (e.g., manidipine, nifedipine, amlodipine, efonidipine, nicardipine, cilnidipine) and β -blockers (e.g., metoprolol, atenolol, propranolol, carvedilol, pindolol).

[0413] In some embodiments, the one or more additional therapeutic agents include those useful, for example, as diuretics. Non-limiting examples include xanthine derivatives (e.g., theobromine sodium salicylate, theobromine calcium salicylate), thiazide preparations (e.g., ethiazide, cyclothiazide, trichloromethiazide, hydrochlorothiazide,

hydroflumethiazide, benzylhydrochlorothiazide, penfluthiazide, polythiazide, methyclothiazide), antialdosterone preparations (e.g., spironolactone, triamterene), carbonic anhydrase inhibitors (e.g., acetazolamide) and chlorobenzene-sulfonamide agents (e.g., chlortalidone, mefruside, indapamide).

[0414] In some embodiments, the one or more additional therapeutic agents include those useful, for example, as immunotherapeutic agents. Non-limiting examples include microbial or bacterial compounds (e.g., muramyl dipeptide derivative, picibanil), polysaccharides having immuno-enhancing activity (e.g., lentinan, sizofiran, krestin), cytokines obtained by genetic engineering approaches (e.g., interferon, interleukin (IL) such as IL-1, IL-2, IL-12), and colony-stimulating factors (e.g., granulocyte colony-stimulating factor, erythropoietin).

[0415] In some embodiments, the one or more additional therapeutic agents include those useful, for example, as anti-thrombotic agents. Non-limiting examples include heparins (e.g., heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium) warfarin (e.g., warfarin potassium); anti-thrombin drugs (e.g., aragatroban, dabigatran) FXa inhibitors (e.g., rivaroxaban, apixaban, edoxaban, betrixaban, YM150, compounds described in WO02/06234, WO2004/048363, WO2005/030740, WO2005/058823, and WO2005/113504) thrombolytic agents (e.g., urokinase, tisokinase, alteplase, nateplase, monteplase, pamiteplase), and platelet aggregation inhibitors (e.g., ticlopidine hydrochloride, clopidogrel, prasugrel, E5555, SHC530348, cilostazol, ethyl icosapentate, beraprost sodium, and sarpogrelate hydrochloride).

[0416] In some embodiments, the one or more additional therapeutic agents include those useful, for example, for treating osteoporosis. Non-limiting examples include alfacalcidol, calcitriol, elcatonin, calcitonin salmon, estriol, ipriflavone, pamidronate disodium, alendronate sodium hydrate, incadronate disodium, and risedronate disodium. Suitable examples of vitamins include vitamin B1 and vitamin B12. Suitable examples of erectile dysfunction drugs include apomorphine and sildenafil citrate. Suitable examples of therapeutic agents for urinary frequency or urinary incontinence include flavorxate hydrochloride, oxybutynin hydrochloride and propiverine hydrochloride. Suitable examples of therapeutic agents for dysuria include acetylcholine esterase inhibitors (e.g., distigmine). Suitable examples of anti-inflammatory agents include nonsteroidal anti-inflammatory drugs such as aspirin, acetaminophen, indomethacin.

[0417] Other exemplary additional therapeutic agents include agents that modulate hepatic glucose balance (e.g., fructose 1,6-bisphosphatase inhibitors, glycogen phosphorylase inhibitors, glycogen synthase kinase inhibitors, glucokinase activators), agents designed to treat the complications of prolonged hyperglycemia, such as aldose reductase inhibitors (e.g. epalrestat and ranirestat), agents used to treat complications related to micro-angiopathies, anti-dyslipidemia agents, such as HMG-CoA reductase inhibitors (statins, e.g. rosuvastatin), cholesterol-lowering agents, bile acid sequestrants (e.g., colestyramine), cholesterol absorption inhibitors (e.g. plant sterols such as phytosterols), cholesterol ester transfer protein (CETP) inhibitors, inhibitors of the ileal bile acid transport system (IBAT inhibitors), bile acid binding resins, nicotinic acid (niacin) and analogues thereof, anti-oxidants (e.g., probucol), omega-3 fatty acids,

antihypertensive agents, including adrenergic receptor antagonists, such as beta blockers (e.g. atenolol), alpha blockers (e.g. doxazosin), and mixed alpha/beta blockers (e.g. labetalol), adrenergic receptor agonists, including alpha-2 agonists (e.g. clonidine), angiotensin converting enzyme (ACE) inhibitors (e.g. lisinopril), calcium channel blockers, such as dihydropyridines (e.g. nifedipine), phenylalkylamines (e.g. verapamil), and benzothiazepines (e.g. diltiazem), angiotensin II receptor antagonists (e.g. candesartan), aldosterone receptor antagonists (e.g. eplerenone), centrally acting adrenergic drugs, such as central alpha agonists (e.g. clonidine), diuretic agents (e.g. furosemide), haemostasis modulators, including antithrombotics (e.g., activators of fibrinolysis), thrombin antagonists, factor VIIa inhibitors, anticoagulants (e.g., vitamin K antagonists such as warfarin), heparin and low molecular weight analogues thereof, factor Xa inhibitors, and direct thrombin inhibitors (e.g. argatroban), antiplatelet agents (e.g., cyclooxygenase inhibitors (e.g. aspirin)), adenosine diphosphate (ADP) receptor inhibitors (e.g. clopidogrel), phosphodiesterase inhibitors (e.g. cilostazol), glycoprotein IIB/IIA inhibitors (e.g. tirofiban), adenosine reuptake inhibitors (e.g. dipyridamole), noradrenergic agents (e.g. phentermine), serotonergic agents (e.g. sibutramine), diacyl glycerolacyltransferase (DGAT) inhibitors, feeding behavior modifying agents, pyruvate dehydrogenase kinase (PDK) modulators, serotonin receptor modulators, monoamine transmission-modulating agents, such as selective serotonin reuptake inhibitors (SSRI) (e.g. fluoxetine), noradrenaline reuptake inhibitors (NARI), noradrenaline-serotonin reuptake inhibitors (SNRI), and monoamine oxidase inhibitors (MAOI) (e.g. toloxatone and amitriptyline), compounds described in WO0007/013694, WO2007/018314, WO2008/093639 and WO2008/099794, GPR40 agonists (e.g., fasiglifam or a hydrate thereof, compounds described in WO2004/041266, WO2004/106276, WO2005/063729, WO2005/063725, WO2005/087710, WO2005/095338, WO2007/013689 and WO2008/001931), SGLT1 inhibitors, adiponectin or agonist thereof, IKK inhibitors (e.g., AS-2868), somatostatin receptor agonists, ACC2 inhibitors, cachexia-ameliorating agents, such as a cyclooxygenase inhibitors (e.g., indomethacin), progesterone derivatives (e.g., megestrol acetate), glucocorticoids (e.g., dexamethasone), metoclopramide agents, tetrahydrocannabinol agents, agents for improving fat metabolism (e.g., eicosapentaenoic acid), growth hormones, IGF-1, antibodies against a cachexia-inducing factor TNF- α , LIF, IL-6, and oncostatin M, metabolism-modifying proteins or peptides such as glucokinase (GK), glucokinase regulatory protein (GKRP), uncoupling proteins 2 and 3 (UCP2 and UCP3), peroxisome proliferator-activated receptor α (PPAR α), MC4r agonists, insulin receptor agonist, PDE 5 inhibitors, glycation inhibitors (e.g., ALT-711), nerve regeneration-promoting drugs (e.g., Y-128, VX853, prosaptide), antidepressants (e.g., desipramine, amitriptyline, imipramine), antiepileptic drugs (e.g., lamotrigine, trileptal, keppra, zonegran, pregabalin, harkoseride, carbamazepine), antiarrhythmic drugs (e.g., mexiletine), acetylcholine receptor ligands (e.g., ABT-594), endothelin receptor antagonists (e.g., ABT-627), narcotic analgesics (e.g., morphine), α 2 receptor agonists (e.g., clonidine), local analgesics (e.g., capsaicin), antianxiety drugs (e.g., benzothiazepine), phosphodiesterase inhibitors (e.g., sildenafil), dopamine receptor agonists (e.g., apomorphine), cytotoxic antibodies (e.g., T-cell receptor and IL-2 receptor-specific antibodies), B cell

depleting therapies (e.g., anti-CD20 antibody (e.g., rituxan), i-BLyS antibody), drugs affecting T cell migration (e.g., anti-integrin alpha 4/beta 1 antibody (e.g., tysabri), drugs that act on immunophilins (e.g., cyclosporine, tacrolimus, sirolimus, rapamicin), interferons (e.g., IFN- β), immuno-modulators (e.g., glatiramer), TNF-binding proteins (e.g., circulating receptors), immunosuppressants (e.g., mycophenolate), and metaglidases, AMG-131, balaglitazone, MBX-2044, rivoglitzalone, aleglitazar, chiglitazar, lobeglitzalone, PLX-204, PN-2034, GFT-505, THR-0921, exenatide, exendin-4, memantine, midazolam, ketoconazole, ethyl icosa-pentate, clonidine, azosemide, isosorbide, ethacrynic acid, piretanide, bumetanide, etoposide, piroxicam, NO donating agents (e.g., organonitrates), and NO promoting agents (e.g., phosphodiesterase inhibitors).

[0418] In some embodiments, the one or more additional therapeutic agents include those useful, for example, as anti-emetic agents. As used herein, an "anti-emetic" agent refers to any agent that counteracts (e.g., reduces or removes) nausea or emesis (vomiting). It is to be understood that when referring to a therapeutically effective amount of an anti-emetic agent, the amount administered is an amount needed to counteract (e.g., reduce or remove) nausea or emesis (vomiting). While not wishing to be bound by theory, it is believed that administering one or more anti-emetic agents in combination with the formula (I) compounds described herein may allow higher dosages of the formula (I) compounds to be administered, e.g., because the patient may be able to have a normal food intake and thereby respond faster to the treatment.

[0419] Non-limiting examples of anti-emetic agents include 5HT3-receptor antagonists (serotonin receptor antagonists), neuroleptics/anti-psychotics, antihistamines, anticholinergic agents, steroids (e.g., corticosteroids), NK1-receptor antagonists (e.g., Neurokinin 1 substance P receptor antagonists), antidopaminergic agents/dopamine receptor antagonists, benzodiazepines, cannabinoids.

[0420] For example, the antiemetic agent can be selected from the group consisting of; neuroleptics, antihistamines, anti-cholinergic agents, steroids, 5HT-3-receptor antagonists, NK1-receptor antagonists, anti-dopaminergic agents/dopamine receptor antagonists, benzodiazepines and non-psychoactive cannabinoids.

[0421] In some embodiments, the anti-emetic agent is a 5HT3-receptor antagonist (serotonin receptor antagonist). Non-limiting examples of 5HT3-receptor antagonists (serotonin receptor antagonists) include: granisetron (Kytril), dolasetron, ondansetron (Zofran), tropisetron, ramosetron, palonosetron, alosetron, azasetron, bemesetron, zatisetron, batanopiride, MDL-73147EF; Metoclopramide, N-3389 (endo-3,9-dimethyl-3,9-diazabicyclo[3.3.1]non-7-yl-1H-indazole-3-carboxamide dihydrochloride), Y-25130 hydrochloride, MDL 72222, Tropanyl-3,5-dimethylbenzoate, 3-(4-Allylpiperazin-1-yl)-2-quinoxalinecarbonitrile maleate, zacopride hydrochloride, and mirtazepine. Other non-limiting examples of 5HT3-receptor antagonists (serotonin receptor antagonists) include: cilansetron, clozapine, cyproheptadine, dazopride, hydroxyzine, lerisetron, metoclopramide, mianserin, olanzapine, palonosetron (+netupitant), quetiapine, qamsetron, ramosteron, ricasetron, risperidone, ziprasidone, and zatosetron.

[0422] In certain embodiments, the 5HT-3-receptor antagonist is granisetron, dolasetron, ondansetron hydrochloride, tropisetron, ramosetron, palonosetron, alosetron,

bemesetron, zatisetron, batanopirde, MDL-73147EF, metoclopramide, N-3389, Y-25130 hydrochloride, MDL 72222, tropanyl-3,5-dimethylbenzoate 3-(4-Allyl-piperazin-1-yl)-2-quinoxalinecarbonitrile maleate, zacopride hydrochloride and mirtazepine.

[0423] In certain embodiments, the 5HT-3-receptor antagonist is granisetron, dolasetron, ondansetron hydrochloride, tropisetron, ramosetron, palonosetron, alosetron, bemesetron, and zatisetron.

[0424] In certain embodiments, the 5HT-3-receptor antagonist is granisetron, dolasetron and ondansetron.

[0425] In certain embodiments, the 5HT-3-receptor antagonist is granisetron.

[0426] In certain embodiments, the 5HT-3-receptor antagonist is ondansetron.

[0427] In some embodiments, the anti-emetic agent is an antihistamine. Non-limiting examples of antihistamines include: piperazine derivatives (e.g., cyclizine, meclizine, and cinnarizine); promethazine; dimenhydrinate (Dramamine, Gravol); diphenhydramine; hydroxyzine; buclizine; and meclizine hydrochloride (Bonine, Antivert), doxylamine, and mirtazapine.

[0428] In some embodiments, the anti-emetic agent is an anticholinergic agent (inhibitors of the acetylcholine receptors). Non-limiting examples of anticholinergic agents include: atropine, scopolamine, glycopyrron, hyoscine, artane (trihexy-5 trihexyphenidyl hydrochloride), cogentin (benztropine mesylate), akineton (biperiden hydrochloride), disipal (norflex orphenadrine citrate), diphenhydramine, hydroxyzine, hyoscyamine, and kemadrin (procyclidine hydrochloride).

[0429] In some embodiments, the anti-emetic agent is a steroid (e.g., a corticosteroid). Non-limiting examples of steroids include: betamethasone, dexamethasone, methylprednisolone, Prednisone®, and trimethobenzamide (Tigan).

[0430] In some embodiments, the anti-emetic agent is an NK1-receptor antagonists (e.g., Neurokinin 1 substance P receptor antagonists). Non-limiting examples of NK1-receptor antagonists include: aprepitant, casopitant, ezlopitant, fosaprepitant, maropitant, netupitant, rolapitant, and vestipitant.

[0431] Other non-limiting examples of NK1-receptor antagonists include: MPC-4505, GW597599, MPC-4505, GR205171, L-759274, SR 140333, CP-96,345, BIIF 1149, NKP 608C, NKP 608A, CGP 60829, SR 140333 (Nolpitanium besilate/chloride), LY 303870 (Lanepitant), MDL-105172A, MDL-103896, MEN-11149, MEN-11467, DNK 333A, YM-49244, YM-44778, ZM-274773, MEN-10930, S-19752, Neuronorm, YM-35375, DA-5018, MK-869, L-754030, CJ-11974, L-758298, DNK-33A, 6b-1, CJ-11974 j. Benserazide and carbidopa k. TAK-637 [(aR,9R)-7-[3,5-bis(trifluoromethyl)benzyl]-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione], PD 154075, [(2-benzofuran)-CH₂OCO]—(R)-alpha-MeTrp-(S)-NHCH(CH₃) Ph, FK888, and (D-Pro⁴, D-Trp^{7,9,10}, Phe¹¹)SP4-11.

[0432] In some embodiments, the anti-emetic agent is an anti-dopaminergic agents/dopamine receptor antagonist (e.g., dopamine receptor antagonist, e.g., D2 or D3 antagonists). Non-limiting examples include phenothiazines (e.g., promethazine, chlorpromazine, prochlorperazine, perphenazine, hydroxyzine, thiethylperazine, metopimazine); benzamides (e.g., metoclopramide, domperidone), butyro-

phenes (e.g., haloperidol, droperidol); alizapride, bromopride, clebopride, domperidone, itopride, metoclopramide, trimethobenzamide, and amisulpride.

[0433] In some embodiments, the anti-emetic agent is a non-psychoactive cannabinoids (e.g., Cannabidiol (CBD), Cannabidiol dimethylheptyl (CBD-DMH), Tetra-hydro-cannabinol (THC), Cannabinoid agonists such as WIN 55-212 (a CB1 and CB2 receptor agonist), Dronabinol (Marinol®), and Nabilone (Cesamet)).

[0434] Other exemplary anti-emetic agents include: c-9280 (Merck); benzodiazepines (diazepam, midazolam, lorazepam); neuroleptics/anti-psychotics (e.g., dixyrazine, haloperidol, and Prochlorperazine (Compazine®)); cerium oxalate; propofol; sodium citrate; dextrose; fructose (Nauzen); orthophosphoric acid; fructose; glucose (Emetrol); bismuth subsalicylate (Pepto Bismol); ephedrine; vitamin B6; peppermint, lavender, and lemon essential oils; and ginger.

[0435] Still other exemplary anti-emetic agents include those disclosed in US 20120101089A1; U.S. Pat. No. 10,071,088 B2; U.S. Pat. No. 6,673,792 B1; U.S. Pat. No. 6,197,329 B1; U.S. Pat. No. 10,828,297 B2; U.S. Pat. No. 10,322,106 B2; U.S. Pat. No. 10,525,033 B2; WO 2009080351 A1; WO 2019203753 A2; WO 2002020001 A2; U.S. Pat. No. 8,119,697 B2; U.S. Pat. No. 5,039,528; US20090305964A1; and WO 2006/111169, each of which is incorporated by reference in its entirety.

[0436] In some embodiments, the additional therapeutic agent or regimen is administered to the patient prior to contacting with or administering the compounds and pharmaceutical compositions (e.g., about one hour prior, or about 6 hours prior, or about 12 hours prior, or about 24 hours prior, or about 48 hours prior, or about 1 week prior, or about 1 month prior).

[0437] In some embodiments, the additional therapeutic agent or regimen is administered to the patient at about the same time as contacting with or administering the compounds and pharmaceutical compositions. By way of example, the additional therapeutic agent or regimen and the compounds and pharmaceutical compositions are provided to the patient simultaneously in the same dosage form. As another example, the additional therapeutic agent or regimen and the compounds and pharmaceutical compositions are provided to the patient concurrently in separate dosage forms.

Patient Selection

[0438] In some embodiments, the methods described herein further include the step of identifying a patient (e.g., a subject) in need of such treatment (e.g., by way of blood assay, body mass index, or other conventional method known in the art).

[0439] In some embodiments, the methods described herein further include the step of identifying a patient (e.g., patient) that has type 2 diabetes mellitus. In some embodiments, determining if the patient has type 2 diabetes mellitus includes performing an assay to determine the level of hemoglobin A1c (HbA1c), fasting plasma glucose, non-fasting plasma glucose, or any combination thereof. In some embodiments, the level of HbA1c is about 6.5% to about 24.0%. In some embodiments, the level of HbA1c is greater than or about 6.5%. In some embodiments, the level of HbA1c is greater than or about 8.0%. In some embodiments, the level of HbA1c is greater than or about 10.0%. In some embodiments, the level of HbA1c is greater than or about 12.0%. In some embodiments, the level of HbA1c is greater than or about 14.0%. In some embodiments, the level of

HbA1c is greater than or about 16.0%. In some embodiments, the level of HbA1c is greater than or about 18.0%. In some embodiments, the level of HbA1c is greater than or about 20.0%. In some embodiments, the level of HbA1c is greater than or about 22.0%. In some embodiments, the level of HbA1c is greater than or about 24.0%.

[0440] In some embodiments, the level of fasting plasma glucose is greater than or about 120 mg/dL to greater than or about 750 mg/dL. In some embodiments, the level of fasting plasma glucose is greater than or about 200 mg/dL to greater than or about 500 mg/dL. In some embodiments, the level of fasting plasma glucose is greater than or about 300 mg/dL to greater than or about 700 mg/dL.

[0441] In some embodiments, the level of non-fasting plasma glucose is greater than or about 190 mg/dL to greater than or about 750 mg/dL. In some embodiments, the level of non-fasting plasma glucose is greater than or about 250 mg/dL to greater than or about 450 mg/dL. In some embodiments, the level of non-fasting plasma glucose is greater than or about 400 mg/dL to greater than or about 700 mg/dL.

[0442] In some embodiments, determining if the patient has type 2 diabetes mellitus further includes determining the patient's BMI. In some embodiments, the BMI of the patient is greater than or about 22 kg/m² to greater than or about 100 kg/m². In some embodiments, the BMI of the patient is greater than or about 30 kg/m² to greater than or about 90 kg/m². In some embodiments, the BMI of the patient is greater than or about 40 kg/m² to greater than or about 80 kg/m². In some embodiments, the BMI of the patient is greater than or about 50 kg/m² to greater than or about 70 kg/m².

[0443] In some embodiments, additional factors (e.g. risk factors) used for determining if the patient has type 2 diabetes mellitus further includes age and ethnicity of the patient. In some embodiments, the patient's age is greater than or about 10 years. In some embodiments, the patient's age is greater than or about 15 years. In some embodiments, the patient's age is greater than or about 20 years. In some embodiments, the patient's age is greater than or about 25 years. In some embodiments, the patient's age is greater than or about 30 years. In some embodiments, the patient's age is greater than or about 35 years. In some embodiments, the patient's age is greater than or about 40 years. In some embodiments, the patient's age is greater than or about 42 years. In some embodiments, the patient's age is greater than or about 44 years. In some embodiments, the patient's age is greater than or about 46 years. In some embodiments, the patient's age is greater than or about 48 years. In some embodiments, the patient's age is greater than or about 50 years. In some embodiments, the patient's age is greater than or about 52 years. In some embodiments, the patient's age is greater than or about 54 years. In some embodiments, the patient's age is greater than or about 56 years. In some embodiments, the patient's age is greater than or about 58 years. In some embodiments, the patient's age is greater than or about 60 years. In some embodiments, the patient's age is greater than or about 62 years. In some embodiments, the patient's age is greater than or about 64 years. In some embodiments, the patient's age is greater than or about 66 years. In some embodiments, the patient's age is greater than or about 68 years. In some embodiments, the patient's age is greater than or about 70 years. In some embodiments, the patient's age is greater than or about 72 years. In some embodiments, the patient's age is greater than or about 74 years. In some embodiments, the patient's age is greater than or about 76 years. In some embodiments, the patient's age is greater than or about 78 years. In some embodiments, the

patient's age is greater than or about 80 years. In some embodiments, the patient's age is greater than or about 85 years. In some embodiments, the patient's age is greater than or about 90 years. In some embodiments, the patient's age is greater than or about 95 years. In some embodiments, the ethnicity of the patient may be African American, American Indian or Alaska Native, Asian American, Hispanics or Latinos, or Native Hawaiian or Pacific Islander.

Synthesis of the Compounds


[0444] The compounds of this disclosure can be prepared from readily available starting materials using, for example, the following general methods, and procedures. It will be appreciated that where certain process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.

[0445] Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting certain functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and G. M. Wuts (1999) Protecting Groups in Organic Synthesis, 3rd Edition, Wiley, New York, and references cited therein.

[0446] Furthermore, the compounds of this disclosure may contain one or more chiral centers. Accordingly, if desired, such compounds can be prepared or isolated as pure stereoisomers, i.e., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures. All such stereoisomers (and enriched mixtures) are included within the scope of this disclosure, unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optically active starting materials or stereoselective reagents well-known in the art. Alternatively, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents, and the like.

[0447] The starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many of the starting materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA), Bachem (Torrance CA USA), EMKA-Chemie GmbH & Co. KG (Eching Germany), or Millipore Sigma (Burlington MA USA). Others may be prepared by procedures, or obvious modifications thereof, described in standard reference texts such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-15 (John Wiley, and Sons, 1991), Rodd's Chemistry of Carbon Compounds, Volumes 1-5, and Supplements (Elsevier Science Publishers, 1989), Organic Reactions, Volumes 1-40 (John Wiley, and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley, and Sons, 5th Edition, 2001), and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).

[0448] Scheme I illustrates a general method which can be employed for the synthesis of compounds described herein, wherein each of A, X¹, X², X³, X⁴, L¹, L², Y¹, Y², Y³, R⁴, and R⁵, are independently as defined herein, and R⁵⁰ is an alkyl or substituted alkyl.




[0449] As shown in Scheme I, coupling compound I-1 with compound I-2 provides compound I-3. Compound I-3 may then undergo a Hantzsch style pyridine reaction with compound I-4 and compound I-5 to provide compound I-6. In some embodiments, the reaction is performed under heated conditions in a suitable solvent. Oxidation of I-6, such as by CAN or DDQ, provides compounds of Formula I.


[0450] For any compound shown in Scheme I, it should be understood that various derivatives can be provided by functional group interconversion at any step. In some embodiments, the various substituents of compounds I-1, I-2, I-3, I-4, I-5, or I-6 (e.g., A, X¹, X², X³, X⁴, L¹, L², Y¹, Y², Y³, R⁴, and R⁵) are as defined herein. However, derivatization of compounds I-1, I-2, I-3, I-4, I-5, or I-6 prior to reacting in any step, and/or further derivatization of the resulting reaction product, provides various compounds of Formula I. Appropriate starting materials and reagents can be purchased or prepared by methods known to one of skill in the art.

[0451] Upon reaction completion, compounds of Formula I can be recovered by conventional techniques such as neutralization, extraction, precipitation, chromatography, filtration and the like. In certain embodiments, when control of stereochemistry is desired, proper control of reaction conditions and selection of substituents for the reagents can at least partially dictate or preserve the formation of the various stereoisomers.

[0452] Furthermore, compounds of Formula IB may be synthesized according to the route shown in Scheme II, wherein each of A, X¹, X², X³, X⁴, Ring B, L¹, L², Y¹, Y², Y³, R⁴, and R⁵, are independently as defined herein, R⁵⁰ is an alkyl or substituted alkyl, and PG is a suitable protecting group (such as tert-butoxycarbonyl).



-continued



[0453] As shown in Scheme II, compound I-7 can undergo Hantzsch style pyridine reaction with compound I-5 and compound I-8, followed by oxidation under suitable conditions (such as in the presence of CAN or DDQ) to provide compound I-9. Alternatively, compound I-10 may be reacted with compound I-5 and compound I-8 under similar conditions to provide compound I-11. Compound I-11 can then be reacted sequentially with hydroxylamine to provide a N-hydroxycarboximidamide intermediate, followed by reaction with CDI to provide compound I-9.

[0454] Compound I-9 may then undergo deprotection and subsequent cyclization under suitable conditions (such as in the presence of TFA) to provide compounds of Formula IB. In certain embodiments, when control of stereochemistry is desired, proper control of reaction conditions and selection of substituents for the reagents can at least partially dictate or preserve the formation of the various stereoisomers.

[0455] Upon each reaction completion, each of the intermediates or final compounds can be recovered, and optionally purified, by conventional techniques such as neutralization, extraction, precipitation, chromatography, filtration, and the like. Other modifications to arrive at compounds of this disclosure are within the skill of the art.

General Synthesis


[0456] Typical embodiments of compounds described herein may be synthesized using the general reaction schemes described below. It will be apparent given the description herein that the general schemes may be altered by substitution of the starting materials with other materials having similar structures to result in products that are correspondingly different. Descriptions of syntheses follow to provide numerous examples of how the starting materials may vary to provide corresponding products. Given a desired product for which the substituent groups are defined, the necessary starting materials generally may be determined by inspection. Starting materials are typically obtained from commercial sources or synthesized using published methods. For synthesizing compounds which are embodiments described in the present disclosure, inspection of the structure of the compound to be synthesized will provide the identity of each substituent group. The identity of the final product will generally render apparent the identity of the necessary starting materials by a simple process of inspection, given the examples herein. In general, compounds described herein are typically stable and isolatable at room temperature and pressure.

EXAMPLES


[0457] The following examples are included to demonstrate specific embodiments of the disclosure. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques to function well in the practice of the disclosure, and thus can be considered to constitute specific modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the disclosure.

[0458] General information: All evaporation or concentrations were carried out in vacuo with a rotary evaporator. Analytical samples were dried in vacuo (1-5 mmHg) at rt. Thin layer chromatography (TLC) was performed on silica gel plates, spots were visualized by UV light (214 and 254 nm). Purification by column and flash chromatography was carried out using silica gel (100-200 mesh). Solvent systems were reported as mixtures by volume. NMR spectra were recorded on a Bruker 400 or Varian (400 MHz) spectrometer. ¹H chemical shifts are reported in δ values in ppm with the deuterated solvent as the internal standard. Data are reported as follows: chemical shift, multiplicity (s=singlet, d=doublet, t=triplet, q=quartet, br=broad, m=multiplet), coupling constant (Hz), integration. LCMS spectra were obtained on SHIMADZU LC20-MS2020 or Agilent 1260 series 6125B mass spectrometer or Agilent 1200 series, 6110 or 6120 mass spectrometer with electrospray ionization and excepted as otherwise indicated.

[0459] Unless otherwise indicated in the examples described herein, certain compounds comprise a stereocenter at the carbon atom indicated below (e.g., compounds with stereochemistry at C3 or the C9a fusion), the composition obtained and tested in the assays which follow was a scalemic composition with respect to that stereocenter. It is contemplated that a certain amount of racemization (e.g., less than 50%, or less than 20%) occurs during the Hantzsch style pyridine synthesis. However, the compositions tested favor the stereoisomer indicated in the Examples and Table 1.



-continued





[0460] For certain compounds which were prepared without a chiral influence, the stereochemistry as indicated in the Examples and Table 1 may have been assigned based on expected potencies (e.g., the compounds of Examples 33, 34, 35, and 42).


[0461] Separation of the stereoisomers is or can, be, performed using standard techniques (e.g., SFC). For example:

Column name:	ChiralPak IH
Column size:	250*30 mm 10 μ m
Mobile Phase A:	Supercritical CO_2 ,
Mobile Phase B:	EtOH (0.1% $\text{NH}_3\text{H}_2\text{O}$)
A:B:	70:30
Flow:	150 mL/min
Gradient Time	4 min


Example 1: Compound 101



-continued




-continued




Step A ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-5-cyano-4-(5-((3,4-difluorobenzyl)carbamoyl)thiophen-2-yl)-6-(4-fluorophenethyl)-1,4-dihydropyridine-3-carboxylate

Step B ethyl (S)-2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-5-cyano-4-(5-((3,4-difluorobenzyl)carbamoyl)thiophen-2-yl)-6-(4-fluorophenethyl)nicotinate




[0462] A mixture of 5-(4-fluorophenyl)-3-oxopentanenitrile (350 mg, 1.830 mmol), N-(3,4-difluorobenzyl)-5-formylthiophene-2-carboxamide (514.87 mg, 1.830 mmol) and tert-butyl (S)-2-(3-ethoxy-1-imino-3-oxopropyl)pyrrolidine-1-carboxylate (520.51 mg, 1.830 mmol) in EtOH (1 mL) was stirred at 110° C. for 12 h. The mixture reaction was concentrated under reduced pressure to afford ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-5-cyano-4-(5-((3,4-difluorobenzyl)carbamoyl)thiophen-2-yl)-6-(4-fluorophenethyl)-1,4-dihydropyridine-3-carboxylate (1.2 g, crude). LC-MS: m/z 721.0 (M+H)⁺.




[0463] To a mixture of ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-5-cyano-4-(5-((3,4-difluorobenzyl)carbamoyl)thiophen-2-yl)-6-(4-fluorophenethyl)-1,4-dihydropyridine-3-carboxylate (1.2 g, 1.665 mmol) and diammonium cerium(IV) nitrate (1.37 g, 2.497 mmol) in EtOH (10 mL) was stirred at 50° C. for 2 hr. After the reaction was completed, the reaction was washed with H₂O (100 mL) and extracted with EA (60 mL×3), the organic layer dried over sodium sulfate, filtered and concentrated in vacuum. The reaction was purified by column chromatography (PE/EA=1/1) to afford ethyl (S)-2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-5-cyano-4-(5-((3,4-difluorobenzyl)carbamoyl)thiophen-2-yl)-6-(4-fluorophenethyl)nicotinate (200 mg, 0.278 mmol, 16.71%). LC-MS: m/z 618.7 (M-100)⁺.

Step C ethyl (S)-5-cyano-4-(5-((3,4-difluorobenzyl)carbamoyl)thiophen-2-yl)-6-(4-fluorophenethyl)-2-(pyrrolidin-2-yl)nicotinate




[0464] To a mixture of ethyl (S)-2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-5-cyano-4-(5-((3,4-difluorobenzyl)carbamoyl)thiophen-2-yl)-6-(4-fluorophenethyl)nicotinate (200 mg, 0.278 mmol) in DCM (2 mL) was added TFA (2 mL) and stirred at room temperature for 1 hour. After the reaction was completed, the reaction was concentrated in vacuum to afford ethyl (S)-5-cyano-4-(5-((3,4-difluorobenzyl)carbamoyl)thiophen-2-yl)-6-(4-fluorophenethyl)-2-(pyrrolidin-2-yl)nicotinate TFA (170 mg crude). LC-MS: m/z 618.8 ($M+H$)⁺.

Step D (S)-5-(3-cyano-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-N-(3,4-difluorobenzyl)thiophene-2-carboxamide




[0465] To a mixture of ethyl (S)-5-cyano-4-(5-((3,4-difluorobenzyl)carbamoyl)thiophen-2-yl)-6-(4-fluorophenethyl)-2-(pyrrolidin-2-yl)nicotinate TFA (170 mg, 0.275 mmol) in DCM (1.5 mL) was added TEA (0.3 mL, 2.158 mmol) and stirred at room temperature for 1 hour. The reaction was concentrated in vacuum and purified by reversed phase chromatography (0.1% FA) to afford (S)-5-(3-cyano-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-N-(3,4-difluorobenzyl)thiophene-2-carboxamide (80 mg, 0.140 mmol, 50.84%). LC-MS: m/z 573.2 ($M+H$)⁺.

Step E (S,Z)—N-(3,4-difluorobenzyl)-5-(2-(4-fluorophenethyl)-3-(N'-hydroxycarbamimidoyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-thiophene-2-carboxamide



[0466] A mixture of (S)-5-(3-cyano-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-N-(3,4-difluorobenzyl)thiophene-2-carboxamide (60 mg, 0.105 mmol), NH₂OH in water (0.5 mL, 0.017 mmol) and TEA (0.044 mL, 0.314 mmol) in EtOH (1.0 mL) was stirred at 120° C. for 2 hr. The reaction was diluted with H₂O (40 mL) and extracted with EA (30 mL×3), the organic layer dried over sodium sulfate, filtered and concentrated in vacuum. The reaction was purified by column chromatography (DCM/MeOH=15/1) to afford (S,Z)—N-(3,4-difluorobenzyl)-5-(2-(4-fluorophenethyl)-3-(N'-hydroxycarbamimidoyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-thiophene-2-carboxamide (15 mg, 0.025 mmol, 23.64%). LC-MS: m/z 605.7 ($M+H$)⁺.

Step F Compound 101




[0467] To a mixture of (S,Z)—N-(3,4-difluorobenzyl)-5-(2-(4-fluorophenethyl)-3-(N'-hydroxycarbamimidoyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-thiophene-2-carboxamide (15 mg, 0.025 mmol), CDI (4.02 mg, 0.025 mmol) and TEA (0.010 mL, 0.074 mmol) in THF (2 mL) was stirred at 70° C. for 6 hr. The reaction was washed with H₂O (40 mL) and extracted with EA (40 mL×3), the organic layer dried over sodium sulfate, filtered

and concentrated in vacuum. The reaction was purified by Prep-HPLC to afford Compound 101 (1.02 mg, 0.002 mmol, 6.52%).

[0468] ^1H NMR (400 MHz, $\text{CDCl}_3\text{-d+CD}_3\text{OD}$): δ 7.45-7.50 (m, 1H), 7.10-7.22 (m, 6H), 6.97 (t, $J=8.0$ Hz, 2H), 4.72-4.82 (m, 1H), 4.52 (s, 2H), 3.69-3.76 (m, 1H), 3.37-3.47 (m, 1H), 3.01-3.20 (m, 4H), 2.20-2.34 (m, 3H), 1.39-1.46 (m, 1H). ^{19}F NMR (377 MHz, $\text{CDCl}_3\text{-d+CD}_3\text{OD-d4}$): -116.83, -137.52, -139.81. LC-MS: m/z 632.2 (M+H^+).


Compound 110



[0469] Compound 110 was synthesized using similar procedure as described in Example 1 above by using the appropriate materials.

[0470] ^1H NMR (400 MHz, DMSO-d6): δ 7.43-7.54 (m, 3H), 7.28-7.35 (m, 2H), 7.20-7.24 (m, 2H), 7.05-7.15 (m, 4H), 4.87 (d, $J=3.2$ Hz, 1H), 4.74 (dd, $J=6.0$ Hz, $J=10.0$ Hz, 1H), 4.39 (t, $J=7.6$ Hz, 2H), 3.49-3.52 (m, 1H), 3.23-3.25 (m, 1H), 3.09 (t, $J=8.0$ Hz, 2H), 2.97-3.04 (m, 4H), 2.33-2.39 (m, 1H), 2.20-2.25 (m, 2H), 1.31-1.36 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d6): δ -117.45, -139.15, -142.17. LC-MS: m/z 636.3 (M+H^+).


Compound 111



[0471] Compound 111 was synthesized using similar procedure as described in Example 1 above by using the appropriate materials.

[0472] ^1H NMR (400 MHz, DMSO-d6): δ 12.72 (br s, 1H), 8.27 (d, $J=8.8$ Hz, 1H), 8.10-8.17 (m, 1H), 7.87 (d, $J=5.6$ Hz, 1H), 7.63 (br s, 1H), 7.31-7.44 (m, 3H), 7.19-7.28 (m, 3H), 7.10 (t, $J=8.8$ Hz, 2H), 6.90 (d, $J=5.6$ Hz, 1H), 4.87 (dd, $J=5.6$ Hz, $J=10.0$ Hz, 1H), 4.73 (d, $J=5.6$ Hz, 2H), 3.48-3.59 (m, 1H), 3.24-3.27 (m, 1H), 2.98-3.17 (m, 4H), 2.22-2.41 (m, 3H), 1.32-2.46 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d6): -117.10, -139.25, -142.13. LC-MS: m/z 649.1 (M+H^+).


Compound 113



[0473] Compound 113 was synthesized using similar procedure as described in Example 1 above by using the appropriate materials.

[0474] ^1H NMR (400 MHz, DMSO-d6): δ 12.65 (br s, 1H), 7.38-7.46 (m, 3H), 7.20-7.25 (m, 4H), 7.05-7.12 (m, 3H), 5.06 (t, $J=5.6$ Hz, 1H), 4.83 (dd, $J=6.4$ Hz, $J=10.4$ Hz, 1H), 4.55-4.65 (m, 2H), 3.49-3.56 (m, 1H), 3.21-3.25 (m, 1H), 2.95-3.13 (m, 5H), 2.75-2.84 (m, 1H), 2.21-2.43 (m, 4H), 1.98-2.10 (m, 1H), 1.31-1.43 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d6): -117.10, -138.93, -140.74. LC-MS: m/z 639.2 (M+H^+).

Compound 114




[0475] Compound 114 was synthesized using similar procedure as described in Example 1 above by using the appropriate materials.


[0476] ^1H NMR (400 MHz, DMSO-d₆): δ 12.52 (br s, 1H), 7.39-7.51 (m, 1H), 7.31-7.38 (m, 1H), 7.18-7.25 (m, 2H), 7.06-7.16 (m, 3H), 6.97 (dd, $J=8.4$ Hz, $J=2.4$ Hz, 1H), 6.89-6.93 (m, 1H), 6.60-6.71 (m, 1H), 4.78 (dd, $J=10.0$ Hz, $J=6.0$ Hz, 1H), 3.48-3.53 (m, 2H), 3.20-3.31 (m, 3H), 3.01-3.12 (m, 3H), 2.78-2.86 (m, 2H), 2.57-2.66 (m, 2H), 2.18-2.40 (m, 4H), 1.74-1.86 (m, 2H), 1.18-1.37 (m, 2H). ^{19}F NMR (377 MHz, DMSO-d₆): -74.40, -117.10, -139.21, -142.51. LC-MS: m/z 652.3 ($\text{M}+\text{H}$)⁺

Example 2


5-((S)-2-(4-fluorophenethyl)-4-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one
(Compound 102)



-continued




Step A 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one




[0477] To a solution of LDA (2.0 M, 10.70 mL) in THF (25 mL) was added 5-methyl-3H-1,3,4-oxadiazol-2-one (1.02 g, 10.19 mmol) at -10°C under N₂. The mixture was stirred at -10°C for 30 min. Ethyl 3-(4-fluorophenyl)propanoate (1.0 g, 5.10 mmol) in THF (5.0 mL) was added into the reaction solution. The mixture was stirred at -10°C for 1 hr. To the solution was added HCl (1 M) until pH=6~7. The mixture was extracted with EtOAc (100 mL). The organic layer was washed with brine (80 mL), dried over anhydrous of Na₂SO₄, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (ISCO®, 20 g SepaFlash® Silica Flash Column, Eluent of 0~60% Ethyl acetate/Petroleum ether, gradient @25 mL/min) to give 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one (166 mg, 663.40 μmol , 13.02% yield, 80% purity by TLC). LC-MS: m/z 250.0

Step B 5-((9aS)-2-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-1,5,7,8,9,9a-hexahydro-4H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one



[0478] A mixture of (8S)-5,6,7,8-tetrahydropyrrolizine-1,3-dione (21.45 mg, 154.13 µmol), (R)-7-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (50 mg, 154.13 µmol), NH₄OAc (17.82 mg, 231.20 µmol) and 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one (38.57 mg, 154.13 µmol) in AcOH (0.5 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 120° C. for 2 hrs under N₂ atmosphere. The mixture was cooled to room temperature and poured into water (5 mL), extracted with EtOAc (25 mL). The organic layer was washed with the aqueous of NaHCO₃ solution (25 mL), then brine (25 mL), dried over anhydrous of Na₂SO₄, concentrated in vacuum. The crude product 5-((9aS)-2-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-1,5,7,8,9,9a-hexahydro-4H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (56 mg, crude) was obtained. LC-MS: m/z 677.7 (M+H)⁺.


Step C 5-((S)-2-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one



[0479] To a solution of 5-((9aS)-2-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-1,5,7,8,9,9a-hexahydro-4H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (56.00 mg, crude) in ACN (5 mL) and water (2.5 mL) was added CAN (90.73 mg, 165.49 µmol). The mixture was stirred at 20° C. for 16 hrs. The mixture was poured into water (25 mL), extracted with EtOAc (25 mL). The organic layer was washed with brine (25 mL), dried over Na₂SO₄, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0~10% MeOH/DCM gradient @12 mL/min), then re-purified by prep-HPLC (FA condition). Column: Kromasil C18 150*30 mm*5 µm; Condition: water (0.2% Formic acid)-ACN; Begin B: 25 End B: 55; Gradient Time (min): 10; 100% B Hold Time (Time): 5; Flow Rate (mL/min): 25; Detection wavelength: 220 nm and 254 nm) to give 5-((S)-2-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (1.77 mg, 2.49 µmol, 3.01% yield, 95% purity).

[0480] ¹H NMR (400 MHz, CDCl₃) δ ppm 8.06 (d, J=5.6 Hz, 1H), 7.39 (s, 1H), 7.17-7.22 (m, 1H), 7.09-7.16 (m, 2H), 7.06 (d, J=5.60 Hz, 1H), 6.93-7.02 (m, 3H), 6.76 (d, J=8.0 Hz, 1H), 5.83 (s, 1H), 4.74-4.78 (m, 1H), 3.85 (s, 3H), 3.71-3.80 (m, 1H), 3.39-3.43 (m, 1H), 2.95-3.22 (m, 5H), 2.79-2.88 (m, 1H), 2.72-2.78 (m, 1H), 2.48-2.55 (m, 1H), 2.32-2.41 (m, 2H), 1.91-1.99 (m, 2H), 1.47 (m, 1H). LC-MS: m/z 675.2 (M+H)⁺.


(S)—N-(3,4-difluorobenzyl)-5-(2-(4-fluorophenethyl)-5-oxo-3-(3-oxo-2,3-dihydroisoxazol-5-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)thiophene-2-carboxamide (Compound 103)




[0481] Compound 103 was synthesized using similar procedure as described in Example 2 above by using the appropriate materials.

[0482] ¹H NMR (400 MHz, DMSO-d₆) δ ppm 11.42 (s, 1H), 9.11-9.39 (m, 1H), 7.70 (d, J=4.0 Hz, 1H), 7.35-7.44 (m, 2H), 7.03-7.20 (m, 6H), 6.04 (s, 1H), 4.81-4.85 (m, 1H), 4.38-4.49 (m, 2H), 3.51-3.60 (m, 1H), 2.88-3.08 (m, 4H), 2.11-2.44 (m, 4H), 1.33-1.45 (m, 1H). LC-MS: m/z 633.2


Example 3: Compound 104



-continued




Step A {2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolan-2-yl}acetonitrile



[0483] To a solution of 5-(4-fluorophenyl)-3-oxopenta-nitrile (5 g, 26.149 mmol) in DCM (130 mL) were added ethylene glycol (4.375 mL, 78.448 mmol) and TMSCl (8.52 g, 78.448 mmol), and the reaction was stirred at 40° C. for 48 hr. The reaction was diluted with EA (200 mL) and water (100 mL). The organic layer was separated, washed with further water (100 mL×2) and saturated NaCl (100 mL). The organic layer was separated, dried with Na₂SO₄ and then filtered. The organic layer was collected, concentrated in vacuo. The residue was purified using silica gel column chromatography eluting with PE:EA=3:1. The organic layer was collected, concentrated in vacuo, and dried to afford the


title compound {2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolan-2-yl}acetonitrile (5.8 g, 24.654 mmol, 94.28%). LC-MS: m/z 257.9 ($M+Na^+$)⁺.

Step B [(Z)-1-amino-2-{2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolan-2-yl}ethylidene]hydroxylamine




[0484] To a solution of {2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolan-2-yl}acetonitrile (5.8 g, 24.654 mmol) in EtOH (110 mL) were added hydroxyaminehydrochloride (5.14 g, 73.962 mmol) and DIEA (19.12 g, 147.921 mmol), and the reaction was stirred at 50° C. for 18 hr. The reaction was diluted with EA (100 mL) and water (50 mL). The organic layer was separated, washed with further water (100 mL×2) and saturated NaCl (50 mL). The organic layer was dried with Na_2SO_4 and then filtered. The organic layer was collected, concentrated in vacuo. The residue was purified using silica gel column chromatography eluting with PE:EA=1:1. The organic layer was collected, concentrated in vacuo, and dried to afford the title compound [(1Z)-1-amino-2-{2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolan-2-yl}ethylidene]hydroxylamine (4.7 g, 17.518 mmol, 71.06%). LC-MS: m/z 269.1 ($M+H^+$)⁺.

Step C 3-{2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolan-2-yl}methyl)-4H,5H-1,2,4-oxadiazol-5-one




[0485] To a solution of [(1Z)-1-amino-2-{2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolan-2-yl}ethylidene]hydroxyl amine (2 g, 7.455 mmol) in dioxane (100 mL) were added CDI (1.21 g, 7.455 mmol), and the reaction was stirred at 70° C. for 18 hr. The reaction was diluted with EA (100 mL) and water (50 mL). The organic layer was separated, washed with further water (100 mL×2) and saturated NaCl (50 mL). The organic layer was dried with Na_2SO_4 and then filtered. The organic layer was collected, concentrated in vacuo. The residue was purified using silica gel column chromatography eluting with DCM:MeOH=96:4. The organic layer was collected, concentrated in vacuo, and dried to afford the title compound 3-{2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolan-2-yl}methyl)-4H,5H-1,2,4-oxadiazol-5-one (1.7 g, 5.777 mmol, 77.49%). LC-MS: m/z 317.2 ($M+Na^+$)⁺.

Step D 3-[4-(4-fluorophenyl)-2-oxobutyl]-4H,5H-1,2,4-oxadiazol-5-one




[0486] To a solution of 3-{2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolan-2-yl}methyl)-4H,5H-1,2,4-oxadiazol-5-one (700 mg, 2.379 mmol) in FA (7 mL) were added conc. H_2SO_4 (0.127 mL, 2.379 mmol), and the reaction was stirred at 45° C. for 1 hr. The reaction was diluted with EA (50 mL) and water (20 mL). The organic layer was separated, washed with further water (20 mL×2) and saturated NaCl (20 mL). The organic layer was dried with Na_2SO_4 and then filtered. The organic layer was collected, concentrated in vacuo. The residue was purified using silica gel column chromatography eluting with DCM:MeOH=96:4. The organic layer was collected, concentrated in vacuo, and dried to afford the title compound 3-[4-(4-fluorophenyl)-2-oxobutyl]-4H,5H-1,2,4-oxadiazol-5-one (490 mg, 1.958 mmol, 82.32%). LC-MS: m/z 273.0 ($M+Na^+$)⁺.

Step E ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-chlorothieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,4-dihydropyridine-3-carboxylate




[0487] A mixture of 3-(4-(4-fluorophenyl)-2-oxobutyl)-1,2,4-oxadiazol-5(4H)-one (1000 mg, 3.996 mmol), 7-chlorothieno[2,3-c]pyridine-2-carbaldehyde (789.83 mg, 3.996 mmol), tert-butyl (S)-2-(3-ethoxy-3-oxopropanoyl)pyrrolidine-1-carboxylate (1140.31 mg, 3.996 mmol), NH₄OAC (616.07 mg, 7.993 mmol) and Yb((OTf)₃ (247.77 mg, 0.400 mmol) in EtOH (20 mL) was stirred at room temperature for overnight. After the reaction was completed, the mixture was diluted with EA (50 mL) and washed with water (150 mL). The organic layers were dried over Na_2SO_4 , filtered and concentrated to give ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-chlorothieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,4-dihydropyridine-3-carboxylate (2800 mg, crude). LC-MS: m/z 695.4 ($M+H^+$)⁺.

Step F ethyl (S)-2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-chlorothieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)nicotinate



[0488] To a solution of ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-chlorothieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,4-dihydropyridine-3-carboxylate (2800 mg, crude) in THF (30 mL) was added DDQ (1278.16 mg, 5.631 mmol), and the reaction was stirred at 50° C. for 12 hr. After the reaction was completed, the mixture was diluted with EA (50 mL) and washed with water (200 mL). The organic layers were dried over Na₂SO₄, filtered and concentrated under vacuum to dryness. The residue was purified by column chromatography on silica gel (DCM/MeOH=20/1) to give ethyl (S)-2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-chlorothieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)nicotinate (2 g, impure). LC-MS: m/z 693.4 (M+H)⁺.


Step G ethyl (S)-4-(7-chlorothieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-2-(pyrrolidin-2-yl)nicotinate TFA salt



[0489] To a solution of ethyl (S)-2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-chlorothieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)nicotinate (2.0 g, impure) in DCM (30 mL) was added TFA (7 mL, 91.414 mmol) and the reaction was stirred at room temperature for 1 hr. After the reaction was completed, the mixture was concentrated to give ethyl


(S)-4-(7-chlorothieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-2-(pyrrolidin-2-yl)nicotinate TFA salt (2.5 g, crude). LC-MS: m/z 593.4 (M+H)⁺.

Step H (S)-3-(4-(7-chlorothieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one



[0490] To a solution of ethyl (S)-4-(7-chlorothieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-2-(pyrrolidin-2-yl)nicotinate TFA salt (2.5 g, crude) in DCM (30 mL) was added TEA (12 mL, 86.333 mmol), and the reaction was stirred at room temperature for 1 hr. After the reaction was completed, the mixture was diluted with EA (100 mL), washed with water (300 mL). The organic layers were dried over Na₂SO₄, filtered and concentrated under vacuum to dryness. The residue was purified by column chromatography on silica gel (DCM/MeOH=20/1) to give (S)-3-(4-(7-chlorothieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (640 mg, 1.168 mmol, 29.22%). LC-MS: m/z 547.4 (M+H)⁺.


Step I—Compound 104



[0491] To a solution of (S)-3-(4-(7-chlorothieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (100 mg, 0.183 mmol), (R)-4-methoxy-2,3-dihydro-1H-inden-1-amine (61.85 mg, 0.311 mmol), RuPhos Pd G₃ (15.29 mg, 0.018 mmol), RuPhos (16.80 mg, 0.036 mmol) and Cs₂CO₃ (119.20 mg, 0.366 mmol) in toluene (3 mL) in a 10 mL sealed tube under N₂. The mixture was stirred at 110° C. for overnight. After the reaction was completed, the mixture was filtered and concentrated under vacuum to dryness. The residue was purified by column chromatography on silica gel (DCM/MeOH=20/1) to give Compound 104 (20 mg, crude). The residue was purified by column chromatography on C₁₈-25 g (FA 0.1%/ACN=36%) to give Compound 104 (2.98 mg, 2.43%).

[0492] ¹H NMR (400 MHz, DMSO-d₆): δ 12.79 (br s, 1H), 7.98 (d, J=5.2 Hz, 1H), 7.41 (s, 1H), 7.19-7.33 (m, 3H), 7.04-7.17 (m, 4H), 6.79-6.88 (m, 2H), 5.90 (q, J=8.0 Hz, 1H), 4.87 (dd, J=6.0 Hz, J=10.0 Hz, 1H), 3.79 (s, 3H), 3.50-3.59 (m, 1H), 3.26-3.28 (m, 1H), 2.89-3.18 (m, 6H), 2.65-2.75 (m, 1H), 2.22-2.40 (m, 3H), 1.95-2.07 (m, 1H), 1.33-1.46 (m, 1H). ¹⁹F NMR (377 MHz, DMSO-d₆): -117.07. LC-MS: m/z 675.3 (M+H)⁺.


4-(5-((3,4-difluorobenzyl)carbamoyl)thiophen-2-yl)-6-(4-fluorobenzyl)-2-isobutyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)nicotinamide (Compound 123)



[0493] Compound 123 was synthesized using a similar procedure described in the Example 3 above by using the appropriate materials.

[0494] ¹H NMR (400 MHz, MeOD-d₄) δ 7.78 (d, J=6.85 Hz, 1H), 7.65 (s, 1H), 7.57 (br d, J=7.95 Hz, 2H), 7.37-7.45 (m, 1H), 7.41 (dd, J=7.64, 10.33 Hz, 3H), 7.28 (t, J=7.89 Hz, 1H), 6.98 (d, J=7.46 Hz, 1H), 6.92 (d, J=8.19 Hz, 1H), 5.52 (br t, J=6.85 Hz, 1H), 3.86 (s, 3H), 3.61-3.73 (m, 1H), 3.40-3.52 (m, 1H), 3.26-3.30 (m, 4H), 3.17-3.26 (m, 1H), 3.05-3.17 (m, 1H), 2.83-2.96 (m, 1H), 2.69-2.70 (m, 1H), 2.68-2.81 (m, 1H), 2.37-2.53 (m, 3H), 2.10-2.22 (m, 1H), 1.37-1.50 (m, 1H). LC-MS: m/z 725.4 (M+H)⁺.


3-((S)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-2-(3-(trifluoromethyl)phenethyl)-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (Compound 124)



[0495] Compound 124 was synthesized using a similar procedure described in the Example 3 above by using the appropriate materials.

[0496] ¹H NMR (400 MHz, MeOD) δ ppm 8.24 (s, 1H), 7.79 (d, J=6.36 Hz, 1H), 7.44-7.55 (m, 5H), 7.16-7.30 (m, 2H), 6.94 (d, J=7.34 Hz, 1H), 6.87 (d, J=8.07 Hz, 1H), 5.61 (t, J=6.91 Hz, 1H), 4.65 (m, 1H), 3.85 (s, 3H), 3.55-3.73 (m, 1H), 3.35-3.51 (m, 1H), 3.04-3.25 (m, 5H), 2.83 (dt, J=16.11, 7.90 Hz, 1H), 2.65-2.75 (m, 1H), 2.42 (d, J=13.69 Hz, 3H), 2.04-2.15 (m, 1H), 1.34-1.46 (m, 1H). LC-MS: m/z 725.4 (M+H)⁺.


3-((S)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-2-(2-(trifluoromethyl)phenethyl)-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (Compound 125)



[0497] Compound 125 was synthesized using a similar procedure described in the Example 3 above by using the appropriate materials.

[0498] ^1H NMR (400 MHz, MeOD-d₄) δ 7.66-7.71 (m, 1H), 7.53-7.59 (m, 2H), 7.42-7.50 (m, 1H), 7.25-7.37 (m, 3H), 7.14-7.21 (m, 1H), 6.80-6.92 (m, 2H), 5.37-5.47 (m, 1H), 3.73-3.81 (m, 3H), 3.49-3.63 (m, 1H), 3.30-3.40 (m, 1H), 3.17 (d, J=1.71 Hz, 4H), 2.97-3.05 (m, 1H), 2.75-2.82 (m, 1H), 2.58-2.71 (m, 1H), 2.27-2.47 (m, 3H), 2.00-2.13 (m, 1H), 1.31-1.45 (m, 1H), 1.21-1.24 (m, 1H). LC-MS: m/z 725.4 (M+H)⁺.


3-((S)-2-(4-isopropylphenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (Compound 126)



[0499] Compound 126 was synthesized using a similar procedure described in the Example 3 above by using the appropriate materials.

[0500] ^1H NMR (400 MHz, DMSO-d₆) δ 9.24 (s, 1H), 7.89 (d, J=6.60 Hz, 1H), 7.63 (s, 1H), 7.40 (d, J=6.60 Hz, 1H), 7.23 (t, J=7.82 Hz, 1H), 7.11-7.16 (m, 5H), 6.94 (dd, J=7.83, 15.16 Hz, 2H), 5.64 (q, J=7.09 Hz, 1H), 4.91 (dd, J=6.30, 10.21 Hz, 1H), 3.81 (s, 3H), 3.12-3.17 (m, 2H), 3.05 (d, J=5.50 Hz, 1H), 2.94-3.00 (m, 2H), 2.71-2.86 (m, 4H), 2.62 (td, J=4.55, 12.65 Hz, 1H), 2.32-2.38 (m, 1H), 2.23-2.31 (m, 2H), 2.10 (dd, J=7.89, 12.78 Hz, 1H), 1.35-1.47 (m, 1H), 1.16 (d, J=6.85 Hz, 6H). LC-MS: m/z 699.4 (M+H)⁺.


3-((S)-2-(4-cyclopropylphenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (Compound 127)



[0501] Compound 127 was synthesized using a similar procedure described in the Example 3 above by using the appropriate materials.

[0502] ^1H NMR (400 MHz, MeOD-d₄) δ ppm 8.32 (s, 1H), 7.84 (d, J=6.24 Hz, 1H), 7.51 (s, 1H), 7.19-7.28 (m, 2H), 7.07 (d, J=7.95 Hz, 2H), 6.93-7.01 (m, 3H), 6.87 (d, J=7.44 Hz, 1H), 5.67 (t, J=6.79 Hz, 1H), 4.63 (s, 1H), 3.86 (m, 3H), 3.62-3.73 (m, 1H), 3.38-3.48 (m, 1H), 3.13-3.20 (m, 2H), 2.98-3.12 (m, 3H), 2.84 (dt, J=16.11, 8.15 Hz, 1H), 2.67-2.76 (m, 1H), 2.37-2.54 (m, 3H), 2.09 (br dd, J=12.41, 8.13 Hz, 1H), 1.83-1.90 (m, 1H), 1.38-1.50 (m, 1H), 0.89-0.95 (m, 2H), 0.64 (d, J=4.89 Hz, 2H). LC-MS: m/z 697.5 (M+H)⁺.


4-(5-((3,4-difluorobenzyl)carbamoyl)thiophen-2-yl)-6-(4-fluorobenzyl)-2-isobutyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)nicotinamide (Compound 128)



[0503] Compound 128 synthesized using a similar procedure described in the Example 3 above by using the appropriate materials.

[0504] ^1H NMR (400 MHz, MeOD-d₄) δ 7.78 (d, J=6.85 Hz, 1H), 7.67 (d, J=2.57 Hz, 1H), 7.43 (d, J=6.85 Hz, 1H), 7.28 (t, J=7.83 Hz, 1H), 6.90-7.10 (m, 3H), 6.78-6.88 (m, 1H), 5.52 (t, J=6.66 Hz, 1H), 3.86 (s, 3H), 3.63-3.81 (m, 2H), 3.46 (dd, J=5.93, 11.19 Hz, 1H), 3.36-3.43 (m, 1H), 3.36-3.42 (m, 1H), 3.07-3.16 (m, 1H), 2.65-3.06 (m, 6H), 2.39-2.56 (m, 3H), 2.10-2.27 (m, 2H), 1.80-1.98 (m, 1H), 1.50 (d, J=3.91 Hz, 1H). LC-MS: m/z 701.4 (M+H)⁺.


Compound 130



[0505] Compound 130 was synthesized using a similar procedure described in the Example 3 above by using the appropriate materials.

[0506] ^1H NMR (400 MHz, DMSO-d₆): δ 12.84 (br s, 1H), 7.85-7.95 (m, 1H), 7.17-7.66 (m, 8H), 7.10 (t, J=8.8 Hz, 2H), 4.86-4.97 (m, 1H), 4.64-4.79 (m, 2H), 3.54-3.58 (m, 1H), 3.16-3.21 (m, 2H), 3.03-3.15 (m, 3H), 2.36-2.40 (m, 1H), 2.26-2.34 (m, 2H), 1.36-1.48 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d₆): -117.01, -71.08, -69.19. LC-MS: m/z 655.2 (M+H)⁺.


(S)-3-(4-(7-((3,4-difluorobenzyl)oxy)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (Compound 133)



[0507] Compound 133 was synthesized using a similar procedure described in the Example 3 above by using the appropriate materials.

[0508] ^1H NMR (400 MHz, MeOD-d₄) δ 7.92-7.99 (m, 1H), 7.40-7.49 (m, 1H), 7.29-7.38 (m, 2H), 7.14-7.24 (m, 2H), 7.06-7.12 (m, 2H), 6.84-6.93 (m, 2H), 5.45 (s, 2H), 3.51-3.62 (m, 1H), 3.28-3.39 (m, 1H), 3.07-3.14 (m, 2H), 2.91-3.04 (m, 2H), 2.23-2.45 (m, 3H), 1.29-1.45 (m, 1H), 1.19 (m, 1H). LC-MS: m/z 656.1 (M+H)⁺.


(S)-3-(4-(7-(4-fluoroisoindolin-2-yl)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (Compound 137)



[0509] Compound 137 was synthesized using a similar procedure described in the Example 3 above by using the appropriate materials.

[0510] ^1H NMR (400 MHz, MeOD-d₄) δ 7.79-7.89 (m, 1H), 7.72 (s, 1H), 7.44-7.56 (m, 2H), 7.35 (d, J=7.70 Hz, 1H), 7.16-7.27 (m, 3H), 6.94-7.07 (m, 2H), 5.39-5.54 (m, 4H), 3.64-3.77 (m, 1H), 3.43-3.53 (m, 1H), 3.23-3.31 (m, 3H), 3.22 (m, 2H), 2.40-2.59 (m, 3H), 1.43-1.57 (m, 1H). LC-MS: m/z 649.3 (M+H)⁺.


(S)-3-(4-(7-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (Compound 138)



[0511] Compound 138 was synthesized using a similar procedure described in the Example 3 above by using the appropriate materials.

[0512] ^1H NMR (400 MHz, MeOD-d₄) δ 7.83-7.90 (m, 1H), 7.70-7.76 (m, 1H), 7.50 (d, J=6.72 Hz, 1H), 7.32-7.40 (m, 1H), 7.18-7.25 (m, 2H), 7.06-7.15 (m, 2H), 7.01 (t, J=8.74 Hz, 2H), 5.06 (s, 2H), 4.14 (s, 2H), 3.63-3.76 (m, 1H), 3.39-3.53 (m, 1H), 3.19-3.28 (m, 5H), 3.10-3.19 (m, 2H), 2.41-2.60 (m, 3H), 1.41-1.56 (m, 1H). LC-MS: m/z 663.3 ($\text{M}+\text{H}$)⁺.


Compound 139






[0513] Compound 139 was synthesized using a similar procedure described in the Example 3 above by using the appropriate materials.

[0514] ^1H NMR (400 MHz, DMSO-d₆): δ 12.79 (br s, 1H), 7.97 (d, J=5.6 Hz, 1H), 7.41 (s, 1H), 7.20-7.37 (m, 4H), 7.05-7.17 (m, 6H), 5.57-5.67 (m, 1H), 4.89 (dd, J=10.0 Hz, J=6.0 Hz, 1H), 3.49-3.60 (m, 1H), 3.24-3.28 (m, 1H), 2.99-3.18 (m, 4H), 2.72-2.84 (m, 2H), 2.23-2.38 (m, 3H), 1.71-2.04 (m, 4H), 1.34-1.47 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d₆): δ -117.06. LC-MS: m/z 659.3 ($\text{M}+\text{H}$)⁺.


Example 4 (Compound 148)



-continued




Step A ethyl (S)-2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-(((2,3-dihydro-1H-inden-5-yl)methyl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)nicotinate




[0515] A mixture of ethyl (S)-2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-chlorothieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)nicotinate (100 mg, 0.144 mmol), (2,3-dihydro-1H-inden-5-yl)methanamine (106.04 mg, 0.720 mmol), Cs_2CO_3 (234.68 mg, 0.720 mmol), RuPhos (13.44 mg, 0.029 mmol) and RuPhos-Pd-G3 (12.06 mg, 0.014 mmol) in NMP (2 mL) was stirred at 130° C. overnight under N_2 . After the reaction was completed, the mixture was filtered, diluted with EA (20 mL), washed with water (40 mL). The organic layers were dried over Na_2SO_4 , filtered and concentrated under vacuum to dryness. The residue was purified by Prep-TLC (DCM/MeOH=15/1) to give ethyl (S)-2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-(((2,3-dihydro-1H-inden-5-yl)methyl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)nicotinate (40 mg, 0.050 mmol, 34.49%). LC-MS: m/z 804.4 ($\text{M}+\text{H}^+$).

Step B ethyl (S)-4-(7-(((2,3-dihydro-1H-inden-5-yl)methyl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-2-(pyrrolidin-2-yl)nicotinate TFA Salt



[0516] To a solution of ethyl (S)-2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-(((2,3-dihydro-1H-inden-5-yl)methyl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)nicotinate (40 mg, 0.050 mmol) in DCM (3 mL) was added TFA (1 mL) and the reaction was stirred at room temperature for 1 h. After the reaction was completed, the mixture was concentrated to give ethyl (S)-4-(7-(((2,3-dihydro-1H-inden-5-yl)methyl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-2-(pyrrolidin-2-yl)nicotinate TFA salt (50 mg, crude). LC-MS: m/z 704.5 ($\text{M}+\text{H}^+$).


Step C Compound 148



[0517] To a solution of ethyl (S)-4-(7-(((2,3-dihydro-1H-inden-5-yl)methyl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-2-(pyrrolidin-2-yl)nicotinate TFA salt (50 mg, crude) in DCM (2 mL) was added TEA (1 mL), and the reaction was stirred at room temperature for 1 h. After the reaction was completed, the mixture was filtered, diluted with EA (20 mL), washed with water (40 mL). The organic layers were dried over Na_2SO_4 , filtered and concentrated under vacuum to dryness. The residue was purified by Prep-HPLC to give Compound 148 (9.99 mg, 0.015 mmol, 30.54%).

[0518] ^1H NMR (400 MHz, DMSO-d6): δ 12.79 (bs, 1H), 7.97 (d, $J=5.2$ Hz, 1H), 7.52 (s, 1H), 7.44 (s, 1H), 7.17-7.30 (m, 3H), 7.01-7.16 (m, 5H), 4.85-4.94 (m, 1H), 4.65 (d, $J=5.6$ Hz, 2H), 3.49-3.65 (m, 1H), 2.95-3.22 (m, 5H), 2.72-2.86 (m, 4H), 2.20-2.42 (m, 3H), 1.88-2.07 (m, 2H), 1.31-1.48 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d6): -117.05. LC-MS: m/z 659.3 ($\text{M}+\text{H}^+$).


(S)-3-(4-(7-((3,4-difluorobenzyl)(methyl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (Compound 107)



[0519] Compound 107 was synthesized using a similar procedure described in the Example 4 above by using the appropriate materials.

[0520] ^1H NMR (400 MHz, DMSO-d6): δ 12.81 (br s, 1H), 8.04 (d, $J=5.2$ Hz, 1H), 7.53 (s, 1H), 7.30-7.42 (m, 2H), 7.19-7.27 (m, 3H), 7.04-7.16 (m, 3H), 4.80-4.95 (m, 3H), 3.51-3.60 (m, 1H), 3.25 (s, 3H), 2.95-3.18 (m, 5H), 2.23-2.39 (m, 3H), 1.31-1.46 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d6): -141.23, -138.54, -117.07. LC-MS: m/z 669.3 ($\text{M}+\text{H}$) $^+$.


Compound 117



[0521] Compound 117 was synthesized using a similar procedure described in the Example 4 above by using the appropriate materials.

[0522] ^1H NMR (400 MHz, DMSO-d6): δ 12.77 (br s, 1H), 7.79-7.85 (m, 1H), 7.41 (s, 1H), 7.19-7.33 (m, 4H), 7.00-7.17 (m, 4H), 5.44-5.53 (m, 1H), 4.79-4.89 (m, 1H), 4.13-4.26 (m, 1H), 3.91-4.01 (m, 1H), 3.51-3.57 (m, 1H), 2.93-3.16 (m, 4H), 2.32-2.38 (m, 2H), 2.22-2.31 (m, 2H), 1.77-2.06 (m, 4H), 1.33-1.43 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d6): -142.17, -138.87, -117.17. LC-MS: m/z 695.2


Compound 140



[0523] Compound 140 was synthesized using a similar procedure described in the Example 4 above by using the appropriate materials.

[0524] ^1H NMR (400 MHz, DMSO-d6): δ 12.77 (br s, 1H), 7.86 (d, $J=5.2$ Hz, 1H), 7.44-7.55 (m, 2H), 7.18-7.43 (m, 5H), 7.04-7.17 (m, 3H), 5.35-5.47 (m, 1H), 4.87-4.95 (m, 1H), 3.51-3.59 (m, 1H), 2.98-3.22 (m, 5H), 2.36-2.42 (m, 1H), 2.25-2.33 (m, 2H), 1.47-1.59 (m, 3H), 1.36-1.46 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d6): -142.39, -139.21, -117.02. LC-MS: m/z 669.3 ($\text{M}+\text{H}$) $^+$.


Compound 141



[0525] Compound 141 was synthesized using a similar procedure described in the Example 4 above by using the appropriate materials.

[0526] ^1H NMR (400 MHz, DMSO-d6): δ 12.81 (br s, 1H), 7.86 (d, $J=6.0$ Hz, 1H), 7.45-7.53 (m, 2H), 7.18-7.44 (m, 5H), 7.05-7.17 (m, 3H), 5.36-5.47 (m, 1H), 4.91 (dd, $J=10.0$ Hz, $J=6.0$ Hz, 1H), 3.51-3.60 (m, 1H), 3.29-3.31 (m, 1H), 3.00-3.21 (m, 4H), 2.24-2.40 (m, 3H), 1.54 (d, $J=6.8$ Hz, 3H), 1.34-1.48 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d6): -142.03, -139.00, -117.02. LC-MS: m/z 669.3


Compound 146



[0527] Compound 146 was synthesized using a similar procedure described in the Example 4 above by using the appropriate materials.

[0528] ^1H NMR (400 MHz, DMSO-d6): δ 12.81 (br s, 1H), 7.92 (d, $J=5.6$ Hz, 1H), 7.51-7.68 (m, 2H), 7.47 (s, 1H), 7.29-7.38 (m, 2H), 7.21-7.27 (m, 2H), 7.04-7.16 (m, 3H), 4.90 (dd, $J=10.4$ Hz, $J=6.8$ Hz, 1H), 4.66 (d, $J=5.6$ Hz, 2H), 3.52-3.61 (m, 1H), 3.00-3.19 (m, 5H), 2.24-2.40 (m, 3H), 1.36-1.46 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d6): δ -117.03, -119.79. LC-MS: m/z 671.1 ($\text{M}+\text{H}$) $^+$.


Compound 147



[0529] Compound 147 was synthesized using a similar procedure described in the Example 4 above by using the appropriate materials.

[0530] ^1H NMR (400 MHz, DMSO-d6): δ 12.80 (br s, 1H), 7.91 (d, $J=5.6$ Hz, 1H), 7.58-7.65 (m, 1H), 7.50 (t, $J=8.0$ Hz, 1H), 7.45 (s, 1H), 7.35 (d, $J=10.0$ Hz, 1H), 7.18-7.28 (m, 3H), 7.05-7.13 (m, 3H), 4.89 (dd, $J=10.0$ Hz, $J=6.0$ Hz, 1H), 4.64-4.72 (m, 2H), 3.50-3.61 (m, 1H), 2.95-3.23 (m, 5H), 2.20-2.44 (m, 3H), 1.34-1.49 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d6): δ -116.94, -117.05. LC-MS: m/z 671.2 ($\text{M}+\text{H}$) $^+$.


Compound 149




[0531] Compound 149 was synthesized using a similar procedure described in the Example 4 above by using the appropriate materials.

[0532] ^1H NMR (400 MHz, DMSO-d6): δ 12.79 (br s, 1H), 7.91 (d, $J=5.2$ Hz, 1H), 7.51 (t, $J=6.0$ Hz, 1H), 7.43 (s, 1H), 7.22-7.26 (m, 2H), 7.16 (dd, $J=8.4$ Hz, 5.6 Hz, 1H), 7.04-7.11 (m, 4H), 6.85-6.89 (m, 1H), 4.87 (dd, $J=10.4$ Hz, $J=6.4$ Hz, 1H), 4.64 (d, $J=5.6$ Hz, 2H), 4.05 (q, $J=7.2$ Hz, 2H), 3.51-3.59 (m, 1H), 3.22-3.30 (m, 1H), 2.97-3.17 (m, 4H), 2.22-2.40 (m, 3H), 1.34-1.47 (m, 1H), 1.32 (t, $J=6.8$ Hz, 3H). ^{19}F NMR (377 MHz, DMSO-d6): δ -117.10, -138.13. LC-MS: m/z 681.2 ($\text{M}+\text{H}$) $^+$.

Example 5: Compound 109




-continued




Step A ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(5-(methoxycarbonyl)thiophen-2-yl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,4-dihydropyridine-3-carboxylate

trated in vacuo to afford the crude ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(5-(methoxycarbonyl)thiophen-2-yl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,4-dihydropyridine-3-carboxylate (2.5 g, crude). LC-MS: m/z 669.3 ($M+H$)⁺.



[0533] To a solution of 3-(4-(4-fluorophenyl)-2-oxobutyl)-1,2,4-oxadiazol-5(4H)-one (1 g, 4.00 mmol) in EtOH (10 mL) were added methyl 5-formylthiophene-2-carboxylate (680 mg, 4.00 mmol), tert-butyl (S)-2-(3-ethoxy-3-oxopropanoyl)pyrrolidine-1-carboxylate (1140 mg, 4.00 mmol), Yb(OTf)₃ (248 mg, 0.40 mmol) and NH₄OAc (616 mg, 8.00 mmol). The reaction was stirred at room temperature for 12 hours. The mixture was diluted with EA (200 mL×2), washed with water (50 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The reaction was concen-


Step B ethyl (S)-2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(5-(methoxycarbonyl)thiophen-2-yl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)nicotinate



[0534] A mixture of ethyl 4-((benzyloxy)carbonyl)thiophen-2-yl-2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-5-(5-methyl-1,3,4-oxadiazol-2-yl)-6-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1,4-dihydropyridine-3-carboxylate (2.5 g, crude), DDQ (1816 mg, 8.0 mmol) in THF (50 mL) was


stirred at 50° C. for 2 hours. The mixture was diluted with EA (500 mL) and washed with water (100 mL). The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with MeOH/DCM (1/20) to give ethyl (S)-2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(5-(methoxycarbonyl)thiophen-2-yl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)nicotinate (1.1 g, yield: 41.4%). LC-MS: m/z 667.3

Step C (S)-5-(2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-3-(ethoxycarbonyl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-4-yl)thiophene-2-carboxylic acid




[0535] To a solution of ethyl (S)-2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(5-(methoxycarbonyl)thiophen-2-yl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)nicotinate (1.1 g, 1.65 mmol) in THF (50 mL) was added NaOH (5 mL, 2 M in water) at room temperature and stirred at room temperature for 3 hours. The mixture was diluted with EA (100 mL) and adjusted by 1 M HCl (15 mL) until the pH<7. Then, the mixture was washed with H₂O (50 mL) and extracted with EA (100 mL×3). The organic layer was concentrated under reduced pressure to give (S)-5-(2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-3-(ethoxycarbonyl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-4-yl)thiophene-2-carboxylic acid (900 mg, yield: 83.6%). LC-MS: m/z 653.1 (M+H)⁺.

Step D (S)-5-(3-(ethoxycarbonyl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-2-(pyrrolidin-2-yl)pyridin-4-yl)thiophene-2-carboxylic acid TFA Salt




[0536] To a solution of (S)-5-(2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-3-(ethoxycarbonyl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)pyridin-4-yl)thiophene-2-carboxylic acid (900 mg, 1.38 mmol) in DCM (9 mL) was added TFA (9 mL) at room temperature and stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure to give (S)-5-(3-(ethoxycarbonyl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-2-(pyrrolidin-2-yl)pyridin-4-yl)thiophene-2-carboxylic acid TFA salt (1 g, crude). LC-MS: m/z 553.2 (M+H)⁺.

Step E (S)-5-(2-(4-fluorophenethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)thiophene-2-carboxylic acid



[0537] To a solution of (S)-5-(3-(ethoxycarbonyl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-2-(pyrrolidin-2-yl)pyridin-4-yl)thiophene-2-carboxylic acid TFA salt (1 g, crude) in DCM (5 mL) was added TEA (10 mL) at room temperature and stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure and purified by prep-HPLC to give (S)-5-(2-(4-fluorophenethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)thiophene-2-carboxylic acid (500 mg, yield: 71.6%). LC-MS: m/z 507.1 (M+H)⁺.

Step F Compound 109




[0538] To a solution of (S)-5-(2-(4-fluorophenethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)thiophene-2-carboxylic acid (40 mg, 0.079 mmol) in DMA (1 mL) were added HATU (36 mg, 0.0949 mmol), (3-methoxyphenyl)methanamine (14 mg, 0.103 mmol), and DIEA (39 mg, 0.103 mmol). The reaction was stirred at room temperature for 2 hours. The residue was purified by prep-HPLC to afford the Compound 109 (26.52 mg, yield: 54.1%).

[0539] ^1H NMR (400 MHz, DMSO-d₆): δ 12.78 (br s, 1H), 9.18 (t, J =6.0 Hz, 1H), 7.79 (d, J =4.0 Hz, 1H), 7.19-7.30 (m, 4H), 7.05-7.13 (m, 2H), 6.89-6.91 (m, 2H), 6.80-6.85 (m, 1H), 4.86 (dd, J =6.0 Hz, J =10.0 Hz, 1H), 4.44 (d, J =6.0 Hz, 2H), 3.74 (s, 3H), 3.53-3.61 (m, 1H), 3.31-3.32 (m, 1H), 2.94-3.15 (m, 4H), 2.24-2.38 (m, 3H), 1.34-1.45 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d₆): -117.05. LC-MS: m/z 626.2 ($\text{M}+\text{H}$)⁺.

5-((S)-2-(4-fluorophenethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-N—(R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)thiophene-2-carboxamide (Compound 108)


Compound 115



[0542] Compound 115 was synthesized using a similar procedure described in the Example 5 above by using the appropriate materials.


[0543] ^1H NMR (400 MHz, DMSO-d₆): δ 12.80 (br s, 1H), 7.34-7.70 (m, 3H), 7.19-7.28 (m, 3H), 7.05-7.18 (m, 3H), 4.85 (dd, J =10.4 Hz, J =6.0 Hz, 1H), 4.69 (s, 2H), 3.52-3.62 (m, 1H), 3.26-3.29 (m, 1H), 2.95-3.20 (m, 7H), 2.20-2.40 (m, 3H), 1.34-1.43 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d₆): -117.05, -138.50, -140.71. LC-MS: m/z 646.2 ($\text{M}+\text{H}$)⁺.

Compound 116



[0540] Compound 108 was synthesized using a similar procedure described in the Example 5 above by using the appropriate materials.

[0541] ^1H NMR (400 MHz, DMSO-d₆): δ 12.80 (br s, 1H), 8.94 (d, J =8.4 Hz, 1H), 7.78 (d, J =3.6 Hz, 1H), 7.17-7.28 (m, 4H), 7.04-7.13 (m, 2H), 6.86 (d, J =7.6 Hz, 2H), 5.46-5.56 (m, 1H), 4.79-4.89 (m, 1H), 3.80 (s, 3H), 3.49-3.62 (m, 2H), 2.91-3.05 (m, 3H), 2.66-2.75 (m, 2H), 2.22-2.39 (m, 4H), 1.87-2.05 (m, 2H), 1.33-1.45 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d₆): -117.09. LC-MS: m/z 652.3 ($\text{M}+\text{H}$)⁺.




[0544] Compound 116 was synthesized using a similar procedure described in the Example 5 above by using the appropriate materials.

[0545] ^1H NMR (400 MHz, DMSO-d₆): δ 12.80 (br s, 1H), 7.73 (s, 1H), 7.31-7.41 (m, 2H), 7.19-7.29 (m, 3H), 7.03-7.15 (m, 3H), 5.13-5.21 (m, 1H), 4.80-4.90 (m, 1H), 4.11-4.22 (m, 1H), 3.85-3.97 (m, 1H), 3.49-3.63 (m, 1H), 2.95-3.18 (m, 4H), 2.65-2.70 (m, 1H), 2.21-2.36 (m, 4H), 1.93-2.02 (m, 2H), 1.67-1.79 (m, 1H), 1.30-1.43 (m, 1H).

¹⁹F NMR (377 MHz, DMSO-d6): -117.06, -139.00, -141.97. LC-MS: m/z 672.2 (M+H)⁺.


Compound 120



[0546] Compound 118 was synthesized using a similar procedure described in the Example 5 above by using the appropriate materials.


[0547] ¹H NMR (400 MHz, DMSO-d6): δ 12.79 (br s, 1H), 9.25 (t, J=6.0 Hz, 1H), 7.77 (d, J=4.0 Hz, 1H), 7.58-7.61 (m, 2H), 7.32 (dd, J=1.6 Hz, J=8.0 Hz, 1H), 7.21-7.37 (m, 3H), 7.08 (t, J=8.8 Hz, 2H), 4.85 (dd, J=5.6 Hz, J=9.6 Hz, 1H), 4.46 (d, J=5.6 Hz, 2H), 3.54-3.59 (m, 1H), 3.27-3.33 (m, 1H), 2.97-3.15 (m, 4H), 2.27-2.36 (m, 3H), 1.36-1.40 (m, 1H). ¹⁹F NMR (377 MHz, DMSO-d6): -117.04. LC-MS: m/z 664.3 (M+H)⁺.

Compound 119



[0548] Compound 119 was synthesized using a similar procedure described in the Example 5 above by using the appropriate materials.


[0549] ¹H NMR (400 MHz, DMSO-d6): δ 12.80 (br s, 1H), 9.02 (t, J=6.0 Hz, 1H), 7.82 (d, J=4.0 Hz, 1H), 7.41-7.49 (m, 2H), 7.20-7.28 (m, 4H), 7.06-7.12 (m, 2H), 4.82-4.92 (m, 1H), 4.50 (d, J=5.6 Hz, 2H), 3.50-3.64 (m, 1H), 3.25-3.30 (m, 1H), 2.98-3.18 (m, 4H), 2.24-2.40 (m, 3H), 1.32-1.47 (m, 1H). ¹⁹F NMR (377 MHz, DMSO-d6): -113.52, -117.05. LC-MS: m/z 648.1 (M+H)⁺.



[0550] Compound 120 was synthesized using a similar procedure described in the Example 5 above by using the appropriate materials.

[0551] ¹H NMR (400 MHz, DMSO-d6): δ 12.81 (br s, 1H), 8.99 (d, J=8.0 Hz, 1H), 7.80 (d, J=4.0 Hz, 1H), 7.20-7.40 (m, 5H), 7.05-7.13 (m, 2H), 5.45 (q, J=8.0 Hz, 1H), 4.86 (dd, J=6.0 Hz, J=10.0 Hz, 1H), 3.53-3.60 (m, 1H), 3.28-3.34 (m, 2H), 2.94-3.17 (m, 5H), 2.78-2.88 (m, 1H), 2.26-2.38 (m, 3H), 1.97-2.06 (m, 1H), 1.34-1.44 (m, 1H). ¹⁹F NMR (377 MHz, DMSO-d6): -117.05, -139.94, -141.15. LC-MS: m/z 658.4 (M+H)⁺.


Compound 121






[0552] Compound 121 was synthesized using a similar procedure described in the Example 5 above by using the appropriate materials.

[0553] ¹H NMR (400 MHz, DMSO-d6): δ 12.80 (br s, 1H), 9.05 (d, J=8.8 Hz, 1H), 7.81 (dd, J=1.2 Hz, J=4.0 Hz, 1H), 7.37-7.42 (m, 1H), 7.19-7.34 (m, 6H), 7.06-7.12 (m, 2H), 5.39 (q, J=8.4 Hz, 1H), 4.78-4.89 (m, 2H), 3.52-3.62 (m, 1H), 3.44 (s, 3H), 3.28-3.29 (m, 1H), 2.91-3.13 (m, 5H), 2.24-2.38 (m, 3H), 1.81-1.92 (m, 1H), 1.33-1.44 (m, 1H). ¹⁹F NMR (377 MHz, DMSO-d6): -117.13. LC-MS: m/z 652.3 (M+H)⁺.

Compound 122





-continued




Example 6


3-((S)-2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-4-methyl-1,2,4-oxadiazol-5(4H)-one (Compound 112)



-continued




Step A 3-((2-(4-fluorophenyl)-1,3-dioxolan-2-yl)methyl)-4-methyl-1,2,4-oxadiazol-5(4H)-one



[0556] A mixture of 3-[[2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolan-2-yl]methyl]-4H-1,2,4-oxadiazol-5-one (500 mg, 1.70 mmol), CH_3I (1.37 g, 9.64 mmol, 0.6 mL), K_2CO_3 (705 mg, 5.10 mmol) in DMF (5 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 22° C. for 16 hrs under N_2 atmosphere. The reaction mixture was diluted with water (100 mL) and extracted with EtOAc (100 mL). The organic layer was washed with brine (50 mL \times 2), dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography on silica gel (eluted with 0-30% EA in PE). 3-[[2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolan-2-yl]methyl]-4-methyl-1,2,4-oxadiazol-5-one (352 mg, 1.14 mmol, 67.2% yield) was obtained.

[0557] ^1H NMR (400 MHz, CDCl_3) δ ppm 7.07 (dd, $J=8.44, 5.50$ Hz, 2H), 6.86-6.96 (m, 2H), 3.82-3.97 (m, 4H), 3.20 (s, 3H), 2.82-2.89 (m, 1H), 2.86 (s, 2H), 2.61-2.71 (m, 2H), 1.88-2.02 (m, 2H).


Step B 3-(4-(4-fluorophenyl)-2-oxobutyl)-4-methyl-1,2,4-oxadiazol-5(4H)-one



[0558] A mixture of 3-[[2-[2-(4-fluorophenyl)ethyl]-1,3-dioxolan-2-yl]methyl]-4-methyl-1,2,4-oxadiazol-5-one (350 mg, 1.14 mmol) in formic acid (5 mL) and H_2SO_4 (1 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 45° C. for 2 hrs under N_2 atmosphere. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was diluted with water (80 mL) and extracted with EtOAc (100 mL \times 2). The combined organic layers were washed with brine (50 mL), dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. Crude compound 3-[4-(4-fluorophenyl)-2-oxo-butyl]-4-methyl-1,2,4-oxadiazol-5-one (291 mg) was obtained.


[0559] ^1H NMR (400 MHz, CDCl_3) δ ppm 7.07 (dd, $J=8.44, 5.50$ Hz, 2H), 6.91 (t, $J=8.62$ Hz, 2H), 3.61 (s, 2H), 2.99 (s, 3H), 2.79-2.91 (m, 4H). LC-MS: m/z 263.4 ($\text{M}+\text{H}$) $^+$.

Step C ethyl 2-((R)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(4-methyl-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,4-dihydropyridine-3-carboxylate




[0560] A mixture of 3-[4-(4-fluorophenyl)-2-oxo-butyl]-4-methyl-1,2,4-oxadiazol-5-one (50 mg, 189.21 μ mol), 7-[[1(R)-4-methoxyindan-1-yl]amino]thieno[2,3-c]pyridine-2-carbaldehyde (62 mg, 191.12 μ mol), tris(trifluoromethylsulfonyloxy)ytterbium (59 mg, 95.12 μ mol), NH₄OAc (30 mg, 389.19 μ mol) and tert-butyl (2S)-2-(3-ethoxy-3-oxo-propanoyl)pyrrolidine-1-carboxylate (54 mg, 189.25 μ mol) in EtOH (5 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 50° C. for 16 hrs under N₂ atmosphere. The reaction mixture was concentrated under reduced pressure to give crude ethyl 2-[(2R)-1-tert-butoxycarbonylpyrrolidin-2-yl]-6-[2-(4-fluorophenyl)ethyl]-4-[7-[[1(R)-4-methoxyindan-1-yl]amino]thieno[2,3-c]pyridin-2-yl]-5-(4-methyl-5-oxo-1,2,4-oxadiazol-3-yl)-1,4-dihydropyridine-3-carboxylate (170 mg, crude) was obtained. LC-MS: m/z 837.9 (M+H)⁺.

Step D ethyl 2-((R)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(4-methyl-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)nicotinate



[0561] A mixture of ethyl 2-[(2R)-1-tert-butoxycarbonylpyrrolidin-2-yl]-6-[2-(4-fluorophenyl)ethyl]-4-[7-[[1(R)-4-methoxyindan-1-yl]amino]thieno[2,3-c]pyridin-2-yl]-5-(4-methyl-5-oxo-1,2,4-oxadiazol-3-yl)-1,4-dihydropyridine-3-carboxylate (170 mg, 203.11 μ mol), dipotassium sulfonatoxy sulfate (55 mg, 203.46 μ mol) in MeCN (6 mL) and H₂O (2 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 85° C. for 2 hrs under N₂ atmosphere. The reaction mixture was diluted with H₂O (50 mL) and extracted with EtOAc (100 mL×2). The combined organic layers were washed with brine (50 mL×3), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-TLC (SiO₂, PE/EA=1:1). Crude ethyl 2-[(2R)-1-tert-butoxycarbonylpyrrolidin-2-yl]-6-[2-(4-fluorophenyl)ethyl]-4-[7-[[1(R)-4-methoxyindan-1-yl]amino]thieno[2,3-c]pyridin-2-yl]-5-(4-methyl-5-oxo-1,2,4-oxadiazol-3-yl)pyridine-3-carboxylate (38 mg) was obtained. LC-MS: m/z 835.9 (M+H)⁺.


Step E ethyl 6-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(4-methyl-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-2-((R)-pyrrolidin-2-yl)nicotinate



[0562] A mixture of ethyl 6-[2-(4-fluorophenyl)ethyl]-5-(4-methyl-5-oxo-1,2,4-oxadiazol-3-yl)-2-[rac-(2R)-1-tert-butoxycarbonylpyrrolidin-2-yl]-4-[7-[[rac-(1R)-4-methoxyindan-1-yl]amino]thieno[2,3-c]pyridin-2-yl]pyridine-3-carboxylate (20 mg, crude) in DCM (2 mL) and HCl/dioxane (4 M, 2 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 22° C. for 1 hr under N₂ atmosphere. The reaction mixture was concentrated under reduced pressure to give crude compound ethyl 6-[2-(4-fluorophenyl)ethyl]-5-(4-methyl-5-oxo-1,2,4-oxadiazol-3-yl)-4-[7-[[rac-(1R)-4-methoxyindan-1-yl]amino]thieno[2,3-c]pyridin-2-yl]-2-[rac-(2R)-pyrrolidin-2-yl]pyridine-3-carboxylate (18 mg, crude). LC-MS: m/z 735 (M+H)⁺.

Step I 3-((S)-2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-4-methyl-1,2,4-oxadiazol-5(4H)-one

-continued








[0563] A mixture of ethyl 6-[2-(4-fluorophenyl)ethyl]-5-(4-methyl-5-oxo-1,2,4-oxadiazol-3-yl)-4-[7-[(rac-(1R)-4-methoxyindan-1-yl)amino]thieno[2,3-c]pyridin-2-yl]-2-[rac-(2R)-pyrrolidin-2-yl]pyridine-3-carboxylate (18 mg, crude), TEA (363.50 mg, 3.59 mmol, 0.5 mL) in DCM (5 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 22° C. for 16 hrs under N₂ atmosphere. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was purified by reversed-phase HPLC (Column: Kromasil 100-5-C18; Eluent: 30% to 60% water (0.1% NH₃·H₂O)-ACN). 4-methyl-3-[rac-(9aS)-2-[2-(4-fluorophenyl)ethyl]-5-oxo-4-[7-[(rac-(1R)-4-methoxyindan-1-yl)amino]thieno[2,3-c]pyridin-2-yl]-7,8,9,9a-tetrahydropyrido[2,3-a]pyrrolizin-3-yl]-1,2,4-oxadiazol-5-one (1.2 mg, 1.70 μmol, 6.25% yield, 97.7% purity) was obtained.


[0564] ¹H NMR (400 MHz, MeOD) δ ppm 7.94 (d, J=5.62 Hz, 1H), 7.52 (s, 1H), 7.07-7.22 (m, 4H), 6.97 (t, J=8.19 Hz, 2H), 6.89 (d, J=9.05 Hz, 1H), 6.81 (d, J=8.07 Hz, 1H), 5.80 (d, J=7.82 Hz, 1H), 3.83 (s, 3H), 3.69 (s, 1H), 3.46 (s, 1H), 3.29-3.30 (m, 3H), 3.10-3.23 (m, 4H), 3.02 (d, J=12.47 Hz, 1H), 2.59-2.84 (m, 3H), 2.43 (s, 2H), 2.16-2.22 (m, 1H), 2.03 (m, 1H), 1.60 (m, 1H). LC-MS: m/z 689.2 (M+H)⁺.

Example 7


(S)-3-(4-(2-(3,4-difluorobenzyl)-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-al]pyrazin-6-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one
(Compound 129)



-continued




Step B 2-(3,4-difluorobenzyl)-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carbaldehyde



[0567] To a solution of 2-[3,4-difluorophenyl]methyl-3,4-dihydropyrrolo[1,2-a]pyrazin-1-one (250 mg, 953 µmol) in DCE (5 mL) was added DMF (139 mg, 1.91 mmol) and POCl_3 (292 mg, 1.91 mmol). The mixture was stirred at 0-85°C. for 16 hrs. The reaction mixture was quenched with ice-water (5 mL) at 0°C., then diluted with EtOAc (15 mL) and extracted with EtOAc (20 mL×3). The combined organic layers were washed with brine (30 mL), dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 4 g SepaFlash® Silica Flash Column, Eluent of 0~40% Ethyl acetate/Petroleum ether gradient @20 mL/min). 2-(3,4-difluorobenzyl)-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carbaldehyde (254 mg, 875 µmol, 91.8% yield) was obtained.

[0568] ^1H NMR (400 MHz, CDCl_3) δ ppm 9.68 (s, 1H), 7.13-7.19 (m, 2H), 7.07 (m, 1H) 7.00-7.03 (m, 1H), 6.97 (d, $J=4.16$ Hz, 1H), 4.71 (s, 2H), 4.62 (t, $J=6.05$ Hz, 2H), 3.61 (t, $J=6.05$ Hz, 2H).

Step C ethyl 2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(2-(3,4-difluorobenzyl)-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-6-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,6-dihydropyridine-3-carboxylate




[0565] To a solution of 3,4-dihydro-2H-pyrrolo[1,2-a]pyrazin-1-one (200 mg, 1.47 mmol) in DMF (5 mL) was added NaH (235 mg, 5.88 mmol, 60% purity) and 4-(chloromethyl)-1,2-difluoro-benzene (239 mg, 1.47 mmol). The mixture was stirred at 0-20°C. for 16 hrs. The reaction mixture was quenched with ice-water (5 mL) at 0°C., then diluted with EtOAc (15 mL) and extracted with EtOAc (20 mL×3). The combined organic layer was washed with brine (30 mL), dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0~30% Ethyl acetate/Petroleum ether gradient @40 mL/min). 2-(3,4-difluorobenzyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-1(2H)-one (328 mg, 1.25 mmol, 85.1% yield) was obtained.

[0566] ^1H NMR (400 MHz, CDCl_3) δ ppm 7.03-7.20 (m, 3H), 6.96-7.02 (m, 1H), 6.73 (s, 1H), 6.21-6.28 (m, 1H), 4.70 (s, 2H), 4.05-4.16 (m, 2H), 3.50-3.62 (m, 2H).

[0569] To a solution of 2-[3,4-difluorophenyl]methyl-1-oxo-3,4-dihydropyrrolo[1,2-a]pyrazine-6-carbaldehyde (100 mg, 345 µmol) in EtOH (3 mL) was added tris(trifluoromethylsulfonyloxy)ytterbium (21.4 mg, 34.5 µmol), 3-(4-(4-fluorophenyl)-2-oxobutyl)-1,2,4-oxadiazol-5(4H)-one (86.2 mg, 345 µmol), tert-butyl (S)-2-(3-ethoxy-3-oxopropanoyl)pyrrolidine-1-carboxylate (98.3 mg, 345 µmol) and NH_4OAc (53.1 mg, 689 µmol). The mixture was stirred at 50°C. for 16 hrs. The reaction mixture was concentrated under reduced pressure. Crude product ethyl 2-(1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(2-(3,4-difluorobenzyl)-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-6-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,6-dihydropyridine-3-carboxylate (254 mg, 875 µmol, 91.8% yield) was obtained.


robenzyl)-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-6-yl]-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-1,6-dihydropyridine-3-carboxylate (272 mg) was obtained.

Step D ethyl 2-(1-tert-butoxycarbonylpyrrolidin-2-yl)-4-[2-[(3,4-difluorophenyl)methyl]-1-oxo-3,4-dihydropyrrolo[1,2-a]pyrazin-6-yl]-6-[2-(4-fluorophenyl)ethyl]-5-(5-oxo-4H-1,2,4-oxadiazol-3-yl)pyridine-3-carboxylate




[0570] To a solution of ethyl 6-(1-tert-butoxycarbonylpyrrolidin-2-yl)-4-[2-[(3,4-difluorophenyl)methyl]-1-oxo-3,4-dihydropyrrolo[1,2-a]pyrazin-6-yl]-2-[2-(4-fluorophenyl)ethyl]-3-(5-oxo-4H-1,2,4-oxadiazol-3-yl)-1,2-dihydropyridine-5-carboxylate (272 mg, 344 μmol) in MeCN (3 mL)/H₂O (1 mL) was added dipotassium sulfonatoxy sulfate (186 mg, 689 μmol, 138 L). The mixture was stirred at 85° C. for 2 hrs. The reaction mixture was diluted with H₂O (10 mL) and extracted with EtOAc (15 mL×3). The combined organic layers were washed with brine (20 mL×3), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-TLC (SiO₂, Ethyl acetate). ethyl 2-(1-tert-butoxycarbonylpyrrolidin-2-yl)-4-[2-[(3,4-difluorophenyl)methyl]-1-oxo-3,4-dihydropyrrolo[1,2-a]pyrazin-6-yl]-6-[2-(4-fluorophenyl)ethyl]-5-(5-oxo-4H-1,2,4-oxadiazol-3-yl)pyridine-3-carboxylate (80 mg, 101.68 μmol, 29.52% yield) was obtained. LC-MS: m/z 787.8 (M+H)⁺.

Step E ethyl 4-[2-[(3,4-difluorophenyl)methyl]-1-oxo-3,4-dihydropyrrolo[1,2-a]pyrazin-6-yl]-6-[2-(4-fluorophenyl)ethyl]-5-(5-oxo-4H-1,2,4-oxadiazol-3-yl)-2-pyrrolidin-2-yl-pyridine-3-carboxylate



[0571] To a solution of ethyl 2-(1-tert-butoxycarbonylpyrrolidin-2-yl)-4-[2-[(3,4-difluorophenyl)methyl]-1-oxo-3,4-dihydropyrrolo[1,2-a]pyrazin-6-yl]-6-[2-(4-fluorophenyl)ethyl]-5-(5-oxo-4H-1,2,4-oxadiazol-3-yl)pyridine-3-carboxylate (80 mg, 102 μmol) in DCM (5 mL) was added TFA (1.54 g, 13.5 mmol, 1 mL). The mixture was stirred at 20° C. for 16 hrs. The reaction mixture was concentrated under reduced pressure to remove solvent. The crude ethyl 4-[2-[(3,4-difluorophenyl)methyl]-1-oxo-3,4-dihydropyrrolo[1,2-a]pyrazin-6-yl]-6-[2-(4-fluorophenyl)ethyl]-5-(5-oxo-4H-1,2,4-oxadiazol-3-yl)-2-pyrrolidin-2-yl-pyridine-3-carboxylate (69.8 mg).

Step F (S)-3-(4-(2-(3,4-difluorobenzyl)-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-6-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one




[0572] To a solution of ethyl 4-[2-[(3,4-difluorophenyl)methyl]-1-oxo-3,4-dihydropyrrolo[1,2-a]pyrazin-6-yl]-6-[2-(4-fluorophenyl)ethyl]-5-(5-oxo-4H-1,2,4-oxadiazol-3-yl)-2-pyrrolidin-2-yl-pyridine-3-carboxylate (69.8 mg, 102 μmol) in DCM (5 mL) was added TEA (2.18 g, 21.5 mmol, 3 mL). The mixture was stirred at 20° C. for 16 hrs. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was purified by prep-TLC (SiO₂, Ethyl acetate), and further purified by prep-HPLC (Column: Kromasil 100-5-C18; Eluent: 45% to 70% water (0.1% FA)-ACN). (S)-3-(4-(2-(3,4-difluorobenzyl)-1-oxo-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazin-6-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (4.7 mg, 6.96 μmol, 7.43% yield, 94.8% purity) was obtained.


[0573] ¹H NMR (400 MHz, CDCl₃) δ ppm 7.00-7.16 (m, 7H), 6.92 (t, J=8.50 Hz, 3H), 6.08-6.22 (m, 1H), 4.75-4.85 (m, 1H), 4.52-4.68 (m, 2H), 3.92-4.09 (m, 1H), 3.64-3.87 (m, 3H), 3.42 (s, 2H), 3.05-3.26 (m, 3H), 2.28-2.57 (m, 3H), 1.40-1.50 (m, 1H). LC-MS: m/z 641.4 (M+H)⁺.

Example 8


5-((S)-2-(4-fluorophenethyl)-4-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3(2H)-one (Compound 150)



-continued




Step A 5-((9aS)-2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-1,5,7,8,9,9a-hexahydro-4H-pyrido[2,3-a]pyrrolizin-3-yl)isoxazol-3(2H)-one



[0574] A mixture of (8S)-5,6,7,8-tetrahydropyrrolizine-1,3-dione (17.16 mg, 123.31 μ mol), (R)-7-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (40 mg, 123.31 μ mol), NH₄OAc (14.26 mg, 184.96 μ mol) and 5-(4-(4-fluorophenyl)-2-oxobutyl)isoxazol-3(2H)-one (30.73 mg, 123.31 μ mol) in AcOH (1.5 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 120° C. for 2 hrs under N₂ atmosphere. The solution was cooled to room temperature and poured into water (25 mL), extracted with EtOAc (25 mL). The organic layer was washed with the aqueous NaHCO₃ solution (25 mL), then brine (25 mL), dried over anhydrous of Na₂SO₄, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (ISCO®; 4 g SepaFlash® Silica Flash Column, Eluent of 0~10% MeOH/DCM gradient @12 mL/min) to give 5-((9aS)-2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-1,5,7,8,9,9a-hexahydro-4H-pyrido[2,3-a]pyrrolizin-3-yl)isoxazol-3(2H)-one (47 mg, 69.55 μ mol, 56.40% yield). LC-MS: m/z 676.7 (M+H)⁺.

Step B 5-((S)-2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)isoxazol-3(2H)-one




[0575] To a solution of 5-((9aS)-2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-1,5,7,8,9,9a-hexahydro-4H-pyrido[2,3-a]pyrrolizin-3-yl)isoxazol-3(2H)-one (47 mg, 69.55 μ mol) in ACN (10 mL) and water (5 mL) was added CAN (76.26 mg, 139.10 μ mol). The mixture was stirred at 20° C. for 2 hrs. Water (25 mL) was added and the mixture was extracted with EtOAc (25 mL). The organic layer was washed with brine (25 mL), dried over Na₂SO₄, filtered and concentrated in vacuum. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0~10% MeOH/DCM gradient @12 mL/min), then re-purified by prep-HPLC (FA condition). Column: Kromasil C18 150*30 mm*5 um; Condition: water (0.2% Formic acid)-ACN; Begin B: 30; End B: 85; Gradient Time (min): 20; 100% B Hold Time (Time): 5; Flow Rate(ml/min): 20; Detection wavelength: 220 nm and 254 nm) to give 5-((S)-2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)isoxazol-3(2H)-one (2.58 mg, 3.83 μ mol, 5.51% yield).

[0576] ¹H NMR (400 MHz, DMSO-d₆) δ ppm 11.47 (s, 1H), 7.88 (d, J=6.0 Hz, 1H), 7.51 (s, 1H), 7.31 (s, 1H),

7.02-7.25 (m, 6H), 6.88-6.99 (m, 2H), 6.06 (s, 1H), 5.57-5.73 (m, 1H), 4.87-4.91 (m, 1H), 3.81 (s, 3H), 2.90-3.06 (m, 6H), 2.72-2.79 (m, 1H), 2.55-2.65 (m, 2H), 2.37-2.39 (m, 1H), 2.26-2.29 (m, 2H), 2.06-2.09 (m, 1H), 1.33-1.50 (m, 1H). LC-MS: m/z 674.4 (M+H)⁺.


3-((9aS)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-2-(3-(tetrahydrofuran-3-yl)phenethyl)-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (Compound 151)



[0577] Compound 151 was synthesized using a similar procedure described in the Example 3 above by using the appropriate materials.

[0578] ¹H NMR (400 MHz, MeOD-d₄) δ ppm 7.78 (d, J=6.72 Hz, 1H), 7.66 (s, 1H), 7.41 (d, J=6.72 Hz, 1H), 7.22-7.31 (m, 1H), 7.14-7.20 (m, 2H), 7.08-7.13 (m, 2H), 6.97 (d, J=7.21 Hz, 1H), 6.93-6.94 (m, 1H), 6.88-6.93 (m, 1H), 5.53 (t, J=6.48 Hz, 1H), 4.30-4.72 (m, 1H), 3.99-4.10 (m, 2H), 3.86-3.91 (m, 1H), 3.86 (s, 3H), 3.59-3.68 (m, 2H), 3.35-3.47 (m, 2H), 3.21 (d, J=7.58 Hz, 2H), 3.02-3.16 (m, 3H), 2.83-2.95 (m, 1H), 2.75 (d, J=6.60 Hz, 1H), 2.37-2.54 (m, 3H), 2.33 (d, J=5.99 Hz, 1H), 2.15 (dd, J=12.65, 6.54 Hz, 1H), 1.91-2.04 (m, 1H), 1.45 (q, J=10.21 Hz, 1H). LC-MS: m/z 727.4 (M+H)⁺.


Compound 152



[0579] Compound 152 was synthesized using similar procedure as described in Example 1 above by using the appropriate materials.

[0580] ¹H NMR (400 MHz, DMSO-d₆): δ 8.38 (d, J=3.6 Hz, 1H), 8.24 (s, 1H), 7.64 (s, 1H), 7.37-7.42 (m, 2H), 7.30 (t, J=7.2 Hz, 1H), 7.05-7.23 (m, 7H), 6.22 (dd, J=6.0 Hz, J=8.0 Hz, 1H), 4.75 (dd, J=6.0 Hz, J=8.8 Hz, 1H), 3.46-3.53 (m, 1H), 3.19-3.25 (m, 2H), 2.95-3.06 (m, 5H), 2.71-2.76 (m, 1H), 2.57-2.62 (m, 1H), 2.31-2.36 (m, 1H), 2.19-2.27 (m, 2H), 1.32-1.36 (m, 1H). ¹⁹F NMR (377 MHz, DMSO-d₆): δ -117.43. LC-MS: m/z 613.3 (M+H)⁺


Compound 153



[0581] Compound 153 was synthesized using similar procedure as described in Example 1 above by using the appropriate materials.

[0582] ¹H NMR (400 MHz, DMSO-d₆): δ 12.51 (s, 1H), 7.61 (d, J=3.2 Hz, 1H), 7.52-7.56 (m, 2H), 7.34-7.49 (m, 2H), 7.19-7.27 (m, 2H), 7.06-7.15 (m, 3H), 7.02 (dd, J=8.4 Hz, J=1.2 Hz, 1H), 6.54 (d, J=3.2 Hz, 1H), 5.44 (s, 2H), 4.83 (dd, J=10.0 Hz, J=6.0 Hz, 1H), 3.46-3.58 (m, 1H), 3.21-3.31 (m, 1H), 2.95-3.16 (m, 4H), 2.18-2.42 (m, 3H), 1.30-1.43 (m, 1H). ¹⁹F NMR (377 MHz, DMSO-d₆): δ -117.09, -138.27, -140.28. LC-MS: m/z 622.3 (M+H)⁺


5-(7-((R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-3-isopropyl-1,1-dioxido-5-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-2,3-dihydrothieno[3,2-b]pyridin-6-yl)isoxazol-3(2H)-one (Compound 154)



[0583] Compound 154 was synthesized using similar procedure as described in Example 2 above by using the appropriate materials.

[0584] ^1H NMR (400 MHz, MeOD-d₄) δ 8.32-8.40 (m, 1H), 7.93-8.01 (m, 1H), 7.71-7.79 (m, 1H), 7.57-7.63 (m, 1H), 7.19-7.27 (m, 1H), 7.11-7.18 (m, 1H), 5.94-6.00 (m, 1H), 5.85-5.93 (m, 1H), 3.88-3.95 (m, 2H), 3.77-3.82 (m, 1H), 3.37-3.43 (m, 2H), 3.11-3.17 (m, 1H), 2.99-3.09 (m, 1H), 2.86-2.96 (m, 2H), 2.70-2.84 (m, 2H), 2.04-2.25 (m, 2H), 1.68-1.78 (m, 2H), 1.56-1.67 (m, 3H), 1.35 (d, J=1.34 Hz, 2H), 1.22-1.29 (m, 2H), 1.12-1.20 (m, 3H), 0.91 (d, J=6.36 Hz, 3H). LC-MS: m/z 672.2 (M+H)⁺.


Compound 155



[0585] Compound 155 was synthesized using similar procedure as described in Example 2 above by using the appropriate materials.

[0586] ^1H NMR (400 MHz, DMSO-d₆): δ 7.98 (d, J=5.6 Hz, 1H), 7.51 (s, 1H), 7.20-7.30 (m, 3H), 7.04-7.15 (m, 4H), 6.83 (t, J=8.8 Hz, 2H), 5.90 (q, J=8.0 Hz, 1H), 3.97 (t, J=6.8 Hz, 2H), 3.85 (t, J=6.8 Hz, 2H), 3.79 (s, 3H), 3.07-3.10 (m, 2H), 2.89-3.05 (m, 3H), 2.58-2.74 (m, 4H), 1.97-2.06 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d₆): -117.08. LC-MS: m/z 676.0 (M+H)⁺.


5-(5-(4-fluorophenethyl)-3-isopropyl-7-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-1,1-dioxido-2,3-dihydrothieno[3,2-b]pyridin-6-yl)-1,3,4-oxadiazol-2(3H)-one
(Compound 156)



[0587] Compound 156 was synthesized using similar procedure as described in Example 2 above by using the appropriate materials.

[0588] ^1H NMR (400 MHz, MeOD-d₄) δ ppm 7.92-7.97 (m, 1H), 7.65-7.71 (m, 1H), 7.12-7.17 (m, 4H), 6.93-6.99 (m, 2H), 6.86-6.91 (m, 1H), 6.79 (d, J=7.87 Hz, 1H), 5.77-5.83 (m, 1H), 3.82-3.84 (m, 3H), 3.72-3.81 (m, 2H), 3.52-3.59 (m, 1H), 3.21-3.29 (m, 1H), 2.99-3.15 (m, 3H), 2.71-2.82 (m, 2H), 2.60-2.69 (m, 1H), 1.96-2.04 (m, 1H), 1.12-1.16 (m, 3H), 0.84 (dd, J=6.56, 3.22 Hz, 3H). LC-MS: m/z 712.2 (M+H)⁺.


2-fluoro-4-((5-(3-isopropyl-1,1-dioxido-6-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-5-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-2,3-dihydrothieno[3,2-b]pyridin-7-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)benzonitrile (Compound 157)



[0589] Compound 157 was synthesized using similar procedure as described in Example 2 above by using the appropriate materials.

[0590] ^1H NMR (400 MHz, CDCl₃) δ ppm 8.93-9.08 (m, 1H), 8.31 (d, J=1.79 Hz, 1H), 8.12-8.23 (m, 1H), 7.54-7.66 (m, 1H), 7.26 (d, J=3.70 Hz, 1H), 7.03-7.14 (m, 2H), 6.56-6.73 (m, 1H), 5.48-5.66 (m, 2H), 3.93-4.02 (m, 2H), 3.70-3.80 (m, 1H), 3.55-3.66 (m, 1H), 3.30-3.46 (m, 3H), 2.80-3.01 (m, 3H), 1.72-1.80 (m, 2H), 1.65 (dd, J=8.17, 1.97 Hz, 3H), 1.30-1.39 (m, 2H), 1.16 (d, J=6.91 Hz, 3H), 0.86-0.94 (m, 3H). LC-MS: m/z 657.2 (M+H)⁺.


2-fluoro-4-((5-(2-(4-fluorophenethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-8,9-dihydro-5H,7H-pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridin-4-yl)-1H-indol-1-yl)methyl)benzonitrile (Compound 158)



[0591] Compound 158 was synthesized using similar procedure as described in Example 2 above by using the appropriate materials.

[0592] ^1H NMR (400 MHz, MeOD-d₄) δ ppm 7.64-7.69 (m, 2H), 7.36-7.40 (m, 1H), 7.30-7.34 (m, 1H), 7.14-7.19 (m, 2H), 7.07-7.13 (m, 2H), 7.02-7.06 (m, 1H), 6.93-7.00 (m, 2H), 6.59-6.63 (m, 1H), 5.52-5.56 (m, 2H), 4.08-4.13 (m, 2H), 3.96-4.02 (m, 2H), 3.10-3.14 (m, 2H), 3.03-3.09 (m, 2H), 2.72-2.80 (m, 2H). LC-MS: m/z 630.1 (M+H)⁺.


2-fluoro-4-[1-[5-[11-[2-(4-fluorophenyl)ethyl]-7-oxo-10-(2-oxo-3H-1,3,4-oxadiazol-5-yl)-2,6,12-triazatricyclo[6.4.0.02,6]dodeca-1(8),9,11-trien-9-yl]indol-1-yl]ethyl]benzonitrile (Compound 159)



[0593] Compound 159 was synthesized using similar procedure as described in Example 2 above by using the appropriate materials.

[0594] ^1H NMR (400 MHz, MeOD-d₄) δ ppm 7.61-7.70 (m, 2H), 7.55-7.60 (m, 1H), 7.26-7.31 (m, 1H), 7.13-7.21 (m, 3H), 7.06-7.13 (m, 2H), 6.94-6.99 (m, 2H), 6.59-6.68 (m, 1H), 5.85-5.95 (m, 1H), 4.04-4.14 (m, 2H), 3.93-4.02 (m, 2H), 3.02-3.16 (m, 4H), 2.70-2.81 (m, 2H), 1.94-2.00 (m, 3H). LC-MS: m/z 644.3 (M+H)⁺.


Compound 161



[0595] Compound 161 was synthesized using similar procedure as described in Example 2 above by using the appropriate materials.

[0596] ^1H NMR (400 MHz, DMSO-d₆) 12.45 (br s, 1H), 8.13 (d, J=2.0 Hz, 1H), 7.99 (d, J=2.0 Hz, 1H), 7.87 (t, J=7.6 Hz, 1H), 7.75 (d, J=3.6 Hz, 1H), 7.41 (d, J=10.0 Hz, 1H), 7.21-7.27 (m, 2H), 7.19 (d, J=7.6 Hz, 1H), 7.04-7.12 (m, 2H), 6.62 (d, J=3.2 Hz, 1H), 5.62 (s, 2H), 3.97 (t, J=6.8 Hz, 2H), 3.82 (t, J=6.8 Hz, 2H), 3.05-3.13 (m, 2H), 2.98-3.05 (m, 2H), 2.60 (t, J=7.2 Hz, 2H). ^{19}F NMR (377 MHz, DMSO-d₆): δ -108.14, -117.12. LC-MS: m/z 631.1 (M+H)⁺.


6-[[6-[(9aS)-2-[2-(4-fluorophenyl)ethyl]-5-oxo-3-(2-oxo-3H-1,3,4-oxadiazol-5-yl)-7,8,9a-tetrahydro-pyrido[2,3-a]pyrrolizin-4-yl]-2-oxo-1,3-benzoxazol-3-yl]methyl]pyridine-3-carbonitrile (Compound 176)



[0597] Compound 176 was synthesized using similar procedure as described in Example 2 above by using the appropriate materials.

[0598] ^1H NMR (400 MHz, DMSO-d₆) δ ppm 8.94 (d, J=1.6 Hz, 1H), 8.35 (dd, J=2.0, 8.4 Hz, 1H), 7.73 (d, J=8.0 Hz, 1H), 7.40 (s, 1H), 7.18-7.24 (m, 3H), 7.04-7.10 (m, 2H), 6.98-7.03 (m, 1H), 5.33 (s, 2H), 4.83 (dd, J=6.4, 10.2 Hz, 1H), 3.43-3.57 (m, 2H), 3.11-3.17 (m, 2H), 2.96-3.09 (m, 2H), 2.22-2.36 (m, 3H), 1.32-1.45 (m, 1H). ^{19}F NMR (400 MHz, DMSO-d₆): δ ppm -117.067. LC-MS: m/z 630.1 (M+H)⁺.


2-fluoro-4-((6-(2-(4-fluorophenyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-8,9-dihydro-5H,7H-pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)methyl)benzonitrile (Compound 162)



[0599] Compound 162 was synthesized using similar procedure as described in Example 2 above by using the appropriate materials.

[0600] ^1H NMR (400 MHz, DMSO-d₆) δ 12.52 (s, 1H), 7.94 (t, J=7.2 Hz, 1H), 7.63 (d, J=10.0 Hz, 1H), 7.40-7.46 (m, 2H), 7.29 (d, J=8.0 Hz, 1H), 7.19-7.26 (m, 2H), 7.04-7.11 (m, 3H), 5.19 (s, 2H), 3.96 (t, J=6.8 Hz, 2H), 3.82 (t, J=6.8 Hz, 2H), 2.97-3.11 (m, 4H), 2.55-2.64 (m, 2H). ^{19}F NMR (377 MHz, DMSO-d₆) δ -107.78, -117.09. LC-MS: m/z 648.2 (M+H)⁺.


6-((6-(4-fluorophenethyl)-3-isopropyl-1,1-dioxido-6-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2,3-dihydrothieno[3,2-b]pyridin-7-yl)-2-oxobenzo[d]oxazol-3(2H-yl)methyl)nicotinonitrile (Compound 163)



[0601] Compound 163 was synthesized using similar procedure as described in Example 2 above by using the appropriate materials.

[0602] ^1H NMR (400 MHz, DMSO-d₆) δ 12.67 (s, 1H), 8.94 (dd, J=2.0 Hz, J=0.8 Hz, 1H), 8.36 (dd, J=8.4 Hz, J=2.4 Hz, 1H), 7.74 (d, J=8.0 Hz, 1H), 7.41 (s, 1H), 7.30 (d, J=8.4 Hz, 1H), 7.15-7.24 (m, 2H), 7.02-7.09 (m, 3H), 5.34 (s, 2H), 3.71-3.87 (m, 2H), 3.59 (dd, J=13.6 Hz, J=4.8 Hz, 1H), 3.17-3.28 (m, 2H), 3.00-3.10 (m, 2H) 2.54-2.64 (m, 1H), 1.05 (d, J=6.8 Hz, 3H), 0.76 (d, J=6.8 Hz, 3H). ^{19}F NMR (377 MHz, DMSO-d₆) δ -117.09. LC-MS: m/z 667.2 (M+H)⁺.


6-[1-[6-[(9aS)-2-[2-(4-fluorophenyl)ethyl]-5-oxo-3-(2-oxo-3H-1,3,4-oxadiazol-5-yl)-7,8,9a-tetrahydropyrido[2,3-a]pyrrolizin-4-yl]-2-oxo-1,3-benzoxazol-3-yl]ethyl]pyridine-3-carbonitrile (Compound 160)



[0603] Compound 160 was synthesized using similar procedure as described in Example 2 above by using the appropriate materials.

[0604] ^1H NMR (400 MHz, DMSO-d₆) δ ppm 8.97 (s, 1H), 8.29-8.51 (m, 1H), 7.77 (d, J=8.4 Hz, 1H), 7.33-7.51 (m, 1H), 7.13-7.30 (m, 3H), 7.01-7.12 (m, 2H), 6.97 (d, J=8.0 Hz, 1H), 5.80 (q, J=7.2 Hz, 1H), 4.70-4.90 (m, 1H), 3.49-3.61 (m, 2H), 3.09-3.19 (m, 2H), 2.92-3.07 (m, 2H), 2.20-2.40 (m, 3H), 1.93 (d, J=7.2 Hz, 3H), 1.30-1.47 (m, 1H). ^{19}F NMR (400 MHz, DMSO-d₆) δ ppm -117.059. LC-MS: m/z 644.1 (M+H)⁺.


(S)-6-(2-(4-fluorophenethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-3-((5-fluoropyridin-2-yl)methyl)benzo[d]oxazol-2(3H)-one
(Compound 164)




[0605] Compound 164 was synthesized using similar procedure as described in Example 2 above by using the appropriate materials.

[0606] ^1H NMR (400 MHz, CDCl₃) δ ppm 8.47-8.58 (m, 1H), 8.43 (s, 1H), 7.39-7.45 (m, 2H), 7.22 (s, 1H), 7.13 (dd, J=8.46, 5.60 Hz, 2H), 7.08 (s, 2H), 6.94-7.00 (m, 2H), 5.08-5.19 (m, 2H), 4.71-4.82 (m, 1H), 3.65-3.80 (m, 1H), 3.34-3.49 (m, 1H), 3.02-3.19 (m, 4H), 2.46-2.55 (m, 1H), 2.32-2.41 (m, 2H), 1.39-1.48 (m, 1H). LC-MS: m/z 623.2 (M+H)⁺.


Example 9: (R)-6-fluoro-1-((2-((S)-2-(4-fluorophenyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)thieno[2,3-c]pyridin-7-yl)amino)-2,3-dihydro-1H-indene-5-carbonitrile (Compound 165)



-continued




Step A 6-fluoro-1-oxo-2,3-dihydro-1H-indene-5-carbonitrile



[0607] To a solution of 5,6-difluoroindan-1-one (3.4 g, 20.22 mmol) in DMSO (40 mL) was added NaCN (991 mg, 20.22 mmol). The mixture was stirred at 40° C. for 16 hrs. The solution was diluted with water (40 mL) and filtered by Celite. The filtrate was extracted with ethyl acetate (50 mL×2). The combined organic phases were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, concentrated in vacuum to give a residue. The residue was purified by column chromatography (SiO_2 , 16% ethyl acetate in petroleum ether) to give 6-fluoro-1-oxo-2,3-dihydro-1H-indene-5-carbonitrile (560 mg, 15.81% yield) as a black oil.

[0608] ^1H NMR (400 MHz, CDCl_3) δ 7.79 (d, $J=5.2$ Hz, 1H), 7.54 (d, $J=7.2$ Hz, 1H), 3.13-3.29 (m, 2H), 2.72-2.99 (m, 2H). ^{19}F NMR (377 MHz, chloroform-d) δ -107.985. LC-MS: m/z 176.1 ($\text{M}+\text{H}$) $^+$.

Step B (R,Z)—N-(5-cyano-6-fluoro-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide




[0609] To a solution of 6-fluoro-1-oxo-2,3-dihydro-1H-indene-5-carbonitrile (280 mg, 1.60 mmol) and (R)-2-methylpropane-2-sulfonamide (200 mg, 1.65 mmol) in 2-methyltetrahydrofuran (5 mL) was added Ti(OEt)_4 (663 μL , 3.20

mmol). The mixture was stirred at 80° C. for 16 hrs. The mixture was combined with another batch from ES28217-38 (280 mg of compound ketone) was poured into water (50 mL) at 0° C., and diluted with ethyl acetate (50 mL). The mixture was added with diatomite (10 g) and stirred for 10 min. Then the mixture was filtered to remove the precipitate. The filtrate was extracted with ethyl acetate (50 mL×2). The combined organic phases were washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered, concentrated in vacuum to give a residue. The residue was purified by flash column chromatography (SiO_2 , 27% ethyl acetate in petroleum ether) to give (R,Z)—N-(5-cyano-6-fluoro-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide (275 mg, 30.90% average yield) as a brown oil.

[0610] ^1H NMR (400 MHz, CDCl_3) δ 7.68 (d, $J=5.2$ Hz, 1H), 7.54 (d, $J=8.0$ Hz, 1H), 3.52-3.65 (m, 1H), 3.27 (s, 1H), 3.14-3.19 (m, 2H), 1.34 (s, 9H). LC-MS: m/z 279.1 ($\text{M}+\text{H}$) $^+$.

Step C (R)—N—((R)-5-cyano-6-fluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfonamide




[0611] To a solution of (R,Z)—N-(5-cyano-6-fluoro-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide (275 mg, 0.99 mmol) in THF (5 mL) was added NaBH_4 (150 mg, 3.97 mmol) at -70° C. under nitrogen atmosphere. The reaction mixture was stirred at -70° C. for 30 mins, then warmed to 0° C. naturally. The mixture was stirred at 0° C. for 1 hr under nitrogen atmosphere. The reaction mixture was quenched with saturated NH_4Cl solution (20 mL), and extracted with ethyl acetate (20 mL×2). The combined organic phases were washed with brine (20 mL), dried over anhydrous sodium sulfate, filtered, concentrated in vacuum to give a residue. The residue was purified by column chromatography (SiO_2 , 30-40% ethyl acetate in

petroleum ether) to give (R)—N—((R)-5-cyano-6-fluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfonamide (100 mg, 36.10% yield).

[0612] ^1H NMR (400 MHz, CDCl_3) δ 7.58 (d, $J=8.4$ Hz, 1H), 7.44 (d, $J=5.6$ Hz, 1H), 4.91 (q, $J=7.2$ Hz, 1H), 3.54 (d, $J=6.4$ Hz, 1H), 2.94-3.06 (m, 1H), 2.77-2.88 (m, 1H), 2.54-2.67 (m, 1H), 2.00-2.08 (m, 1H), 1.26 (s, 9H). LC-MS: m/z 281.1 ($\text{M}+\text{H}$)⁺.


Step D (R)-1-amino-6-fluoro-2,3-dihydro-1H-indene-5-carbonitrile



[0613] A mixture of (R,Z)—N-(5-cyano-6-fluoro-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide (100 mg, 0.36 mmol) in HCl/dioxane (2M, 2 mL) was stirred at 20° C. for 1.5 hrs. The mixture was concentrated to give (R)-1-amino-6-fluoro-2,3-dihydro-1H-indene-5-carbonitrile (130 mg, 99.49% yield, 68% purity, 2HCl).

[0614] ^1H NMR (400 MHz, chloroform-d) δ 7.76 (d, $J=6.0$ Hz, 1H), 7.49 (d, $J=9.2$ Hz, 1H), 4.84-4.90 (m, 1H), 3.11-3.22 (m, 1H), 2.95-3.07 (m, 1H), 2.65-2.75 (m, 1H), 2.08-2.23 (m, 1H).

Step E (R)-1-((2-(1,3-dioxolan-2-yl)thieno[2,3-c]pyridin-7-yl)amino)-6-fluoro-2,3-dihydro-1H-indene-5-carbonitrile




[0615] A mixture of (R)—N—((R)-5-cyano-6-fluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfonamide (110 mg, 0.30 mmol, 2HCl), 7-chloro-2-(1,3-dioxolan-2-yl)thieno[2,3-c]pyridine (73 mg, 0.30 mmol), Cs_2CO_3 (300 mg, 0.92 mmol), $\text{Pd}(\text{OAc})_2$ (7 mg, 0.03 mmol) and BINAP (40 mg, 0.06 mmol) in dioxane (5 mL) was degassed and purged with nitrogen for 3 times, and then the mixture was stirred at 100° C. for 16 hrs under nitrogen atmosphere. The mixture was combined with ES28217-44 (20 mg of heterocyclic compound), and concentrated. The residue was purified by flash column chromatography (SiO_2 , 34% ethyl acetate in petroleum ether) to give (R)-1-((2-(1,3-dioxolan-2-yl)thieno[2,3-c]pyridin-7-yl)amino)-6-fluoro-2,3-dihydro-1H-indene-5-carbonitrile (120 mg, 88.79% average yield).

[0616] ^1H NMR (400 MHz, DMSO-d_6) δ 7.96 (d, $J=5.6$ Hz, 1H), 7.81 (d, $J=6.4$ Hz, 1H), 7.50 (s, 1H), 7.29 (d, $J=8.0$

Hz, 1H), 7.21-7.26 (m, 1H), 7.09 (d, $J=5.6$ Hz, 1H), 6.21 (s, 1H), 5.89 (q, $J=8.4$ Hz, 1H), 3.92-4.14 (m, 4H), 2.95-3.07 (m, 1H), 2.79-2.93 (m, 1H), 2.54-2.60 (m, 1H), 2.03-2.17 (m, 1H). LC-MS: m/z 382.1 ($\text{M}+\text{H}$)⁺.


Step F (R)-6-fluoro-1-((2-formylthieno[2,3-c]pyridin-7-yl)amino)-2,3-dihydro-1H-indene-5-carbonitrile



[0617] A mixture of (R)-1-amino-6-fluoro-2,3-dihydro-1H-indene-5-carbonitrile (120 mg, 0.31 mmol), aqueous HCl solution (4 M, 400 L) in THF (2 mL) was stirred at 45° C. for 16 hrs. The reaction mixture was quenched by addition of aq. NaHCO_3 (10 mL) at 0° C., then diluted with ethyl acetate (50 mL) and extracted with ethyl acetate (10 mL×3). The combined organic layers were washed with brine (10 mL), dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash column chromatography (SiO_2 , 34% ethyl acetate in petroleum ether) to give (R)-1-((2-(1,3-dioxolan-2-yl)thieno[2,3-c]pyridin-7-yl)amino)-6-fluoro-2,3-dihydro-1H-indene-5-carbonitrile (70 mg, 8.2% yield).

[0618] ^1H NMR (400 MHz, DMSO-d_6) δ 10.18 (s, 1H), 8.34 (s, 1H), 8.05 (d, $J=5.6$ Hz, 1H), 7.82 (d, $J=5.6$ Hz, 1H), 7.63 (d, $J=8.0$ Hz, 1H), 7.24-7.31 (m, 2H), 5.91 (q, $J=8.0$ Hz, 1H), 2.96-3.07 (m, 1H), 2.81-2.94 (m, 1H), 2.55-2.64 (m, 1H), 2.02-2.22 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d_6) δ -112.17. LC-MS: m/z 338.1 ($\text{M}+\text{H}$)⁺.


Step G (1R)-6-fluoro-1-((2-((9aS)-2-(4-fluorophenyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-4,5,7,8,9a-hexahydro-1H-pyrido[2,3-a]pyrrolizin-4-yl)thieno[2,3-c]pyridin-7-yl)amino)-2,3-dihydro-1H-indene-5-carbonitrile



[0619] To a solution of (R)-1-((2-(1,3-dioxolan-2-yl)thieno[2,3-c]pyridin-7-yl)amino)-6-fluoro-2,3-dihydro-1H-indene-5-carbonitrile (65 mg, 0.19 mmol) and 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one (52 mg, 0.21 mmol) and (S)-tetrahydro-1H-pyrrolizine-1,3(2H)-dione (39 mg, 0.28 mmol) in HOAc (3 mL) was added NH₄OAc (40 mg, 0.52 mmol). The mixture was stirred at 120° C. for 1 hr. The mixture was combined with ES28217-49 (5 mg of nitrile compound) was concentrated in vacuum to give a residue. The residue was purified by column chromatography (SiO₂, ethyl acetate) to give (1R)-6-fluoro-1-((2-((9aS)-2-(4-fluorophenethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-4,5,7,8,9,9a-hexahydro-1H-pyrido[2,3-a]pyrrolizin-4-yl)thieno[2,3-c]pyridin-7-yl)amino)-2,3-dihydro-1H-indene-5-carbonitrile (35 mg, 24.61% average yield).

[0620] ¹H NMR (400 MHz, DMSO-d₆) δ 12.19 (d, J=8.4 Hz, 1H), 9.69-10.06 (m, 1H), 7.88 (d, J=5.6 Hz, 1H), 7.78 (d, J=6.0 Hz, 1H), 7.19-7.29 (m, 4H), 7.06-7.13 (m, 3H), 6.99 (dd, J=2.4, 5.6 Hz, 1H), 5.77-5.96 (m, 1H), 5.08-5.24 (m, 1H), 4.18-4.34 (m, 1H), 3.24-3.29 (m, 1H), 2.93-3.04 (m, 2H), 2.79-2.92 (m, 6H), 2.03-2.15 (m, 4H), 1.22-1.35 (m, 1H). LC-MS: m/z 690.2 (M+H)⁺.

Step H (R)-6-fluoro-1-((2-((S)-2-(4-fluorophenethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)thieno[2,3-c]pyridin-7-yl)amino)-2,3-dihydro-1H-indene-5-carbonitrile




[0621] A mixture of (1R)-6-fluoro-1-((2-((9aS)-2-(4-fluorophenethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-4,5,7,8,9,9a-hexahydro-1H-pyrido[2,3-a]pyrrolizin-4-yl)thieno[2,3-c]pyridin-7-yl)amino)-2,3-dihydro-1H-indene-5-carbonitrile (35 mg, 0.05 mmol), CAN (28 mg, 0.05 mmol) in acetonitrile (2 mL) was stirred at 50° C. for 1 hr. The reaction mixture was concentrated. The mixture was purified by reversed-phase HPLC (column: Welch Xti-mate C18 150*25 mm*5 um; mobile phase: [water (NH₃H₂O+NH₄HCO₃)-ACN]; gradient: 26%-56% B over 8 min) and lyophilized to give (R)-6-fluoro-1-((2-((S)-2-(4-fluorophenethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)thieno[2,3-c]pyridin-7-yl)amino)-2,3-dihydro-1H-indene-5-carbonitrile (5.97 mg, 17.11% yield).

[0622] ¹H NMR (400 MHz, DMSO-d₆) δ 7.99 (d, J=5.6 Hz, 1H), 7.81 (d, J=5.6 Hz, 1H), 7.41-7.47 (m, 2H), 7.28


(dd, J=9.2, 2.4 Hz, 1H), 7.21 (dd, J=8.8, 5.6 Hz, 2H), 7.14 (d, J=5.6 Hz, 1H), 7.01-7.10 (m, 2H), 5.81-6.02 (m, 1H), 4.87 (dd, J=6.4, 10.2 Hz, 1H), 3.51-3.57 (m, 1H), 3.16-3.23 (m, 2H), 2.97-3.13 (m, 3H), 2.80-2.93 (m, 1H), 2.54-2.63 (m, 2H), 2.35-2.39 (m, 1H), 2.23-2.30 (m, 2H), 2.08-2.16 (m, 1H), 1.37-1.49 (m, 1H). ¹⁹F NMR (377 MHz, DMSO-d₆) δ -112.11, -117.04. LC-MS: m/z 688.0 (M+H)⁺.

Example 10


5-((S)-4-((R)-5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one
(Compound 166)



-continued




Step A (R)—N-(5,6-difluoro-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide



[0623] To a mixture of 5,6-difluoroindan-1-one (2 g, 11.89 mmol) and (R)-2-methylpropane-2-sulfonamide (1.51 g, 12.49 mmol) in 2-MeTHF (20 mL) was added tetraethoxoxtitanium (4.93 mL, 23.79 mmol) under nitrogen and stirred at 80° C. for 14 hrs. The reaction was diluted with water (500 mL) and ethyl acetate (500 mL) and filtered through Celite. The mixture was extracted with ethyl acetate (300 mL×3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in vacuum. The crude product was purified by silica gel column chromatography (35% ethyl acetate in petroleum ether) to give (R)—N-(5,6-difluoro-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide (2.73 g, 42.29% yield).

[0624] ¹H NMR (400 MHz, DMSO-d₆) δ 7.59-7.71 (m, 2H), 3.32-3.29 (m, 1H), 3.08-3.14 (m, 2H), 2.98-3.08 (m, 1H), 1.22 (s, 9H). ¹⁹F NMR (377 MHz, DMSO-d₆) δ -129.75, -138.67. LC-MS: m/z 272.1 (M+H)⁺.

Step B (R)—N—((R)-5,6-difluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfonamide





[0625] To a mixture of (R)—N-(5,6-difluoro-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide (2.73 g, 10.06 mmol) in DCM (150 mL) was added DIBAL-H (1 M in toluene, 30.19 mL) dropwise under nitrogen at -70° C. and stirred for 3 hrs. The reaction was quenched with MeOH (10 mL) slowly, then warmed to 0° C. 50 mL of saturated NH₄Cl solution was added and the resulting mixture was stirred for 30 min. Then the organic layer was separated. The aqueous layer was washed with DCM (300 mL). The combined organic layers were washed with brine (500 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum to give a residue. The crude product was purified by silica gel column chromatography (50% ethyl acetate in petroleum ether) to give (R)—N—((R)-5,6-difluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfonamide (1.19 g, 43.27% yield).

[0626] ¹H NMR (400 MHz, DMSO-d₆) δ 7.56 (dd, J=7.9, 10.7 Hz, 1H), 7.29 (dd, J=7.5, 10.5 Hz, 1H), 5.86 (d, J=8.8 Hz, 1H), 4.71 (q, J=8.4 Hz, 1H), 2.80-2.92 (m, 1H), 2.67-

2.77 (m, 1H), 2.36-2.45 (m, 1H), 1.91-2.00 (m, 1H), 1.15 (s, 9H). ^{19}F NMR (377 MHz, DMSO-d₆) δ -140.55, -141.44. LC-MS: m/z 274.1 (M+H)⁺. SFC t_R=1.712 min, 100%.

Step E (R)-7-((5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde


Step C
(R)-5,6-difluoro-2,3-dihydro-1H-inden-1-amine



[0627] A mixture of (R)—N—((R)-5,6-difluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfonamide (1.19 g, 4.35 mmol, 1 eq) in HCl/dioxane (20 mL) was stirred at 15-20° C. for 14 hrs. The reaction was concentrated in vacuum to give (R)-5,6-difluoro-2,3-dihydro-1H-inden-1-amine (960 mg, 99.73% yield, HCl).

[0628] ^1H NMR (400 MHz, DMSO-d₆) δ 8.71 (s, 3H), 7.77 (dd, J=7.8, 10.8 Hz, 1H), 7.41 (dd, J=7.7, 10.6 Hz, 1H), 4.58-4.84 (m, 1H), 3.00-3.11 (m, 1H), 2.78-2.90 (m, 1H), 2.51-2.56 (m, 1H), 2.43-2.49 (m, 1H), 1.99-2.11 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d₆) δ -137.90, -140.58.

Step D (R)—N-(5,6-difluoro-2,3-dihydro-1H-inden-1-yl)-2-(1,3-dioxolan-2-yl)thieno[2,3-c]pyridin-7-amine




[0629] To a mixture of (R)-5,6-difluoro-2,3-dihydro-1H-inden-1-amine (204 mg, 0.99 mmol, HCl), 7-chloro-2-(1,3-dioxolan-2-yl)thieno[2,3-c]pyridine (200 mg, 0.83 mmol), Pd(OAc)₂ (20 mg, 0.09 mmol), BINAP (104 mg, 0.17 mmol) and Cs₂CO₃ (800 mg, 2.46 mmol) under nitrogen was added dioxane (6 mL) and stirred at 100° C. for 16 hrs under nitrogen. The reaction was filtered and concentrated in vacuum. The crude product was purified by silica gel column chromatography (50% ethyl acetate in petroleum ether) to give (R)—N-(5,6-difluoro-2,3-dihydro-1H-inden-1-yl)-2-(1,3-dioxolan-2-yl)thieno[2,3-c]pyridin-7-amine (353 mg, 91.15% yield).

[0630] ^1H NMR (400 MHz, DMSO-d₆) δ ppm 7.96 (d, J=5.5 Hz, 1H), 7.48 (s, 1H), 7.33 (dd, J=7.6, 10.7 Hz, 1H), 7.14-7.21 (m, 2H), 7.07 (d, J=5.5 Hz, 1H), 6.21 (s, 1H), 5.80 (q, J=7.9 Hz, 1H), 4.03-4.06 (m, 2H), 3.99-4.03 (m, 2H), 2.94-3.04 (m, 1H), 2.76-2.90 (m, 1H), 2.52-2.58 (m, 1H), 2.01-2.13 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d₆) δ -140.59, -140.65, -141.71, -141.77. LC-MS: m/z 375.0 (M+H)⁺.

[0631] To a mixture of (R)—N-(5,6-difluoro-2,3-dihydro-1H-inden-1-yl)-2-(1,3-dioxolan-2-yl)thieno[2,3-c]pyridin-7-amine (353 mg, 0.94 mmol) in THF (3 mL) was added 4M aqueous HCl (1.18 mL) and stirred at 50° C. for 16 hrs under nitrogen. The reaction was diluted with NaHCO₃ solution (aq., 30 mL) and extracted with ethyl acetate (20 mL×3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and concentrated in vacuum. The crude product was purified by silica gel column chromatography (35% ethyl acetate in petroleum ether) to give (R)-7-((5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (300 mg, 96.32% yield).

[0632] ^1H NMR (400 MHz, DMSO-d₆) δ 10.18 (s, 1H), 8.33 (s, 1H), 8.06 (d, J=5.6 Hz, 1H), 7.53 (d, J=7.9 Hz, 1H), 7.34 (dd, J=7.6, 10.7 Hz, 1H), 7.26 (d, J=5.5 Hz, 1H), 7.20 (dd, J=7.9, 10.3 Hz, 1H), 5.82 (q, J=8.0 Hz, 1H), 2.95-3.05 (m, 1H), 2.75-2.90 (m, 1H), 2.54-2.60 (m, 1H), 2.01-2.16 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d₆) δ -140.41, -140.47, -141.60, -141.66.


Step F 5-((9aS)-4-(7-((R)-5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-4,5,7,8,9,9a-hexahydro-1H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one



[0633] To a mixture of (R)-7-((5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (50 mg, 0.15 mmol), (S)-tetrahydro-1H-pyrrolizine-1,3(2H)-dione (25 mg, 0.18 mmol) and 5-(4-(4-fluorophenyl)-

2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one (40 mg, 0.16 mmol) in HOAc (5 mL) was added NH₄OAc (25 mg, 0.32 mmol) and stirred at 120° C. for 1 hr. The reaction was filtered and concentrated in vacuum. The crude product was purified by silica gel column chromatography (100% ethyl acetate in petroleum ether) to give 5-((9aS)-4-(7-(((R)-5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-4,5,7,8,9,9a-hexahydro-1H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (36 mg, 34.84% yield). LC-MS: m/z 683.1 (M+H)⁺.


Step G 5-((S)-4-(7-(((R)-5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one



[0634] To a mixture of 5-((9aS)-4-(7-(((R)-5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-4,5,7,8,9,9a-hexahydro-1H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (36 mg, 0.05 mmol) in DCM (2 mL) was added CAN (29 mg, 0.05 mmol) and stirred at 50° C. for 1 hr. The reaction was filtered and concentrated in vacuum. The crude product was purified by prep-HPLC [column: Welch Xtimate C18 150*25 mm*5 um; mobile phase: [water(NH₃H₂O+NH₄HCO₃)-ACN]; gradient: 34%-64% B over 8 min] and fractions containing the desired compound was lyophilized to give 5-((S)-4-(7-(((R)-5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (2.89 mg, 8.05% yield).

[0635] ¹H NMR (400 MHz, DMSO-d₆) δ 12.69 (s, 1H), 8.00 (d, J=5.6 Hz, 1H), 7.45 (d, J=2.3 Hz, 1H), 7.29-7.38 (m, 2H), 7.17-7.26 (m, 3H), 7.02-7.11 (m, 3H), 5.81 (q, J=7.6 Hz, 1H), 4.87 (dd, J=6.3, 10.1 Hz, 1H), 3.50-3.59 (m, 1H), 3.26-3.30 (m, 1H), 3.16-3.23 (m, 2H), 3.04-3.13 (m, 1H), 2.95-3.04 (m, 2H), 2.77-2.89 (m, 1H), 2.54-2.59 (m, 1H), 2.32-2.40 (m, 1H), 2.23-2.32 (m, 2H), 2.01-2.13 (m, 1H), 1.37-1.47 (m, 1H). ¹⁹F NMR (377 MHz, DMSO-d₆) δ -117.02, -140.55, -141.60. LC-MS: m/z 681.1


5-((S)-4-(7-(((R)-5-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 167)



[0636] Compound 167 was synthesized using similar procedure as described in Example 10 above by using the appropriate materials.

[0637] ¹H NMR (400 MHz, MeOD-d₄) δ ppm 7.78-7.83 (m, 1H), 7.63-7.67 (m, 1H), 7.43-7.46 (m, 1H), 7.12-7.19 (m, 2H), 7.06-7.10 (m, 2H), 6.95-7.01 (m, 2H), 5.47-5.53 (m, 1H), 4.91-4.97 (m, 1H), 3.98-3.99 (m, 3H), 3.64-3.74 (m, 1H), 3.41-3.52 (m, 1H), 2.90-3.25 (m, 6H), 2.75-2.83 (m, 1H), 2.40-2.56 (m, 3H), 2.18-2.27 (m, 1H), 1.45-1.56 (m, 1H). ¹⁹F NMR (377 MHz, MeOD-d₄) δ -77.16, -118.97, -134.63. LC-MS: m/z 693.1 (M+H)⁺.

5-((S)-4-(7-(((R)-4-chloro-5-fluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 168)




[0638] Compound 168 was synthesized using similar procedure as described in Example 10 above by using the appropriate materials.


[0639] ^1H NMR (400 MHz, CDCl_3) δ ppm 7.95-8.06 (m, 1H), 7.40-7.40 (m, 1H), 7.34-7.44 (m, 1H), 7.23 (dd, $J=7.93$, 4.83 Hz, 1H), 7.12 (td, $J=9.09$, 5.66 Hz, 3H), 6.94-7.01 (m, 3H), 5.78-5.95 (m, 1H), 4.74-4.84 (m, 1H), 3.69-3.86 (m, 1H), 3.37-3.50 (m, 1H), 3.05-3.21 (m, 5H), 2.89-2.98 (m, 1H), 2.73-2.82 (m, 1H), 2.50-2.56 (m, 1H), 2.33-2.43 (m,

2H), 2.00-2.09 (m, 1H), 1.43-1.50 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d_6) δ -116.57. LC-MS: m/z 697.0 ($\text{M}+\text{H}^+$).

Example 11


5-((S)-4-(7-(((S)-2,3-dihydrobenzofuran-3-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 169)






Step A (S)-7-((2,3-dihydrobenzofuran-3-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde

7.72-7.90 (m, 1H), 7.35-7.44 (m, 1H), 7.29-7.33 (m, 1H),
7.18-7.26 (m, 1H), 6.84-6.92 (m, 2H), 5.97-6.06 (m, 1H),
4.83 (t, J=9.12 Hz, 1H), 4.40 (br dd, J=9.54, 5.25 Hz, 1H).
LC-MS: m/z 296.8 (M+H)⁺.



Step B ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-((S)-2,3-dihydrobenzofuran-3-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1,4-dihydropyridine-3-carboxylate




[0640] A mixture of (3S)-2,3-dihydrobenzofuran-3-amine (50 mg, 369.92 μmol), 7-chlorothieno[2,3-c]pyridine-2-carbaldehyde (74 mg, 374.42 μmol), Pd(OAc)₂ (9 mg, 40.09 μmol), BINAP (24 mg, 38.54 μmol) and Cs₂CO₃ (241. mg, 739.67 μmol) in dioxane (5 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 100° C. for 16 hrs under N₂ atmosphere. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was purified by column chromatography on silica gel (eluted with 0~30% PE in EA). Compound (S)-7-((2,3-dihydrobenzofuran-3-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (40 mg, 32.84% yield, 90% purity) was obtained.

[0641] ¹H NMR (400 MHz, DMSO-d₆) δ ppm 10.18 (s, 1H), 8.27 (dd, J=5.19, 3.04 Hz, 1H), 8.01-8.13 (m, 1H),

[0642] A mixture of (S)-7-((2,3-dihydrobenzofuran-3-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (40 mg, 134.


98 μmol), tert-butyl (S)-2-(3-ethoxy-3-oxopropanoyl)pyrrolidine-1-carboxylate (39 mg, 136.68 μmol), NH_4OAc (21 mg, 272.44 μmol), tris(trifluoromethylsulfonyloxy)ytterbium (9 mg, 14.51 μmol), 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one (34 mg, 135.88 μmol) in EtOH (50 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 50° C. for 16 hrs under N_2 atmosphere. The reaction mixture was concentrated under reduced pressure to remove solvent. Crude compound ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-(((S)-2,3-dihydrobenzofuran-3-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1,4-dihydropyridine-3-carboxylate (108 mg, crude) was obtained. LC-MS: m/z 795.3 ($\text{M}+\text{H}^+$).

Step C ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-(((S)-2,3-dihydrobenzofuran-3-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)nicotinate




[0643] A mixture of ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-(((S)-2,3-dihydrobenzofuran-3-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1,4-dihydropyridine-3-carboxylate (108 mg, 135.87 μmol), CAN (148 mg, 269.96 μmol) in MeCN (3 mL) and H_2O (3 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 22° C. for 16 hrs under N_2 atmosphere. The reaction mixture was quenched by addition NaHCO_3 (50 mL) at 22° C., and then diluted with H_2O (100 mL) and extracted with EtOAc (100 mL $\times 2$). The combined organic layer was washed with brine (50 mL), dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography on silica gel (eluted with 0~30% PE in EA). Compound ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-(((S)-2,3-dihydrobenzofuran-3-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)nicotinate (70 mg, 45.49% yield, 70% purity) was obtained. LC-MS: m/z 793.3 ($\text{M}+\text{H}^+$).

Step D ethyl 4-(7-(((S)-2,3-dihydrobenzofuran-3-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-((S)-pyrrolidin-2-yl)nicotinate



[0644] To a solution of ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-(((S)-2,3-dihydrobenzofuran-3-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)nicotinate (60 mg, 75.67 μmol) in DCM (5 mL) was added trimethylsilyl trifluoromethanesulfonate (369.00 mg, 1.66 mmol) and 2,6-dimethylpyridine (184.00 mg, 1.72 mmol). The mixture was stirred at 25° C. for 0.5 hr. The reaction mixture was concentrated under reduced pressure to remove solvent. Crude compound ethyl 4-(7-(((S)-2,3-dihydrobenzofuran-3-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-((S)-pyrrolidin-2-yl)nicotinate (80 mg, crude) was obtained. LC-MS: m/z 693.1 ($\text{M}+\text{H}^+$).

Step E 5-((S)-4-(7-(((S)-2,3-dihydrobenzofuran-3-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one




[0645] A mixture of ethyl 4-((S)-2,3-dihydrobenzofuran-3-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-((S)-pyrrolidin-2-yl)nicotinate (80 mg, 115.48 μ mol), TEA (545.25 mg, 5.39 mmol) in DCM (2 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 25° C. for 2 hrs under N₂ atmosphere. The reaction mixture was concentrated under reduced pressure to remove solvent. The crude product was purified by reversed-phase HPLC (column: Boston Green ODS 150*30 mm*5 um; mobile phase: [water(FA)-ACN]; gradient: 45%-65% B over 10 min). Compound 5-((S)-4-(7-((S)-2,3-dihydrobenzofuran-3-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (0.97 mg, 1.30% yield) was obtained.

[0646] ¹H NMR (400 MHz, CDCl₃) δ ppm 8.05-8.14 (m, 1H), 7.40-7.48 (m, 1H), 7.34-7.40 (m, 1H), 7.24 (s, 1H), 7.10-7.16 (m, 3H), 6.93-7.00 (m, 3H), 6.72-6.84 (m, 1H), 5.88-5.97 (m, 1H), 4.82-4.91 (m, 1H), 4.70-4.80 (m, 2H), 4.41-4.50 (m, 1H), 3.70-3.82 (m, 1H), 3.35-3.48 (m, 1H), 3.15 (br s, 4H), 2.48-2.56 (m, 1H), 2.34-2.45 (m, 2H), 1.46 (m, 1H). LC-MS: m/z 647.3 (M+H)⁺.

5-((S)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-2-(3-(trifluoromethyl)phenethyl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 171)


5-((S)-2-(2-cyclohexylethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one
(Compound 172)



[0649] Compound 172 was synthesized using similar procedure as described in Example 2 above by using the appropriate materials.


[0650] ¹H NMR (500 MHz, MeOD-d₄) δ 7.90-8.00 (d, J=4.8 Hz, 1H), 7.49 (s, 1H), 7.12-7.22 (m, 2H), 6.88-6.96 (m, 1H), 6.82 (dd, J=8.09, 2.44 Hz, 1H), 5.75-5.86 (t, J=6 Hz, 1H), 3.84 (s, 3H), 3.63-3.74 (m, 1H), 3.40-3.50 (m, 1H), 3.01-3.10 (m, 1H), 2.90-3.01 (m, 2H), 2.75-2.84 (m, 1H), 2.64-2.72 (m, 1H), 2.46-2.55 (m, 1H), 2.38-2.46 (m, 2H), 1.98-2.07 (m, 1H), 1.71-1.80 (m, 4H), 1.60-1.70 (m, 3H), 1.43-1.56 (m, 1H), 1.15-1.38 (m, 5H), 0.90-1.01 (m, 2H). LC-MS: m/z 663.2 (M+H)⁺.

5-((S)-4-(7-((R)-5-chloro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 173)



[0647] Compound 171 was synthesized using similar procedure as described in Example 2 above by using the appropriate materials.

[0648] ¹H NMR (400 MHz, MeOD-d₄) δ 7.74-7.83 (m, 1H), 7.60-7.66 (m, 1H), 7.38-7.51 (m, 5H), 7.22-7.31 (m, 1H), 6.89-7.00 (m, 2H), 5.47-5.57 (m, 1H), 4.91-4.94 (m, 1H), 3.83-3.90 (m, 3H), 3.60-3.74 (m, 1H), 3.42-3.49 (m, 1H), 3.34-3.39 (m, 2H), 3.19-3.29 (m, 2H), 3.07-3.15 (m, 1H), 2.85-2.97 (m, 1H), 2.70-2.79 (m, 1H), 2.38-2.53 (m, 3H), 2.11-2.21 (m, 1H), 1.41-1.53 (m, 1H). ¹⁹F NMR (376 MHz, CDCl₃) δ -64.01 (s, 3F). LC-MS: m/z 725.1 (M+H)⁺.





[0651] Compound 173 was synthesized using similar procedure as described in Example 10 above by using the appropriate materials.

[0652] ^1H NMR (400 MHz, CDCl_3) δ ppm 7.99-8.11 (m, 1H), 7.34-7.45 (m, 1H), 7.18-7.24 (m, 1H), 7.01-7.16 (m, 4H), 6.91-7.01 (m, 2H), 5.60-5.99 (m, 1H), 4.75-4.81 (m, 1H), 3.90 (s, 3H), 3.69-3.82 (m, 1H), 3.35-3.49 (m, 1H), 3.03 (m, 5H), 2.87-2.99 (m, 1H), 2.67-2.79 (m, 1H), 2.47-2.56 (m, 1H), 2.33-2.44 (m, 2H), 1.95-2.02 (m, 1H), 1.43-1.51 (m, 1H). LC-MS: m/z 709.1


-continued

Example 12

(R)-2-(4-fluorophenethyl)-4-((R)-4-methoxy-2,3-dihydro-1*H*-inden-1-yl)amino)thieno[2,3-*c*]pyridin-2-yl)-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,10,10*a*-tetrahydro-5*H*-pyrido[2',3':3,4]pyrrolo[2,1-*c*][1,4]oxazin-5-one (Compound 174)




Step A tert-butyl (3R)-3-[(Z)-1-amino-3-ethoxy-3-oxo-prop-1-enyl]morpholine-4-carboxylate



[0653] To a solution of tert-butyl (3S)-3-(3-ethoxy-3-oxopropanoyl)morpholine-4-carboxylate (2 g, 6.64 mmol) in EtOH (20 mL) was added NH₄OAc (2.56 g, 33.19 mmol). The mixture was stirred at 80° C. for 16 hrs. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0~18% Ethyl acetate/Petroleum ether gradient @40 mL/min). Compound tert-butyl (3R)-3-[(Z)-1-amino-3-ethoxy-3-oxo-prop-1-enyl]morpholine-4-carboxylate (1.12 g, 3.73 mmol, 56.18% yield, 60% purity) was obtained as a colorless oil.

[0654] ¹H NMR (400 MHz, CDCl₃) δ ppm 4.39-4.49 (m, 1H), 4.17-4.23 (m, 1H), 4.07-4.16 (m, 2H), 3.86-3.93 (m, 1H), 3.76-3.85 (m, 1H), 3.63-3.71 (m, 1H), 3.49-3.57 (m, 1H), 3.20-3.31 (m, 1H), 1.49 (s, 9H), 1.24-1.27 (m, 3H).


Step B tert-butyl (3S)-3-(3-(ethoxycarbonyl)-6-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1,4-dihydropyridin-2-yl)morpholine-4-carboxylate



[0655] A mixture of 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one (100 mg, 399.64 μmol), (R)-7-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (129.64 mg, 399.64 μmol), NH₄OAc (61.61 mg, 799.28 μmol), Yb(OTf)₃ (24.79 mg,


39.96 μmol) and tert-butyl (3R)-3-[(Z)-1-amino-3-ethoxy-3-oxo-prop-1-enyl]morpholine-4-carboxylate (120.03 mg, 399.64 μmol) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 100° C. for 1 hr under N₂ atmosphere. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was purified by flash silica gel chromatography (ISCO®; 4 g SepaFlash® Silica Flash Column, Eluent of 0~100% Ethyl acetate/Petroleum ether gradient @40 mL/min). Compound tert-butyl (3S)-3-(3-(ethoxycarbonyl)-6-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1,4-dihydropyridin-2-yl)morpholine-4-carboxylate (357 mg, 255.32 μmol, 63.89% yield, 60% purity) was obtained. LC-MS: m/z 839.5 (M+H)⁺.

Step C tert-butyl (3S)-3-[3-ethoxycarbonyl-6-[2-(4-fluorophenyl)ethyl]-4-[7-[[1R)-4-methoxyindan-1-yl]amino]thieno[2,3-c]pyridin-2-yl]-5-(2-oxo-3H-1,3,4-oxadiazol-5-yl)-2-pyridyl)morpholine-4-carboxylate




[0656] To a solution of tert-butyl (3S)-3-[3-ethoxycarbonyl-6-[2-(4-fluorophenyl)ethyl]-4-[7-[[1R)-4-methoxyindan-1-yl]amino]thieno[2,3-c]pyridin-2-yl]-5-(2-oxo-3H-1,3,4-oxadiazol-5-yl)-1,4-dihydropyridin-2-yl)morpholine-4-carboxylate (357 mg, 425.54 μmol) in MeCN (2 mL)/H₂O (2 mL) was added CAN (466.58 mg, 851.07 μmol). The mixture was stirred at 20° C. for 2 hrs. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was purified by flash silica gel chromatography (ISCO®; 4 g SepaFlash® Silica Flash Column, Eluent of 0~100% Ethyl acetate/Petroleum ether gradient @20 mL/min). Compound tert-butyl (3S)-3-[3-ethoxycarbonyl-6-[2-(4-fluorophenyl)ethyl]-4-[7-[[1R)-4-methoxyindan-1-yl]amino]thieno[2,3-c]pyridin-2-yl]-5-(2-oxo-3H-1,3,4-oxadiazol-5-yl)-2-pyridyl)morpholine-4-carboxylate (356.1 mg, 425.49 μmol, 99.99% yield) was obtained. LC-MS: m/z 837.3 (M+H)⁺.

Step D ethyl 6-[2-(4-fluorophenyl)ethyl]-4-[7-[(1R)-4-methoxyindan-1-yl]amino]thieno[2,3-c]pyridin-2-yl]-2-[(3S)-morpholin-3-yl]-5-(2-oxo-3H-1,3,4-oxadiazol-5-yl)pyridine-3-carboxylate



[0657] To a solution of tert-butyl (3S)-3-[3-ethoxycarbonyl-6-[2-(4-fluorophenyl)ethyl]-4-[7-[(1R)-4-methoxyindan-1-yl]amino]thieno[2,3-c]pyridin-2-yl]-5-(2-oxo-3H-1,3,4-oxadiazol-5-yl)-2-pyridylmorpholine-4-carboxylate (356.1 mg, 425.49 µmol) in DCM (4 mL) was added HCl/dioxane (3 M, 17 mL). The mixture was stirred at 20° C. for 2 hrs. The reaction mixture was concentrated under reduced pressure to remove solvent. The crude product ethyl 6-[2-(4-fluorophenyl)ethyl]-4-[7-[(1R)-4-methoxyindan-1-yl]amino]thieno[2,3-c]pyridin-2-yl]-2-[(3S)-morpholin-3-yl]-5-(2-oxo-3H-1,3,4-oxadiazol-5-yl)pyridine-3-carboxylate (313.5 mg, 425.48 µmol, 100.00% yield) was used into the next step without further purification. LC-MS: m/z 737.1 (M+H)⁺.

Step E (R)-2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,10,10a-tetrahydro-5H-pyrido[2',3':3,4]pyrrolo[2,1-c][1,4]oxazin-5-one




[0658] To a solution of ethyl 6-[2-(4-fluorophenyl)ethyl]-4-[7-[(1R)-4-methoxyindan-1-yl]amino]thieno[2,3-c]pyridin-2-yl]-2-[(3S)-morpholin-3-yl]-5-(2-oxo-3H-1,3,4-oxadiazol-5-yl)pyridine-3-carboxylate (313.5 mg, 425.48 µmol) in DCM (2 mL) was added TEA (43.05 mg, 425.48 µmol). The mixture was stirred at 20° C. for 16 hrs. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was purified by prep-HPLC (column: Boston Green ODS 150*30 mm*5 um; mobile phase: [water (TFA)-ACN]; gradient: 38%-58% B over 11 min). Compound (R)-2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,10,10a-tetrahydro-5H-pyrido[2',3':3,4]pyrrolo[2,1-c][1,4]oxazin-5-one (11.66 mg, 16.66 µmol, 3.92% yield, 98.7% purity) was obtained.


[0659] ¹H NMR (400 MHz, CDCl₃) δ ppm 7.75-7.84 (m, 1H), 7.64-7.69 (m, 1H), 7.41-7.46 (m, 1H), 7.26-7.33 (m, 1H), 7.11-7.18 (m, 2H), 6.89-7.02 (m, 4H), 5.47-5.60 (m, 1H), 4.60-4.69 (m, 1H), 4.18-4.26 (m, 1H), 4.03-4.10 (m, 1H), 3.81-3.93 (m, 3H), 3.34-3.48 (m, 5H), 3.19-3.27 (m, 1H), 3.06-3.17 (m, 3H), 2.86-2.99 (m, 1H), 2.71-2.83 (m, 1H), 2.09-2.25 (m, 1H). LC-MS: m/z 691.3 (M+H)⁺.

Example 13


5-((S)-2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5,5-dioxido-7,8,9a-tetrahydropyrrolo[1',2':3,4]isothiazolo[4,5-b]pyridin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 175)



-continued




Step A 5-((9aS)-2-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5,5-dioxido-1,4,7,8,9,9a-hexahydropyrrolo[1',2':2,3]isothiazolo[4,5-b]pyridin-3-yl)-1,3,4-oxadiazol-2(3H)-one



[0660] A mixture of 5-[4-(4-fluorophenyl)-2-oxo-butyl]-3H-1,3,4-oxadiazol-2-one (40 mg, 159.86 μ mol), 7-[(1R)-4-methoxyindan-1-yl]amino)thieno[2,3-c]pyridine-2-carbaldehyde (52 mg, 160.30 μ mol), (3aS)-1,1-dioxo-3a,4,5,6-tetrahydropyrrolo[1,2-b]isothiazol-3-one (28.0 mg, 159.81 μ mol), NH₄OAc (25 mg, 324.33 μ mol) in AcOH (2 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 120° C. for 2 hrs under N₂ atmosphere. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was diluted with H₂O (100 mL) and extracted with EtOAc (50 mL×2). The combined organic layer was washed with brine (50 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-TLC (SiO₂, EA). Compound 5-((9aS)-2-(4-fluoro-

phenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5,5-dioxido-1,4,7,8,9,9a-hexahydropyrrolo[1',2':2,3]isothiazolo[4,5-b]pyridin-3-yl)-1,3,4-oxadiazol-2(3H)-one (18 mg, 22.73 μ mol, 14.22% yield, 90% purity) was obtained. LC-MS: m/z 713.1 (M+H)⁺.

Step B 5-((S)-2-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5,5-dioxido-7,8,9,9a-tetrahydropyrrolo[1',2':2,3]isothiazolo[4,5-b]pyridin-3-yl)-1,3,4-oxadiazol-2(3H)-one




[0661] A mixture of 5-((9aS)-2-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5,5-dioxido-1,4,7,8,9,9a-hexahydropyrrolo[1',2':2,3]isothiazolo[4,5-b]pyridin-3-yl)-1,3,4-oxadiazol-2(3H)-one (18 mg, 25.25 μ mol), CAN (28 mg, 51.07 μ mol) in MeCN (2 mL) and H₂O (2 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 22° C. for 1 hr under N₂ atmosphere. The reaction mixture was quenched by aq. NaHCO₃ (30 mL) at 22° C., and then diluted with H₂O (50 mL) and extracted with EtOAc (50 mL×2). The combined organic layer was washed with brine (50 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Boston Green ODS 150*30 mm*5 um; mobile phase: [water(FA)-ACN]; gradient: 45%-65% B over 10 min). Compound 5-((S)-2-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5,5-dioxido-7,8,9,9a-tetrahydropyrrolo[1',2':2,3]isothiazolo[4,5-b]pyridin-3-yl)-1,3,4-oxadiazol-2(3H)-one (4.77 mg, 6.64 μ mol, 26.31% yield, 99% purity) was obtained.


[0662] ¹H NMR (400 MHz, CDCl₃) δ ppm 8.01-8.11 (m, 1H), 7.69-7.78 (m, 1H), 7.16-7.23 (m, 1H), 7.08-7.14 (m, 3H), 6.94-7.01 (m, 3H), 6.73-6.80 (m, 1H), 5.68-5.84 (m, 1H), 5.02-5.07 (m, 1H), 3.81-3.89 (m, 4H), 3.44 (dt, J=11.47, 6.90 Hz, 1H), 3.23 (br s, 5H), 2.81 (dt, J=16.06, 7.88 Hz, 1H), 2.64-2.73 (m, 1H), 2.51-2.60 (m, 1H), 2.28-2.35 (m, 1H), 1.91-2.05 (m, 2H), 1.73-1.82 (m, 1H). LC-MS: m/z 711.2 (M+H)⁺.

Example 14

6-[[6-[(9aS)-2-[2-(4-fluorophenyl)ethyl]-5-oxo-3-(2-oxo-3H-1,3,4-oxadiazol-5-yl)-7,8,9,9a-tetrahydro-pyrido[2,3-a]pyrrolizin-4-yl]-2-oxo-1,3-benzoxazol-3-yl]methyl]pyridine-3-carbonitrile (Compound 176)




Step A 6-[(6-formyl-2-oxo-1,3-benzoxazol-3-yl)methyl]pyridine-3-carbonitrile



[0663] To a mixture of 2-oxo-3H-1,3-benzoxazole-6-carbaldehyde (100 mg, 0.61 mmol), 6-(bromomethyl)pyridine-3-carbonitrile (363 mg, 1.84 mmol) and K_2CO_3 (170 mg, 1.23 mmol) in DMF (10 mL) was stirred at 50°C . for 14 hrs. The reaction was diluted with water (20 mL) and extracted with ethyl acetate (20 mL \times 3). The reaction mixture (combined with another batch from 100 mg of 2-oxo-3H-1,3-benzoxazole-6-carbaldehyde) were washed by 4% LiCl solution (aq., 20 mL), dried over anhydrous sodium sulfate, filtered and concentrated in vacuum. The crude product was purified by silica gel column chromatography (50% ethyl acetate in petroleum ether) to give 6-[(6-formyl-2-oxo-1,3-benzoxazol-3-yl)methyl]pyridine-3-carbonitrile (260 mg, 0.93 mmol, 75.94% average yield).

[0664] ^1H NMR (400 MHz, DMSO-d_6) δ ppm 9.93 (s, 1H), 8.93 (d, $J=1.6$ Hz, 1H), 8.35 (dd, $J=2.0, 8.0$ Hz, 1H), 7.86 (s, 1H), 7.82 (dd, $J=1.2, 8.0$ Hz, 1H), 7.74 (d, $J=8.2$ Hz, 1H), 7.40 (d, $J=8.0$ Hz, 1H), 5.37 (s, 2H). LC-MS: m/z 280.0 ($\text{M}+\text{H}$) $^+$.

Step B: 6-[[6-[(9aS)-2-[2-(4-fluorophenyl)ethyl]-5-oxo-3-(2-oxo-3H-1,3,4-oxadiazol-5-yl)-1,4,7,8,9,9a-hexahydropyrido[2,3-a]pyrrolizin-4-yl]-2-oxo-1,3-benzoxazol-3-yl]methyl]pyridine-3-carbonitrile




[0665] To a mixture of 6-[(6-formyl-2-oxo-1,3-benzoxazol-3-yl)methyl]pyridine-3-carbonitrile (50 mg, 0.18 mmol), 5-[4-(4-fluorophenyl)-2-oxo-butyl]-3H-1,3,4-oxadiazol-2-one (46 mg, 0.18 mmol) and (8S)-5,6,7,8-tetrahydropyrrrolizine-1,3-dione (28 mg, 0.20 mmol) in acetic acid (5 mL) was added NH_4OAc (28 mg, 0.36 mmol) and stirred at 120°C . for 1 hr. The reaction was concentrated in vacuum

and the residue was purified by silica gel column chromatography (100% ethyl acetate) to give 6-[[6-[(9aS)-2-[2-(4-fluorophenyl)ethyl]-5-oxo-3-(2-oxo-3H-1,3,4-oxadiazol-5-yl)-1,4,7,8,9a-hexahydropyrido[2,3-a]pyrrolizin-4-yl]-2-oxo-1,3-benzoxazol-3-yl]methyl]pyridine-3-carbonitrile (51 mg, 0.081 mmol, 45.10% yield).

[0666] ^1H NMR (400 MHz, DMSO-d₆) δ ppm 12.07 (d, J=12.4 Hz, 1H), 9.63-9.77 (m, 1H), 8.94 (t, J=2.8 Hz, 1H), 8.30-8.35 (m, 1H), 7.65-7.72 (m, 1H), 7.26-7.32 (m, 2H), 7.06-7.15 (m, 3H), 6.93-7.01 (m, 2H), 5.22 (d, J=2.0 Hz, 2H), 4.68 (s, 1H), 4.16-4.29 (m, 1H), 3.06-3.21 (m, 1H), 2.93-3.05 (m, 1H), 2.85-2.92 (m, 3H), 2.35-2.44 (m, 1H), 2.01-2.13 (m, 3H). ^{19}F NMR (400 MHz, DMSO-d₆) δ ppm -116.926. LC-MS: m/z 632.1 (M+H)⁺.

Step C: 6-[[6-[(9aS)-2-[2-(4-fluorophenyl)ethyl]-5-oxo-3-(2-oxo-3H-1,3,4-oxadiazol-5-yl)-7,8,9,9a-tetrahydropyrido[2,3-a]pyrrolizin-4-yl]-2-oxo-1,3-benzoxazol-3-yl]methyl]pyridine-3-carbonitrile




[0667] To a mixture of 6-[[6-[(9aS)-2-[2-(4-fluorophenyl)ethyl]-5-oxo-3-(2-oxo-3H-1,3,4-oxadiazol-5-yl)-1,4,7,8,9,9a-hexahydropyrido[2,3-a]pyrrolizin-4-yl]-2-oxo-1,3-benzoxazol-3-yl]methyl]pyridine-3-carbonitrile (51 mg, 0.081 mmol) in DCM (3 mL) was added CAN (45 mg, 0.082 mmol) and the mixture was stirred at 50° C. for 1 hr. The reaction mixture was concentrated in vacuum and the residue was purified by prep-HPLC {column: Welch Xtimate C18 150*25 mm*5 um; mobile phase: [water(NH₃H₂O+NH₄HCO₃)-ACN]; gradient: 11%-41% B over 8 min} and fractions containing the desired compound was lyophilized to give 6-[[6-[(9aS)-2-[2-(4-fluorophenyl)ethyl]-5-oxo-3-(2-oxo-3H-1,3,4-oxadiazol-5-yl)-7,8,9,9a-tetrahydropyrido[2,3-a]pyrrolizin-4-yl]-2-oxo-1,3-benzoxazol-3-yl]methyl]pyridine-3-carbonitrile (19.22 mg, 30.53 μ mol, 37.81% yield, 100% purity).


[0668] ^1H NMR (400 MHz, DMSO-d₆) δ ppm 8.94 (d, J=1.6 Hz, 1H), 8.35 (dd, J=2.0, 8.4 Hz, 1H), 7.73 (d, J=8.0 Hz, 1H), 7.40 (s, 1H), 7.18-7.24 (m, 3H), 7.04-7.10 (m, 2H), 6.98-7.03 (m, 1H), 5.33 (s, 2H), 4.83 (dd, J=6.4, 10.2 Hz, 1H), 3.43-3.57 (m, 2H), 3.11-3.17 (m, 2H), 2.96-3.09 (m, 2H), 2.22-2.36 (m, 3H), 1.32-1.45 (m, 1H). ^{19}F NMR (400 MHz, DMSO-d₆) δ ppm -117.067. LC-MS: m/z 630.1 (M+H)⁺.

Example 15

(S)-5-(2-(4-fluorophenethyl)-4-(1-((5-fluoropyridin-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 177)




Step A (5-fluoropyridin-2-yl)methyl methanesulfonate



[0669] To a solution of (5-fluoro-2-pyridyl)methanol (300 mg, 2.36 mmol) in DCM (5 mL) was added TEA (7.08 mmol, 985.47 L) at 0° C. To the mixture was added MsCl (2.01 mmol, 155.41 L) and the mixture was stirred at 25° C. for 30 min. The reaction mixture was added H₂O (10 mL) and extracted with DCM (10 mL×2). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude (5-fluoropyridin-2-yl)methyl methanesulfonate (530 mg, 98.49% yield) was obtained as a yellow oil.


Step B 1-((5-fluoropyridin-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde



[0670] To a solution of 1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde (200 mg, 1.37 mmol) in ACN (3 mL) was added K_2CO_3 (567.42 mg, 4.11 mmol) and (5-fluoro-2-pyridyl) methyl methanesulfonate (530 mg, 2.58 mmol). The mixture was stirred at 85° C. for 16 hrs. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (Biotage®; 4 g SepaFlash® Silica Flash Column, Eluent of 0~100% Ethylacetate/Petroleum ether gradient @18 mL/min) to give 1-((5-fluoropyridin-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde (130 mg, 37.22% yield) as a pink oil.

[0671] 1H NMR (400 MHz, $CDCl_3$) δ ppm 10.06 (s, 1H), 8.76 (d, $J=1.79$ Hz, 1H), 8.31-8.38 (m, 1H), 8.29-8.47 (m, 2H), 7.37 (d, $J=3.70$ Hz, 1H), 7.25 (m, 1H), 7.08 (m, 1H), 6.60 (d, $J=3.58$ Hz, 1H), 5.57 (s, 2H). LC-MS: m/z 256.1 ($M+H$) $^+$.


Step C 5-((9aS)-2-(4-fluorophenethyl)-4-(1-((5-fluoropyridin-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-oxo-1,5,7,8,9,9a-hexahydro-4H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one



[0672] A mixture of 1-((5-fluoropyridin-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridine-5-carbaldehyde (70 mg, 230.37 μ mol), (8S)-5,6,7,8-tetrahydropyrrolizine-1,3-dione (32.06 mg, 230.37 μ mol), 5-[4-(4-fluorophenyl)-2-oxo-butyl]-3H-1,3,4-oxadiazol-2-one (57.64 mg, 230.37 μ mol) and NH_4OAc (35.51 mg, 460.73 μ mol) in HOAc (2 mL) was stirred at 120° C. for 1 hr. The mixture was added H_2O (10 mL) and extracted with ethyl acetate (10 mL \times 3). The

combined organic layers were washed with brine (10 mL), dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (Biotage®; 4 g SepaFlash® Silica Flash Column, Eluent of 0~100% Ethylacetate/Petroleum ether gradient @18 mL/min) to give 5-((9aS)-2-(4-fluorophenethyl)-4-(1-((5-fluoropyridin-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-oxo-1,5,7,8,9,9a-hexahydro-4H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (60 mg, 98.75 μ mol, 42.87% yield). LC-MS: m/z 608.2 ($M+H$) $^+$.


Step D (S)-5-(2-(4-fluorophenethyl)-4-(1-((5-fluoropyridin-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one



[0673] To a solution of 5-((9aS)-2-(4-fluorophenethyl)-4-(1-((5-fluoropyridin-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-oxo-1,5,7,8,9,9a-hexahydro-4H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (60 mg, 98.75 μ mol) in ACN (2 mL) and H_2O (2 mL) was added CAN (54.14 mg, 98.75 μ mol). The mixture was stirred at 25° C. for 1 hr. The mixture was added H_2O (5 mL) and extracted with ethyl acetate (5 mL \times 3). The combined organic layers were washed with brine (5 mL), dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. The residue was further purification by pre-HPLC (Boston Green ODS 150 \times 30 mm \times 5 um, water (0.2% FA)-ACN) to give (S)-5-(2-(4-fluorophenethyl)-4-(1-((5-fluoropyridin-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (12.7 mg, 20.97 μ mol, 21.24% yield).

[0674] 1H NMR (400 MHz, $MeOD-d_4$) δ ppm 8.44 (d, $J=2.98$ Hz, 1H), 8.15 (d, $J=2.03$ Hz, 1H), 8.03 (d, $J=2.15$ Hz, 1H), 7.56 (d, $J=3.46$ Hz, 1H), 7.54-7.58 (m, 1H), 7.52 (m, 1H), 7.17 (m, 2H), 7.07 (m, 1H), 6.93-7.01 (m, 2H), 6.64 (d, $J=3.58$ Hz, 1H), 5.64 (s, 2H), 4.92-4.92 (m, 1H), 4.92 (br s, 1H), 3.67 (m, 1H), 3.43 (m, 1H), 3.26 (m, 2H), 3.06-3.18 (m, 2H), 2.52 (m, 1H), 2.38-2.47 (m, 2H), 1.43-1.57 (m, 1H). ^{19}F NMR (376 MHz, $MeOD-d_4$) δ ppm -119.06 (s, 1F), -130.86 (s, 1F). LC-MS: m/z 606.1 ($M+H$) $^+$.

5-((S)-2-(4-fluorophenethyl)-4-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-9a-methyl-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 178)






[0675] Compound 178 was synthesized using similar procedure as described in Example 2 above by using the appropriate materials.


[0676] ^1H NMR (400 MHz, DMSO-d₆): δ 12.71 (br s, 1H), 7.98 (d, $J=5.2$ Hz, 1H), 7.44 (s, 1H), 7.18-7.25 (m, 3H), 7.13 (t, $J=7.6$ Hz, 1H), 7.04-7.09 (m, 3H), 6.84 (dd, $J=7.6$ Hz, $J=9.2$ Hz, 2H), 5.86-5.93 (m, 1H), 3.79 (s, 3H), 3.58-3.67 (m, 1H), 3.27-3.30 (m, 1H), 3.19-3.23 (m, 2H), 2.92-3.07 (m, 3H), 2.66-2.72 (m, 1H), 2.20-2.43 (m, 3H), 1.97-2.08 (m, 2H), 1.54-1.65 (m, 4H). ^{19}F NMR (377 MHz, DMSO-d₆): -117.07. LC-MS: m/z 689.1 (M+H)⁺.

Example 16


(R)-2-(4-fluorophenethyl)-4-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-10a-methyl-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,10,10a-tetrahydro-5H-pyrido[2',3':3,4]pyrrolo[2,1-c][1,4]oxazin-5-one (Compound 179)



-continued




Step A: 4-(tert-butyl) 3-methyl (S)-3-methylmorpholine-3,4-dicarboxylate



[0677] To a solution of (S)-4-(tert-butoxycarbonyl)-3-methylmorpholine-3-carboxylic acid (1.1 g, 4.485 mmol) in Acetonitrile (120 mL) was added potassium carbonate (1.24 g, 8.969 mmol) and iodomethane (0.728 mL, 8.969 mmol), and the reaction was stirred at 60° C. for 18 hours. The reaction was concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with 10% ethyl acetate in petroleum ether to afford 4-(tert-butyl) 3-methyl (S)-3-methylmorpholine-3,4-dicarboxylate (1.12 g, 4.319 mmol, 96.31%).


[0678] ¹H NMR (400 MHz, CDCl₃): 3.82-3.91 (m, 1H), 3.66-3.76 (m, 5H), 3.58-3.66 (m, 1H), 3.52-3.56 (m, 1H), 3.20-3.30 (m, 1H), 1.54 (s, 3H), 1.44 (s, 9H).

Step B: methyl (S)-3-methylmorpholine-3-carboxylate




[0679] To a solution of 4-(tert-butyl) 3-methyl (S)-3-methylmorpholine-3,4-dicarboxylate (1.12 g, 4.319 mmol) in dioxane (6 mL) was added HCl-dioxane (4 M, 6 mL). The reaction was stirred at room temperature for 2 hrs. The reaction was concentrated to afford methyl (S)-3-methylmorpholine-3-carboxylate HCl salt (943 mg, crude). LC-MS: m/z 160.0 (M+H)⁺.

Step C: methyl (S)-4-acetyl-3-methylmorpholine-3-carboxylate




[0680] To a solution of methyl (S)-3-methylmorpholine-3-carboxylate HCl salt (943 mg, crude) in DCM (10 mL) was added TEA (2.470 mL, 17.771 mmol) and acetyl chloride (0.631 mL, 8.886 mmol), and the reaction was stirred at room temperature for 3 hours. After the reaction was completed, the mixture was quenched with ice water (10 mL), extracted with DCM (20 mL*3). The organic layers were combined, dried over Na_2SO_4 , filtered and concentrated under vacuum to dryness. The crude product was purified by column chromatography on silica gel eluted with ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ 20:1) to give methyl (S)-4-acetyl-3-methylmorpholine-3-carboxylate (657 mg, 3.265 mmol, 55.12%). LC-MS: m/z 202.0 ($\text{M}+\text{H}^+$).

Step D: (S)-8a-methyltetrahydro-6H-pyrrolo[2,1-c][1,4]oxazine-6,8(7H)-dione



[0681] To a solution of methyl (S)-4-acetyl-3-methylmorpholine-3-carboxylate (150 mg, 0.745 mmol) in THF (2 mL) was added Potassium tert-butoxide solution 1.0 M in THF (0.894 mL, 0.894 mmol), and the reaction was stirred at 80° C. for 30 minutes. The reaction was concentrated in vacuo to afford (S)-8a-methyltetrahydro-6H-pyrrolo[2,1-c][1,4]oxazine-6,8(7H)-dione (160 mg, crude). LC-MS: m/z 170.1 ($\text{M}+\text{H}^+$).


Step E: (10aR)-2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-10a-methyl-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1,4,7,8,10,10a-hexahydro-5H-pyrido[2',3':3,4]pyrrolo[2,1-c][1,4]oxazin-5-one



[0682] To a solution of (S)-8a-methyltetrahydro-6H-pyrrolo[2,1-c][1,4]oxazine-6,8(7H)-dione (10.43 mg, crude) in HOAc (1 mL) was added 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one (15.43 mg, 0.062

mmol), (R)-7-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (20 mg, 0.062 mmol) and NH_4OAc (9.50 mg, 0.123 mmol). The reaction was stirred at 100° C. for overnight. The reaction was concentrated in vacuo to afford (10aR)-2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-10a-methyl-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1,4,7,8,10,10a-hexahydro-5H-pyrido[2',3':3,4]pyrrolo[2,1-c][1,4]oxazin-5-one (50 mg, crude). LC-MS: m/z 707.0 ($\text{M}+\text{H}^+$).


Step F: (R)-2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-10a-methyl-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,10,10a-tetrahydro-5H-pyrido[2',3':3,4]pyrrolo[2,1-c][1,4]oxazin-5-one
(Compound 179)



[0683] To a solution of (10aR)-2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-10a-methyl-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1,4,7,8,10,10a-hexahydro-5H-pyrido[2',3':3,4]pyrrolo[2,1-c][1,4]oxazin-5-one (50 mg, crude) in EtOH (3 mL) was added cerium ammonium nitrate (77.57 mg, 0.141 mmol). The reaction was stirred at room temperature for 1 hour. The reaction mixture was purified by prep-HPLC to afford (R)-2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-10a-methyl-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,10,10a-tetrahydro-5H-pyrido[2',3':3,4]pyrrolo[2,1-c][1,4]oxazin-5-one (Compound 179) (2.21 mg, 0.003 mmol, 4.23%).

[0684] ^1H NMR (400 MHz, DMSO-d_6): δ 7.94 (d, $J=5.2$ Hz, 1H), 7.35 (s, 1H), 7.18-7.24 (m, 2H), 7.09-7.15 (m, 2H), 7.02-7.09 (m, 3H), 6.86 (d, $J=7.6$ Hz, 1H), 6.82 (d, $J=8.0$ Hz, 1H), 5.87-5.94 (m, 1H), 4.09 (d, $J=10.8$ Hz, 1H), 3.97-4.02 (m, 1H), 3.89-3.95 (m, 1H), 3.79 (s, 3H), 3.26-3.28 (m, 1H), 3.22-3.26 (m, 1H), 3.10-3.20 (m, 4H), 2.90-3.00 (m, 3H), 2.64-2.72 (m, 1H), 1.96-2.07 (m, 1H), 1.62 (s, 3H). ^{19}F NMR (377 MHz, DMSO-d_6): -117.33. LC-MS: m/z 705.2 ($\text{M}+\text{H}^+$).

5-(8-(4-fluorophenethyl)-6-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-1a,2,3-tetrahydro-5H-cyclopropa[g]pyrido[2,3-a]pyrrolizin-7-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 180)




[0685] Compound 180 was synthesized using similar procedure as described in Example 2 above by using the appropriate materials.


[0686] ^1H NMR (400 MHz, DMSO- d_6): δ 7.94 (d, $J=5.6$ Hz, 1H), 7.32 (d, $J=0.8$ Hz, 1H), 7.22 (dd, $J=6.0$ Hz, $J=8.8$ Hz, 2H), 7.02-7.13 (m, 5H), 6.87 (t, $J=7.2$ Hz, 1H), 6.81 (dd, $J=4.0$ Hz, $J=8.4$ Hz, 1H), 5.86-5.95 (m, 1H), 3.84-3.91 (m, 1H), 3.79 (d, $J=1.2$ Hz, 3H), 3.01-3.10 (m, 3H), 2.88-2.97 (m, 3H), 2.64-2.73 (m, 2H), 2.30-2.35 (m, 2H), 2.14-2.21 (m, 1H), 2.01-2.06 (m, 1H), 1.88-1.95 (m, 1H), 1.78 (t, $J=5.6$ Hz, 1H). ^{19}F NMR (377 MHz, DMSO- d_6): -117.30. LC-MS: m/z 687.1 ($\text{M}+\text{H}$) $^+$.


Example 17

(R)-5-(2-(4-fluorophenethyl)-4-(7-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 181)




-continued






Step A: 2-(tert-butyl) 1-methyl 2-azabicyclo[2.1.1]hexane-1,2-dicarboxylate




[0687] To a solution of 2-(tert-butoxycarbonyl)-2-azabicyclo[2.1.1]hexane-1-carboxylic acid (500 mg, 2.20 mmol) in ACN (2 mL) was added potassium carbonate (608 mg, 4.40 mmol) and iodomethane (0.357 mL, 4.40 mmol), and the reaction was stirred at 60° C. for 18 hours. The reaction was concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with 10% ethyl acetate in petroleum ether to afford 2-(tert-butyl) 1-methyl 2-azabicyclo[2.1.1]hexane-1,2-dicarboxylate (450 mg, 84.8%). LC-MS: m/z 242.1 ($M+H$)⁺.

Step B: methyl 2-azabicyclo[2.1.1]hexane-1-carboxylate HCl salt




[0688] To a solution of 2-(tert-butyl) 1-methyl 2-azabicyclo[2.1.1]hexane-1,2-dicarboxylate (400 mg, 1.66 mmol) in dioxane (4 mL) was added HCl-dioxane (4 M, 4 mL). The reaction was stirred at room temperature for 18 hours. The reaction was concentrated to afford methyl 2-azabicyclo[2.1.1]hexane-1-carboxylate HCl salt (300 mg, crude). LC-MS: m/z 142.1 ($M+H$)⁺.

Step C: methyl 2-acetyl-2-azabicyclo[2.1.1]hexane-1-carboxylate




[0689] To a solution of methyl 2-azabicyclo[2.1.1]hexane-1-carboxylate HCl salt (300 mg, crude) in DCM (3 mL) were added TEA (0.87 mL, 6.38 mmol) and acetyl chloride (0.23 mL, 3.20 mmol), and the reaction was stirred at room temperature for 3 hours. After the reaction was completed, the mixture was quenched with ice water (5 ml), extracted with DCM (20 mL*3). The organic layers were combined, dried over Na_2SO_4 , filtered and concentrated under vacuum to dryness. The crude product was purified by column chromatography on silica gel eluted with ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ 20:1) to give methyl 2-acetyl-2-azabicyclo[2.1.1]hexane-1-carboxylate (300 mg, 77.1%). LC-MS: m/z 184.1 ($M+H$)⁺.

Step D: dihydro-1H,5H-2,7a-methanopyrrolizine-5,7(6H)-dione




[0690] To a solution of methyl 2-acetyl-2-azabicyclo[2.1.1]hexane-1-carboxylate (50 mg, 0.273 mmol) in THF (2 mL) were added t-BuOK (61 mg, 0.546 mmol), and the reaction was stirred at 80° C. for 30 minutes. The reaction was concentrated in vacuo to afford dihydro-1H,5H-2,7a-methanopyrrolizine-5,7(6H)-dione (41 mg, crude). LC-MS: m/z 208.0 ($M+\text{H}_2\text{O}+\text{H}$)⁺.

Step E: 5-(2-(4-fluorophenethyl)-4-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-1,5,8,9-tetrahydro-4H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one



[0691] To a solution of dihydro-1H,5H-2,7a-methanopyrrolizine-5,7(6H)-dione (20 mg, crude) in HOAc (1 mL) was added 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2 (3H)-one (17 mg, 0.053 mmol), (R)-7-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (13 mg, 0.053 mmol) and NH₄OAc (8 mg, 0.106 mmol). The reaction was stirred at 100° C. for 3 hours. The reaction was concentrated in vacuo to afford 5-(2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-1,5,8,9-tetrahydro-4H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (91 mg, crude). LC-MS: m/z 689.5

Step F: (R)-5-(2-(4-fluorophenethyl)-4-(7-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 181)




[0692] To a solution of 5-(2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-1,5,8,9-tetrahydro-4H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2 (3H)-one (91 mg, crude) in EtOH (3 mL) was added cerium ammonium nitrate (72 mg, 0.132 mmol). The reaction was stirred at room temperature for 1 hour. The reaction mixture was purified by prep-HPLC to afford (R)-5-(2-(4-fluorophenethyl)-4-(7-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 181) (5.50 mg, 6.06%).


[0693] ¹H NMR (400 MHz, DMSO-d₆): δ 12.69 (br s, 1H), 7.98 (d, J=5.2 Hz, 1H), 7.41 (s, 1H), 7.18-7.24 (m, 3H), 7.02-7.14 (m, 4H), 6.84 (dd, J=7.6 Hz, J=11.6 Hz, 2H), 5.90 (q, J=8.0 Hz, 1H), 3.79 (s, 3H), 3.56 (s, 2H), 3.17-3.22 (m, 3H), 3.01-3.05 (m, 2H), 2.89-2.97 (m, 1H), 2.62-2.72 (m, 4H), 1.96-2.07 (m, 1H), 1.71-1.78 (m, 2H). ¹⁹F NMR (377 MHz, DMSO-d₆): -117.03. LC-MS: m/z 687.2 (M+H)⁺.

Example 18


5-((S)-2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-9,9-dimethyl-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2 (3H)-one (Compound 182)




-continued



-continued




Step A tert-butyl (S)-2-(3-ethoxy-3-oxopropanoyl)-3,3-dimethylpyrrolidine-1-carboxylate



[0694] To a solution of (S)-1-(tert-butoxycarbonyl)-3,3-dimethylpyrrolidine-2-carboxylic acid (300 mg, 1.233 mmol) in THF (3 mL) and Acetonitrile (3 mL) were added CDI (239.93 mg, 1.480 mmol) and the reaction was stirred at room temperature for 1 hr. Then potassium 3-ethoxy-3-oxopropanoate (314.82 mg, 1.850 mmol) and magnesium chloride (140.86 mg, 1.480 mmol) was added and the reaction was stirred at 50° C. for 18 hr. The reaction was diluted with EA (50 mL) and water (20 mL). The organic layer was separated, washed with further water (20 mL×2) and saturated NaCl (20 mL). The organic layer was separated, dried with Na₂SO₄ and then filtered. The organic layer was collected, concentrated in vacuo. The residue was purified using silica gel column chromatography eluting with PE:EA=1:1. The organic layer was collected, concentrated in vacuo to afford the title compound tert-butyl (S)-2-(3-ethoxy-3-oxopropanoyl)-3,3-dimethylpyrrolidine-1-carboxylate (170 mg, 0.542 mmol, 43.99%). LC-MS: m/z 314.2 (M+H)⁺.

Step B ethyl 2-((S)-1-(tert-butoxycarbonyl)-3,3-dimethylpyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-((7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1,4-dihydropyridine-3-carboxylate





[0695] A solution of tert-butyl (S)-2-(3-ethoxy-3-oxopropanoyl)-3,3-dimethylpyrrolidine-1-carboxylate (170 mg, 0.542 mmol), 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one (135.74 mg, 0.542 mmol) and (R)-7-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (175.97 mg, 0.542 mmol) in EtOH (2 mL) were added NH₄OAc (167.25 mg, 2.170 mmol) and Yb(OTf)₃ (33.63 mg, 0.054 mmol). The reaction was stirred at 60° C. for 18 hr. The reaction was diluted with EA (50

mL) and water (20 mL). The organic layer was separated, washed with further water (20 mL×2) and saturated NaCl (20 mL). The organic layer was separated, dried with Na₂SO₄ and then filtered. The organic layer was collected, concentrated in vacuo to give ethyl 2-((S)-1-(tert-butoxycarbonyl)-3,3-dimethylpyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1,4-dihdropyridine-3-carboxylate (crude 200 mg, 0.235 mmol, 43.32%). LC-MS: m/z 851.3 (M+H)⁺.

Step C ethyl 2-((S)-1-(tert-butoxycarbonyl)-3,3-dimethylpyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)nicotinate


Step D ethyl 2-((S)-3,3-dimethylpyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)nicotinate



[0696] A solution of ethyl 2-((S)-1-(tert-butoxycarbonyl)-3,3-dimethylpyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1,4-dihdropyridine-3-carboxylate (crude 200 mg, 0.235 mmol) in EtOH (2 mL) were added ammonium cerium(IV) nitrate (257.68 mg, 0.470 mmol). The reaction was stirred at R.T. for 2 hr. The reaction was concentrated and purified by chromatography on C18 (FA) to give ethyl 2-((S)-1-(tert-butoxycarbonyl)-3,3-dimethylpyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)nicotinate (100 mg, 0.118 mmol, 50.12%). LC-MS: m/z 849.3 (M+H)⁺.

[0697] A solution of ethyl 2-((S)-1-(tert-butoxycarbonyl)-3,3-dimethylpyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)nicotinate (100 mg, 0.118 mmol) in AcOH (4 mL) and H₂O (2 mL) were added H₂SO₄ (0.006 mL, 0.118 mmol). The reaction was stirred at 40° C. for 18 hr. The reaction was diluted with EA (50 mL) and water (20 mL). The organic layer was separated, washed with further water (20 mL×2) and saturated NaCl (20 mL). The organic layer was separated, dried with Na₂SO₄ and then filtered. The organic layer was collected, concentrated in vacuo. The residue was concentrated give ethyl 2-((S)-3,3-dimethylpyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)nicotinate (crude 80 mg, 0.107 mmol, 90.69%). LC-MS: m/z 749.2 (M+H)⁺.

Step E 5-((S)-2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-9,9-dimethyl-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 182)




[0698] A solution of ethyl 2-((S)-3,3-dimethylpyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)nicotinate (50 mg, 0.067 mmol) in DCM (2 mL) and H₂O (2 mL) were added Na₂CO₃ (21.30 mg, 0.201 mmol). The reaction was stirred at R.T. for 1 hr. The reaction was purified by Prep-HPLC (FA) to give 5-((S)-2-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-9,9-dimethyl-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 182) (14.45 mg, 0.021 mmol, 30.80%).

[0699] ¹H NMR (400 MHz, DMSO-d₆): δ 7.97 (d, J=5.2 Hz, 1H), 7.44 (s, 1H), 7.19-7.25 (m, 3H), 7.11-7.15 (m, 1H), 7.02-7.08 (m, 3H), 6.81-6.86 (m, 2H), 5.86-5.92 (m, 1H), 4.61 (s, 1H), 3.79 (s, 3H), 3.43-3.51 (m, 1H), 3.19-3.26 (m, 3H), 3.08-3.14 (m, 1H), 3.00-3.05 (m, 1H), 2.91-2.98 (m, 1H), 2.66-2.74 (m, 2H), 2.53-2.55 (m, 1H), 2.17-2.28 (m, 1H), 1.94-2.06 (m, 2H), 1.40 (s, 3H), 0.31 (s, 3H). ¹⁹F NMR (377 MHz, DMSO-d₆): δ -117.19. LC-MS: m/z 703.3 (M+H)⁺.

5-((S)-4-(7-(((R)-4,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one
(Compound 183)


5-((S)-4-(7-(((R)-5-fluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one
(Compound 184)



[0702] Compound 184 was synthesized using similar procedure as described in Example 10 above by using the appropriate materials.

[0703] ¹H NMR (400 MHz, CDCl₃) δ 8.04 (d, J=6 Hz, 1H) 7.40 (s, 1H) 7.29-7.36 (m, 1H) 7.11-7.18 (m, 2H) 7.07 (d, J=5.60 Hz, 1H) 6.93-7.01 (m, 3H) 6.89 (m, 1H) 5.73-5.83 (m, 1H) 4.86-4.97 (m, 1H) 4.75-4.83 (m, 1H) 3.73-3.83 (m, 1H) 3.38-3.48 (m, 1H) 3.16-3.23 (m, 2H) 3.06-3.14 (m, 2H) 2.97-3.04 (m, 1H) 2.84-2.94 (m, 1H) 2.67-2.79 (m, 1H) 2.49-2.59 (m, 1H) 2.33-2.45 (m, 2H) 1.97-2.04 (m, 1H) 1.41-1.53 (m, 1H). ¹⁹F NMR (376 MHz, CDCl₃) δ -115.13 (s, 1F) -116.62 (s, 1F). LC-MS: m/z 663.1 (M+H)⁺.


5-((S)-2-isopropyl-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 185)



[0700] Compound 183 was synthesized using similar procedure as described in Example 10 above by using the appropriate materials.

[0701] ¹H NMR (400 MHz, CDCl₃) δ ppm 8.05-8.10 (m, 1H), 7.40 (s, 1H), 7.09-7.17 (m, 3H), 6.90-7.00 (m, 3H), 6.65-6.74 (m, 1H), 5.75-6.03 (m, 1H), 4.56-4.88 (m, 2H), 3.70-3.81 (m, 1H), 3.39-3.50 (m, 1H), 3.02-3.21 (m, 5H), 2.75-2.89 (m, 2H), 2.48-2.56 (m, 1H), 2.35-2.45 (m, 2H), 2.01 (m, 1H), 1.45 (m, 1H). LC-MS: m/z 681.1 (M+H)⁺.


[0704] Compound 185 was synthesized using similar procedure as described in Example 2 above by using the appropriate materials.




[0705] ^1H NMR (400 MHz, DMSO-d₆): δ 7.98 (d, J=5.2 Hz, 1H), 7.42 (s, 1H), 7.25 (d, J=8.4 Hz, 1H), 7.13 (t, J=7.6 Hz, 1H), 7.07 (d, J=5.6 Hz, 1H), 6.84 (dd, J=7.2 Hz, J=11.2 Hz, 2H), 5.90 (q, J=8.4 Hz, 1H), 4.87 (dd, J=6.4 Hz, J=9.6 Hz, 1H), 3.79 (s, 3H), 3.51-3.56 (m, 1H), 3.25-3.28 (m, 1H), 3.16-3.20 (m, 1H), 2.92-2.98 (m, 1H), 2.68-2.72 (m, 1H), 2.22-2.41 (m, 4H), 1.96-2.05 (m, 1H), 1.45 (t, J=10.4 Hz, 1H), 1.28 (dd, J=3.2 Hz, J=6.4 Hz, 6H). LC-MS: m/z 595.2 (M+H)⁺.

Example 19

(S)-7-(2-(4-fluorophenethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-4-((5-fluoropyridin-2-yl)methyl)-2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-one (Compound 186)



Step A 4-((5-fluoropyridin-2-yl)methyl)-2,2-dimethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carbaldehyde





[0706] To a solution of 2,2-dimethyl-3-oxo-4H-1,4-benzoxazine-7-carbaldehyde (65 mg, 316.75 µmol) in DMF (3 mL) was added K_2CO_3 (131.0 mg, 950.25 µmol) and 2-(chloromethyl)-5-fluoro-pyridine (69.0 mg, 380.10 µmol, HCl salt). The mixture was stirred at 60° C. for 2 hrs. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2 , Petroleum ether/Ethyl acetate=1/0 to 5/1). Compound 4-((5-fluoropyridin-2-yl)methyl)-2,2-dimethyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-7-carbaldehyde (80 mg, 80.36% yield) was obtained. LC-MS: m/z 315.0 ($M+H^+$).

Step B 7-((9aS)-2-(4-fluorophenethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-4,4a,5,7,8,9,9a,9b-octahydro-1H-pyrido[2,3-a]pyrrolizin-4-yl)-4-((5-fluoropyridin-2-yl)methyl)-2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-one

tetrahydropyrrolizine-1,3-dione (31.0 mg, 222.71 µmol) in AcOH (2 mL) was added NH_4OAc (34.0 mg, 445.42 µmol). The mixture was stirred at 120° C. for 1 hr. The reaction mixture was concentrated under reduced pressure to give crude product 7-((9aS)-2-(4-fluorophenethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-4,4a,5,7,8,9a,9b-octahydro-1H-pyrido[2,3-a]pyrrolizin-4-yl)-4-((5-fluoropyridin-2-yl)methyl)-2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-one (150 mg, crude). LC-MS: m/z 667.2 ($M+H^+$).

Step C (S)-7-(2-(4-fluorophenethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-4-((5-fluoropyridin-2-yl)methyl)-2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-one (Compound 186)








[0707] To a solution of 4-[(5-fluoro-2-pyridyl)methyl]-2,2-dimethyl-3-oxo-1,4-benzoxazine-7-carbaldehyde (70 mg, 222.71 µmol), 5-[4-(4-fluorophenyl)-2-oxo-butyl]-3H-1,3,4-oxadiazol-2-one (55.0 mg, 222.71 µmol), (8S)-5,6,7,8-

[0708] To a solution of 7-((9aS)-2-(4-fluorophenethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-4,4a,5,7,8,9,9a,9b-octahydro-1H-pyrido[2,3-a]pyrrolizin-4-yl)-4-((5-fluoropyridin-2-yl)methyl)-2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-one (60 mg, 90.00 µmol) in MeCN (3 mL) was added CAN (49.34 mg, 90.00 µmol). The mixture was stirred at 25° C. for 1 hr. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: YMC-Actus Triart C18 150*30 mm*5 um; mobile phase: [water(TFA)-ACN]; gradient: 46%-66% B over 11.5 min). Compound (S)-7-(2-(4-fluorophenethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-4-((5-fluoropyridin-2-yl)methyl)-2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-one (4.38 mg, 7.32% yield) was obtained.






[0709] 1H NMR (400 MHz, MeOD-d₄) δ ppm 8.39-8.48 (m, 1H), 7.54-7.65 (m, 1H), 7.32-7.38 (m, 1H), 7.11-7.17 (m, 2H), 7.03-7.08 (m, 1H), 6.89-7.01 (m, 4H), 5.25-5.32 (m, 2H), 4.83-4.87 (m, 1H), 3.61-3.71 (m, 1H), 3.39-3.48 (m, 1H), 3.19-3.27 (m, 2H), 3.01-3.16 (m, 2H), 2.38-2.55 (m, 3H), 1.52-1.58 (m, 6H), 1.42-1.50 (m, 1H). LC-MS: m/z 665.2 ($M+H^+$).

Example 20


(R)-5-(4-((7-((5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 191)




-continued



-continued




Step A: methyl 5-bromothieno[2,3-c]pyridine-2-carboxylate



[0710] A mixture of 2-bromo-5-fluoroisonicotinaldehyde (10 g, 49.0 mmol), K_2CO_3 (20.3 g, 147 mmol) in DMF (100 mL) was stirred at room temperature for 30 minutes. Then, methyl 2-mercaptoacetate (10.4 g, 98.0 mmol) was added and the reaction was stirred at 100° C. for 2 hours. The reaction was poured into 1 L water, filtered and dried to give methyl 5-bromothieno[2,3-c]pyridine-2-carboxylate (10.8 g, 81.0%). LC-MS: m/z 271.9 ($M+H^+$).


Step B: methyl 5-methylthieno[2,3-c]pyridine-2-carboxylate



[0711] To a solution of 5-bromothieno[2,3-c]pyridine-2-carboxylate (5 g, 18.4 mmol) in dioxane (100 mL) was added 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (23.1 g, 183 mmol), K_2CO_3 (7.62 g, 55.1 mmol), and $Pd(dppf)Cl_2 \cdot CH_2Cl_2$ (1.50 g, 1.84 mmol). The reaction was stirred at


90° C. for 18 hours under N_2 . The reaction was concentrated in vacuo and purified by silica gel column chromatography eluting with 10% ethyl acetate in petroleum ether to afford methyl 5-methylthieno[2,3-c]pyridine-2-carboxylate (3.8 g, 99.8%). LC-MS: m/z 208.0 ($M+H^+$).

Step C: 2-(methoxycarbonyl)-5-methylthieno[2,3-c]pyridine 6-oxide




[0712] To a solution of methyl 5-methylthieno[2,3-c]pyridine-2-carboxylate (2 g, 9.65 mmol) in DCM (30 mL) was added m-CPBA (2.50 g, 14.48 mmol). The reaction was stirred at room temperature for 18 hours. The reaction was diluted with DCM (100 mL) and water (50 mL). The organic layer was separated, washed with further saturated $NaCl$ solution (50 mL), and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with 1% methanol in dichloroform to afford 2-(methoxycarbonyl)-5-methylthieno[2,3-c]pyridine 6-oxide (4 g, impure). LC-MS: m/z 224.1 ($M+H^+$).

Step D: methyl 7-chloro-5-methylthieno[2,3-c]pyridine-2-carboxylate




[0713] A solution of 2-(methoxycarbonyl)-5-methylthieno[2,3-c]pyridine 6-oxide (3.5 g, impure) in $POCl_3$ (30 mL) was stirred at 100° C. for 3 hours. The reaction was concentrated and diluted with DCM (50 mL), adjusted by saturated Na_2CO_3 solution (100 mL) to pH>7. The organic phase was separated, the aqueous phase was extracted with DCM (100 mL*2). The combined organic layer was washed with saturated $NaCl$ solution (50 mL), and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with 6% ethyl acetate in petroleum ether to afford methyl 7-chloro-5-methylthieno[2,3-c]pyridine-2-carboxylate (1 g, 26.39%). LC-MS: m/z 242.0 ($M+H^+$).

Step E: methyl (R)-7-((5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridine-2-carboxylate




[0714] To a solution of methyl 7-chloro-5-methylthieno[2,3-c]pyridine-2-carboxylate (500 mg, 2.07 mmol) in Toluene (10 mL) was added (R)-5,6-difluoro-2,3-dihydro-1H-inden-1-amine (412 mg, 2.48 mmol), Pd₂(dba)₃ (167 mg, 0.207 mmol), and Xantphos (120 mg, 0.207 mmol), Cs₂CO₃ (2.02 g, 6.21 mmol). The mixture reaction was stirred at 110° C. for 18 hours under N₂. The mixture reaction was concentrated and purified by silica gel column chromatography eluting with 6% ethyl acetate in petroleum ether to afford methyl (R)-7-((5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridine-2-carboxylate (400 mg, 51.6%). LC-MS: m/z 374.9 (M+H)⁺.

Step F: (R)-7-((5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl methanol




[0715] To a solution of methyl (R)-7-((5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridine-2-carboxylate (350 mg, 0.935 mmol) in THF (5 mL) was added LiAlH₄ (107 mg, 2.80 mmol) slowly at 0° C. The reaction was stirred at room temperature for 10 minutes. The reaction was diluted with EA (10 mL) and water (20 mL). The organic layer was separated, washed with further saturated NaCl solution, and concentrated to afford (R)-7-((5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)methanol (320 mg, crude). LC-MS: m/z 347.0 (M+H)⁺.

Step G: (R)-7-((5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridine-2-carbaldehyde



[0716] To a solution of (R)-7-((5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl methanol (320 mg, 0.924 mmol) in DCM (5 mL) was added 4-Methylmorpholine N-oxide (230 mg, 1.96 mmol), Tetrapropylammonium Perruthenate (34 mg, 0.098 mmol). The reaction was stirred at room temperature for 3 hours. The reaction was diluted with EA (10 mL), washed with water (30 mL*3), then the organic phase was concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with 5% ethyl acetate in petroleum ether to afford (R)-7-((5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridine-2-carbaldehyde (310 mg, 97.44%). LC-MS: m/z 345.1 (M+H)⁺.


Step H: 5-(4-((R)-5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl-2-(4-fluorophenethyl)-5-oxo-1,5,8,9-tetrahydro-4H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one



[0717] To a solution of (R)-7-((5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridine-2-carbaldehyde (30 mg, 0.0872 mmol) in HOAc (1 mL) was added 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one (22 mg, 0.0872 mmol), potassium 5-oxo-2,3-dihydro-1H,5H-2,7a-methanopyrrololin-7-olate (20 mg, 0.105 mmol), and NH₄OAc (13 mg, 0.174 mmol). The reaction was stirred at 100° C. for 1 hour. The reaction was concentrated in vacuo to afford 5-(4-((R)-5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]

pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-1,5,8,9-tetrahydro-4H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (41 mg, crude). LC-MS: m/z 709.2 (M+H)⁺.

Step I: (R)-5-(4-(7-((5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H,8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 191)




[0718] To a solution of 5-(4-(7-((R)-5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-1,5,8,9-tetrahydro-4H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (41 mg, crude) in EtOH (2 mL) were added ceric ammonium nitrate (63 mg, 0.116 mmol). The reaction was stirred at room temperature for 1 hour. The reaction was diluted with EA (10 mL) and water (20 mL). The organic layer was separated, washed with further saturated NaCl solution (10 mL), and concentrated in vacuo. The residue was purified by prep-HPLC to afford (R)-5-(4-(7-((5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (3.13 mg, 7.66%).

[0719] ¹H NMR (400 MHz, DMSO-d₆): δ 7.30-7.35 (m, 2H), 7.17-7.25 (m, 4H), 7.07 (t, J=8.8 Hz, 2H), 6.94 (s, 1H), 5.79-5.85 (m, 1H), 3.56 (s, 2H), 3.15-3.22 (m, 3H), 2.97-3.

07 (m, 3H), 2.79-2.88 (m, 1H), 2.61-2.68 (m, 2H), 2.55-2.57 (m, 1H), 2.41 (s, 3H), 2.03-2.14 (m, 1H), 1.74 (d, J=4.0 Hz, 2H). ¹⁹F NMR (377 MHz, DMSO-d₆): δ -117.03, -140.59, -141.547. LC-MS: m/z 707.3 (M+H)⁺.

5-((S)-4-(7-((R)-5-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 187)




[0720] Compound 187 was synthesized using similar procedure as described in Example 20 above by using the appropriate materials.


[0721] ¹H NMR (400 MHz, DMSO-d₆): δ 7.32 (s, 1H), 7.18-7.25 (m, 2H), 7.16 (d, J=8.4 Hz, 1H), 7.07 (t, J=8.8 Hz, 2H), 6.98-7.03 (m, 1H), 6.90-6.95 (m, 2H), 5.83-5.88 (m, 1H), 4.86 (dd, J=6.0 Hz, J=10.4 Hz, 1H), 3.87 (s, 3H), 3.50-3.59 (m, 2H), 3.16-3.19 (m, 2H), 2.97-3.10 (m, 4H), 2.81-2.89 (m, 2H), 2.40 (s, 3H), 2.27-2.31 (m, 2H), 2.00-2.12 (m, 1H), 1.37-1.47 (m, 1H). ¹⁹F NMR (377 MHz, DMSO-d₆): δ -117.04, -135.41. LC-MS: m/z 707.3 (M+H)⁺.

Example 21




5-((S)-4-(5-(difluoromethyl)-7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 188)




-continued



-continued




Step A: methyl 5-(bromomethyl)-7-chlorothieno[2,3-c]pyridine-2-carboxylate




[0722] To a solution of methyl 7-chloro-5-methylthieno[2,3-c]pyridine-2-carboxylate (500 mg, 2.07 mmol) in CCl_4 (5 mL) was added NBS (405 mg, 2.28 mmol), AIBN (68 mg, 0.414 mmol). The reaction was stirred at 80°C . for 18 hours. The reaction was diluted with DCM (50 mL), washed with further saturated NaCl solution (20 mL*2), dried over Na_2SO_4 and concentrated to afford methyl 5-(bromomethyl)-7-chlorothieno[2,3-c]pyridine-2-carboxylate (663 mg, crude). LC-MS: m/z 319.8 ($\text{M}+\text{H}^+$).

Step B: methyl 7-chloro-5-formylthieno[2,3-c]pyridine-2-carboxylate



[0723] To a solution of methyl 5-(bromomethyl)-7-chlorothieno[2,3-c]pyridine-2-carboxylate (663 mg, 2.07 mmol) in Acetonitrile (10 mL) was added 4-Methylmorpholine N-oxide (485 mg, 4.14 mmol). The reaction was stirred at 25°C . for 1 hour. The reaction was diluted with DCM (50 mL), washed with further saturated NaCl solution (20 mL*3) and concentrated in vacuo. The residue was purified by prep-TLC eluting with 10% ethyl acetate in petroleum ether to afford methyl 7-chloro-5-formylthieno[2,3-c]pyridine-2-carboxylate (240 mg, 45.4%). LC-MS: m/z 255.9 ($\text{M}+\text{H}^+$).


Step C: methyl 7-chloro-5-(difluoromethyl)thieno[2,3-c]pyridine-2-carboxylate



[0724] To a solution of methyl 7-chloro-5-formylthieno[2,3-c]pyridine-2-carboxylate (240 mg, 0.939 mmol) in DCM (1 mL) were added DAST (1513 mg, 9.39 mmol), and the

reaction was stirred at room temperature for 30 minutes. The reaction was diluted with DCM (30 mL), washed with further saturated NaCl solution (20 mL*3) and concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with 8% ethyl acetate in petroleum ether to afford methyl 7-chloro-5-(difluoromethyl)thieno[2,3-c]pyridine-2-carboxylate (200 mg, 76.7%). LC-MS: m/z 278.0 ($\text{M}+\text{H}^+$).


5-((S)-4-(5-(difluoromethyl)-7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 188)



[0725] Compound 188 was synthesized using similar procedure as described in Example 20 above by using the appropriate materials.

[0726] ^1H NMR (400 MHz, DMSO-d_6): δ 12.70 (br s, 1H), 7.65 (d, $J=8.0$ Hz, 1H), 7.53 (s, 1H), 7.38 (s, 1H), 7.22 (dd, $J=5.6$ Hz, $J=8.8$ Hz, 2H), 7.13 (t, $J=8.0$ Hz, 1H), 7.07 (t, $J=8.8$ Hz, 2H), 6.71-6.99 (m, 3H), 5.90 (q, $J=8.0$ Hz, 1H), 4.88 (dd, $J=6.0$ Hz, $J=10.0$ Hz, 1H), 3.79 (s, 3H), 3.51-3.59 (m, 1H), 3.20 (t, $J=8.0$ Hz, 2H), 2.95-3.10 (m, 3H), 2.67-2.77 (m, 2H), 2.54-2.56 (m, 1H), 2.24-2.38 (m, 3H), 1.99-2.08 (m, 1H), 1.39-1.49 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d_6): δ -114.68, -117.02. LC-MS: m/z 725.3 ($\text{M}+\text{H}^+$).

(R)-5-(4-(7-((5-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 189)





[0727] Compound 189 was synthesized using similar procedure as described in Example 17 above by using the appropriate materials.

[0728] ^1H NMR (400 MHz, DMSO-d₆) δ 8.36 (br s, 1H), 7.96 (d, J=5.6 Hz, 1H), 7.37 (s, 1H), 7.17-7.25 (m, 3H), 7.04-7.12 (m, 3H), 6.90-7.02 (m, 2H), 5.80-5.90 (m, 1H), 3.87 (d, J=1.2 Hz, 3H), 3.55 (s, 2H), 3.12-3.21 (m, 3H), 2.96-3.07 (m, 3H), 2.78-2.90 (m, 1H), 2.60-2.65 (m, 2H), 2.53-2.56 (m, 1H), 2.02-2.15 (m, 1H), 1.70-1.76 (m, 2H). ^{19}F NMR (377 MHz, DMSO-d₆): -117.11, -135.40. LC-MS: m/z 705.3 (M+H)⁺.

(R)-5-(4-(7-((5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 190)

5-((S)-4-(7-(((R)-5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 192)




[0729] Compound 190 was synthesized using similar procedure as described in Example 17 above by using the appropriate materials.

[0730] ^1H NMR (400 MHz, DMSO-d₆): δ 12.71 (br s, 1H), 8.00 (d, J=5.2 Hz, 1H), 7.43 (s, 1H), 7.30-7.36 (m, 2H), 7.19-7.25 (m, 3H), 7.05-7.11 (m, 3H), 5.81 (q, J=7.6 Hz, 1H), 3.56 (s, 2H), 3.18-3.22 (m, 3H), 2.95-3.06 (m, 3H), 2.79-2.88 (m, 1H), 2.63-2.67 (m, 2H), 2.54-2.58 (m, 1H), 2.02-2.12 (m, 1H), 1.75 (d, J=4.0 Hz, 2H). ^{19}F NMR (377 MHz, DMSO-d₆): -117.01, -140.53-141.58. LC-MS: m/z 693.1 (M+H)⁺.

[0731] Compound 192 was synthesized using similar procedure as described in Example 10 above by using the appropriate materials.

[0732] ^1H NMR (400 MHz, DMSO-d₆) δ ppm 8.00 (d, J=5.48 Hz, 1H), 7.43-7.47 (m, 1H), 7.31-7.35 (m, 1H), 7.19-7.25 (m, 2H), 7.04-7.15 (m, 3H), 6.91-6.97 (m, 1H), 5.76-5.86 (m, 1H), 4.89 (dd, J=10.19, 6.26 Hz, 1H), 3.96 (d, J=1.43 Hz, 3H), 3.48-3.61 (m, 1H), 3.30 (br s, 2H), 3.17-3.24 (m, 2H), 2.98-3.12 (m, 3H), 2.80-2.89 (m, 1H), 2.25-2.39 (m, 3H), 2.02-2.09 (m, 1H), 1.39-1.50 (m, 1H). ^{19}F NMR (376 MHz, DMSO-d₆) δ ppm -117.01 (s, 1F), -140.71--136.40 (s, 1F), -160.23--156.59 (s, 1F). LC-MS: m/z 711.1 (M+H)⁺.

(R)-5-(4-(7-((5-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 193)




[0733] Compound 193 was synthesized using similar procedure as described in Example 20 above by using the appropriate materials.

[0734] ^1H NMR (400 MHz, DMSO-d₆): δ 12.70 (br s, 1H), 7.32 (s, 1H), 7.20-7.23 (m, 2H), 7.15 (d, $J=8.4$ Hz, 1H), 7.05-7.09 (m, 2H), 6.96-7.03 (m, 1H), 6.90-6.93 (m, 2H), 5.86 (q, $J=8.0$ Hz, 1H), 3.87 (d, $J=1.2$ Hz, 3H), 3.56 (s, 2H), 3.16-3.21 (m, 3H), 2.96-3.07 (m, 3H), 2.78-2.90 (m, 1H), 2.60-2.67 (m, 2H), 2.53-2.56 (m, 1H), 2.34 (s, 3H), 2.00-2.14 (m, 1H), 1.75 (d, $J=4.4$ Hz, 2H). ^{19}F NMR (377 MHz,


DMSO-d₆): δ -117.01, -135.42. LC-MS: m/z 719.3 (M+H)⁺.

Example 22


5-((S)-4-(7-(((S)-2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 194)




-continued




-continued



Step A N-(4-methoxy-2,3-dihydro-1H-inden-1-ylidene)butan-1-amine




[0735] The solution of 4-methoxy-2,3-dihydro-1H-inden-1-one (5 g, 30.83 mmol), butan-1-amine (2.71 g, 36.99 mmol) and TFA (703.04 mg, 6.17 mmol) in toluene (60 mL) was refluxed at 110° C. for 16 hrs. The reaction mixture was concentrated to remove the solvent, and to the residue was added ethyl acetate (100 mL). The resulting mixture was washed with saturated aqueous sodium bicarbonate (30 mL). The organic layer was dried over Na_2SO_4 and concentrated to give N-(4-methoxy-2,3-dihydro-1H-inden-1-ylidene)butan-1-amine (6.7 g, crude). LC-MS: m/z 218.1 ($\text{M}+\text{H}$)⁺.

Step B
2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-one

[0736] N-(4-methoxy-2,3-dihydro-1H-inden-1-ylidene)butan-1-amine (6.7 g, 30.83 mmol) was dissolved in acetonitrile (100 mL). Then to the solution was added 1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane ditetrafluoroborate (21.85 g, 61.66 mmol). The solution was refluxed at 80° C. for 16 hrs. The reaction solution was cooled to rt, and con. HCl (18.74 g, 184.99 mmol, 36% purity) was added dropwise slowly. The resulting mixture


was stirred for 10 min. Then ethyl acetate (100 mL) was added. The mixture was washed with water (50 mL×2). The organic layer was dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography (SiO_2 , petroleum ether/ethyl acetate=1/0 to 5/1) to give 2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-one (1.58 g, 7.97 mmol, 25.86% yield). ¹H NMR (400 MHz, CDCl_3) δ 7.41–7.54 (m, 2H), 7.15–7.23 (m, 1H), 3.94 (s, 3H), 3.41–3.55 (m, 2H).

Step C (R,E)-N-(2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide



[0737] tetraethoxytitanium (4.83 g, 21.19 mmol) was added to a mixture of 2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-one (1.4 g, 7.06 mmol) and (R)-2-methylpropane-2-sulfonamide (899.07 mg, 7.42 mmol) in THF (20 mL). The mixture was stirred for 16 hrs at 70° C. Ethyl acetate (25 mL) and water (5 mL) were added to the mixture, and the formed precipitate was removed by filtration. The filtrate was concentrated in vacuo to give a residue. The residue was purified by column chromatography (SiO_2 , petroleum ether/ethyl acetate=1/0 to 0/1) to give (R,E)-N-(2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide (1.8 g, 76.28% yield, 90.22% purity). LC-MS: m/z 301.9 ($\text{M}+\text{H}$)⁺.

Step D (R)—N—((S)-2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfinamide and (R)—N—((R)-2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfinamide




[0738] To a solution of (R,E)-N-(2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide (1.8 g, 5.97 mmol) in DCM (40 mL) was added dropwise DIBAL-H (1.5 M, 7.96 mL) at -70° C. After addition, the mixture was stirred at this temperature for 2 hrs. The reaction mixture was quenched by addition (MeOH 10 mL) at 0° C., and then diluted with H₂O (10 mL) and extracted with DCM (20 mL×2). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, petroleum ether/ethyl acetate=1/0 to 1/1) to give (R)—N—((S)-2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfonamide (470 mg, 24.49% yield, 94.43% purity) and (R)—N—((R)-2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfonamide (680 mg, 37.07% yield, 98.78% purity).

[0739] ¹H NMR (400 MHz, CDCl₃) δ 7.20-7.25 (m, 1H), 6.89-6.94 (m, 1H), 6.72-6.78 (m, 1H), 4.82-4.93 (m, 1H), 3.82-3.88 (m, 1H), 3.77 (s, 3H), 3.30-3.43 (m, 1H), 3.11-3.27 (m, 1H), 1.22-1.26 (m, 9H). LC-MS: m/z 304.0 (M+H)⁺.

[0740] ¹H NMR (400 MHz, CDCl₃) δ 7.30-7.36 (m, 1H), 7.24-7.28 (m, 1H), 6.80-6.88 (m, 1H), 4.94-5.05 (m, 1H), 3.83-3.88 (m, 3H), 3.63-3.70 (m, 1H), 3.37-3.50 (m, 1H), 3.18-3.32 (m, 1H), 1.32 (s, 9H). LC-MS: m/z 304.0 (M+H)⁺.


Step E (S)-2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-amine



[0741] A mixture of (R)—N—((S)-2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-


sulfonamide (470.00 mg, 1.55 mmol) and HCl/MeOH (2 M, 3.87 mL) in MeOH (3 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 20° C. for 2 hr under N₂ atmosphere. The reaction mixture was concentrated under reduced pressure to give a residue. The resulting product was dissolved in petroleum ether/ethyl acetate=3/1 (10 mL) and filtered to give (S)-2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-amine (310 mg, crude, HCl). ¹H NMR (400 MHz, MeOD-d₄) δ 7.41-7.51 (m, 1H), 7.06-7.18 (m, 2H), 5.04-5.15 (m, 1H), 3.90 (s, 3H), 3.45-3.62 (m, 2H).

Step F (S)—N—(2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)-2-(1,3-dioxolan-2-yl)thieno[2,3-c]pyridin-7-amine



[0742] A mixture of 7-chloro-2-(1,3-dioxolan-2-yl)thieno[2,3-c]pyridine (200.00 mg, 827.49 μmol), (S)-2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-amine (195.01 mg, 827.49 μmol, HCl salt), Cs₂CO₃ (808.84 mg, 2.48 mmol), Pd(OAc)₂ (18.58 mg, 82.75 μmol) and BINAP (103.05 mg, 165.50 μmol) in dioxane (5 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 110° C. for 16 hrs under N₂ atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, petroleum ether/ethyl acetate=1/0 to 1/1) to give (S)—N—(2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)-2-(1,3-dioxolan-2-yl)thieno[2,3-c]pyridin-7-amine (220 mg, 60.58% yield, 92.15% purity). LC-MS: m/z 405.2

Step G (S)-7-((2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde




[0743] A mixture of (S)—N-(2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)-2-(1,3-dioxolan-2-yl)thieno[2,3-c]pyridin-7-amine (220.00 mg, 543.98 μ mol) and HCl (2 M, 2.72 mL) in THF (2 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 45° C. for 16 hrs under N_2 atmosphere. The reaction mixture was filtered and quenched by addition aq. NaHCO₃ (10 mL) at 0° C., and then diluted with ethyl acetate (10 mL) and extracted with ethyl acetate (10 mL×3). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give (S)-7-((2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (190 mg, 527.23 μ mol).

[0744] ¹H NMR (400 MHz, CDCl₃) δ 10.05-10.13 (s, 1H), 8.06-8.14 (d, J=5.6 Hz, 1H), 7.93 (s, 1H), 7.16-7.19 (m, 1H), 6.82-6.88 (m, 1H), 6.73-6.78 (m, 1H), 6.27-6.40 (m, 1H), 4.8p-4.91 (d, J=9.6 Hz, 1H), 3.79 (s, 3H), 3.76-3.77 (m, 1H), 3.22-3.47 (m, 2H).


Step H ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-(((S)-2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1,4-dihydropyridine-3-carboxylate

Step J ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-(((S)-2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)nicotinate




[0746] A mixture of ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-(((S)-2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1,4-dihydropyridine-3-carboxylate (140.00 mg, 162.99 μ mol) and CAN (178.71 mg, 325.99 μ mol) in EtOH (4 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 20° C. for 1 hr under N_2 atmosphere. The reaction mixture was diluted with ethyl acetate (20 mL) and washed with brine (5 mL×2), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-(((S)-2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)nicotinate (150 mg, crude). LC-MS: m/z 857.3 (M+H)⁺.

Step J ethyl 4-(7-(((S)-2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-((S)-pyrrolidin-2-yl)nicotinate




[0745] A mixture of tert-butyl (S)-2-(3-ethoxy-3-oxopropyl)pyrrolidine-1-carboxylate (45 mg, 157.71 μ mol), 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one (39.46 mg, 157.71 μ mol), (S)-7-((2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (56.83 mg, 157.71 μ mol), NH₄OAc (24.31 mg, 315.42 μ mol) and Yb(oTf)₃ (9.78 mg, 15.77 μ mol) in EtOH (2 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 50° C. for 16 hr under N_2 atmosphere. The reaction mixture was concentrated under reduced pressure to give ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-(((S)-2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1,4-dihydropyridine-3-carboxylate (140 mg, crude). LC-MS: m/z 859.2 (M+H)⁺.



[0747] A mixture of ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-(((S)-2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)nicotinate (150.00 mg, 175.05 μ mol) and HCl/dioxane (2 M, 1.75 mL) in dioxane (2 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 20° C. for 2 hrs under N₂ atmosphere. The reaction mixture was concentrated under reduced pressure to give ethyl 4-(7-(((S)-2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-((S)-pyrrolidin-2-yl)nicotinate (150 mg, crude). LC-MS: m/z 757.3 (M+H)⁺.

Step K 5-((S)-4-(7-(((S)-2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one




[0748] A mixture of ethyl 4-(7-(((S)-2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-((S)-pyrrolidin-2-yl)nicotinate (150 mg, 189.09 μ mol, HCl salt) and Na₂CO₃ (400.84 mg, 3.78 mmol) in dioxane (4 mL) and H₂O (4 mL) was degassed and purged with N₂ for 3 times. Then the mixture was stirred at 20° C. for 16 hrs under N₂ atmosphere. The reaction mixture was extracted with ethyl acetate (10 mL×3). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: C18 150×30 mm; mobile phase: [water(FA)-ACN]; gradient: 45%-75% B over 7 min) to give 5-((S)-4-(7-(((S)-2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (7.61 mg, 5.30% yield, 93.64% purity).


[0749] ¹H NMR (400 MHz, MeOD-d₄) δ 7.96-8.04 (d, J=14 Hz, 1H), 7.46 (s, 1H), 7.26-7.33 (m, 1H), 7.14-7.21 (m, 3H), 6.90-7.02 (m, 4H), 6.26 (t, J=11.32 Hz, 1H), 3.88 (s, 3H), 3.69 (dt, J=11.44, 8.46 Hz, 1H), 3.36-3.52 (m, 3H), 3.21-3.30 (m, 2H), 3.03-3.19 (m, 2H), 2.37-2.57 (m, 3H), 1.45-1.50 (m, 1H). ¹⁹F NMR (376 MHz, MeOD-d₄) δ -103.35-101.50 (m, 1F) -110.55--109.05 (m, 1F) -119.03 (s, 1F). LC-MS: m/z 711.1 (M+H)⁺.

Example 23


(R)-5-(4-(7-((5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (195)




-continued



-continued



Step A 3-(2-bromo-3,4-difluorophenyl)propanoic acid




[0750] To a solution of FA (10.40 mL) in Et₃N (12.60 mL) was added 2-bromo-3,4-difluorobenzene-1-carbaldehyde

(10.0 g, 45.249 mmol) at 0° C. and the 2,2-dimethyl-1,3-dioxane-4,6-dione (7.83 g, 54.299 mmol) was added slowly for stirring 30 min at the same temperature and the reaction was warmed to stir at 100° C. overnight under N₂. LCMS showed raw material had disappeared and the product was detected. The reaction was diluted with DCM (1000 mL) and water (500 mL). The organic layer was separated, washed with further brine (500 mL×2), dried over Na₂SO₄ and concentrated in vacuum to afford the title compound 3-(2-bromo-3,4-difluorophenyl)propanoic acid (9.50 g, 35.842 mmol, 79.21%). ¹H NMR (400 MHz, DMSO-d₆) δ ppm 12.28 (s, 1H), 7.40-7.47 (m, 1H), 7.23-7.27 (m, 1H), 2.95 (t, J=7.60 Hz, 2H), 2.51-2.57 (m, 2H).


Step B

4-bromo-5,6-difluoro-2,3-dihydro-1H-inden-1-one



Step D

5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-one



[0751] To a solution of 3-(2-bromo-3,4-difluorophenyl)propanoic acid (8.10 g, 30.560 mmol) in DCM (100.00 mL) were added (COCl)₂ (5.245 mL, 61.121 mmol) and DMF (0.246 mL, 3.056 mmol) at 0° C. and warmed to rt and stirred for 3 h under N_2 . The mixture was concentrated in vacuo to afford 3-(2-bromo-3,4-difluorophenyl)propanoyl chloride (8.60 g, 30.335 mmol, 99.26%). To a solution of 3-(2-bromo-3,4-difluorophenyl)propanoyl chloride (8.60 g, 30.335 mmol) in DCM (100.00 mL) was added AlCl_3 (6.05 g, 45.503 mmol) at 0° C. with stirring for 10 min and the reaction was warmed to stir at rt for 40 min under N_2 . The mixture was poured into the ice-water and stirred for 30 min. The reaction was diluted with DCM (500 mL). The organic layer was separated, washed with further brine (500 mL×2), dried over Na_2SO_4 and concentrated in vacuo. The residue was purified using silica gel column chromatography eluting with PE:EA=40:1 to 20:1. The organic product was concentrated in vacuum to afford the title compound 4-bromo-5,6-difluoro-2,3-dihydro-1H-inden-1-one (4.50 g, 18.216 mmol, 60.05%). ¹H NMR (400 MHz, DMSO-d_6) δ ppm 7.30 (dd, $J_1=7.20$ Hz/ $J_2=8.80$ Hz, 1H), 3.00 (t, $J=5.20$ Hz, 2H), 2.73-2.76 (m, 2H).

Step C


5,6-difluoro-4-hydroxy-2,3-dihydro-1H-inden-1-one



[0752] To a solution of 4-bromo-5,6-difluoro-2,3-dihydro-1H-inden-1-one (4.50 g, 18.29 mmol) in dioxane (50 mL) and water (10.0 mL) were added $\text{Pd}_2(\text{dba})_3$ (1.68 g, 1.83 mmol), KOH (2.05 g, 36.58 mmol) and t-Buphos (1.56 g, 3.66 mmol), and the reaction was stirred at 100° C. overnight. The mixture was poured into water (500 mL) and DCM (2×500 mL) was added. The inorganic layer was separated, and the pH was adjusted to 6.0-7.0. DCM (500 mL×2) and water (250 mL) were added to the inorganic phase, the organic layer was separated, combined and washed with brine (1000 mL×2), dried over Na_2SO_4 and concentrated in vacuum to afford the title compound 5,6-difluoro-4-hydroxy-2,3-dihydro-1H-inden-1-one (2.40 g, 13.04 mmol, 61.75%). ¹H NMR (400 MHz, DMSO-d_6) δ ppm 10.82 (s, 1H), 7.09 (dd, $J_1=6.40$ Hz/ $J_2=8.40$ Hz, 1H), 2.97 (t, $J=5.60$ Hz, 2H), 2.62-2.65 (m, 2H). LC-MS: m/z 185.20 ($\text{M}+\text{H}$)⁺


[0753] To a solution of 5,6-difluoro-4-hydroxy-2,3-dihydro-1H-inden-1-one (2.40 g, 13.034 mmol) in DMF (80.00 mL) was added K_2CO_3 (5.40 g, 39.101 mmol) at rt. Then iodomethane (4.463 mL, 71.685 mmol) was added slowly and the mixture was stirred 30 min at the same temperature before it was warmed to 50° C. and stirred overnight under N_2 . LCMS showed raw material had disappeared and the product was detected. The reaction was diluted with DCM (700 mL) and water (500 mL). The organic layer was separated, washed with brine (500 mL×2), dried over Na_2SO_4 and concentrated in vacuum to afford the title crude compound 5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-one (2.60 g, 13.120 mmol, >99.99%). LC-MS: m/z 199.20 ($\text{M}+\text{H}$)⁺. ¹H NMR (400 MHz, $\text{CDCl}_3\text{-d}$) δ ppm 7.21 (dd, $J_1=6.80$ Hz/ $J_2=8.00$ Hz, 1H), 4.09 (d, $J=2.80$ Hz, 3H), 3.06 (t, $J=6.40$ Hz, 2H), 2.66-2.69 (m, 2H).

Step E (R,Z)—N-(5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide




[0754] To a solution of 5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-one (2.60 g, 13.120 mmol) in THF (20.00 mL) were added (R)-2-methylpropane-2-sulfonamide (1.83 g, 15.088 mmol) and Ti(OEt)_4 (5.489 mL, 26.240 mmol) at rt and the reaction was warmed to stir at 80° C. overnight under N_2 . LCMS showed raw materials had disappeared and the product was detected. The reaction was diluted with EA (200 mL) and water (250 mL). The organic layer was separated, washed with further brine (250 mL×2), dried over Na_2SO_4 and concentrated in vacuo. The residue was purified using silica gel column chromatography eluting with PE:EA=10:1 to 5:1. The organic product was concentrated in vacuum to afford the title compound (R,Z)—N-(5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide (1.30 g, 4.314 mmol, 32.88%). LC-MS: m/z 302.20 ($\text{M}+\text{H}$)⁺

Step F (R)—N—((R)-5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfonamide




[0755] To a solution of (R,Z)—N-(5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide (1.30 g, 4.314 mmol) in DCM (55.00 mL) was added dropwise DIBAL-H (17.256 mL, 17.256 mmol, 1.0 M in toluene) at -78° C. The mixture was stirred at -78° C. under Ar for 2 h. TLC showed reaction was completed and the product was detected by LCMS. The mixture was added dropwise H₂O (0.50 mL), NaOH aq (15% in water, 0.15 mL) and another water (0.15 mL) in turn at -78° C. Then, Na₂SO₄ was added to the mixture and filtered, the filtrate was concentrated in vacuum. The residue was purified by column chromatography (PE/EtOAc=10/1 to 5/1) on silica gel to obtain (R)—N—((R)-5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfonamide (1.10 g, 3.626 mmol, 84.05%). LC-MS: m/z 304.20 (M+H)⁺.

Step G (R)-5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-amine hydrochloride




[0756] A mixture of (R)—N—((R)-5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfonamide (1.00 g, 3.296 mmol) and HCl in dioxane (9.971 mL, 39.885 mmol, 4 M in dioxane) in 1,4-dioxane (5.00 mL) was stirred at 0° C. for 30 min and the reaction was warmed to rt and stirred for 1 h. TLC showed reaction was completed. The mixture was concentrated to obtain (1R)-5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-amine (0.900 g, 3.30 mmol, >99.99%) after being washed with MTBE (60 mL). LC-MS: m/z 200.20 (M+H)⁺

Step H 5-(4-(4-fluorophenyl)-2-iminobutyl)-1,3,4-oxadiazol-2(3H)-one




[0757] To a solution of 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one (20 g, 79.926 mmol) in EtOH (200 mL) was added NH₄OAc (24.64 g, 319.706 mmol), and the reaction was stirred at room temperature for 2 hr. After the reaction was completed, the mixture was added to aqueous ammonia (200 mL) at 0° C., filtered and concentrated to give 5-(4-(4-fluorophenyl)-2-iminobutyl)-1,3,4-oxadiazol-2(3H)-one (17 g, 68.205 mmol, 85.33%). ¹H NMR (400 MHz, DMSO-d₆) δ 7.26-7.30 (m, 2H), 7.08-7.13 (m, 2H), 6.66 (br s, 2H), 4.51 (s, 1H), 2.80-2.85 (m, 2H), 2.40-2.44 (m, 2H).

Step I (7-chloro-5-methylthieno[2,3-c]pyridin-2-yl)methanol




[0758] To a solution of methyl 7-chloro-5-methylthieno[2,3-c]pyridine-2-carboxylate (1000 mg, 4.138 mmol) in THF (15 mL) and H₂O (2.5 mL) were added LiCl (526.17 mg, 12.413 mmol) and NaBH₄ (469.57 mg, 12.413 mmol). The reaction was stirred at rt for 3 hr. The reaction was concentrated in vacuo. The residue was purified using silica gel column chromatography eluting with ethyl acetate in petroleum ether. The collected fraction was concentrated in vacuo to afford the title compound (7-chloro-5-methylthieno[2,3-c]pyridin-2-yl)methanol (556 mg, 2.602 mmol, 62.89%). LC-MS: m/z 214.1 (M+H)⁺.

Step J 7-chloro-5-methylthieno[2,3-c]pyridine-2-carbaldehyde




[0759] To a solution of (7-chloro-5-methylthieno[2,3-c]pyridin-2-yl)methanol (5000 mg, 23.399 mmol) in DCM (80 mL) were added Dess-martin periodinane (19849.31 mg, 46.799 mmol), and the reaction was stirred at 0° C. for 10 min, and the reaction was stirred at 0° C. for 2 hr. LCMS showed the reaction was completed. The NaHCO₃ solution (saturated, 55 mL) was added and the reaction mixture was extracted with DCM (2×50 mL). The organic extract was washed with brine (2×50 mL), dried over Na₂SO₄, filtered and concentrated. The residue was purified by flash column chromatography using silica gel and eluting with DCM/MeOH (10/1, v/v) to give compound 7-chloro-5-methylthieno[2,3-c]pyridine-2-carbaldehyde (4900 mg, 23.150 mmol, 98.94%). LC-MS: m/z 212.1 (M+H)⁺.

Step K 7-chloro-2-(1,3-dioxolan-2-yl)-5-methylthieno[2,3-c]pyridine



[0760] To a solution of 7-chloro-5-methylthieno[2,3-c]pyridine-2-carbaldehyde (10600 mg, 50.080 mmol) in Toluene (150 mL) was added ethylene glycol (13.964 mL, 250.400 mmol), 4-Methylbenzenesulfonic acid hydrate (952.57 mg, 5.008 mmol), the reaction was stirred at 110° C. for 4 hr under N₂. LCMS showed raw materials had disappeared and the product was detected. The reaction was diluted with EA (2000 mL) and saturated NaHCO₃ solution. The organic layer was separated, washed with brine (2000 mL×2), dried over Na₂SO₄ and concentrated in vacuo. The residue was purified using silica gel column chromatography eluting with PE:EA=5:1. The residue was concentrated in vacuo to afford the title compound 7-chloro-2-(1,3-dioxolan-2-yl)-5-methylthieno[2,3-c]pyridine (7600 mg, 29.720 mmol, 59.34%). ¹H NMR (400 MHz, CD₃OD-d₄): δ 7.72 (s, 1H), 7.66 (s, 1H), 6.25 (s, 1H), 3.97-4.12 (m, 4H), 2.55 (s, 3H). LC-MS: m/z 256.1 (M+H)⁺.


Step L (R)—N-(5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)-2-(1,3-dioxolan-2-yl)-5-methylthieno[2,3-c]pyridin-7-amine



[0761] To a solution of 7-chloro-2-(1,3-dioxolan-2-yl)-5-methylthieno[2,3-c]pyridine (3.83 g, 14.974 mmol) in toluene (120 mL) was added (R)-5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-amine (3.132 g, 15.723 mmol), Pd₂(dba)₃ (29.14 mg, 0.036 mmol), Xantphos (0.87 g, 1.497 mmol) and Cs₂CO₃ (12.20 g, 37.435 mmol). The reaction was stirred at 110° C. for 18 hr under N₂. After the reaction was completed, the mixture was diluted with EA (100 mL), washed with water (150 mL). The organic layers were separated, dried over Na₂SO₄, filtered and concentrated


under vacuum to dryness. The residue was purified by column chromatography on silica gel (PE/EA=10/1) to give (R)—N-(5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)-2-(1,3-dioxolan-2-yl)-5-methylthieno[2,3-c]pyridin-7-amine (5.175 g, 12.367 mmol, 82.59%). LC-MS: m/z 419.2 (M+H)⁺.

Step M (R)-7-((5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridine-2-carbaldehyde



[0762] To a solution of (R)—N-(5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)-2-(1,3-dioxolan-2-yl)-5-methylthieno[2,3-c]pyridin-7-amine (5.175 g, 12.38 mmol) in THF (12 mL), H₂O (12 mL) was added 4 N HCl (12 mL), the reaction was stirred at room temperature for 1 h. After the reaction was completed, the mixture reaction was basified with Na₂CO₃ to pH=8, the mixture was extracted with EA. The organic phase was washed with water, concentrated to give (R)-7-((5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridine-2-carbaldehyde (4.2 g, 11.218 mmol). LC-MS: m/z 375.1 (M+H)⁺.


Step N 5-(4-(7-(((R)-5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-1,5,8,9-tetrahydro-4H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one



[0763] A mixture of (R)-7-((5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyri-

dine-2-carbaldehyde (4000 mg, 10.683 mmol), 5-(4-(4-fluorophenyl)-2-iminobutyl)-1,3,4-oxadiazol-2(3H)-one (2662.86 mg, 10.683 mmol), 7-hydroxy-2,3-dihydro-1H,5H-2,7a-methanopyrrolizin-5-one (1614.91 mg, 10.683 mmol), and Yb(OTf)₃ (662.63 mg, 1.068 mmol) in ethanol (16 mL), tetrahydrofuran (16 mL), acetonitrile (16 mL) was stirred at room temperature overnight. Then 7-hydroxy-2,3-dihydro-1H,5H-2,7a-methanopyrrolizin-5-one (645.97 mg, 4.273 mmol) was added and stirred for 2 hr. After the reaction was completed, the mixture was concentrated and the residue was dissolved in HOAc (50 mL), heated to 100° C. and stirred for 0.5 hr. After the reaction was completed, the mixture reaction was concentrated and purified by column chromatography on silica gel (MeOH/DCM/0% to 10%) to give 5-(4-(7-((R)-5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-1,5,8,9-tetrahydro-4H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (5.6 g). LC-MS: m/z 739.2 (M+H)⁺.

Step O (R)-5-(4-(7-((5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (195)




[0764] To a mixture of 5-(4-(7-((R)-5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-1,5,8,9-tetrahydro-4H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (5.62 g, 7.607 mmol) in ethanol (60 mL) was added Ceric ammonium nitrate (8.07 g, 15.214 mmol) in portions at 0° C., the mixture was stirred at room temperature for 1 hr. After the reaction was completed, the mixture reaction was diluted with EA, washed with water, dried, concentrated. The residue was purified by column chromatography on silica gel (MeOH/DCM/0% to 10%) to give crude product (5.3 g). The crude product was purified by Prep-HPLC (NH₃H₂O) to give (R)-5-(4-(7-((5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (4267.98 mg, 5.697 mmol, 74.89%). ¹H NMR (400 MHz, DMSO-d6): δ 12.70 (br s, 1H), 7.33 (s, 1H), 7.17-7.25 (m, 3H), 7.03-7.11 (m, 2H), 6.90-6.97 (m, 2H), 5.82 (q, J=8.0 Hz, 1H), 3.94 (d, J=1.2 Hz, 3H), 3.56 (s, 2H), 3.16-3.22 (m, 3H), 3.00-3.09 (m, 3H), 2.79-2.90 (m, 1H), 2.61-2.67 (m, 2H), 2.52-2.57


(m, 1H), 2.41 (s, 3H), 2.00-2.11 (m, 1H), 1.70-1.79 (m, 2H). ¹⁹F NMR (377 MHz, DMSO-d6): -117.01, -138.68, -158.74. LC-MS: m/z 737.2 (M+H)⁺.

Example 24

5-(4-(7-(((S,2R)-2,5-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (196)




-continued




(PE/EtOAc=5/1) on silica gel to obtain (R)—N—((S,E)-2,5-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide (25.3 g, 83.956 mmol, 31.81%) as a brown oil and (R)—N—((R,E)-2,5-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide (23.4 g, 77.651 mmol, 29.42%) as a brown oil. LC-MS: m/z 302.20 (M+H)⁺.

Step C (R)—N—((1S,2R)-2,5-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfonamide



[0765] A mixture of 5-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-one (49 g, 271.950 mmol), Selectfluor (192.68 g, 543.901 mmol) and H₂SO₄ (2.913 mL, 54.390 mmol) in MeOH (350 mL) was stirred at 35° C. for 16 h under N₂ atmosphere. The mixture was poured into water (1 L) and extracted with EtOAc (2×1 L), the combined organic layer was washed with brine, dried over sodium sulfate, filtered and the residue was purified by column chromatography (PE/EtOAc=5/1) on silica gel to obtain 2,5-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-one (52.30 g, 263.915 mmol, 97.05%). LC-MS: m/z 199.20 (M+H)⁺.


Step B (R)—N—((R,E)-2,5-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide



[0766] A mixture of 2,5-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-one (52.30 g, 263.915 mmol), (R)-2-methylpropane-2-sulfonamide (31.99 g, 263.915 mmol) and Ti(OEt)₄ (120.40 g, 527.830 mmol) in THF (500 mL) was stirred at 80° C. for 16 h under N₂ atmosphere. LCMS showed reaction was completed. The reaction was concentrated in vacuo. The residue was purified by column chromatography


[0767] To a solution of (R)—N—((R,E)-2,5-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide (11.2 g, 37.166 mmol) in DCM (500 mL) was added DIBAL-H (1.5 M in toluene, 99.110 mL, 148.664 mmol) at -78° C. for 2 h under N₂. The reaction mixture was diluted with water (3.7 mL), 15% NaOH aq (11.1 mL, 15% in water) and water (11.1 mL) in turn at -78° C. The organic layer was dried by Na₂SO₄, filtered and the residue was purified by column chromatography (PE/EtOAc=5/1) on silica gel to obtain (R)—N—((1S,2R)-2,5-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfonamide (7 g, 23.074 mmol, 62.06%). LC-MS: m/z 304.20 (M+H)⁺.

Step D (1S,2R)-2,5-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-amine hydrochloride




[0768] To a solution of (R)—N—((1S,2R)-2,5-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfonamide (7.00 g, 23.074 mmol) in dioxane (20 mL) was added HCl (6 M in dioxane, 40 mL) at 0° C. for 10 min, then the reaction was stirred at rt 1 h under N₂. The reaction was concentrated in vacuo to afford the title compound (1S,2R)-2,5-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-amine hydrochloride (4.80 g, 20.368 mmol, 88.27%) after being washed with MTBE (50 mL). LC-MS: m/z 200.20 (M+H)⁺. ¹H NMR (400 MHz, DMSO-d₆) δ 9.08 (s, 3H), 7.41 (q, J=4.0 Hz, 1H), 7.26 (dd, J=12.0 Hz/J=8.4 Hz, 1H), 5.62 (t, J=4.4 Hz, 0.5H), 5.49 (t, J=4.4 Hz, 0.5H), 4.83 (dd, J=22.4 Hz/J=4.0 Hz, 1H), 3.89 (d, J=1.2 Hz, 3H), 3.19-3.39 (m, 2H). ¹⁹F NMR (400 MHz, DMSO-d₆) δ -132.14, -193.89.

5-(4-((1*S*,2*R*)-2,5-difluoro-4-methoxy-2,3-dihydro-1*H*-inden-1-yl)amino)-5-methylthieno[2,3-*c*]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5*H*,7*H*-8,9*a*-methanopyrido[2,3-*a*]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3*H*)-one (196)



-continued






Yb(OTf)₃, NH₄OAc, 50° C.
Step C



[0769] Compound 196 was synthesized using similar procedure as described in Example 23 above by using the appropriate materials. ¹H NMR (400 MHz, DMSO-d₆) δ 12.69 (br s, 1H), 7.33 (s, 1H), 7.20-7.24 (m, 2H), 7.17-7.19 (m, 1H), 7.15-7.16 (m, 1H), 7.05-7.10 (m, 2H), 6.95-7.01 (m, 2H), 5.88-6.00 (m, 1H), 5.47-5.65 (m, 1H), 3.90 (d, J=1.2 Hz, 3H), 3.57 (s, 2H), 3.56-3.44 (m, 1H), 3.25-3.29 (m, 1H), 3.15-3.23 (m, 3H), 3.00-3.07 (m, 2H), 2.62-2.67 (m, 2H), 2.42 (s, 3H), 1.71-1.79 (m, 2H). ¹⁹F NMR (377 MHz, DMSO-d₆): -117.02, -134.35, -191.64. LC-MS: m/z 737.3 (M+H)⁺.

Example 25


5-((S)-4-(7-(((R)-6,7-dihydro-5*H*-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-*c*]pyridin-2-yl)-5-oxo-2-(2-(tetrahydro-2*H*-pyran-4-yl)ethyl)-7,8,9,9*a*-tetrahydro-5*H*-pyrido[2,3-*a*]pyrrolizin-3-yl)isoxazol-3(2*H*)-one (Compound 197)



-continued




Step A N-methoxy-N-methyl-3-(tetrahydro-2H-pyran-4-yl)propanamide



[0770] 3-(tetrahydro-2H-pyran-4-yl)propanoic acid (500 mg, 3.16 mmol) was dissolved in DCM (10 mL). Carbonyldiimidazole (563.75 mg, 3.48 mmol) was added slowly and the reaction was stirred at 20° C. for 1 hr. N, O-dimethylhydroxylamine hydrochloride (339.13 mg, 3.48 mmol) and TEA (351.81 mg, 3.48 mmol) were added and the reaction was stirred at 20° C. for 16 hrs. The mixture was diluted with DCM (20 mL) and washed with HCl (10 mL, 1M), saturated aqueous NaHCO₃ (10 mL) and saturated brine (10 mL). The organic phase was dried over anhydrous Na₂SO₄. The solvent was filtered and concentrated under reduced pressure to give N-methoxy-N-methyl-3-(tetrahydro-2H-pyran-4-yl)propanamide (560 mg, 2.78 mmol, 88.03% yield).

[0771] ¹H NMR (400 MHz, MeOD-d₄) δ 3.90-3.99 (m, 2H), 3.69-3.78 (m, 3H), 3.37-3.49 (m, 2H), 3.20 (s, 3H), 2.45-2.57 (m, 2H), 1.63-1.72 (m, 2H), 1.57 (t, J=5.99 Hz, 3H), 1.19-1.36 (m, 2H).


Step B 5-(2-oxo-4-(tetrahydro-2H-pyran-4-yl)butyl)isoxazol-3(2H)-one



[0772] To a mixture of LDA (2.0 M, 2.61 mL) in THF (5 mL) was added 5-methylisoxazol-3-one (246.17 mg, 2.48 mmol) at -10° C. under N₂. The mixture was stirred at -10° C. for 30 min. N-methoxy-N-methyl-3-(tetrahydro-2H-pyran-4-yl)propanamide (250 mg, 1.24 mmol) in THF (2 mL) was added into the reaction solution. The solution was stirred at -10° C. for 1 hr. The solution was quenched with 1 M HCl until pH=1. The mixture was poured into water (20 mL), washed with ethyl acetate (20 mL) to remove the impurities. The aqueous layer was adjusted with the sat. NaHCO₃ solution until pH=7, extracted with ethyl acetate (30 mL×3), then brine (50 mL), dried over anhydrous of Na₂SO₄, filtered and concentrated in vacuum to a residue. The residue was purified by flash silica gel chromatography (ISCO®, 20 g SepaFlash® Silica Flash Column, Eluent of 0~80% Ethyl acetate/Petroleum ether gradient @25 mL/min) to give 5-(2-oxo-4-(tetrahydro-2H-pyran-4-yl)butyl)isoxazol-3(2H)-one (114 mg, 476.46 μmol, 38.36% yield, 100% purity).

[0773] ¹H NMR (400 MHz, DMSO-d₆) δ 5.85-5.92 (m, 1H), 3.90-3.98 (m, 2H), 3.77-3.86 (m, 2H), 3.18-3.29 (m, 2H), 2.52-2.58 (m, 2H), 1.49-1.57 (m, 2H), 1.35-1.46 (m, 3H), 1.03-1.17 (m, 2H). LC-MS: m/z 240.0 (M+H)⁺.



Step C ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-((R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)aminothieno[2,3-c]pyridin-2-yl)-5-(3-oxo-2,3-dihydroisoxazol-5-yl)-6-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1,4-dihydropyridine-3-carboxylate



[0774] A mixture of tert-butyl (S)-2-(3-ethoxy-3-oxopropanoyl)pyrrolidine-1-carboxylate (50 mg, 175.23 µmol), 5-(2-oxo-4-(tetrahydro-2H-pyran-4-yl)butyl)isoxazol-3-(2H)-one (41.93 mg, 175.23 µmol), (R)-7-((6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (51.76 mg, 175.23 µmol), NH₄OAc (14.86 mg, 192.76 µmol) and Yb(OTf)₃ (10.87 mg, 17.52 µmol) in EtOH (2 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 50° C. for 16 hrs under N₂ atmosphere. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, petroleum ether/ethyl acetate=1/0 to 0/1) to give ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-((R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(3-oxo-2,3-dihydroisoxazol-5-yl)-6-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1,4-dihdropyridine-3-carboxylate (90 mg, 58.51 µmol, 33.39% yield, 50.90% purity). LC-MS: m/z 793.3 (M+H)⁺.

Step D ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-((R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(3-oxo-2,3-dihydroisoxazol-5-yl)-6-(2-(tetrahydro-2H-pyran-4-yl)ethyl)nicotinate


Step E ethyl 4-(7-((R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(3-oxo-2,3-dihydroisoxazol-5-yl)-2-((S)-pyrrolidin-2-yl)-6-(2-(tetrahydro-2H-pyran-4-yl)ethyl)nicotinate



[0775] A mixture of ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-((R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(3-oxo-2,3-dihydroisoxazol-5-yl)-6-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-1,4-dihdropyridine-3-carboxylate (90 mg, 114.95 µmol) and CAN (126.04 mg, 229.90 µmol) in CH₃CN (2 mL) and H₂O (2 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 20° C. for 2 hrs under N₂ atmosphere. The reaction mixture was diluted with ethyl acetate (10 mL) and washed with brine (5 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give ethyl 5-(3-oxoisoxazol-5-yl)-2-[rac-(2S)-1-tert-butoxycarbonylpyrrolidin-2-yl]-4-[7-[[rac-(5R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl]amino]thieno[2,3-c]pyridin-2-yl]-6-(2-tetrahydropyran-4-ylethyl)pyridine-3-carboxylate (62 mg, 32.02 µmol, 27.85% yield, 40.33% purity). LC-MS: m/z 781.3 (M+H)⁺.

[0776] A mixture of ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-((R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(3-oxo-2,3-dihydroisoxazol-5-yl)-6-(2-(tetrahydro-2H-pyran-4-yl)ethyl)nicotinate (62 mg, 79.39 µmol) and TFA (460.50 mg, 4.04 mmol) in DCM (3 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 20° C. for 2 hrs under N₂ atmosphere. The reaction mixture was concentrated under reduced pressure to give ethyl 4-(7-((R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(3-oxo-2,3-dihydroisoxazol-5-yl)-2-((S)-pyrrolidin-2-yl)-6-(2-(tetrahydro-2H-pyran-4-yl)ethyl)nicotinate (65 mg, crude, TFA). LC-MS: m/z 681.2 (M+H)⁺.

Step F 5-((S)-4-(7-((R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-2-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)isoxazol-3(2H)-one



[0777] To a solution of ethyl 4-(7-((R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(3-oxo-2,3-dihydroisoxazol-5-yl)-2-((S)-pyrrolidin-2-


yl)-6-(2-(tetrahydro-2H-pyran-4-yl)ethyl)nicotinate (65 mg, 95.47 μ mol) in DCM (2 mL) was added TEA (1.45 g, 14.37 mmol). The mixture was stirred at 20° C. for 16 hrs. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (FA) to give 5-((S)-4-(7-(((R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-2-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)isoxazol-3(2H)-one (6.78 mg, 10.54 μ mol, 11.04% yield, 98.68% purity).

[0778] 1 H NMR (400 MHz, CDCl₃) δ 8.36-8.46 (m, 1H), 7.95-8.06 (m, 1H), 7.85 (d, J=1.47 Hz, 1H), 7.35-7.45 (m, 1H), 7.07-7.17 (m, 2H), 5.80-5.94 (m, 1H), 5.68-5.78 (m, 1H), 4.67-4.81 (m, 1H), 3.88-3.98 (m, 2H), 3.69-3.79 (m, 1H), 3.30-3.44 (m, 3H), 2.82 (d, J=3.18 Hz, 2H), 2.67-2.75 (m, 2H), 2.47-2.54 (m, 2H), 2.35-2.41 (m, 2H), 1.76-1.86 (m, 2H), 1.65-1.73 (m, 2H), 1.55-1.61 (m, 2H), 1.38-1.51 (m, 2H), 1.23-1.33 (m, 2H). LC-MS: m/z 635.4 (M+H)⁺.

5-[(2S)-9-[7-[(5R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl]amino]thieno[2,3-c]pyridin-2-yl]-7,7-dioxo-11-(2-tetrahydropyran-4-ylethyl)-7-thia-6,12-diazatricyclo[6.4.0.02,6]dodeca-1(12),8,10-trien-10-yl]isoxazol-3-one (Compound 198)


Example 26

3-((9aS)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-2-(3-(tetrahydrofuran-3-yl)phenethyl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,2,4-oxadiazol-5(4H)-one (Compound 199)




[0779] Compound 198 was synthesized using a similar procedure described in the Example 13 above by using the appropriate materials.


[0780] 1 H NMR (500 MHz, MeOD-d₄) δ ppm 8.36 (d, J=5.19 Hz, 1H), 7.99 (d, J=5.80 Hz, 1H), 7.76 (d, J=7.63 Hz, 1H), 7.65 (s, 1H), 7.23 (dd, J=7.55, 5.11 Hz, 1H), 7.16 (d, J=5.65 Hz, 1H), 6.03 (s, 1H), 5.90 (t, J=7.78 Hz, 1H), 5.09 (dd, J=8.16, 4.96 Hz, 1H), 3.89-3.94 (m, 2H), 3.76-3.83 (m, 1H), 3.35-3.47 (m, 4H), 3.13-3.19 (m, 1H), 3.04 (dt, J=16.94, 8.62 Hz, 1H), 2.86-2.93 (m, 2H), 2.70-2.77 (m, 1H), 2.56-2.63 (m, 1H), 2.35 (dq, J=12.26, 6.14 Hz, 1H), 2.09-2.18 (m, 1H), 1.98-2.06 (m, 1H), 1.77-1.84 (m, 1H), 1.52-1.74 (m, 5H), 1.21-1.40 (m, 3H). LC-MS: m/z 671.2 (M+H)⁺.



-continued




Step A 2-fluoro-4-[(5-formylindol-1-yl)methyl]benzonitrile



[0781] To a solution of 1H-indole-5-carbaldehyde (500 mg, 3.44 mmol) in THF (10 mL) was added NaH (206.65 mg, 5.17 mmol, 60% purity) at 0° C. The mixture was stirred at 0° C. for 30 mins. Then 4-(bromomethyl)-2-fluoro-benzonitrile (1.11 g, 5.17 mmol) was added. The mixture was stirred at 25° C. for 90 mins. The reaction mixture was quenched by addition aqueous NH₄Cl (20 mL) at 0° C., and then extracted with EtOAc (20 mL×2). The combined organic layer was washed with brine (20 mL×2), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, Petroleum ether/Ethyl acetate=1/10 to 3/1) to give 2-fluoro-4-[(5-formylindol-1-yl)methyl]benzonitrile (700 mg, 2.52 mmol, 73.03% yield).


[0782] ¹H NMR (500 MHz, DMSO-d₆) δ ppm 9.94-10.05 (m, 1H), 8.14-8.27 (m, 1H), 7.82-7.93 (m, 1H), 7.70-7.75 (m, 1H), 7.63-7.68 (m, 2H), 7.33-7.38 (m, 1H), 7.08-7.14 (m, 1H), 6.75-6.81 (m, 1H), 5.57-5.72 (m, 2H).

Step B 2-fluoro-4-[[5-[3-isopropyl-1,1-dioxo-6-(3-oxoisoxazol-5-yl)-5-(2-tetrahydropyran-4-ylethyl)-2,3,4,7-tetrahydrothieno[3,2-b]pyridin-7-yl]indol-1-yl]methyl]benzonitrile



[0783] To a solution of 4-isopropyl-1,1-dioxo-thiolan-3-one (28.50 mg, 161.71 μmol), 5-(2-oxo-4-tetrahydropyran-4-yl-butyl)isoxazol-3-one (38.69 mg, 161.71 μmol), 2-fluoro-4-[(5-formylindol-1-yl)methyl]benzonitrile (45 mg, 161.71 μmol) in AcOH (3 mL) was added NH₄OAc (12.46 mg, 161.71 μmol). The mixture was stirred at 120° C. for 1 hr. The reaction mixture was concentrated under reduced pressure to give crude product 2-fluoro-4-[[5-[3-isopropyl-1,1-dioxo-6-(3-oxoisoxazol-5-yl)-5-(2-tetrahydropyran-4-ylethyl)-2,3,4,7-tetrahydrothieno[3,2-b]pyridin-7-yl]indol-1-yl]methyl]benzonitrile (110 mg, crude). LC-MS: m/z 657.2 (M+H)⁺.

Step C 2-fluoro-4-[[5-[3-isopropyl-1,1-dioxo-6-(3-oxoisoxazol-5-yl)-5-(2-tetrahydropyran-4-ylethyl)-2,3-dihydrothieno[3,2-b]pyridin-7-yl]indol-1-yl]methyl]benzonitrile




[0784] To a solution of 2-fluoro-4-[[5-[3-isopropyl-1,1-dioxo-6-(3-oxoisoxazol-5-yl)-5-(2-tetrahydropyran-4-ylethyl)-2,3,4,7-tetrahydrothieno[3,2-b]pyridin-7-yl]indol-1-yl]methyl]benzonitrile (100 mg, 152.26 μmol) in DCM (3 mL) was added CAN (83.47 mg, 152.26 μmol). The mixture was stirred at 50° C. for 1 hr. The reaction mixture was concentrated under reduced pressure to give a residue. The crude product was purified by prep-HPLC (column: Boston

Prime C18 150*30 mm*5 um; mobile phase: [water (NH₃H₂O+NH₄HCO₃)-ACN]; gradient: 22%-52% B over 11 min). 2-fluoro-4-[[5-[3-isopropyl-1,1-dioxo-6-(3-oxoisoxazol-5-yl)-5-(2-tetrahydropyran-4-ylethyl)-2,3-dihydrothieno[3,2-b]pyridin-7-yl]indol-1-yl]methyl]benzonitrile (1.86 mg, 2.84 μmol, 1.87% yield) was obtained.

[0785] ¹H NMR (400 MHz, MeOD-d₄) δ ppm 7.64-7.71 (m, 2H), 7.34-7.39 (m, 1H), 7.25-7.30 (m, 1H), 7.02-7.13 (m, 3H), 6.57-6.60 (m, 1H), 5.57-5.63 (m, 1H), 5.48-5.53 (m, 2H), 3.87-3.94 (m, 2H), 3.67-3.77 (m, 2H), 3.44-3.50 (m, 1H), 3.36-3.41 (m, 2H), 2.76-2.86 (m, 3H), 1.67-1.75 (m, 2H), 1.54-1.66 (m, 3H), 1.22-1.29 (m, 2H), 1.13-1.16 (m, 3H), 0.88-0.92 (m, 3H). LC-MS: m/z 655.4 (M+H)⁺.


4-[[5-[(2S)-7,7-dioxo-10-(3-oxoisoxazol-5-yl)-11-(2-tetrahydropyran-4-ylethyl)-7-thia-6,12-diazatricyclo[6.4.0.2,6]dodeca-1(8),9,11-trien-9-yl]indol-1-yl]methyl]-2-fluoro-benzonitrile (Compound 200)



[0786] Compound 200 was synthesized using a similar procedure described in the Example 13 above by using the appropriate materials.

[0787] ¹H NMR (400 MHz, MeOD-d₄) δ ppm 8.50-8.59 (m, 1H), 7.62-7.75 (m, 2H), 7.35-7.39 (m, 1H), 7.26-7.32 (m, 1H), 7.03-7.15 (m, 3H), 6.57-6.61 (m, 1H), 5.49-5.57 (m, 3H), 5.00-5.05 (m, 1H), 3.86-3.95 (m, 2H), 3.71-3.78 (m, 1H), 3.56-3.67 (m, 1H), 3.35-3.41 (m, 2H), 2.81-2.87 (m, 2H), 2.51-2.62 (m, 1H), 2.18-2.37 (m, 2H), 1.95-2.01 (m, 1H), 1.75-1.84 (m, 1H), 1.66-1.72 (m, 2H), 1.46-1.53 (m, 1H), 1.19 (s, 2H). LC-MS: m/z 654.4 (M+H)⁺.


(S)-5-(4-(1-(3,4-difluorobenzyl)-1H-indol-5-yl)-5-oxo-2-(2-tetrahydro-2H-pyran-4-yl)ethyl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)isoxazol-3(2H)-one (Compound 201)



[0788] Compound 201 was synthesized using a similar procedure described in the Example 26 above by using the appropriate materials.

[0789] ¹H NMR (500 MHz, MeOD-d₄) δ 8.32-8.40 (m, 1H), 7.34-7.41 (m, 1H), 7.20-7.23 (m, 1H), 7.17 (d, J=8.39 Hz, 1H), 7.05-7.10 (m, 1H), 6.93-6.99 (m, 1H), 6.84-6.90 (m, 2H), 6.39-6.44 (m, 1H), 5.44-5.47 (m, 1H), 5.22-5.30 (m, 3H), 3.77-3.82 (m, 2H), 3.50-3.55 (m, 1H), 3.26-3.31 (m, 3H), 2.65-2.75 (m, 2H), 2.37-2.42 (m, 1H), 2.26-2.32 (m, 2H), 2.09 (t, J=7.63 Hz, 1H), 1.54-1.60 (m, 2H), 1.51 (m, 2H), 1.41-1.45 (m, 1H), 1.30-1.39 (m, 2H). LC-MS: m/z 611.2 (M+H)⁺.


5-((9aS)-4-(1-(3,4-difluorophenyl)ethyl)-1H-indol-5-yl)-5-oxo-2-(2-tetrahydro-2H-pyran-4-yl)ethyl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)isoxazol-3(2H)-one (Compound 202)



[0790] Compound 202 was synthesized using a similar procedure described in the Example 25 above by using the appropriate materials.

[0791] ¹H NMR (500 MHz, MeOD-d₄) δ 7.34-7.41 (m, 2H), 7.12-7.17 (m, 1H), 7.04-7.09 (m, 1H), 6.96-7.02 (m, 1H), 6.88-6.92 (m, 1H), 6.80-6.85 (m, 1H), 6.41-6.47 (m, 1H), 5.62-5.72 (m, 1H), 5.44-5.52 (m, 1H), 5.21-5.28 (m, 1H), 3.77-3.83 (m, 2H), 3.48-3.56 (m, 1H), 3.30 (m, 2H), 2.65-2.76 (m, 2H), 2.36-2.42 (m, 1H), 2.25-2.33 (m, 2H), 1.81 (m, 3H), 1.55-1.62 (m, 2H), 1.49 (d, J=13.28 Hz, 3H), 1.41 (m, 2H), 1.28-1.37 (m, 2H). LC-MS: m/z 625.2 (M+H)⁺.

4-[[6-((9aS)-5-oxo-3-(3-oxoisoxazol-5-yl)-2-(2-tetrahydropyran-4-ylethyl)-1,4,7,8,9,9a-hexahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-2-oxo-1,3-benzoxazol-3-yl)methyl]-2-fluoro-benzonitrile (Compound 203)





[0792] Compound 203 was synthesized using a similar procedure described in the Example 25 above by using the appropriate materials.

[0793] ^1H NMR (500 MHz, MeOD-d₄) δ ppm 7.71-7.81 (m, 1H), 7.41-7.46 (m, 1H), 7.36-7.41 (m, 1H), 7.22-7.27 (m, 1H), 6.93-7.08 (m, 2H), 5.63-5.85 (m, 1H), 5.11-5.21 (m, 2H), 4.80-4.85 (m, 1H), 3.85-3.95 (m, 2H), 3.59-3.68 (m, 1H), 3.35-3.42 (m, 3H), 2.77-2.88 (m, 2H), 2.44-2.52 (m, 1H), 2.32-2.43 (m, 2H), 1.63 (s, 2H), 1.59 (d, $J=13.89$ Hz, 2H), 1.48-1.54 (m, 1H), 1.39-1.47 (m, 1H), 1.17-1.27 (m, 2H). LC-MS: m/z 636.3 (M+H)⁺.

2-fluoro-4-(1-(5-((S)-5-oxo-3-(3-oxo-2,3-dihydroisoxazol-5-yl)-2-(tetrahydro-2H-pyran-4-yl)ethyl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-1H-indol-1-yl)ethyl)benzonitrile
(Compound 204)

5-((S)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-2-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)isoxazol-3(2H)-one (Compound 205)




[0796] Compound 205 was synthesized using a similar procedure described in the Example 25 above by using the appropriate materials.

[0797] ^1H NMR (400 MHz, MeOD-d₄) δ ppm 7.88 (d, $J=6.0$ Hz, 1H), 7.31 (s, 1H), 7.16 (t, $J=7.2$ Hz, 1H), 7.09 (d, $J=6.0$ Hz, 1H), 6.89 (d, $J=7.2$ Hz, 1H), 6.81 (d, $J=8.0$ Hz, 1H), 5.93 (s, 1H), 5.75 (t, $J=7.2$ Hz, 1H), 3.89-3.92 (m, 1H), 3.87-3.89 (m, 1H), 3.83 (s, 3H), 3.61-3.69 (m, 1H), 3.35-3.45 (m, 3H), 2.99-3.07 (m, 1H), 2.81-2.89 (m, 2H), 2.74-2.80 (m, 1H), 2.35-2.71 (m, 5H), 1.95-2.03 (m, 1H), 1.63-1.71 (m, 2H), 1.59 (d, $J=12.0$ Hz, 2H), 1.41-1.48 (m, 1H), 1.20-1.32 (m, 3H). LC-MS: m/z 664.3 (M+H)⁺.

(S)-5-(4-(7-((3,4-difluorobenzyl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-2-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)isoxazol-3(2H)-one (Compound 206)

[0794] Compound 204 was synthesized using a similar procedure described in the Example 25 above by using the appropriate materials.


[0795] ^1H NMR (500 MHz, MeOD-d₄) δ ppm 7.64-7.70 (m, 1H), 7.45-7.55 (m, 2H), 7.13-7.23 (m, 3H), 6.89-7.00 (m, 1H), 6.53-6.64 (m, 1H), 5.81-5.94 (m, 1H), 5.35-5.61 (m, 1H), 3.88-3.93 (m, 2H), 3.57-3.66 (m, 1H), 3.36-3.40 (m, 3H), 2.74-2.90 (m, 2H), 2.46-2.54 (m, 1H), 2.36-2.42 (m, 2H), 1.92-1.96 (m, 3H), 1.58-1.71 (m, 5H), 1.50-1.54 (m, 1H), 1.41-1.46 (m, 1H), 1.21-1.28 (m, 2H). LC-MS: m/z 632.4 (M+H)⁺.



[0798] Compound 206 was synthesized using a similar procedure described in the Example 25 above by using the appropriate materials.

[0799] ^1H NMR (400 MHz, MeOD-d₄) δ 7.81-7.89 (m, 1H), 7.32-7.37 (m, 1H), 7.22-7.30 (m, 1H), 7.14-7.21 (m, 2H), 7.04-7.10 (m, 1H), 5.93-5.99 (m, 1H), 3.89-3.96 (m, 2H), 3.63-3.73 (m, 1H), 3.35-3.49 (m, 4H), 2.80-2.93 (m, 2H), 2.48-2.57 (m, 1H), 2.38-2.48 (m, 2H), 1.67-1.78 (m, 2H), 1.62 (d, J=12.99 Hz, 2H), 1.44-1.56 (m, 2H), 1.19-1.33 (m, 4H). LC-MS: m/z 644.1 (M+H)⁺.


5-((S)-2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 207)



[0800] Compound 207 was synthesized using a similar procedure described in the Example 20 above by using the appropriate materials.

[0801] ^1H NMR (400 MHz, DMSO-d₆): δ 7.29 (s, 1H), 7.18-7.24 (m, 2H), 7.03-7.15 (m, 4H), 6.90 (s, 1H), 6.86 (d, J=7.6 Hz, 1H), 6.82 (d, J=8.0 Hz, 1H), 5.92 (q, J=8.0 Hz, 1H), 4.84 (dd, J=6.0 Hz, J=9.6 Hz, 1H), 3.79 (s, 3H), 3.49-3.59 (m, 1H), 3.23-3.28 (m, 1H), 3.10-3.18 (m, 2H), 2.89-3.09 (m, 3H), 2.67-2.75 (m, 1H), 2.43-2.47 (m, 1H), 2.40 (s, 3H), 2.22-2.30 (m, 2H), 1.94-2.05 (m, 1H), 1.35-1.47 (m, 1H), 0.94 (t, J=7.2 Hz, 1H). ^{19}F NMR (377 MHz, DMSO-d₆): -117.10. LC-MS: m/z 689.1 (M+H)⁺.


(S)-3-((5-chloro-3-fluoropyridin-2-yl)methyl)-6-(4-fluorophenethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)benzo[d]oxazol-2(3H)-one
(Compound 208)



[0802] Compound 208 was synthesized using a similar procedure described in the Example 14 above by using the appropriate materials.

[0803] ^1H NMR (400 MHz, CDCl₃) δ ppm 8.52-8.65 (m, 1H), 8.35-8.43 (m, 1H), 7.48-7.55 (m, 1H), 7.20-7.23 (m, 1H), 7.11-7.17 (m, 2H), 7.03-7.11 (m, 2H), 6.95-7.01 (m, 2H), 5.14-5.29 (m, 2H), 4.68-4.89 (m, 1H), 3.68-3.79 (m, 1H), 3.42 (ddd, J=11.80, 8.17, 3.87 Hz, 1H), 3.03-3.26 (m, 4H), 2.48-2.58 (m, 1H), 2.33-2.43 (m, 2H), 1.42-1.50 (m, 1H). LC-MS: m/z 657.2 (M+H)⁺.


2-fluoro-4-(1-(6-((S)-2-(4-fluorophenethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)ethyl)benzonitrile
(Compound 209)



[0804] Compound 209 was synthesized using a similar procedure described in the Example 14 above by using the appropriate materials.

[0805] ^1H NMR (400 MHz, CDCl_3) δ ppm 8.60-8.75 (m, 1H), 7.62-7.72 (m, 1H), 7.31-7.36 (m, 2H), 7.26-7.28 (m, 1H), 7.14 (dd, $J=8.46$, 5.48 Hz, 2H), 7.02-7.08 (m, 1H), 6.94-7.01 (m, 2H), 6.72-6.80 (m, 1H), 5.59-5.70 (m, 1H), 4.72-4.85 (m, 1H), 3.68-3.80 (m, 1H), 3.36-3.50 (m, 1H), 3.02-3.24 (m, 4H), 2.49-2.61 (m, 1H), 2.34-2.46 (m, 2H), 1.98 (br d, $J=6.79$ Hz, 3H), 1.39-1.53 (m, 1H). LC-MS: m/z 661.2 ($\text{M}+\text{H}$) $^+$.

(S)-5-(4-(1-((3,5-difluoropyridin-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 210)




[0806] Compound 210 was synthesized using a similar procedure described in the Example 15 above by using the appropriate materials.

[0807] ^1H NMR (400 MHz, DMSO-d_6) δ ppm 12.61 (s, 1H), 8.42 (d, $J=2.38$ Hz, 1H), 8.06 (d, $J=2.03$ Hz, 1H), 8.00 (td, $J=9.48$, 2.38 Hz, 1H), 7.93 (d, $J=2.03$ Hz, 1H), 7.64 (d, $J=3.46$ Hz, 1H), 7.19-7.27 (m, 2H), 7.08 (t, $J=8.88$ Hz, 2H), 6.57 (d, $J=3.58$ Hz, 1H), 5.69 (s, 2H), 4.86 (dd, $J=10.37$, 6.20 Hz, 1H), 3.45-3.57 (m, 1H), 3.29 (dd, $J=11.50$, 5.90 Hz, 1H), 3.15-3.20 (m, 2H), 2.97-3.12 (m, 1H), 2.96-3.12 (m, 1H), 2.32-2.42 (m, 2H), 2.22-2.31 (m, 2H), 1.34-1.49 (m,

1H). ^{19}F NMR (376 MHz, DMSO-d_6) δ ppm -117.05 (s, 1F), -121.62 (d, $J=4.49$ Hz, 1F), -124.87 (d, $J=6.73$ Hz, 1F). LC-MS: m/z 624.1 ($\text{M}+\text{H}$) $^+$.

(S)-5-(4-(1-((5-chloro-3-fluoropyridin-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one
(Compound 211)




[0808] Compound 211 was synthesized using a similar procedure described in the Example 15 above by using the appropriate materials.


[0809] ^1H NMR (400 MHz, DMSO-d_6) δ 12.57 (br s, 1H), 8.41 (d, $J=1.2$ Hz, 1H), 8.13 (dd, $J=2.0$ Hz, $J=9.6$ Hz, 1H), 8.04 (d, $J=2.0$ Hz, 1H), 7.92 (d, $J=1.6$ Hz, 1H), 7.63 (d, $J=3.6$ Hz, 1H), 7.20-7.24 (m, 2H), 7.05-7.10 (m, 2H), 6.56 (d, $J=3.6$ Hz, 1H), 5.69 (s, 2H), 4.85 (dd, $J=10.0$ Hz, $J=6.4$ Hz, 1H), 3.47-3.55 (m, 1H), 3.24-3.29 (m, 1H), 2.98-3.18 (m, 4H), 2.23-2.39 (m, 3H), 1.36-1.46 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d_6) δ -117.06, -122.91. LC-MS: m/z 640.2 ($\text{M}+\text{H}$) $^+$.

Example 27


5-(5-(4-fluorophenethyl)-3-isopropyl-7-((*R*)-4-methoxy-2,3-dihydro-1*H*-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-3-methyl-1,1-dioxido-2,3-dihydrothieno[3,2-b]pyridin-6-yl)-1,3,4-oxadiazol-2(3*H*)-one (Compound 212)




-continued



Step A diethyl 2-isopropyl-2-methylmalonate




Step C 2-(ethoxycarbonyl)-2,3-dimethylbutanoic (isobutyl carbonic) anhydride



[0810] To a solution of diethyl 2-isopropylmalonate (5 g, 24.72 mmol) in THF (50 mL) was added NaH (1.09 g, 27.19 mmol, 60% purity) at 0° C. After addition, the mixture was stirred at this temperature for 0.5 hr, and then Mel (14.04 g, 98.89 mmol) was added at 0° C. The resulting mixture was stirred at 20° C. for 2 hrs. The reaction mixture was quenched by addition aq. NH₄Cl (20 mL) at 0° C., and then diluted with ethyl acetate (20 mL) and extracted with ethyl acetate (50 mL×2). The combined organic layers were washed with brine (50 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give diethyl 2-isopropyl-2-methylmalonate (5.5 g, crude).

[0811] ¹H NMR (400 MHz, CDCl₃) δ 4.01-4.16 (m, 4H), 2.36-2.49 (m, 1H), 1.25 (m, 3H), 1.18 (t, J=7.09 Hz, 6H), 0.83-0.89 (m, 6H).

Step B 2-(ethoxycarbonyl)-2,3-dimethylbutanoic acid




[0812] aq. KOH (1 M, 5.55 mL) was added under nitrogen dropwise to a solution of diethyl 2-isopropyl-2-methylmalonate (1.2 g, 5.55 mmol) in EtOH (10 mL) at 0° C. After the addition, the reaction was allowed to stir at 20° C. for 16 hrs. Then the reaction was allowed to stir at 45° C. for 16 hrs. The reaction was concentrated under reduced pressure to remove most of the ethanol. The residue was partitioned between water (10 mL) and ethyl acetate (10 mL). The aqueous layer was separated and acidified with 2 M HCl and extracted with ethyl acetate (10 mL×3). The combined extracts were dried (anhydrous Na₂SO₄) and the solvent removed under reduced pressure to give 2-ethoxycarbonyl-2,3-dimethylbutanoic acid (650 mg, 62.24% yield).

[0813] ¹H NMR (400 MHz, CDCl₃) δ 4.12-4.22 (m, 2H), 2.31-2.47 (m, 1H), 1.30 (s, 3H), 1.21 (t, J=7.15 Hz, 3H), 0.90 (t, J=6.44 Hz, 6H).

[0814] To a stirring solution of 2-ethoxycarbonyl-2,3-dimethylbutanoic acid (0.65 g, 3.45 mmol) and triethylamine (419.34 mg, 4.14 mmol) in THF (10 mL) at -10° C., was added isobutyl carbonochloride (518.82 mg, 3.80 mmol) dropwise. Then the reaction mixture was stirred 1 hr at 0° C. The insoluble material was filtered off, and the filtrate was directly used later.


Step D ethyl 2-(hydroxymethyl)-2,3-dimethylbutanoate



[0815] To an ice-cooling solution of NaBH₄ (392.13 mg, 10.36 mmol) in THF (7 mL) and H₂O (1.5 mL) was added abbvie 2-(ethoxycarbonyl)-2,3-dimethylbutanoic (isobutyl carbonic) anhydride (THF solution) dropwise. After the reaction mixture was allowed to stir at 0° C. for 1 h. Then reaction mixture was poured into 10% of aqueous solution HOAc (1 mL), the aqueous phase was extracted with ethyl acetate (20 mL×3), and the combined organic phase was washed with brine (10 mL), dried over Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography (SiO₂, petroleum ether/ethyl acetate=1/0 to 1/1) to give ethyl 2-(hydroxymethyl)-2,3-dimethylbutanoate (350 mg, 58.15% yield).

[0816] ¹H NMR (500 MHz, CDCl₃) δ 4.14-4.23 (m, 2H), 3.72-3.81 (m, 1H), 3.44-3.52 (m, 1H), 2.04-2.15 (m, 1H), 1.25-1.32 (m, 3H), 1.08 (s, 3H), 0.85-0.93 (m, 6H).


Step E ethyl 2,3-dimethyl-2-(((methylsulfonyl)oxy)methyl)butanoate



[0817] Under ice bath condition, MsCl (345.16 mg, 3.01 mmol) was added dropwise to ethyl 2-(hydroxymethyl)-2,3-dimethylbutanoate (350 mg, 2.01 mmol) and TEA (406.53 mg, 4.02 mmol) in a solution of DCM (5 mL). The mixture was stirred at 20° C. for 2 hrs. The reaction solution was diluted with dichloromethane (20 mL), washed with hydrochloric acid (10 mL, 1 M) and brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give ethyl 2,3-dimethyl-2-(methylsulfonyloxy)methylbutanoate (520 mg, crude).

[0818] $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 4.34-4.47 (m, 1H), 4.02-4.19 (m, 3H), 2.93 (s, 3H), 1.89-2.01 (m, 1H), 1.18-1.25 (m, 3H), 1.12-1.16 (m, 3H), 0.81-0.90 (m, 6H).


Step F ethyl
2,3-dimethyl-2-((methylthio)methyl)butanoate



[0819] NaSMc (277.77 mg, 3.96 mmol) was added to a stirred solution of ethyl 2,3-dimethyl-2-(methylsulfonyloxy)methylbutanoate (500 mg, 1.98 mmol) in DMF (5 mL) at 20° C. The resulting brown suspension was stirred at 20° C. for 16 hrs. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL \times 3). The combined organic layer was dried over Na_2SO_4 , filtered, and concentrated under vacuum to give ethyl 2,3-dimethyl-2-((methylthio)methyl)butanoate (350 mg, 86.44% yield).

[0820] $^1\text{H NMR}$ (500 MHz, CDCl_3) δ 4.11-4.16 (m, 2H), 3.00 (s, 3H), 2.84-2.89 (m, 1H), 2.77-2.79 (m, 1H), 2.11 (s, 2H), 1.96-2.01 (m, 1H), 1.24-1.27 (m, 3H), 1.17-1.21 (m, 3H), 0.89-0.92 (m, 6H).

Step G ethyl
2,3-dimethyl-2-((methylsulfonyl)methyl)butanoate




[0821] A mixture of ethyl 2,3-dimethyl-2-(methylsulfonylmethyl)butanoate (350 mg, 1.71 mmol) and m-CPBA (1.04 g, 5.14 mmol, 85% purity) in DCM (5 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 20° C. for 16 hrs under N_2 atmosphere. The reaction mixture was quenched by addition aq. $\text{Na}_2\text{S}_2\text{O}_3$ (20 mL) at 0° C., and then diluted with DCM (20 mL) and extracted with DCM (20 mL \times 2). The combined organic layer was dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. The residue

was purified by column chromatography (SiO_2 , petroleum ether/ethyl acetate=1/0 to 50/50) to give ethyl 2,3-dimethyl-2-((methylsulfonyl)methyl)butanoate (290 mg, 71.64% yield).

[0822] $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 4.09-4.21 (m, 2H), 3.56-3.67 (m, 1H), 3.03-3.12 (m, 1H), 2.87 (s, 3H), 1.78-1.90 (m, 1H), 1.34 (s, 3H), 1.19-1.27 (m, 3H), 0.77-0.88 (m, 6H).


Step H
4-isopropyl-4-methylidihydrothiophen-3(2H)-one
1,1-dioxide



[0823] To a stirred solution of ethyl 2,3-dimethyl-2-(methylsulfonylmethyl)butanoate (290 mg, 1.23 mmol) in THF (3 mL) was added dropwise LiHMDS (1 M, 2.93 mL) at -78° C. with stirring under N_2 . The reaction mixture was left to stir at -78° C. for 1 hr. The reaction mixture was quenched by addition of a saturated aqueous solution of NH_4Cl (10 mL) at -10° C. with stirring. The resulting solution was concentrated in vacuo. The residue was purified by column chromatography (SiO_2 , petroleum ether/ethyl acetate=1/0 to 1/1) to give 4-isopropyl-4-methylidihydrothiophen-3(2H)-one 1,1-dioxide (70 mg, 367.92 μmol , 29.98% yield).

[0824] $^1\text{H NMR}$ (400 MHz, CDCl_3) δ 3.61-3.82 (m, 2H), 3.47-3.57 (m, 1H), 3.05-3.13 (m, 1H), 2.09-2.24 (m, 1H), 1.30-1.36 (m, 3H), 0.84-0.90 (m, 6H).


Step I5-(5-(4-fluorophenethyl)-3-isopropyl-7-(7(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-3-methyl-1,1-dioxido-2,3,4,7-tetrahydrothieno[3,2-b]pyridin-6-yl)-1,3,4-oxadiazol-2(3H)-one



[0825] A HOAc (2 mL) solution of 4-isopropyl-4-methylidihydrothiophen-3(2H)-one 1,1-dioxide (26.61 mg, 139.87 μmol), 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadi-

azol-2(3H)-one (35 mg, 139.87 μmol), (R)-7-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (45.37 mg, 139.87 μmol) and acetic acid ammonia (21.56 mg, 279.75 μmol) was heated to 105°C. for 1 hr. The reaction mixture was quenched by addition H₂O (5 mL) at 0°C., and then extracted with ethyl acetate (10 mL \times 2). The combined organic layer was washed with brine (10 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give 5-(5-(4-fluorophenethyl)-3-isopropyl-7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-3-methyl-1,1-dioxido-2,3,4,7-tetrahydrothieno[3,2-b]pyridin-6-yl)-1,3,4-oxadiazol-2(3H)-one (100 mg, crude). LC-MS: m/z 728.1 (M+H)⁺.

Step J 5-(5-(4-fluorophenethyl)-3-isopropyl-7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-3-methyl-1,1-dioxido-2,3-dihydrothieno[3,2-b]pyridin-6-yl)-1,3,4-oxadiazol-2(3H)-one




[0826] A mixture of 5-(5-(4-fluorophenethyl)-3-isopropyl-7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-3-methyl-1,1-dioxido-2,3,4,7-tetrahydrothieno[3,2-b]pyridin-6-yl)-1,3,4-oxadiazol-2(3H)-one (100 mg, 137.39 μmol) and CAN (150.64 mg, 274.78 μmol) in CH₃CN (2 mL) and H₂O (2 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 20°C. for 2 hrs under N₂ atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, DCM: MeOH=1/0 to 95/5) to give crude product. The crude product was purified by prep-HPLC (column: C18 150 \times 30 mm; mobile phase: [water(FA)-ACN]; gradient: 35%-65% B over 6 min) to give 5-(5-(4-fluorophenethyl)-3-isopropyl-7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-3-methyl-1,1-dioxido-2,3-dihydrothieno[3,2-b]pyridin-6-yl)-1,3,4-oxadiazol-2(3H)-one (1.23 mg, 1.23% yield, 100% purity).

[0827] ¹H NMR (500 MHz, MeOD-d₄) δ 7.83-7.88 (d, J=4.4 Hz, 1H), 7.58 (s, 1H), 6.99-7.08 (m, 4H), 6.82-6.89 (m, 2H), 6.77-6.78 (d, J=6 Hz, 1H), 6.68-6.69 (d, J=6.4 Hz, 1H), 5.67-5.73 (m, 1H), 3.72 (s, 3H), 3.56-3.62 (m, 1H), 3.27-3.32 (m, 1H), 2.98-3.04 (m, 2H), 2.88-2.96 (m, 1H), 2.62-2.71 (m, 1H), 2.50-2.58 (m, 1H), 2.41-2.49 (m, 1H), 1.93 (s, 2H), 1.49-1.55 (m, 1H), 1.47 (d, J=1.53 Hz, 3H),

0.94-0.98 (m, 3H), 0.66 (dd, J=6.79, 2.82 Hz, 3H). ¹⁹F NMR (376 MHz, MeOD-d₄) δ ppm -119.15 (s, 1F). LC-MS: m/z 726.2 (M+H)⁺.


(S)-6-((6-(2-(4-fluorophenethyl)-5,5-dioxido-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,9,9a-tetrahydropyrrolo[1',2':2,3]isothiazolo[4,5-b]pyridin-4-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)methyl)nicotinonitrile (Compound 213)



[0828] Compound 213 was synthesized using a similar procedure described in the Example 14 above by using the appropriate materials.

[0829] ¹H NMR (400 MHz, CDCl₃) δ ppm 8.82-8.89 (m, 1H), 8.15-8.22 (m, 1H), 7.59-7.70 (m, 1H), 7.41-7.50 (m, 1H), 7.13-7.21 (m, 4H), 6.95-7.01 (m, 2H), 5.29-5.33 (m, 2H), 5.07 (br dd, J=7.03, 4.65 Hz, 1H), 3.73-3.82 (m, 1H), 3.38-3.43 (m, 1H), 3.26-3.31 (m, 2H), 3.07-3.15 (m, 2H), 2.52-2.60 (m, 1H), 2.24-2.34 (m, 1H), 1.95-2.07 (m, 1H), 1.70-1.80 (m, 1H). LC-MS: m/z 666.1 (M+H)⁺.

2-fluoro-4-((5-(2-(4-fluorophenethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)benzonitrile (Compound 214)





[0830] Compound 214 was synthesized using a similar procedure described in the Example 15 above by using the appropriate materials.




[0831] ^1H NMR (400 MHz, DMSO-d₆) δ ppm 7.83-8.05 (m, 2H), 7.59-7.80 (m, 2H), 7.15-7.28 (m, 1H), 6.91-7.10 (m, 5H), 6.52-6.67 (m, 1H), 5.48-5.66 (m, 2H), 4.72-4.89 (m, 1H), 3.39-3.55 (m, 1H), 3.09-3.32 (m, 3H), 2.88-3.05 (m, 2H), 2.21-2.38 (m, 3H), 1.22-1.40 (m, 1H). ^{19}F NMR (376 MHz, MeOD-d₄) δ ppm -77.28 (s, 1F), -109.22 (s, 1F), -118.93 (s, 1F). LC-MS: m/z 630.1 (M+H)⁺.

Example 28


5-((S)-2-(4-fluorophenethyl)-4-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-(trifluoromethyl)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 215)



-continued





-continued



Step A methyl 5-(trifluoromethyl)thieno[2,3-c]pyridine-2-carboxylate


Step B 2-(methoxycarbonyl)-5-(trifluoromethyl)thieno[2,3-c]pyridine 6-oxide



[0832] A mixture of methyl 5-bromothieno[2,3-c]pyridine-2-carboxylate (500 mg, 1.837 mmol), ethyl 2,2-difluoro-2-(fluorosulfonyl)acetate (1764.94 mg, 9.187 mmol), CuI (1749.69 mg, 9.187 mmol), Cu (700.61 mg, 11.025 mmol) in DMF (20 mL) was stirred at 100° C. for 2 h in seal tube. After the reaction was completed. The mixture reaction was diluted with EA, filtered and the filtrate was washed with water*3, dried and concentrated. The residue was purified by column chromatography on silica gel (PE/EA=10/1) to give methyl 5-(trifluoromethyl)thieno[2,3-c]pyridine-2-carboxylate (267 mg, 1.022 mmol, 55.63%). LC-MS: m/z 303.1 (M+CH₃CN+H)⁺.


[0833] A mixture of methyl 5-(trifluoromethyl)thieno[2,3-c]pyridine-2-carboxylate (1.7 g, 6.508 mmol), dioxidane oxomethanediamine (82.83 mg, 0.880 mmol), TFAA (1.835 mL, 13.016 mmol) in DCM (5 mL) was stirred at room temperature overnight. After the reaction was completed, the mixture reaction was diluted with EA, washed with aq. Na₂CO₃, dried over Na₂SO₄. The organic layers were concentrated and purified by column chromatography on silica gel (MeOH/DCM=0% to 5%) to give 2-(methoxycarbonyl)-5-(trifluoromethyl)thieno[2,3-c]pyridine 6-oxide (1.1 g, 3.968 mmol, 60.97%). LC-MS: m/z 278.1 (M+H)⁺.

Step C methyl 7-chloro-5-(trifluoromethyl)thieno[2,3-c]pyridine-2-carboxylate




[0834] A mixture of 2-(methoxycarbonyl)-5-(trifluoromethyl)thieno[2,3-c]pyridine 6-oxide (1.1 g, 3.968 mmol), POCl_3 (3.643 mL, 39.680 mmol) in CHCl_3 (30 mL) was stirred at 60° C. overnight. After the reaction was completed, the mixture reaction was diluted with DCM, washed with aq. Na_2CO_3 , filtered and the filtrate was concentrated. The residue was purified by column chromatography on silica gel (PE/EA=10/1) to give methyl 7-chloro-5-(trifluoromethyl)thieno[2,3-c]pyridine-2-carboxylate (1.0 g, 3.382 mmol, 85.24%). LC-MS: m/z 295.9 ($\text{M}+\text{H}$)⁺.

Step D methyl (R)-7-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-(trifluoromethyl)thieno[2,3-c]pyridine-2-carboxylate




[0835] A mixture of methyl 7-chloro-5-(trifluoromethyl)thieno[2,3-c]pyridine-2-carboxylate (300 mg, 1.015 mmol), (R)-4-methoxy-2,3-dihydro-1H-inden-1-amine dihydrochloride (287.53 mg, 1.218 mmol), Cs_2CO_3 (991.81 mg, 3.044 mmol), $\text{Pd}_2(\text{dba})_3$ (92.92 mg, 0.101 mmol), Xantphos (58.71 mg, 0.101 mmol) in Toluene (10 mL) was stirred at 110° C. overnight in seal tube. After the reaction was completed. The mixture reaction was concentrated. The residue was purified by column chromatography on silica gel (PE/EA=10/1) to give methyl (R)-7-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-(trifluoromethyl)thieno[2,3-c]pyridine-2-carboxylate (260 mg, 0.616 mmol, 60.66%). LC-MS: m/z 423.2 ($\text{M}+\text{H}$)⁺.

Step E (R)-7-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-(trifluoromethyl)thieno[2,3-c]pyridin-2-yl)methanol




[0836] To a mixture of methyl (R)-7-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-(trifluoromethyl)thieno[2,3-c]pyridine-2-carboxylate (230 mg, 0.544 mmol) in THF (4 mL) was added LiAlH_4 (61.99 mg, 1.633 mmol) at 0° C., and stirred at room temperature for 3 h. After the reaction was completed. The mixture reaction was diluted with DCM, washed with aq. NH_4Cl , the organic phase was dried over Na_2SO_4 , filtered and the filtrate was concentrated. The residue was purified by column chromatography on silica gel (PE/EA=20/1) to give (R)-7-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-(trifluoromethyl)thieno[2,3-c]pyridin-2-yl)methanol (171 mg, 0.434 mmol, 79.63%). LC-MS: m/z 395.1 ($\text{M}+\text{H}$)⁺.

Step F (R)-7-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-(trifluoromethyl)thieno[2,3-c]pyridine-2-carbaldehyde



[0837] A mixture of (R)-7-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-(trifluoromethyl)thieno[2,3-c]pyridin-2-yl)methanol (187 mg, 0.474 mmol), MnO_2 (824.41 mg, 9.483 mmol) in DCM (8 mL) was stirred at room temperature overnight. After the reaction was completed. The mixture reaction was concentrated. The residue was purified by column chromatography on silica gel (PE/EA=20/1) to give (R)-7-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-(trifluoromethyl)thieno[2,3-c]pyridine-2-carbaldehyde (150 mg, 0.382 mmol, 80.62%). LC-MS: m/z 393.1 ($\text{M}+\text{H}$)⁺.

Step G 5-((S)-2-(4-fluorophenethyl)-4-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-(trifluoromethyl)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one




[0838] Compound 215 was synthesized using a similar procedure described in Example 21 by using the appropriate materials. (6.03 mg)


[0839] ^1H NMR (400 MHz, DMSO-d6): δ 12.72 (br s, 1H), 7.87 (d, $J=8.0$ Hz, 1H), 7.57 (d, $J=9.2$ Hz, 2H), 7.18-7.25 (m, 2H), 7.14 (t, $J=8.0$ Hz, 1H), 7.04-7.10 (m, 2H), 6.88 (d, $J=7.6$ Hz, 1H), 6.84 (d, $J=8.4$ Hz, 1H), 5.85 (q, $J=7.6$ Hz, 1H), 4.88 (dd, $J=10.0$ Hz, $J=6.0$ Hz, 1H), 3.79 (s, 3H), 3.48-3.60 (m, 1H), 3.23-3.32 (m, 1H), 3.20 (t, $J=7.6$ Hz, 2H), 2.93-3.12 (m, 3H), 2.67-2.79 (m, 1H), 2.22-2.43 (m, 4H), 2.00-2.10 (m, 1H), 1.38-1.50 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d6): -66.31, -117.03. LC-MS: m/z 743.4 ($\text{M}+\text{H}^+$).

Example 29

5-((S)-2-(4-fluorophenethyl)-4-(8-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 216)




Step A ethyl (R)-8-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxylate



[0840] To a solution of ethyl 8-chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxylate (1 g, 3.42 mmol) in dioxane (5 mL) was added Pd(OAc)₂ (76.72 mg, 341.72 µmol), (R)-4-methoxy-2,3-dihydro-1H-inden-1-amine (613.51 mg, 3.76 mmol), Cs₂CO₃ (2.23 g, 6.83 mmol) and BINAP (255.33 mg, 410.06 µmol). The mixture was stirred at 100° C. for 16 hrs under N₂. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0-60% Ethyl acetate/Petroleum ether gradient @40 mL/min). Compound ethyl (R)-8-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxylate (953 mg, 2.27 mmol, 66.50% yield) was obtained.

[0841] ¹H NMR (400 MHz, CDCl₃) δ ppm 8.00-8.13 (m, 1H), 7.72-7.85 (m, 1H), 7.10-7.16 (m, 1H), 6.89-7.01 (m, 1H), 6.65-6.80 (m, 1H), 6.20-6.32 (m, 1H), 5.73-5.82 (m, 1H), 5.02-5.15 (m, 1H), 4.24-4.42 (m, 2H), 3.74-3.86 (m, 3H), 2.94-3.06 (m, 1H), 2.76-2.89 (m, 1H), 2.44-2.70 (m, 1H), 1.98-2.09 (m, 1H), 1.27-1.37 (m, 3H). LC-MS: m/z 420.0 (M+H)⁺.


Step B (R)-8-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)methanol



[0842] To a solution of ethyl 8-[(1R)-4-methoxyindan-1-yl]amino]-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxylate (453 mg, 1.08 mmol) in THF (5 mL) was added dropwise DIBAL (1 M, 3.24 mL) at 0° C. over 3 min. The resulting mixture was stirred at 0-20° C. for 16 hrs. The reaction mixture was quenched by 1N HCl (5 mL) at 0° C., and then diluted with H₂O (10 mL) and extracted with EtOAc (15 mL×3). The combined organic layers were washed with brine (20 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 4 g SepaFlash® Silica Flash Column, Eluent of 0-80% Ethyl acetate/Petroleum ether gradient @40 mL/min). Compound (R)-8-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)methanol (300 mg, 73.60% yield) was obtained.

[0843] ¹H NMR (400 MHz, CDCl₃) δ ppm 7.67-7.78 (m, 1H), 7.29-7.39 (m, 1H), 7.08-7.15 (m, 1H), 6.86-7.00 (m, 1H), 6.65-6.77 (m, 1H), 6.23-6.31 (m, 1H), 5.88-6.06 (m, 1H), 4.96-5.11 (m, 1H), 4.47-4.71 (m, 2H), 3.69-3.84 (m, 3H), 2.91-3.02 (m, 1H), 2.73-2.82 (m, 1H), 2.41-2.63 (m, 1H), 1.87-2.03 (m, 1H), 1.12-1.25 (m, 1H).

Step C (R)-8-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-carbaldehyde




[0844] To a solution of (R)-8-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)methanol (300 mg, 795.00 µmol) in DCM (2 mL) was added Dess-Martin (674.38 mg, 1.59 mmol). The mixture was stirred at 20° C. for 16 hrs. The reaction mixture was quenched by addition Na₂SO₃ (10 mL) at 0° C., and then diluted with H₂O (5 mL) and extracted with EtOAc (15 mL×3). The combined organic layers were washed with

Na_2SO_3 (30 mL×3), dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 12 g SepaFlash® Silica Flash Column, Eluent of 0-50% Ethyl acetate/Petroleum ether gradient @40 mL/min). Compound (R)-8-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carbaldehyde (105 mg, 35.19% yield) was obtained.


[0845] ^1H NMR (400 MHz, CDCl_3) δ ppm 10.02-10.13 (m, 1H), 8.07-8.22 (m, 1H), 7.79-8.02 (m, 1H), 7.20-7.26 (m, 1H), 6.98-7.03 (m, 1H), 6.77-6.84 (m, 1H), 6.34-6.41 (m, 1H), 5.71-5.94 (m, 1H), 5.06-5.23 (m, 1H), 3.81-3.99 (m, 3H), 3.02-3.11 (m, 1H), 2.83-2.97 (m, 1H), 2.62-2.70 (m, 1H), 2.09-2.14 (m, 1H), 2.04-2.13 (m, 1H).

Step D 5-((9aS)-2-(4-fluorophenethyl)-4-(8-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)-5-oxo-1,5,7,8,9,9a-hexahydro-4H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one



[0846] To a solution of (R)-8-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carbaldehyde (50 mg, 133.21 μmol) in HOAc (2 mL) was added NH_4OAc (20.54 mg, 266.42 μmol), (S)-tetrahydro-1H-pyrrolizine-1,3(2H)-dione (27.80 mg, 199.82 μmol) and 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one (33.33 mg, 133.21 μmol). The mixture was stirred at 100° C. for 1.5 hrs. The reaction mixture was concentrated under reduced pressure to remove solvent. The crude product 5-((9aS)-2-(4-fluorophenethyl)-4-(8-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)-5-oxo-1,5,7,8,9,9a-hexahydro-4H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (78 mg, 80.46% yield).

Step E 5-((S)-2-(4-fluorophenethyl)-4-(8-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one




[0847] To a solution of 5-((9aS)-2-(4-fluorophenethyl)-4-(8-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)-5-oxo-1,5,7,8,9,9a-hexahydro-4H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (83 mg, 114.06 μmol) in MeCN (2 mL) was added CAN (125.06 mg, 228.11 μmol). The mixture was stirred at 20° C. for 16 hrs. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was purified by prep-HPLC (column: Boston Green ODS 150*30 mm*5 um; mobile phase: [water(TFA)-ACN]; gradient: 75%-95% B over 11 min), further purified by prep-HPLC (column: Waters Xbridge BEH C18 100*30 mm*10 um; mobile phase: [water(NH₄HCO₃)-ACN]; gradient: 32%-62% B over 11 min). Compound 5-((S)-2-(4-fluorophenethyl)-4-(8-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-6-(trifluoromethyl)imidazo[1,2-a]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (1.3 mg, 1.79 μmol , 1.57% yield, 100% purity) was obtained.


[0848] ^1H NMR (400 MHz, MeOD-d_6) δ ppm 8.58-8.66 (m, 1H), 8.26-8.33 (m, 1H), 7.20-7.26 (m, 1H), 7.13-7.18 (m, 2H), 6.93-6.99 (m, 3H), 6.83-6.89 (m, 1H), 6.40-6.44 (m, 1H), 5.20-5.25 (m, 1H), 3.85-3.87 (m, 3H), 3.70-3.78 (m, 1H), 3.44-3.47 (m, 2H), 3.18-3.21 (m, 2H), 3.04-3.08 (m, 2H), 2.80-2.90 (m, 1H), 2.63-2.76 (m, 1H), 2.38-2.53 (m, 3H), 2.17-2.23 (m, 1H), 2.03-2.05 (m, 1H), 1.62-1.64 (m, 1H). LC-MS: m/z 726.2 ($\text{M}+\text{H}$)⁺.

Example 30


5-((S)-2-(((R)-6-fluoro-2,3-dihydrobenzofuran-3-yl)methyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 217)



-continued




Step A
2-(6-fluoro-2,3-dihydrobenzofuran-3-yl)acetic acid




[0849] To a solution of ethyl 2-(6-fluoro-2,3-dihydrobenzofuran-3-yl)acetate (4.7 g, 20.961 mmol) in MeOH/THF/H₂O (20 mL/20 mL/10 mL) was added LiOH·H₂O (4.4 g, 104.803 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was adjusted to pH=1 with 1N aq. HCl. Then the mixture was the reaction was diluted with water and extracted EtOAc. The organic layer was dried over Na₂SO₄, filtered and concentrated under reduced pressure to give 2-(6-fluoro-2,3-dihydrobenzofuran-3-yl)acetic acid (4.0 g, 97.28%).

Step B ethyl 4-(6-fluoro-2,3-dihydrobenzofuran-3-yl)-3-oxobutanoate




[0850] To a solution of 2-(6-fluoro-2,3-dihydrobenzofuran-3-yl)acetic acid (3.9 g, 19.880 mmol) in THF (50 mL) were added CDI (4.84 g, 29.820 mmol) and the reaction was stirred at room temperature for 1 hr. Then added potassium 3-ethoxy-3-oxopropanoate (3.38 g, 19.880 mmol), MgCl₂ (1.95 g, 19.880 mmol) and the reaction was stirred at 50 °C. for 18 hr. After the reaction was completed, the mixture was filtered and concentrated in vacuum, the residue was purified by silica gel column chromatography, eluting with ethyl acetate in petroleum ether to give ethyl 4-(6-fluoro-2,3-dihydrobenzofuran-3-yl)-3-oxobutanoate (4.8 g, 90.68%). LC-MS: m/z 267.1 (M+H)⁺.

Step C ethyl 2-((6-fluoro-2,3-dihydrobenzofuran-3-yl)methyl)-1,3-dioxolan-2-yl)acetate




[0851] A mixture of 4-(6-fluoro-2,3-dihydrobenzofuran-3-yl)-3-oxobutanoate (4.3 g, 16.149 mmol), ethane-1,2-diol (3.01 g, 48.447 mmol) and TMSCl (5.26 g, 48.447 mmol) in DCM (50 mL) was stirred at 40° C. for 16 hours. The reaction mixture was diluted with water and extracted EtOAc. The organic layer was separated, washed with brine, and concentrated in vacuo. The residue was purified by silica gel column chromatography, eluting with ethyl acetate in petroleum ether to give ethyl 2-((6-fluoro-2,3-dihydrobenzofuran-3-yl)methyl)-1,3-dioxolan-2-yl)acetate (3.4 g, 67.85%). LC-MS: m/z 311.2 (M+H)⁺.

Step D 2-((6-fluoro-2,3-dihydrobenzofuran-3-yl)methyl)-1,3-dioxolan-2-yl)acetohydrazide




[0852] A mixture of ethyl 2-((6-fluoro-2,3-dihydrobenzofuran-3-yl)methyl)-1,3-dioxolan-2-yl)acetate (3.4 g, 10.956 mmol) and N₂H₄·H₂O (5.48 g, 109.564 mmol) in EtOH (50 mL) was stirred at 80° C. for 16 hours. The reaction mixture was diluted with water and extracted EtOAc. The organic layer was separated, washed with brine, and concentrated in vacuo. The residue was purified by silica gel column chromatography, eluting with ethyl acetate in petroleum ether to give ethyl 2-((6-fluoro-2,3-dihydrobenzofuran-3-yl)methyl)-1,3-dioxolan-2-yl)acetate (2.4 g, 74.93%). LC-MS: m/z 297.2 (M+H)⁺.

Step E 5-((2-((6-fluoro-2,3-dihydrobenzofuran-3-yl)methyl)-1,3-dioxolan-2-yl)methyl)-1,3,4-oxadiazol-2(3H)-one



[0853] A mixture of ethyl 2-((6-fluoro-2,3-dihydrobenzofuran-3-yl)methyl)-1,3-dioxolan-2-yl)acetate (2.4 g, 8.100 mmol) and CDI (1.97 g, 12.150 mmol) in THF (40 mL) was stirred at 40° C. for 16 hours. The reaction mixture was diluted with water and extracted EtOAc. The organic layer was separated, washed with brine, and concentrated in vacuo. The residue was purified by silica gel column chromatography, eluting with ethyl acetate in petroleum ether to give 5-((2-((6-fluoro-2,3-dihydrobenzofuran-3-yl)methyl)-1,3-dioxolan-2-yl)methyl)-1,3,4-oxadiazol-2(3H)-one (3.4 g, 67.85%). LC-MS: m/z 345.2 (M+Na)⁺.

Step F 5-(3-(6-fluoro-2,3-dihydrobenzofuran-3-yl)-2-oxopropyl)-1,3,4-oxadiazol-2(3H)-one




[0854] A mixture of 5-((2-((6-fluoro-2,3-dihydrobenzofuran-3-yl)methyl)-1,3-dioxolan-2-yl)methyl)-1,3,4-oxadiazol-2(3H)-one (2.3 g, 7.136 mmol) in 0.066 M H₂SO₄ in FA (15 mL) and H₂O (5 mL) was stirred at 60° C. for 8 hours. The reaction mixture was diluted with water and extracted EtOAc. The organic layer was separated, washed with brine, and concentrated in vacuo. The residue was purified by silica gel column chromatography, eluting with ethyl acetate in petroleum ether to give 5-(3-(6-fluoro-2,3-dihydrobenzofuran-3-yl)-2-oxopropyl)-1,3,4-oxadiazol-2(3H)-one (1.97 g, 99.21%). LC-MS: m/z 301.0 (M+Na)⁺.

[0855] Compound 217 was synthesized using a similar procedure described in Example 10 by using the appropriate materials. (1.56 mg, 7.80%)

[0856] ¹H NMR (400 MHz, DMSO-d₆) δ 7.97 (d, J=5.6 Hz, 1H), 7.41 (d, J=5.2 Hz, 1H), 7.21 (d, J=8.4 Hz, 1H), 7.01-7.15 (m, 3H), 6.79-6.87 (m, 2H), 6.57-6.69 (m, 2H), 5.90 (q, J=8.0 Hz, 1H), 4.83-4.90 (m, 1H), 4.67-4.78 (m, 1H), 4.38-4.46 (m, 1H), 3.99-4.13 (m, 1H), 3.79 (s, 3H), 3.50-3.58 (m, 1H), 3.38-3.42 (m, 1H), 3.10-3.20 (m, 1H), 2.90-2.98 (m, 1H), 2.64-2.74 (m, 2H), 2.23-2.40 (m, 4H), 1.97-2.07 (m, 1H), 1.41-1.52 (m, 1H). ¹⁹F NMR (377 MHz, DMSO-d₆) δ -114.04. LC-MS: m/z 703.1 (M+H)⁺.

5-((S)-2-(((S)-6-fluoro-2,3-dihydrobenzofuran-3-yl)methyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 218)




[0857] Compound 218 was synthesized using a similar procedure described in Example 30 by using the appropriate materials. (3.77 mg, 18.85%)


[0858] ^1H NMR (400 MHz, DMSO- d_6) δ 7.97 (d, $J=5.6$ Hz, 1H), 7.42 (s, 1H), 7.23 (d, $J=7.2$ Hz, 1H), 7.02-7.13 (m, 3H), 6.79-6.87 (m, 2H), 6.57-6.68 (m, 2H), 5.90 (q, $J=8.0$ Hz, 1H), 4.94-4.91 (m, 1H), 4.68-4.78 (m, 1H), 4.38-4.47 (m, 1H), 3.99-4.15 (m, 1H), 3.79 (d, $J=1.2$ Hz, 3H), 3.51-3.59 (m, 1H), 3.36-3.42 (m, 1H), 3.11-3.22 (m, 1H), 2.90-2.99 (m, 1H), 2.54-2.74 (m, 2H), 2.23-2.41 (m, 4H), 1.97-2.07 (m, 1H), 1.42-1.54 (m, 1H). ^{19}F NMR (377 MHz, DMSO- d_6) δ -114.02. LC-MS: m/z 703.1 ($M+\text{H}^+$).

Example 31


(S)-5-(4-(1-(2,4-difluorobenzyl)isoquinolin-6-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 219)



-continued




Step A 2-(2,4-difluorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane




[0859] To a solution of 1-(bromomethyl)-2,4-difluorobenzene (2 g, 9.67 mmol) in dioxane (50 mL) was added potassium acetate (2.84 g, 30.0 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (3.48 g, 14.5 mmol), and Pd(pddf)Cl₂·DCM (0.79 g, 0.97 mmol). The reaction was stirred at 90° C. for 18 hours under N₂. The reaction was concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with petroleum ether to afford 2-(2,4-difluorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1 g, 40.74%). LC-MS: m/z 296.2 (M+CH₃CN+H)⁺.

Step B
1-(2,4-difluorobenzyl)isoquinoline-6-carbaldehyde



[0860] To a solution of 2-(2,4-difluorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (796 mg, 3.13 mmol) in dioxane (10 mL) and water (1 mL) was added 1-chloroisoquinoline-6-carbaldehyde (200 mg, 1.04 mmol), potassium carbonate (433 mg, 3.13 mmol), and Pd(pddf)Cl₂·DCM (91 mg, 0.10 mmol). The reaction was stirred at 90° C. for 2 hours under N₂. The reaction was concentrated in vacuo. The residue was purified by silica gel column chromatography eluting with ethyl acetate (5%) in petroleum ether to afford 1-(2,4-difluorobenzyl)isoquinoline-6-carbaldehyde (80 mg, 27.1%). LC-MS: m/z 284.0 (M+H)⁺.


(S)-5-(4-(1-(2,4-difluorobenzyl)isoquinolin-6-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one



[0861] Compound 219 was synthesized using a similar procedure described in Example 15 by using the appropriate materials.

[0862] ¹H NMR (400 MHz, DMSO-d₆): δ 8.38 (d, J=5.6 Hz, 1H), 8.31 (d, J=8.4 Hz, 1H), 7.86 (s, 1H), 7.69 (d, J=5.6 Hz, 1H), 7.53 (d, J=8.0 Hz, 1H), 7.29-7.36 (m, 1H), 7.19-7.26 (m, 3H), 7.06-7.12 (m, 2H), 6.98-7.04 (m, 1H), 4.86 (dd, J=6.8 Hz, J=10.4 Hz, 1H), 4.68 (s, 2H), 3.47-3.54 (m, 1H), 3.24-3.28 (m, 1H), 3.14-3.19 (m, 2H), 2.96-3.09 (m, 2H), 2.37-2.41 (m, 1H), 2.19-2.30 (m, 2H), 1.38-1.44 (m, 1H). ¹⁹F NMR (377 MHz, DMSO-d₆): -112.29, -113.04, -117.13. LC-MS: m/z 634.1 (M+H)⁺.

(S)-5-(4-(1-(2,4-difluorobenzyl)-1,2,3,4-tetrahydro-quinolin-6-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 220)




[0863] Compound 220 was synthesized using a similar procedure described in Example 15 by using the appropriate materials.

[0864] ¹H NMR (400 MHz, DMSO-d₆) δ 7.22-7.30 (m, 2H), 7.16-7.22 (m, 2H), 6.99-7.10 (m, 3H), 6.90 (d, J=2.0 Hz, 1H), 6.85 (dd, J=8.8 Hz, J=2.4 Hz, 1H), 6.46 (d, J=8.8 Hz, 1H), 4.75 (dd, J=9.6 Hz, J=6.0, 1H), 4.54 (s, 2H), 3.48-3.59 (m, 2H), 2.98-3.08 (m, 4H), 2.89-2.97 (m, 1H), 2.46-2.72 (m, 3H), 2.18-2.38 (m, 3H), 1.86-1.98 (m, 2H),

1.30-1.37 (in, 1H). ^{19}F NMR (377 MHz, DMSO-d₆) δ -112.40, -113.54, -117.17. LC-MS: m/z 638.4 (M+H)⁺.


(S)-5-(4-(3-(2,4-difluorobenzyl)benzo[d]isoxazol-6-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 221)



[0865] Compound 221 was synthesized using a similar procedure described in Example 31 by using the appropriate materials.

[0866] ^1H NMR (400 MHz, DMSO-d₆): δ 12.56 (br s, 1H), 7.76 (d, J=7.6 Hz, 1H), 7.69 (br s, 1H), 7.55-7.63 (m, 1H), 7.16-7.31 (m, 4H), 7.04-7.12 (m, 3H), 4.86 (dd, J=6.0 Hz, J=10.0 Hz, 1H), 4.45 (s, 2H), 3.46-3.55 (m, 1H), 3.24-3.29 (m, 1H), 3.17-3.21 (m, 2H), 3.05-3.13 (m, 1H), 2.96-3.04 (m, 1H), 2.32-2.41 (m, 1H), 2.22-2.31 (m, 2H), 1.33-1.47 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d₆): -111.39, -112.23, -117.05. LC-MS: m/z 624.4 (M+H)⁺.

(S)-5-(2-(4-fluorophenethyl)-4-(3-((5-fluoropyridin-2-yl)methyl)benzo[d]isoxazol-6-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 222)




[0867] Compound 222 was synthesized using a similar procedure described in Example 31 by using the appropriate materials.

[0868] ^1H NMR (400 MHz, DMSO-d₆): δ 12.57 (s, 1H), 8.49 (d, J=2.8 Hz, 1H), 7.73-7.77 (m, 1H), 7.62-7.72 (m, 3H), 7.18-7.24 (m, 2H), 7.10-7.15 (m, 1H), 7.04-7.10 (m, 2H), 4.86 (dd, J=10.4 Hz, J=6.4 Hz 1H), 4.60 (s, 2H), 3.53-3.59 (m, 1H), 3.24-3.30 (m, 1H), 3.17-3.21 (m, 2H),

2.99-3.12 (m, 2H), 2.32-2.40 (m, 1H), 3.24-3.31 (m, 2H), 1.34-1.46 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d₆): -117.04, -129.94. LC-MS: m/z 607.2 (M+H)⁺.


(S)-6-((5-(2-(4-fluorophenethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)nicotinonitrile (Compound 223)



[0869] Compound 223 was synthesized using a similar procedure described in Example 15 by using the appropriate materials.

[0870] ^1H NMR (400 MHz, DMSO-d₆): δ 12.57 (br s, 1H), 8.96 (d, J=1.6 Hz, 1H), 8.24 (dd, J=2.4 Hz, J=8.4 Hz, 1H), 8.04 (d, J=1.6 Hz, 1H), 7.96 (d, J=1.6 Hz, 1H), 7.72 (d, J=3.6 Hz, 1H), 7.19-7.25 (m, 3H), 7.04-7.10 (m, 2H), 6.61 (d, J=3.6 Hz, 1H), 5.72 (s, 2H), 4.85 (dd, J=10.4 Hz, J=6.4 Hz, 1H), 3.48-3.55 (m, 1H), 3.23-3.27 (m, 1H), 3.00-3.19 (m, 4H), 2.23-2.38 (m, 3H), 1.38-1.46 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d₆): -117.07. ^{19}F NMR (377 MHz, DMSO-d₆): -117.07. LC-MS: m/z 613.2

5-((S)-2-(((R)-5-fluoro-2,3-dihydro-1H-inden-1-yl)methyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 224)






[0871] Compound 224 was synthesized using a similar procedure described in Example 30 by using the appropriate materials.

[0872] ^1H NMR (400 MHz, MeOD-d₄) δ ppm 7.88-7.97 (m, 1H), 7.41-7.49 (m, 1H), 6.98-7.19 (m, 3H), 6.87-6.96 (m, 2H), 6.75-6.84 (m, 2H), 5.75-5.86 (m, 1H), 3.79-3.88 (m, 3H), 3.64-3.74 (m, 2H), 3.37-3.49 (m, 2H), 2.96-3.05 (m, 2H), 2.87-2.95 (m, 1H), 2.72-2.84 (m, 2H), 2.60-2.70 (m, 1H), 2.37-2.54 (m, 3H), 2.14-2.22 (m, 1H), 1.97-2.03




(m, 1H), 1.86-1.92 (m, 1H), 1.52 (m, 1H), 0.88-0.92 (m, 1H). LC-MS: m/z 701.2 (M+H)⁺.

Example 32


5-((S)-2-(4-fluorophenethyl)-4-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-thiadiazol-2(3H)-one
(Compound 225)




-continued



-continued




Step A 5-methyl-1,3,4-thiadiazol-2(3H)-one



[0873] To a solution of 2-methoxy-5-methyl-1,3,4-thiadiazole (750 mg, 5.76 mmol) in MeOH (5 mL) was added HCl (15 mL) dropwise. The mixture was stirred at 80° C. for 2 hrs. To the solution was added NaHCO₃ until pH-7 at 0° C. Then the mixture was diluted with EtOAc (25 mL)/water (20 mL). The organic layer was separated, washed with brine (20 mL), dried over anhydrous of Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (Biotage®; 20 g SepaFlash® Silica Flash Column, Eluent of 0~100% Ethyl acetate/Petroleum ether gradient @25 mL/min) to give 5-methyl-1,3,4-thiadiazol-2(3H)-one (630 mg, 94.14% yield).

[0874] ¹H NMR (400 MHz, CDCl₃) δ 10.11 (s, 1H), 2.35 (s, 3H).

Step B 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-thiadiazol-2(3H)-one




[0875] A mixture of 5-methyl-1,3,4-thiadiazol-2(3H)-one (109.97 mg, 946.83 μmol) in THF (3 mL) was added LDA (2.0 M, 1.18 mL) at -10° C. under N₂. The mixture was stirred at -10° C. for 30 min. 3-(4-fluorophenyl)-N-methoxy-N-methylpropanamide (100 mg, 473.41 μmol) in THF (1 mL) was added into the reaction solution. The

solution was stirred at -10° C. for 1 hr. The solution was quenched with aq. NH₄Cl (5 mL). The mixture was poured into water (5 mL), extracted with ethyl acetate (10 mL×2). The combined organic layer was washed with brine (10 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column, Eluent of 0~40% Ethyl acetate/Petroleum ether gradient @25 mL/min) to give 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-thiadiazol-2(3H)-one (30 mg, 22.88% yield, 96.153% purity).

[0876] ¹H NMR (400 MHz, CDCl₃) δ 9.17 (s, 1H), 6.99-7.11 (m, 2H), 6.85-6.95 (m, 2H), 3.69 (s, 2H), 2.72-2.93 (m, 4H). LC-MS: m/z 267.0 (M+H)⁺.


Step C ethyl 2-((R)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)-1,4-dihydropyridine-3-carboxylate



[0877] A mixture of tert-butyl (S)-2-(3-ethoxy-3-oxopropanoyl)pyrrolidine-1-carboxylate (32 mg, 112.15 μmol), 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-thiadiazol-2(3H)-


one (29.86 mg, 112.15 μmol), (R)-7-((4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (36.38 mg, 112.15 μmol), NH₄OAc (17.29 mg, 224.30 μmol) and Yb(OTf)₃ (6.96 mg, 11.21 μmol) in EtOH (2 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 50° C. for 16 hrs under N₂ atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to give ethyl 2-((R)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)-1,4-dihydropyridine-3-carboxylate (100 mg, crude). LC-MS: m/z 839.2 (M+H)⁺.

Step D ethyl 2-((R)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)nicotinate




[0878] A mixture of ethyl 2-((R)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)-1,4-dihydropyridine-3-carboxylate (100 mg, 119.19 μmol) and CAN (130.68 mg, 238.38 μmol) in EtOH (3 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 20° C. for 1 hr under N₂ atmosphere. The reaction mixture was diluted with ethyl acetate (20 mL) and washed with brine (5 mL*2), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give ethyl 2-((R)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)nicotinate (100 mg, crude). LC-MS: m/z 837.2 (M+H)⁺.

Step E ethyl 6-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)-2-((R)-pyrrolidin-2-yl)nicotinate



[0879] A mixture of ethyl 2-((R)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)nicotinate (100 mg, 119.48 μmol) and HCl/dioxane (2 M, 2.39 mL) in dioxane (1 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 20° C. for 2 hrs under N₂ atmosphere. The reaction mixture was concentrated under reduced pressure at 20° C. to give ethyl 6-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)-2-((R)-pyrrolidin-2-yl)nicotinate (100 mg, crude). LC-MS: m/z 737.1 (M+H)⁺.


Step F 5-((S)-2-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-thiadiazol-2(3H)-one



[0880] A mixture of ethyl 6-(4-fluorophenethyl)-4-((*(R*)-4-methoxy-2,3-dihydro-1*H*-inden-1-yl)amino)thieno[2,3-*c*]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-thiadiazol-2-yl)-2-((*R*)-pyrrolidin-2-yl)nicotinate (100 mg, 135.71 μ mol) and Na₂CO₃ (287.6 mg, 2.71 mmol) in dioxane (4 mL) and H₂O (4 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 20° C. for 16 hrs under N₂ atmosphere. The reaction mixture was extracted with ethyl acetate (10 mL×3). The combined organic layer was washed with brine (10 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Xtimate C18 150*40 mm*10 um; mobile phase: [water(FA)-ACN]; gradient: 29%-59% B over 10 min) to give 5-((*S*)-2-(4-fluorophenethyl)-4-((*(R*)-4-methoxy-2,3-dihydro-1*H*-inden-1-yl)amino)thieno[2,3-*c*]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5*H*-pyrido[2,3-*a*]pyrrolizin-3-yl)-1,3,4-thiadiazol-2(3*H*)-one (14.87 mg, 15.84% yield, 99.88% purity).

[0881] ¹H NMR (400 MHz, MeOD-d₄) δ ppm 7.93 (d, J=5.84 Hz, 1H), 7.35-7.45 (m, 1H), 7.11-7.23 (m, 4H), 6.95-7.05 (m, 2H), 6.93 (d, J=7.60 Hz, 1H), 6.86 (d, J=8.00 Hz, 1H), 5.79 (t, J=7.60 Hz, 1H), 3.82-3.88 (m, 3H), 3.63-3.73 (m, 1H), 3.39-3.47 (m, 1H), 3.37 (m, 1H), 3.17 (s, 2H), 3.00-3.16 (m, 3H), 2.74-2.86 (m, 1H), 2.63-2.73 (m, 1H), 2.47-2.57 (m, 1H), 2.36-2.46 (m, 2H), 1.98-2.07 (m, 1H), 1.41-1.54 (m, 1H). ¹⁹F NMR (376 MHz, MeOD-d₄) δ ppm -116.63 (s, 1F). LC-MS: m/z 645.1 (M+H)⁺.

5-((*S*)-4-((*(R*)-2,3-dihydro-1*H*-inden-1-yl)amino)thieno[2,3-*c*]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5*H*-pyrido[2,3-*a*]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3*H*)-one (Compound 226)




[0882] Compound 226 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.

[0883] ¹H NMR (400 MHz, CDCl₃) δ ppm 7.97 (s, 1H), 7.27-7.36 (m, 2H), 7.11-7.18 (m, 2H), 7.05 (dd, J=8.58, 5.48 Hz, 2H), 7.00 (d, J=5.84 Hz, 1H), 6.89 (t, J=8.64 Hz, 2H), 5.71-5.81 (m, 1H), 4.70 (dd, J=10.49, 6.20 Hz, 1H), 3.69 (dt, J=11.80, 8.58 Hz, 1H), 3.29-3.42 (m, 1H), 3.07-3.14 (m, 2H), 2.91-3.06 (m, 3H), 2.79-2.89 (m, 1H), 2.60-2.71 (m, 1H), 2.44 (td, J=12.32, 6.03, 6.03, 2.21 Hz, 1H), 2.24-2.36 (m, 2H), 1.83-1.97 (m, 2H), 1.33-1.43 (m, 1H), 1.32-1.44

(m, 1H). ¹⁹F NMR (376 MHz, CDCl₃) δ ppm -116.63 (s, 1F). LC-MS: m/z 645.1 (M+H)⁺.


5-((*S*)-4-((*(R*)-1-(3,4-difluorophenyl)ethyl)amino)thieno[2,3-*c*]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5*H*-pyrido[2,3-*a*]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3*H*)-one (Compound 227)



[0884] Compound 227 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.

[0885] ¹H NMR (400 MHz, MeOD-d₄) δ ppm 7.83 (d, J=5.6 Hz, 1H), 7.43-7.50 (m, 1H), 7.29-7.35 (m, 1H), 7.14-7.24 (m, 4H), 7.10 (d, J=6.0 Hz, 1H), 6.99 (t, J=8.4 Hz, 2H), 5.32-5.43 (m, 1H), 4.90-4.94 (m, 1H), 3.60-3.81 (m, 1H), 3.41-3.52 (m, 1H), 3.24-3.30 (m, 2H), 3.05-3.21 (m, 2H), 2.40-2.60 (m, 3H), 1.61 (d, J=6.4 Hz, 3H), 1.48-1.53 (m, 1H). LC-MS: m/z 669.1 (M+H)⁺.

5-((*S*)-4-((*(R*)-1-(2,4-difluorophenyl)ethyl)amino)thieno[2,3-*c*]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5*H*-pyrido[2,3-*a*]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3*H*)-one (Compound 228)



[0886] Compound 228 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.

[0887] ¹H NMR (400 MHz, MeOD-d₄) δ ppm 7.68-7.72 (m, 1H), 7.63-7.66 (m, 1H), 7.43-7.47 (m, 1H), 7.37-7.41


(m, 1H), 7.19-7.26 (m, 1H), 7.11-7.17 (m, 2H), 7.02-7.10 (m, 1H), 6.95-6.99 (m, 3H), 5.36-5.46 (m, 1H), 4.90-4.98 (m, 1H), 3.63-3.74 (m, 1H), 3.41-3.52 (m, 1H), 3.08-3.16 (m, 2H), 2.85-2.94 (m, 1H), 2.43-2.60 (m, 3H), 1.74-1.77 (m, 3H), 1.46-1.55 (m, 1H), 1.39-1.45 (m, 1H). ^{19}F NMR (377 MHz, MeOD-d₄) δ -77.01, -118.96. LC-MS: m/z 669.1 (M+H)⁺.

Example 33


5-((R)-2-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one
(Compound 229)

5-((S)-2-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one
(Compound 230)




-continued





(Compound 229)



(Compound 230)



Step A 5-((R)-2-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 229) and 5-((S)-2-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 230)




[0888] 5-((S)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-2-(2-(tetrahydro-2H-pyran-4-yl)ethyl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)isoxazol-3(2H)-one (30 mg) was further separated by chiral SFC (column: DAICEL CHIRALPAK AS (250 mm*30 mm, 10 um); mobile phase: [CO₂-EtOH (0.1% NH₃H₂O)]; B %: 40%, isocratic elution mode) to give compound 5-((S)-2-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (12.93 mg) and 5-((R)-2-(4-fluorophenethyl)-4-(7-(((R)-4-

methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (10.47 mg).

[0889] Compound 230: ¹H NMR (400 MHz, MeOD-d₄) δ ppm 7.95 (d, J=6.8 Hz, 1H), 7.46 (s, 1H), 7.12-7.17 (m, 4H), 6.98 (t, J=8.4 Hz, 2H), 6.90 (d, J=7.2 Hz, 1H), 6.82 (d, J=8.0 Hz, 1H), 5.82 (t, J=7.6 Hz, 1H), 4.87 (m, 1H), 3.85 (s, 3H), 3.63-3.74 (m, 1H), 3.40-3.49 (m, 1H), 3.26 (m, 2H), 3.01-3.16 (m, 3H), 2.73-2.84 (m, 1H), 2.61-2.71 (m, 1H), 2.37-2.55 (m, 3H), 2.01-2.04 (m, 1H), 1.46-1.54 (m, 1H). LC-MS: m/z 675.2 (M+H)⁺.

[0890] Compound 229: ¹H NMR (400 MHz, MeOD-d₄) δ ppm 7.95 (d, J=6.8 Hz, 1H), 7.45 (s, 1H), 7.12-7.17 (m, 4H), 6.98 (t, J=8.4 Hz, 2H), 6.90 (d, J=7.2 Hz, 1H), 6.82 (d, J=8.0 Hz, 1H), 5.82 (t, J=7.6 Hz, 1H), 4.87 (m, 1H), 3.85 (s, 3H), 3.63-3.74 (m, 1H), 3.40-3.49 (m, 1H), 3.26 (m, 2H), 3.01-3.16 (m, 3H), 2.73-2.84 (m, 1H), 2.61-2.71 (m, 1H), 2.37-2.55 (m, 3H), 1.98-2.06 (m, 1H), 1.47-1.53 (m, 1H). LC-MS: m/z 675.2 (M+H)⁺.


(S)-4-((5-(2-(2-oxabicyclo[2.2.2]octan-4-yl)ethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)-3-fluorobenzonitrile (Compound 231)



[0891] Compound 231 was synthesized using a similar procedure described in the report of Example 25 by using the appropriate materials.

[0892] ¹H NMR (400 MHz, DMSO-d₆): δ 12.58 (br s, 1H), 8.09 (d, J=2.0 Hz, 1H), 7.96 (d, J=2.0 Hz, 1H), 7.90 (dd, J=10.0 Hz, J=1.6 Hz, 1H), 7.68 (d, J=3.2 Hz, 1H), 7.62 (dd, J=8.0 Hz, J=1.2 Hz, 1H), 7.11 (t, J=7.6 Hz, 1H), 6.61 (d, J=3.6 Hz, 1H), 5.65 (s, 2H), 4.82 (dd, J=10.0 Hz, J=6.4 Hz, 1H), 3.63-3.70 (m, 1H), 3.45-3.54 (m, 3H), 3.20-3.29 (m, 1H), 2.71-2.80 (m, 2H), 2.31-2.39 (m, 1H), 2.19-2.29 (m, 2H), 1.80-1.92 (m, 2H), 1.32-1.63 (m, 9H). ¹⁹F NMR (377 MHz, DMSO-d₆): -115.11. LC-MS: m/z 646.3 (M+H)⁺.


(S)-5-(2-(2-oxabicyclo[2.2.2]octan-4-yl)ethyl)-4-(1-((5-fluoropyridin-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one
(Compound 232)



[0893] Compound 232 was synthesized using a similar procedure described in the report of Example 25 by using the appropriate materials.

[0894] ^1H NMR (400 MHz, DMSO-d₆): δ 8.51 (d, J=2.8 Hz, 1H), 8.07 (d, J=2.0 Hz, 1H), 7.94 (d, J=1.6 Hz, 1H), 7.64-7.72 (m, 2H), 7.21 (dd, J=4.4 Hz, J=8.8 Hz, 1H), 6.58 (d, J=3.6 Hz, 1H), 5.61 (s, 2H), 4.82 (dd, J=10.0 Hz, J=6.0 Hz, 1H), 3.63-3.69 (m, 1H), 3.46-3.56 (m, 3H), 3.23-3.29 (m, 1H), 2.70-2.79 (m, 2H), 2.29-2.39 (m, 1H), 2.20-2.29 (m, 2H), 1.81-1.91 (m, 2H), 1.36-1.61 (m, 9H). ^{19}F NMR (377 MHz, DMSO-d₆): -129.35. LC-MS: m/z 622.2 (M+H)⁺.

(S)-5-(2-(2-oxabicyclo[2.2.2]octan-4-yl)ethyl)-4-(1-((5-chloro-3-fluoropyridin-2-yl)methyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 233)




[0895] Compound 233 was synthesized using a similar procedure described in the report of Example 25 by using the appropriate materials.

[0896] ^1H NMR (400 MHz, DMSO-d₆): δ 8.41 (d, J=2.0 Hz, 1H), 8.13 (dd, J=9.6 Hz, J=2.0 Hz, 1H), 8.05 (d, J=2.0 Hz, 1H), 7.92 (d, J=2.0 Hz, 1H), 7.63 (d, J=3.6 Hz, 1H), 6.56 (d, J=3.6 Hz, 1H), 5.69 (s, 2H), 4.82 (dd, J=10.0 Hz, J=6.4 Hz, 1H), 3.63-3.70 (m, 1H), 3.47-3.54 (m, 3H), 3.23-3.29 (m, 1H), 2.70-2.78 (m, 2H), 2.31-2.39 (m, 1H), 2.20-2.29 (m, 2H), 1.81-1.92 (m, 2H), 1.33-1.62 (m, 9H). ^{19}F NMR (377 MHz, DMSO-d₆): -112.91. LC-MS: m/z 656.2 (M+H)⁺.


Example 34

(S)-2-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,10,10a-tetrahydro-5H-pyrido[2',3':3,4]pyrrolo[2,1-c][1,4]oxazin-5-one (Compound 234)

(R)-2-(4-fluorophenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,10,10a-tetrahydro-5H-pyrido[2',3':3,4]pyrrolo[2,1-c][1,4]oxazin-5-one (Compound 235)



-continued



Step A (S)-2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,10,10a-tetrahydro-5H-pyrido[2',3':3,4]pyrrolo[2,1-c][1,4]oxazin-5-one (Compound 234) & (R)-2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,10,10a-tetrahydro-5H-pyrido[2',3':3,4]pyrrolo[2,1-c][1,4]oxazin-5-one (Compound 235)


[0897] 2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,10,10a-tetrahydro-5H-pyrido[2',3':3,4]pyrrolo[2,1-c][1,4]oxazin-5-one (150 mg) was separated by chiral SFC (column: Boston Green ODS 150*30 mm*5 um; mobile phase: [water(TFA)-ACN]; gradient: 35%-55% B over 11 min). (S)-2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,10,10a-tetrahydro-5H-pyrido[2',3':3,4]pyrrolo[2,1-c][1,4]oxazin-5-one (234) (10.71 mg, 7.14% yield) was obtained. (R)-2-(4-fluorophenethyl)-4-(7-((R)-4-methoxy-2,3-dihydro-1H-

inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,10,10a-tetrahydro-5H-pyrido[2',3':3,4]pyrrolo[2,1-c][1,4]oxazin-5-one (235) (20.16 mg, 40.32% yield) was obtained.

[0898] Compound 234: ^1H NMR (400 MHz, MeOD-d₄) δ ppm 7.93-7.97 (m, 1H), 7.44-7.50 (m, 1H), 7.13-7.18 (m, 4H), 6.95-7.01 (m, 2H), 6.88-6.92 (m, 1H), 6.80-6.83 (m, 1H), 5.79-5.86 (m, 1H), 4.80 (br s, 2H), 4.60-4.65 (m, 2H), 4.20-4.24 (m, 1H), 4.02-4.07 (m, 1H), 3.84-3.86 (m, 3H), 3.38-3.40 (m, 2H), 3.02-3.16 (m, 4H), 2.74-2.84 (m, 1H), 2.64-2.71 (m, 1H), 2.00-2.06 (m, 1H). LC-MS: m/z 691.1 (M+H)⁺.

[0899] Compound 235: ^1H NMR (400 MHz, MeOD-d₄) δ ppm 7.92-7.98 (m, 1H), 7.44-7.49 (m, 1H), 7.13-7.19 (m, 4H), 6.96-7.00 (m, 2H), 6.89-6.92 (m, 1H), 6.80-6.84 (m, 1H), 5.78-5.86 (m, 1H), 4.80-4.83 (m, 2H), 4.57-4.66 (m, 2H), 4.36-4.42 (m, 1H), 4.20-4.25 (m, 1H), 4.02-4.07 (m, 1H), 3.84-3.86 (m, 3H), 3.36-3.41 (m, 2H), 3.09-3.25 (m, 4H), 2.75-2.83 (m, 1H), 2.64-2.70 (m, 1H), 1.97-2.04 (m, 1H). LC-MS: m/z 691.1 (M+H)⁺.


-continued




Example 35

5-((R)-5-(4-fluorophenethyl)-3-isopropyl-7-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-1,1-dioxido-2,3-dihydrothieno[3,2-b]pyridin-6-yl)-1,3,4-oxadiazol-2(3H)-one
(Compound 236)

5-((S)-5-(4-fluorophenethyl)-3-isopropyl-7-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-1,1-dioxido-2,3-dihydrothieno[3,2-b]pyridin-6-yl)-1,3,4-oxadiazol-2(3H)-one
(Compound 237)




-continued




Step A 5-(5-(4-fluorophenethyl)-3-isopropyl-7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-1,1-dioxido-2,3,4,7-tetrahydrothieno[3,2-b]pyridin-6-yl)-1,3,4-oxadiazol-2(3H)-one

[0900] A mixture of 5-[4-(4-fluorophenyl)-2-oxo-butyl]-3H-1,3,4-oxadiazol-2-one (500 mg, 2.00 mmol), 7-[(1*R*)-4-methoxyindan-1-yl]amino]thieno[2,3-c]pyridine-2-carbaldehyde (650.00 mg, 2.00 mmol), 4-isopropyl-1,1-dioxothiolan-3-one (367.50 mg, 2.09 mmol), NH₄OAc (325.00 mg, 4.22 mmol) in AcOH (10 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 120° C. for 3 hrs under N₂ atmosphere. The reaction mixture was concentrated under reduced pressure to remove solvent. The residue was diluted with aqueous NaHCO₃ (200 mL) and extracted with EtOAc (200 mL×2). The combined organic layers were washed with aqueous NaCl (100 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The crude product was purified by silica gel column chromatography (50% ethyl acetate in petroleum ether). Compound 5-(5-(4-fluorophenethyl)-3-isopropyl-7-(7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-1,1-dioxido-2,3,4,7-tetrahydrothieno[3,2-b]pyridin-6-yl)-1,3,4-oxadiazol-2(3H)-one (494 mg, 34.63% yield) was obtained. LC-MS: m/z 714.1 (M+H)⁺.


Step B 5-(5-(4-fluorophenethyl)-3-isopropyl-7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-1,1-dioxido-2,3-dihydrothieno[3,2-b]pyridin-6-yl)-1,3,4-oxadiazol-2(3H)-one



Step C 5-((R)-5-(4-fluorophenethyl)-3-isopropyl-7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-1,1-dioxido-2,3-dihydrothieno[3,2-b]pyridin-6-yl)-1,3,4-oxadiazol-2(3H)-one & 5-((S)-5-(4-fluorophenethyl)-3-isopropyl-7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-1,1-dioxido-2,3-dihydrothieno[3,2-b]pyridin-6-yl)-1,3,4-oxadiazol-2(3H)-one



[0901] A mixture of 5-(5-(4-fluorophenethyl)-3-isopropyl-7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-1,1-dioxido-2,3,4,7-tetrahydrothieno[3,2-b]pyridin-6-yl)-1,3,4-oxadiazol-2(3H)-one (450 mg, 630.39 μ mol), CAN (693.00 mg, 1.26 mmol) in MeCN (6 mL) and H₂O (6 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 22° C. for 2 hrs under N₂ atmosphere. The reaction mixture was quenched by addition NaHCO₃ (30 mL) at 22° C., and then diluted with H₂O (50 mL) and extracted with EtOAc (50 mL×2). The combined organic layers were washed with aqueous NaCl (50 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography on silica gel (eluted with 0~50% PE in EA). Compound 5-(5-(4-fluorophenethyl)-3-isopropyl-7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-1,1-dioxido-2,3-dihydrothieno[3,2-b]pyridin-6-yl)-1,3,4-oxadiazol-2(3H)-one (220 mg, 48.71% yield, 99.35% purity) was obtained. LC-MS: m/z 712.2 (M+H)⁺.



[0902] 5-(5-(4-fluorophenethyl)-3-isopropyl-7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-1,1-dioxido-2,3-dihydrothieno[3,2-b]pyridin-6-yl)-1,3,4-oxadiazol-2(3H)-one (220 mg) was separated by SFC (column: DAICEL CHIRALPAK AS (250 mm×30 mm, 10 μ m); mobile phase: [CO₂-EtOH (0.1% NH₃H₂O)]; B %: 50%, isocratic elution mode). Compound 5-((R)-5-(4-fluorophenethyl)-3-isopropyl-7-((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-1,1-dioxido-2,3-dihydrothieno[3,2-b]pyridin-6-yl)-1,3,4-oxadiazol-2(3H)-one (79.89 mg, 34.57% yield, 95.21%


purity) was obtained. Compound 5-((S)-5-(4-fluorophenethyl)-3-isopropyl-7-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-1,1-dioxido-2,3-dihydrothieno[3,2-b]pyridin-6-yl)-1,3,4-oxadiazol-2(3H)-one (71.93 mg, 32.70% yield) was obtained. LC-MS: m/z 712.1 ($M+H^+$)

[0903] Compound 236: ^1H NMR (400 MHz, CDCl_3) δ ppm 8.03-8.16 (m, 1H), 7.59-7.75 (m, 1H), 7.18-7.23 (m, 1H), 7.10-7.16 (m, 3H), 6.94-7.01 (m, 3H), 6.74-6.84 (m, 1H), 5.72-5.89 (m, 1H), 3.80-3.95 (m, 3H), 3.61-3.75 (m, 2H), 3.40-3.51 (m, 1H), 3.18-3.31 (m, 2H), 2.97-3.13 (m, 3H), 2.69-2.88 (m, 3H), 1.91-2.02 (m, 1H), 1.08-1.18 (m, 3H), 0.85 (d, $J=6.79$ Hz, 3H). ^{19}F NMR (376 MHz, CDCl_3) δ -116.528 ppm.

[0904] Compound 237: ^1H NMR (400 MHz, CDCl_3) δ ppm 8.04-8.15 (m, 1H), 7.65-7.71 (m, 1H), 7.17-7.24 (m, 1H), 7.09-7.16 (m, 3H), 6.93-7.02 (m, 3H), 6.78 (br d, $J=8.34$ Hz, 1H), 5.68-5.91 (m, 1H), 3.81-3.93 (m, 3H), 3.60-3.75 (m, 2H), 3.41-3.51 (m, 1H), 3.15-3.29 (m, 2H), 2.96-3.15 (m, 3H), 2.64-2.91 (m, 3H), 1.89-1.99 (m, 1H), 1.14 (d, $J=6.91$ Hz, 3H), 0.86 (d, $J=6.68$ Hz, 3H). ^{19}F NMR (376 MHz, CDCl_3) δ -116.546 ppm.


Example 36

6-((6-(5'-(4-fluorophenethyl)-1',1'-dioxido-6'-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2'H-spiro[cyclopropane-1,3'-thieno[3,2-b]pyridin]-7'-yl)-2-oxobenzod[d]oxazol-3(2H)-yl)methyl)nicotinonitrile
(Compound 238)



-continued


Step A ethyl 1-(((methylsulfonyl)oxy)methyl)cyclopropane-1-carboxylate



[0905] Under ice bath conditions, MsCl (1.32 g, 11.53 mmol) was added dropwise to methyl 1-(hydroxymethyl)cyclopropane-1-carboxylate (1 g, 7.68 mmol) and TEA (1.56 g, 15.37 mmol) in dichloromethane (20 mL). The mixture was stirred at 20° C. for 2 hrs. The reaction solution was diluted with dichloromethane (20 mL), washed with hydrochloric acid (10 mL, 1 M) and saturated brine (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated under reduced pressure to give methyl 1-(((methylsulfonyl)oxy)methyl)cyclopropane-1-carboxylate (1.6 g, crude).

[0906] ^1H NMR (500 MHz, CDCl_3) δ 4.32 (s, 2H), 3.70 (s, 3H), 3.07 (s, 3H), 1.40-1.47 (m, 2H), 1.03-1.10 (m, 2H).


Step B methyl 1-((methylthio)methyl)cyclopropane-1-carboxylate



[0907] NaSMe (1.08 g, 15.37 mmol) was added to a stirred solution of ethyl 1-(((methylsulfonyl)oxy)methyl)cyclopropane-1-carboxylate (1.6 g, 7.68 mmol) in DMF (10 mL) at 20° C. The resulting brown suspension was stirred at 20° C. for 16 hrs. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL \times 3). The combined organic layer was dried over Na_2SO_4 , filtered, and concentrated by evaporation to give methyl 1-((methylthio)methyl)cyclopropane-1-carboxylate (1.3 g, crude).

[0908] ^1H NMR (400 MHz, CDCl_3) δ 3.70 (s, 3H), 2.85 (s, 2H), 2.18 (s, 3H), 1.31-1.39 (m, 2H), 0.88-0.97 (m, 2H).

Step C methyl 1-((methylsulfonyl)methyl)cyclopropane-1-carboxylate




[0909] A mixture of methyl 1-((methylthio)methyl)cyclopropane-1-carboxylate (1.3 g, 8.11 mmol) and m-CPBA (4.94 g, 24.34 mmol, 85% purity) in dichloromethane (20 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 20° C. for 16 hrs under N_2 .

atmosphere. The reaction mixture was quenched by addition aq. $\text{Na}_2\text{S}_2\text{O}_3$ (20 mL) at 0° C., and then diluted with dichloromethane (20 mL) and extracted with dichloromethane (20 mL \times 2). The combined organic layer was dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2 , Petroleum ether/Ethyl acetate=1/0 to 50/50) to give methyl 1-((methylsulfonyl)methyl)cyclopropane-1-carboxylate (1.3 g, 83.35% yield).

[0910] ^1H NMR (400 MHz, CDCl_3) δ 3.64 (s, 3H), 3.38 (s, 2H), 2.90 (s, 3H), 1.43-1.51 (m, 2H), 1.14-1.24 (m, 2H).


Step D 5-thiaspiro[2.4]heptan-7-one 5,5-dioxide



[0911] To a stirred solution of methyl 1-((methylsulfonyl)methyl)cyclopropane-1-carboxylate (600 mg, 3.12 mmol) in THF (6 mL) was added dropwise LiHMDS (1 M, 7.44 mL) at -78° C. with stirring under N_2 . The reaction mixture was left to stir at this temperature for 1 hr. The reaction mixture was quenched by addition of a saturated aqueous solution of NHC (10 mL) at -10° C. with stirring. The resulting solution was concentrated in vacuo. The residue was purified by column chromatography (SiO_2 , Petroleum ether/Ethyl acetate=1/0 to 1/1) to give 5-thiaspiro[2.4]heptan-7-one 5,5-dioxide (370 mg, 74.00% yield).

[0912] ^1H NMR (500 MHz, CDCl_3) δ 3.82 (s, 2H) 3.57 (s, 2H) 1.65-1.74 (m, 2H) 1.26-1.32 (m, 2H).


Step E 6-((6-(5'-(4-fluorophenethyl)-1',1'-dioxido-6'-
(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-4',7'-di-
hydro-2'H-spiro[cyclopropane-1,3'-thieno[3,2-b]
pyridin]-7'-yl)-2-oxobenzod[d]oxazol-3(2H)-yl)
methyl)nicotinonitrile



[0913] A HOAc (1 mL) solution of 6-((6-formyl-2-oxobenzod[d]oxazol-3(2H)-yl)methyl)nicotinonitrile (43.58

mg, 156.06 µmol), 5-thiaspiro[2.4]heptan-7-one 5,5-dioxide (25 mg, 156.06 µmol), 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one (39.05 mg, 156.06 µmol) and acetic acid ammonia (24.06 mg, 312.13 µmol) was stirred at 105° C. for 1 hr. The reaction mixture was quenched by addition H₂O (5 mL) at 0° C., and then extracted with ethyl acetate (10 mL×2). The combined organic layer was washed with brine (10 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give 6-((6'-(4-fluorophenethyl)-1',1'-dioxido-6'-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2'H-spiro[cyclopropane-1,3'-thieno[3,2-b]pyridin]-7'-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)methyl)nicotinonitrile (100 mg, crude). LC-MS: m/z 653.1 (M+H)⁺.


Step F 6-((6-(4-fluorophenethyl)-1',1'-dioxido-6'-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2'H-spiro[cyclopropane-1,3'-thieno[3,2-b]pyridin]-7'-yl)-2-oxobenzo[d]oxazol-3(2H)-yl)methyl)nicotinonitrile



[0914] A mixture of 6-[[6-[5-[2-(4-fluorophenyl)ethyl]-1,1-dioxo-6-(2-oxo-3H-1,3,4-oxadiazol-5-yl)spiro[4,7-dihydro-2H-thieno[3,2-b]pyridine-3,1'-cyclopropane]-7-yl]-2-oxo-1,3-benzoxazol-3-yl]methyl]pyridine-3-carbonitrile (100 mg, 153.22 µmol) and CAN (168.00 mg, 306.44 µmol) in CH₃CN (2 mL) and H₂O (2 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 20° C. for 2 hrs under N₂ atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The crude product was triturated with MeOH (2 mL) at 20° C. for 30 min and filtered to give 6-[[6-[5-[2-(4-fluorophenyl)ethyl]-1,1-dioxo-6-(2-oxo-3H-1,3,4-oxadiazol-5-yl)spiro[2H-thieno[3,2-b]pyridine-3,1'-cyclopropane]-7-yl]-2-oxo-1,3-benzoxazol-3-yl]methyl]pyridine-3-carbonitrile (37.55 mg, 37.67% yield).

[0915] ¹H NMR (400 MHz, MeOD-d₄) δ 8.82-8.91 (m, 1H), 8.15-8.24 (m, 1H), 7.64 (d, J=7.75 Hz, 1H), 7.40-7.46 (m, 1H), 7.11-7.23 (m, 4H), 6.93-7.04 (m, 2H), 5.30 (s, 2H), 3.75 (s, 2H), 3.20-3.25 (m, 2H), 3.02-3.11 (m, 2H), 1.62-1.69 (m, 2H), 1.41-1.47 (m, 2H). ¹⁹F NMR (376 MHz, MeOD-d₄) δ -119.18 (s, 1F). LC-MS: m/z 651.1 (M+H)⁺.

5-((S)-4-((R)-6-chloro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 239)





[0916] Compound 239 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.

[0917] ¹H NMR (400 MHz, MeOD-d₄) δ ppm 7.95 (d, J=5.84 Hz, 1H), 7.44-7.48 (m, 1H), 7.13-7.20 (m, 3H), 6.98 (t, J=8.82 Hz, 2H), 6.87-6.91 (m, 1H), 6.84 (d, J=1.67 Hz, 1H), 5.79-5.86 (m, 1H), 4.61-4.67 (m, 1H), 3.85 (s, 3H), 3.64-3.74 (m, 1H), 3.41-3.49 (m, 1H), 3.24-3.30 (m, 2H), 3.08-3.17 (m, 2H), 2.97-3.04 (m, 1H), 2.73-2.80 (m, 1H), 2.65-2.71 (m, 1H), 2.40-2.54 (m, 3H), 2.00-2.09 (m, 1H), 1.44-1.55 (m, 1H). ¹⁹F NMR (376 MHz, MeOD-d₄) δ ppm -119.02 (s, 1F). LC-MS: m/z 709.1 (M+H)⁺.


Example 37

(R)-5-(2-(4-fluorophenethyl)-4-(2-(4-methoxy-2,3-dihydro-1H-inden-1-yl)-1-oxoisooindolin-5-yl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 240)






Step B (R)-2-(4-methoxy-2,3-dihydro-1H-inden-1-yl)-5-vinylisoindolin-1-one



[0919] To a solution of (R)-5-bromo-2-(4-methoxy-2,3-dihydro-1H-inden-1-yl)isoindolin-1-one (104 mg, 0.290 mmol) and 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (223.57 mg, 1.452 mmol) in dioxane (5.00 mL) and H₂O (0.5 mL) were added K₂CO₃ (120.36 mg, 0.871 mmol) and Pd(dppf)Cl₂ (11.85 mg, 0.016 mmol), and the reaction was stirred at 90° C. for 18 hr. After the reaction was completed, the mixture was diluted with EA (20 mL), washed with water (20 mL). The organic layers were separated, dried over Na₂SO₄, filtered and concentrated to give (R)-2-(4-methoxy-2,3-dihydro-1H-inden-1-yl)-5-vinylisoindolin-1-one (112 mg, crude). LC-MS: m/z 306.1 (M+H)⁺.


Step C (R)-2-(4-methoxy-2,3-dihydro-1H-inden-1-yl)-1-oxoisindoline-5-carbaldehyde



[0920] To a solution of (R)-2-(4-methoxy-2,3-dihydro-1H-inden-1-yl)-5-vinylisoindolin-1-one (112 mg, crude) in THF (2 mL), was added NaIO₄ (313.78 mg, 1.467 mmol) in H₂O (2 mL), and K₂OsO₄ (13.51 mg, 0.037 mmol), and the reaction was stirred at room temperature for 2 h. After the reaction was completed, the mixture was diluted with EA (20 mL), washed with water (25 mL). The organic layers were separated, dried over Na₂SO₄, filtered and concen-

trated under vacuum to dryness. The residue was purified by column chromatography on silica gel (PE/EA=8/1) to give (R)-2-(4-methoxy-2,3-dihydro-1H-inden-1-yl)-1-oxoisindoline-5-carbaldehyde (75 mg, 0.244 mmol, 66.54%). LC-MS: m/z 308.3 (M+H)⁺.


Step D (R)-5-(2-(4-fluorophenethyl)-4-(2-(4-methoxy-2,3-dihydro-1H-inden-1-yl)-1-oxoisindolin-5-yl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (240)



[0921] To a solution of (R)-2-(4-methoxy-2,3-dihydro-1H-inden-1-yl)-1-oxoisindoline-5-carbaldehyde (50 mg, 0.163 mmol), 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one (40.71 mg, 0.163 mmol), potassium 5-oxo-2,3-dihydro-1H,5H-2,7a-methanopyrrolizin-7-olate (36.90 mg, 0.195 mmol) in HOAc (1 mL) was added NH₄OAc (25.08 mg, 0.325 mmol), the mixture reaction was stirred at 100° C. for overnight. After the reaction was completed, the mixture was diluted with EA (20 mL), washed with water (20 mL). The organic layers was separated, dried over Na₂SO₄, filtered and concentrated under vacuum to dryness. The residue was purified by prep-HPLC (TFA=0.1%) to afford the (R)-5-(2-(4-fluorophenethyl)-4-(2-(4-methoxy-2,3-dihydro-1H-inden-1-yl)-1-oxoisindolin-5-yl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (9.89 mg, 0.015 mmol, 8.97%).

[0922] ¹H NMR (400 MHz, DMSO-d₆) δ 12.60 (br s, 1H), 7.72 (d, J=8.0 Hz, 1H), 7.46 (s, 1H), 7.32 (d, J=8.4 Hz, 1H), 7.17-7.25 (m, 3H), 7.07 (t, J=8.8 Hz, 2H), 6.89 (d, J=8.0 Hz, 1H), 6.71 (d, J=7.2 Hz, 1H), 5.89 (t, J=7.6 Hz, 1H), 4.33-4.45 (m, 1H), 3.88-3.99 (m, 1H), 3.81 (s, 3H), 3.52 (s, 2H), 3.14-3.21 (m, 3H), 2.96-3.04 (m, 3H), 2.77-2.85 (m, 1H), 2.60-2.66 (m, 2H), 2.41-2.48 (m, 1H), 2.12-2.19 (m, 1H), 1.69-1.77 (m, 2H). ¹⁹F NMR (377 MHz, DMSO-d₆): -117.05. LC-MS: m/z 670.3 (M+H)⁺.


5-((S)-2-(2-(imidazo[1,2-a]pyridin-7-yl)ethyl)-4-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 241)



[0923] Compound 241 was synthesized using a similar procedure described in Example 10 by using the appropriate materials. (2.47 mg, 0.004 mmol, 8.72%)

[0924] ^1H NMR (400 MHz, DMSO-d₆): δ 12.70 (br s, 1H), 8.42 (d, J=6.8 Hz, 1H), 7.98 (d, J=5.6 Hz, 1H), 7.84 (s, 1H), 7.48 (d, J=0.8 Hz, 1H), 7.43 (s, 1H), 7.32 (s, 1H), 7.25 (d, J=8.4 Hz, 1H), 7.13 (t, J=7.6 Hz, 1H), 7.07 (d, J=5.2 Hz, 1H), 6.80-6.88 (m, 2H), 6.77 (dd, J=6.8 Hz, J=1.6 Hz, 1H), 5.89 (q, J=8.0 Hz, 1H), 4.84-4.89 (m, 1H), 3.79 (s, 3H), 3.49-3.59 (m, 1H), 3.25-3.29 (m, 3H), 3.02-3.20 (m, 2H), 2.90-2.99 (m, 1H), 2.67-2.74 (m, 1H), 2.44-2.47 (m, 1H), 2.33-2.37 (m, 1H), 2.21-2.29 (m, 2H), 1.96-2.05 (m, 1H), 1.33-1.44 (m, 1H). LC-MS: m/z 697.3 (M+H)⁺.


5-((S)-2-(4-chlorophenethyl)-4-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one
(Compound 242)



[0925] Compound 242 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.

[0926] ^1H NMR (400 MHz, DMSO-d₆): δ 8.37 (br s, 1H), 7.96 (d, J=5.2 Hz, 1H), 7.37-7.39 (m, 1H), 7.29-7.33 (m, 2H), 7.19-7.25 (m, 3H), 7.13 (t, J=7.6 Hz, 1H), 7.06 (d, J=5.6 Hz, 1H), 6.84 (dd, J=15.2 Hz, J=7.6 Hz, 2H), 5.90 (q, J=8.0 Hz, 1H), 4.84 (dd, J=10.4 Hz, J=6.0, 1H), 3.79 (s, 3H), 3.52-3.59 (m, 1H), 3.16 (t, J=7.6 Hz, 2H), 2.93-3.07 (m, 3H), 2.65-2.73 (m, 2H), 2.24-2.38 (m, 4H), 1.96-2.06 (m, 1H), 1.36-1.46 (in, 1H). LC-MS: m/z 691.1 (M+H)⁺.


5-((S)-2-(4-(1H-pyrazol-1-yl)phenethyl)-4-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 243)



[0927] Compound 243 was synthesized using a similar procedure described in Example 10 by using the appropriate materials. (3.21 mg, 0.004 mmol, 4.46%)

[0928] ^1H NMR (400 MHz, DMSO-d₆): δ 12.72 (br s, 1H), 8.43 (d, J=2.4 Hz, 1H), 7.98 (d, J=5.6 Hz, 1H), 7.68-7.73 (m, 3H), 7.44 (d, J=3.6 Hz, 1H), 7.31 (d, J=8.8 Hz, 2H), 7.25 (dd, J=8.8 Hz, J=2.4 Hz, 1H), 7.12 (dd, J=7.2 Hz, J=14.0 Hz, 1H), 7.08 (d, J=5.6 Hz, 1H), 6.79-6.86 (m, 2H), 6.51 (t, J=2.0 Hz, 1H), 5.86-5.93 (m, 1H), 4.88 (dd, J=6.8 Hz, J=10.4 Hz, 1H), 3.79 (s, 3H), 3.51-3.58 (m, 1H), 3.21-3.25 (m, 2H), 3.03-3.15 (m, 2H), 2.90-2.98 (m, 1H), 2.66-2.74 (m, 2H), 2.54-2.58 (m, 1H), 2.23-2.38 (m, 3H), 1.97-2.06 (m, 1H), 1.37-1.49 (m, 1H). LC-MS: m/z 723.3 (M+H)⁺.


5-((S)-2-(3-fluoro-4-methoxyphenethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 244)



[0929] Compound 244 was synthesized using a similar procedure described in the report of Example 10 by using the appropriate materials. (5.19 mg, 0.00737 mmol, 20.9%)

[0930] ^1H NMR (400 MHz, DMSO-d₆): δ 7.94 (d, J=5.6 Hz, 1H), 7.30 (s, 1H), 7.10-7.15 (m, 2H), 7.02-7.06 (m, 3H), 6.95 (d, J=9.6 Hz, 1H), 6.88 (d, J=7.2 Hz, 1H), 6.82 (d, J=8.0 Hz, 1H), 5.91 (q, J=8.0 Hz, 1H), 4.79 (dd, J=5.6 Hz, J=10.0 Hz, 1H), 3.79 (s, 6H), 3.49-3.55 (m, 1H), 3.23-3.27 (m, 1H), 3.03-3.08 (m, 2H), 2.84-2.97 (m, 3H), 2.66-2.71 (m, 1H), 2.17-2.42 (m, 4H), 1.99-2.04 (m, 1H), 1.32-1.44 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d₆): δ -135.63. LC-MS: m/z 705.2 (M+H)⁺.


5-((S)-2-(2-(4-fluorothiophen-2-yl)ethyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 245)



[0931] Compound 245 was synthesized using a similar procedure described in Example 10 by using the appropriate materials. (3.53 mg, 0.005 mmol, 6.20%)

[0932] ^1H NMR (400 MHz, DMSO-d₆): δ 7.96 (d, J=5.6 Hz, 1H), 7.38 (s, 1H), 7.20 (d, J=8.4 Hz, 1H), 7.13 (t, J=5.6 Hz, 1H), 7.06 (d, J=5.6 Hz, 1H), 6.91-6.92 (m, 1H), 6.86 (d, J=7.6 Hz, 1H), 6.80-6.85 (m, 2H), 5.89 (q, J=7.6 Hz, 1H), 4.85 (dd, J=9.6 Hz, J=6.4 Hz, 1H), 3.79 (s, 3H), 3.49-3.58 (m, 1H), 3.25-3.29 (m, 1H), 3.15-3.24 (m, 4H), 2.89-2.98 (m, 1H), 2.65-2.74 (m, 1H), 2.53-2.58 (m, 1H), 2.34-2.41 (m, 1H), 2.22-2.30 (m, 2H), 1.96-2.06 (m, 1H), 1.38-1.49 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d₆): -127.97. LC-MS: m/z 681.1 (M+H)⁺.

5-((S)-4-(7-(((R)-6-fluoro-2,3-dihydro-1H-inden-11-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one
(Compound 246)




[0933] Compound 246 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.


[0934] ^1H NMR (400 MHz, MeOD-d₄): δ ppm 7.93-7.99 (m, 1H), 7.41-7.47 (m, 1H), 7.22-7.26 (m, 1H), 7.13-7.19 (m, 3H), 6.91-7.01 (m, 4H), 5.79-5.86 (m, 1H), 3.65-3.74 (m, 1H), 3.41-3.49 (m, 1H), 3.21-3.29 (m, 3H), 3.00-3.16 (m, 3H), 2.86-2.94 (m, 1H), 2.66-2.73 (m, 1H), 2.40-2.54 (m, 3H), 1.97-2.12 (m, 2H), 1.45-1.52 (m, 1H). ^{19}F NMR (377 MHz, MeOD-d₄): δ -119.00 (s, 1F), -119.25 (s, 1F). LC-MS: m/z 663.1 (M+H)⁺.

Example 38


5-((S)-2-(4-fluorophenethyl)-5-oxo-4-(7-(((R)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 247)




-continued



-continued



Step A ethyl 6-(trifluoromethyl)-2-(((trifluoromethyl)sulfonyl)oxy)nicotinate




[0935] Ethyl 2-hydroxy-6-(trifluoromethyl)pyridine-3-carboxylate (4.5 g, 19.14 mmol) was suspended in DCM (45 mL) and treated with DIEA (4.95 g, 38.27 mmol). Then the mixture was cooled to 0° C. and Tf_2O (8.10 g, 28.70 mmol) in DCM (10 mL) was added dropwise. The cooling bath was removed and the mixture was stirred at 20° C. for 3 hrs. DCM (10 mL) and water (5 mL) were added to the reaction and extracted with DCM (10 mL×2). The organic layer was washed with brine (5 mL), dried over Na_2SO_4 , filtered and concentrated. The residue was purified by column chromatography (SiO_2 , petroleum ether/ethyl acetate=1/0 to 3/1) to

give ethyl 6-(trifluoromethyl)-2-(((trifluoromethyl)sulfonyl)oxy)nicotinate (6 g, 85.38% yield).

[0936] ^1H NMR (400 MHz, CDCl_3) δ 8.70 (d, $J=7.87$ Hz, 1H) 7.89 (d, $J=7.87$ Hz, 1H) 4.53 (q, $J=7.15$ Hz, 2H) 1.48 (t, $J=7.15$ Hz, 3H).


Step B ethyl 2-(3-ethoxy-3-oxopropyl)-6-(trifluoromethyl)nicotinate



[0937] A mixture of ethyl 6-(trifluoromethyl)-2-(((trifluoromethyl)sulfonyl)oxy)nicotinate (6 g, 16.34 mmol), (1-ethoxycyclopropoxy)trimethylsilane (4.27 g, 24.51 mmol), PPh_3 (857.09 mg, 3.27 mmol), and $\text{Pd}(\text{PPh}_3)_2\text{Cl}_2$ (573.41 mg, 816.95 μmol) in toluene (120 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 110° C. for 16 hrs under N_2 atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2 , petroleum ether/ethyl acetate=1/0 to 5/1) to give ethyl 2-(3-ethoxy-3-oxopropyl)-6-(trifluoromethyl)nicotinate (2.9 g, 9.08 mmol, 55.59% yield).

[0938] ^1H NMR (400 MHz, CDCl_3) δ 8.26 (d, $J=7.2$ Hz, 1H) 7.50 (d, $J=7.2$ Hz, 1H) 4.31-4.40 (m, 2H) 4.01-4.12 (m, 2H) 3.45-3.54 (m, 2H) 2.71-2.87 (m, 2H) 1.35 (t, $J=7.09$ Hz, 3H) 1.13-1.22 (m, 3H)


Step C methyl 5-oxo-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridine-6-carboxylate



[0939] To a solution of ethyl 2-(3-ethoxy-3-oxopropyl)-6-(trifluoromethyl)nicotinate (2.8 g, 8.77 mmol) in THF (60 mL) was added LiHMDS (1 M, 17.54 mL). The mixture was stirred at -70° C. for 2 hrs. The reaction mixture was quenched by addition of a saturated aqueous solution of NH_4Cl (10 mL) at -70° C. with stirring. The resulting solution was extracted with ethyl acetate (50 mL). The combined organic layers were washed with brine (50 mL), dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give methyl 5-oxo-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridine-6-carboxylate (2.8 g, crude).

[0940] ^1H NMR (400 MHz, CDCl_3) δ 7.79-7.97 (m, 1H) 7.34-7.52 (m, 1H) 4.02-4.18 (m, 2H) 3.25-3.66 (m, 3H) 1.14 (s, 3H).


Step D 2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-one



[0941] A solution of ethyl 5-oxo-2-(trifluoromethyl)-6,7-dihydrocyclopenta[b]pyridine-6-carboxylate (2.6 g, 9.52 mmol) and LiCl (2.02 g, 47.58 mmol) in DMSO (50 mL) and H_2O (2.5 mL) was stirred at 100° C. for 1 hr. The reaction mixture was quenched by addition H_2O (20 mL) at 0° C., and then extracted with ethyl acetate (30 mL \times 3). The combined organic layers were washed with brine (30 mL), dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO_2 , petroleum ether/ethyl acetate=1/0 to 3/1) to give 2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-one (920 mg, 4.57 mmol, 48.06% yield).


[0942] ^1H NMR (400 MHz, CDCl_3) δ 8.14 (d, $J=8.00$ Hz, 1H) 7.66 (d, $J=8.00$ Hz, 1H) 3.27-3.37 (m, 2H) 2.77-2.87 (m, 2H).

Step E (R,Z)-2-methyl-N-(2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-ylidene)propane-2-sulfonamide




[0943] Tetraethoxytitanium (2.79 g, 12.23 mmol) was added to a mixture of 2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-one (820 mg, 4.08 mmol) and (R)-2-methylpropane-2-sulfonamide (518.80 mg, 4.28 mmol) in THF (15 mL). The mixture was stirred for 16 h at 70° C. Ethyl acetate (25 mL) and water (5 mL) were added to the mixture, and the formed precipitate was removed by filtration. The filtrate was concentrated in vacuo to give a residue. The residue was purified by column chromatography (SiO_2 , petroleum ether/ethyl acetate=1/0 to 3/1) to give (R,Z)-2-methyl-N-(2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-ylidene)propane-2-sulfonamide (400 mg, 29.52% yield, 91.57% purity). LC-MS: m/z 305.1 ($\text{M}+\text{H}$)⁺.

Step F (R)-2-methyl-N—((R)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)propane-2-sulfonamide



[0944] To a solution of (R,Z)-2-methyl-N-(2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-ylidene)propane-2-sulfonamide (400 mg, 1.31 mmol) in DCM (10 mL) was added dropwise DIBAL-H (1 M, 2.63 mL) at -70° C. After addition, the mixture was stirred at this temperature for 2 hrs. The reaction mixture was quenched by addition MeOH (5 mL) at 0° C., and then diluted with H₂O (5 mL) and extracted with DCM (20 mL×2). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, petroleum ether/ethyl acetate=1/0 to 1/1) to give (R)-2-methyl-N—((R)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)propane-2-sulfonamide (288 mg, 71.53% yield). LC-MS: m/z 307.1 (M+H)⁺.


Step G (R)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine



[0945] A mixture of (R)-2-methyl-N—((R)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)propane-2-sulfonamide (288 mg, 940.11 μmol) and HCl/dioxane (2 M, 3.29 mL) in MeOH (3 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 20° C. for 2 hrs under N₂ atmosphere. The reaction mixture was concentrated under reduced pressure to give a residue. The resulting product was dissolved in petroleum ether/ethyl acetate=3/1 (10 mL) and filtered to give (R)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine (150 mg, 65.85% yield, 98.48% purity, HCl salt).


[0946] ¹H NMR (400 MHz, MeOD-d₄) δ 8.14 (d, J=8 Hz, 1H) 7.77 (d, J=8 Hz, 1H) 4.96-4.99 (m, 1H) 3.26-3.32 (m, 1H) 3.13-3.23 (m, 1H) 2.73-2.84 (m, 1H) 2.16-2.28 (m, 1H). LC-MS: m/z 203.0

Step H (R)-2-(1,3-dioxolan-2-yl)-N-(2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)thieno[2,3-c]pyridin-7-amine




[0947] A mixture of 7-chloro-2-(1,3-dioxolan-2-yl)thieno[2,3-c]pyridine (150 mg, 620.62 μmol), (R)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine (148.10 mg, 620.62 μmol, HCl), Cs₂CO₃ (606.63 mg, 1.86 mmol), Pd(OAc)₂ (13.93 mg, 62.06 μmol) and BINAP (77.29 mg, 124.12 μmol) in dioxane (4 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 110° C. for 16 hrs under N₂ atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by column chromatography (SiO₂, petroleum ether/ethyl acetate=1/0 to 2/1) to give (R)-2-(1,3-dioxolan-2-yl)-N-(2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)thieno[2,3-c]pyridin-7-amine (190 mg, 75.14% yield, 100.00% purity). LC-MS: m/z 408.1 (M+H)⁺.

Step I (R)-7-((2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde




[0948] A mixture of (R)-2-(1,3-dioxolan-2-yl)-N-(2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)thieno[2,3-c]pyridin-7-amine (190 mg, 466.36 μmol) and HCl (2 M, 5 mL) in THF (3 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 45° C. for 16 hrs under N₂ atmosphere. The reaction mixture was filtered and quenched by addition aq. NaHCO₃ (10 mL) at 0° C., and then diluted with ethyl acetate (10 mL) and extracted with ethyl acetate (10 mL). The combined organic layers were washed with brine 10 mL (10 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give (R)-7-((2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (150 mg, 88.52% yield). LC-MS: m/z 364.0 (M+H)⁺.

Step J ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-4-(7-(((R)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)-1,4-dihydropyridine-3-carboxylate




[0949] A mixture of tert-butyl (S)-2-(3-ethoxy-3-oxopropyl)pyrrolidine-1-carboxylate (40 mg, 140.19 μ mol), 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one (35.08 mg, 140.19 μ mol), (R)-7-((2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (50.94 mg, 140.19 μ mol), NH₄OAc (21.61 mg, 280.37 μ mol) and Yb(OTf)₃ (8.70 mg, 14.02 μ mol) in EtOH (2 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 50° C. for 16 hrs under N₂ atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to give ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-4-(7-(((R)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)-1,4-dihydropyridine-3-carboxylate (125 mg, crude). LC-MS: m/z 862.2 (M+H)⁺.

Step K ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-4-(7-(((R)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)nicotinate




[0950] A mixture of ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-4-(7-(((R)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)-1,4-dihydropyridine-3-carboxylate (125 mg, 145.03 μ mol) and CAN (159.02 mg, 290.06 μ mol) in EtOH (4 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 20° C. for 1 hr under N₂ atmosphere. The reaction mixture was diluted with ethyl acetate (20 mL) and washed with brine (5 mL×2), dried over Na₂SO₄, filtered and concentrated under reduced pressure to ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-4-(7-(((R)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)nicotinate (150 mg, crude). LC-MS: m/z 860.2 (M+H)⁺.

Step L ethyl 6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-((S)-pyrrolidin-2-yl)-4-(7-(((R)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)nicotinate



[0951] A mixture of ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-4-(7-(((R)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)nicotinate (150 mg, 174.44 μ mol) and HCl (2 M, 1.74 mL) in dioxane (1 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 20° C. for 4 hrs under N₂ atmosphere. The reaction mixture was concentrated under reduced pressure to give ethyl 6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-((S)-pyrrolidin-2-yl)-4-(7-(((R)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)nicotinate (150 mg, crude). LC-MS: m/z 760.2 (M+H)⁺.


Step M 5-((S)-2-(4-fluorophenethyl)-5-oxo-4-(7-((R)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one



[0952] A mixture of ethyl 6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-((S)-pyrrolidin-2-yl)-4-((R)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)nicotinate (150 mg, 197.43 µmol) and Na₂CO₃ (418.50 mg, 3.95 mmol) in dioxane (4 mL) and H₂O (4 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 20° C. for 16 hrs under N₂ atmosphere. The reaction mixture was extracted with ethyl acetate (10 mL×3). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: C18 150×30 mm; mobile phase: [water(FA)-ACN]; gradient: 31%-61% B over 7 min) to give 5-((S)-2-(4-fluorophenethyl)-5-oxo-4-(7-((R)-2-(trifluoromethyl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (8.41 mg, 5.97% yield).

[0953] ¹H NMR (400 MHz, MeOD-d₄) δ 7.97-8.03 (d, J=5.6 Hz, 1H) 7.86-7.92 (m, 1H) 7.60-7.66 (m, 1H) 7.47 (s, 1H) 7.12-7.23 (m, 3H) 6.93-7.03 (m, 2H) 5.92-6.02 (m, 1H) 3.63-3.75 (m, 1H) 3.39-3.49 (m, 1H) 3.21-3.31 (m, 1H) 3.16-3.21 (m, 1H) 3.04-3.16 (m, 3H) 2.74-2.83 (m, 1H) 2.38-2.56 (m, 3H) 2.14-2.27 (m, 1H) 1.42-1.56 (m, 1H). ¹⁹F NMR (376 MHz, METHANOL-d₄) δ -68.69 (s, 1F) -119.08 (s, 1F). LC-MS: m/z 714.2 (M+H)⁺.


(S)-5-(4-(7-(benzofuran-3-ylmethyl)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 248)



[0954] Compound 248 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.

[0955] ¹H NMR (400 MHz, MeOD-d₄) δ ppm 8.55-8.58 (m, 1H), 8.24-8.28 (m, 1H), 7.88-7.89 (m, 1H), 7.85-7.87 (m, 1H), 7.52-7.56 (m, 1H), 7.41-7.45 (m, 1H), 7.32-7.37 (m, 1H), 7.21-7.27 (m, 1H), 7.13-7.18 (m, 2H), 6.95-7.00 (m, 2H), 4.91-4.96 (m, 1H), 4.80-4.82 (m, 2H), 3.62-3.72 (m, 1H), 3.42-3.48 (m, 1H), 3.34-3.37 (m, 1H), 3.30-3.32 (m, 1H), 3.08-3.16 (m, 2H), 2.41-2.55 (m, 3H), 1.46-1.56 (m, 1H). ¹⁹F NMR (376 MHz, MeOD-d₄) δ -118.96 (s, 1F). LC-MS: m/z 644.1 (M+H)⁺.


(S)-5-(2-(4-fluorophenethyl)-4-(7-((1-methyl-1H-indol-3-yl)methyl)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 249)



[0956] Compound 249 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.

[0957] ^1H NMR (400 MHz, CDCl_3) δ 8.51-8.55 (d, $J=5.6$ Hz, 1H), 7.67 (s, 1H), 7.55-7.64 (m, 2H), 7.40-7.47 (m, 1H), 7.30-7.33 (m, 1H), 7.14-7.19 (m, 1H), 7.06-7.12 (m, 2H), 6.92-7.00 (m, 3H), 4.71-4.79 (m, 1H), 4.53 (s, 2H), 3.71-3.83 (m, 4H), 3.39-3.53 (m, 1H), 2.96-3.18 (m, 4H), 2.47-2.59 (m, 1H), 2.30-2.45 (m, 2H), 1.39-1.50 (m, 2H). ^{19}F NMR (376 MHz, CDCl_3) δ -116.70 (s, 1F). LC-MS: m/z 657.2 ($\text{M}+\text{H}^+$)⁺


5-((S)-2-(((S)-5-fluoro-2,3-dihydro-1H-inden-1-yl)methyl)-4-(7-(((R)-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 250)



[0958] Compound 250 was synthesized using a similar procedure described in Example 30 by using the appropriate materials.

[0959] ^1H NMR (400 MHz, MeOD-d_4): δ 7.88-7.99 (m, 1H), 7.46-7.50 (m, 1H), 7.09-7.22 (m, 2H), 6.88-6.99 (m, 3H), 6.79-6.85 (m, 2H), 5.80-5.86 (m, 1H), 3.82-3.89 (m, 3H), 3.65-3.76 (m, 2H), 3.39-3.50 (m, 2H), 2.93-3.09 (m, 3H), 2.74-2.87 (m, 2H), 2.64-2.72 (m, 1H), 2.39-2.54 (m, 3H), 2.18-2.27 (m, 1H), 1.94-2.05 (m, 2H), 1.48-1.57 (m, 1H), 1.29-1.34 (m, 3H), 0.88-0.97 (m, 1H). ^{19}F NMR (400 MHz, MeOD-d_4): 120.0 (s, 1F). LC-MS: m/z 701.2 ($\text{M}+\text{H}^+$)⁺.


5-((S)-4-(7-(((R)-2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 251)



[0960] Compound 251 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.

[0961] ^1H NMR (400 MHz, MeOD-d_4) δ 7.97-8.03 (d, $J=5.6$ Hz, 1H), 7.46 (s, 1H), 7.26-7.34 (m, 1H), 7.13-7.22 (m, 3H), 6.96-7.03 (m, 2H), 6.89-6.95 (m, 2H), 6.22-6.32 (m, 1H), 3.87 (s, 3H), 3.64-3.73 (m, 1H), 3.39-3.54 (m, 3H), 3.36-3.38 (m, 1H), 3.23-3.29 (m, 2H), 3.05-3.19 (m, 2H), 2.39-2.56 (m, 3H), 1.43-1.55 (m, 1H). ^{19}F NMR (376 MHz, MeOD-d_4) δ -103.22--101.71 (m, 1F) -109.86 (m, 1F) -119.02 (s, 1F). LC-MS: m/z 711.1 ($\text{M}+\text{H}^+$)⁺.


6-(1-(7-((S)-2-(4-fluorophenethyl)-5-oxo-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-4-yl)-2,2-dimethyl-3-oxo-2H-benzo[b][1,4]oxazin-4(3H)-yl)ethyl)nicotinonitrile (Compound 252)



[0962] Compound 252 was synthesized using a similar procedure described in Example 19 by using the appropriate materials.

[0963] ^1H NMR (400 MHz, MeOD-d₄) δ ppm 8.84-8.92 (m, 1H), 8.10-8.15 (m, 1H), 7.52-7.56 (m, 1H), 7.12-7.16 (m, 2H), 6.95-7.00 (m, 2H), 6.83-6.93 (m, 2H), 6.11-6.19 (m, 1H), 4.84-4.87 (m, 1H), 3.60-3.74 (m, 1H), 3.39-3.49 (m, 1H), 3.20-3.27 (m, 2H), 3.01-3.15 (m, 2H), 2.37-2.54 (m, 3H), 1.87-1.96 (m, 3H), 1.47-1.51 (m, 6H), 1.42-1.47 (m, 1H). ^{19}F NMR (377 MHz, MeOD-d₄) δ ppm -119.045. LC-MS: m/z 686.2 (M+H)⁺.


5-((S)-4-(7-(((R)-5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 253)



[0964] Compound 253 was synthesized using a similar procedure described in Example 20 by using the appropriate materials.

[0965] ^1H NMR (400 MHz, DMSO-d₆): δ 12.69 (br s, 1H), 7.29-7.36 (m, 2H), 7.17-7.26 (m, 4H), 7.03-7.10 (m, 2H), 6.95 (s, 1H), 5.78-5.87 (m, 1H), 4.83-4.90 (m, 1H), 3.50-3.59 (m, 2H), 3.16-3.20 (m, 2H), 3.05-3.11 (m, 1H), 2.94-3.04 (m, 2H), 2.78-2.88 (m, 2H), 2.41 (s, 3H), 2.35-2.38 (m, 1H), 2.23-2.30 (m, 2H), 2.02-2.14 (m, 1H), 1.36-1.49 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d₆): -117.03, -140.57, -141.53. LC-MS: m/z 695.3 (M+H)⁺.


(R)-4-(7-(((R)-5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,10,10a-tetrahydro-5H-pyrido[2',3':3,4]pyrrolo[2,1-c][1,4]oxazin-5-one (Compound 254)



[0966] Compound 254 was synthesized using a similar procedure described in Example 20 by using the appropriate materials. (2.90 mg, 0.004 mmol, 3.54%)

[0967] ^1H NMR (400 MHz, DMSO-d₆): δ 12.62 (br s, 1H), 7.30-7.36 (m, 2H), 7.16-7.25 (m, 4H), 7.047.09 (m, 2H), 6.96 (s, 1H), 5.79-5.86 (m, 1H), 4.81 (dd, J=10.4 Hz, J=4.4 Hz, 1H), 4.47 (dd, J=11.2 Hz, J=4.0 Hz, 1H), 4.03-4.10 (m, 1H), 3.92-3.99 (m, 1H), 3.24-3.27 (m, 2H), 3.16-3.21 (m, 3H), 2.96-3.07 (m, 3H), 2.79-2.87 (m, 1H), 2.42 (s, 3H), 2.02-2.12 (m, 1H), 1.05 (d, J=6.4 Hz, 1H). ^{19}F NMR (377 MHz, DMSO-d₆): -117.03, -140.58, -141.54. LC-MS: m/z 711.2 (M+H)⁺.

(R)-5-(4-(7-((5,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 255)







[0968] Compound 255 was synthesized using a similar procedure described in Example 20 by using the appropriate materials.


[0969] ^1H NMR (400 MHz, DMSO-d₆): δ 7.30-7.35 (m, 2H), 7.17-7.25 (m, 4H), 7.07 (t, J=8.8 Hz, 2H), 6.94 (s, 1H), 5.79-5.85 (m, 1H), 3.56 (s, 2H), 3.15-3.22 (m, 3H), 2.97-3.07 (m, 3H), 2.79-2.88 (m, 1H), 2.61-2.68 (m, 2H), 2.55-2.57 (m, 1H), 2.41 (s, 3H), 2.03-2.14 (m, 1H), 1.74 (d, J=4.0 Hz, 2H). ^{19}F NMR (377 MHz, DMSO-d₆): δ -117.03, -140.59, -141.547. LC-MS: m/z 707.3 (M+H)⁺.

Example 39


5-[(9a*S*)-4-[7-[[*(1R*)-6-chloro-4-fluoro-5-methoxyindan-1-yl]amino]thieno[2,3-*c*]pyridin-2-yl]-2-[4-fluorophenyl]ethyl]-5-oxo-7,8,9,9a-tetrahydropyrido[2,3-*a*]pyrrolizin-3-yl]-3H-1,3,4-oxadiazol-2-one
(Compound 256)




-continued



-continued



Step A 3-(4-chloro-2-fluoro-3-methoxy-phenyl)
propanoic acid




[0970] To a solution of TEA (5.37 g, 53.03 mmol, 7.38 mL) was added formic acid (7.32 g, 159.08 mmol, 6.00 mL) at 0° C. over 15 min. After addition, the mixture was stirred at this temperature for 10 min and then 2, 2-dimethyl-1, 3-dioxane-4, 6-dione (4.59 g, 31.82 mmol) and 4-chloro-2-fluoro-3-methoxy-benzaldehyde (5 g, 26.51 mmol) were added. The resulting mixture was stirred at 100° C. for 16 hours. The reaction mixture was diluted with H₂O (80 mL) and adjusted pH to 10 by NaOH solid and then and washed with EtOAc (80 mL*2). The aqueous phase adjusted pH to 3 by HCl (12 M), extracted with EtOAc (100 mL*2). The combined organic layers were washed with brine (120 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give crude product 3-(4-chloro-2-fluoro-3-

methoxy-phenyl)propanoic acid (6 g, 25.79 mmol, 97.28% yield), which was used for next step without further purification.

[0971] ¹H NMR (400 MHz, CDCl₃) δ ppm 7.21-7.26 (m, 1H), 7.06 (m, 1H), 3.83-3.88 (m, 3H), 2.82 (m, 2H), 2.54-2.69 (m, 2H).


Step B
3-(4-chloro-2-fluoro-3-methoxy-phenyl)propanoyl
chloride



[0972] To a solution of 3-(4-chloro-2-fluoro-3-methoxy-phenyl)propanoic acid (6 g, 25.79 mmol) in DCM (40 mL) was added (COCl)₂ (9.82 g, 77.37 mmol, 6.77 mL) at 0° C., and then DMF (188.51 mg, 2.58 mmol) was added. The mixture was stirred at 25° C. for 12.5 hours. The reaction mixture was concentrated under reduced pressure to give

3-(4-chloro-2-fluoro-3-methoxy-phenyl) propanoyl chloride (6.4 g, 25.81 mmol, 100% yield), which was used into the next step without further purification.


Step C 6-chloro-4-fluoro-5-methoxy-indan-1-one



[0973] To a solution of 3-(4-chloro-2-fluoro-3-methoxy-phenyl) propanoyl chloride (6.4 g, 25.49 mmol) in DCM (40 mL) was added AlCl_3 (5.10 g, 38.23 mmol). The mixture was stirred at 25° C. for 0.5 hour. The reaction mixture was quenched by ice-water (50 mL) at 0° C., and then diluted with H_2O (100 mL) and extracted with EtOAc (150 mL×3). The combined organic layers were washed with brine (200 mL), dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 0~30% Ethylacetate/Petroleum ether gradient @80 mL/min) to give 6-chloro-4-fluoro-5-methoxy-indan-1-one (4 g, 18.64 mmol, 73.12% yield).

[0974] ^1H NMR (400 MHz, DMSO-d₆) δ ppm 7.50-7.65 (m, 1H), 4.03-4.04 (m, 3H), 3.02-3.16 (m, 2H), 2.64-2.72 (m, 2H), LC-MS: m/z 286.9 ($\text{M}+\text{H}$)⁺.


Step D (NZ,R)—N-(6-chloro-4-fluoro-5-methoxy-indan-1-ylidene)-2-methyl-propane-2-sulfonamide



[0975] A mixture of 6-chloro-4-fluoro-5-methoxy-indan-1-one (4 g, 18.64 mmol, 1.68 eq), (R)-2-methylpropane-2-sulfonamide (1.41 g, 11.66 mmol), tetraethoxytitanium (5.06 g, 22.20 mmol, 4.60 mL) in THF (40 mL) was degassed and purged with N_2 for 3 times, and then the mixture was stirred at 80° C. for 12 hours under N_2 atmosphere. The reaction mixture was diluted with water (50 mL) and EtOAc (100 mL), filtered and extracted with EtOAc (100 mL×3). The combined organic layers were washed with brine (50 mL), dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 80 g SepaFlash® Silica Flash Column, Eluent of 0~50% Ethylacetate/Petroleum ether gradient @80 mL/min) to give (NZ,R)—N-(6-chloro-4-fluoro-5-methoxy-indan-1-ylidene)-2-methyl-propane-2-sulfonamide (1.1 g, 3.46 mmol, 31.18% yield).

[0976] ^1H NMR (400 MHz, DMSO-d₆) δ ppm 7.50-7.65 (m, 1H), 4.03-4.04 (m, 3H), 3.02-3.16 (m, 2H), 2.64-2.72 (m, 2H), LC-MS: m/z 318.1 ($\text{M}+\text{H}$)⁺.


Step E (R)—N-[*(1R)*-6-chloro-4-fluoro-5-methoxy-indan-1-yl]-2-methyl-propane-2-sulfonamide



[0977] To a solution of (NZ,R)—N-(6-chloro-4-fluoro-5-methoxy-indan-1-ylidene)-2-methyl-propane-2-sulfonamide (1.1 g, 3.46 mmol) in DCM (10 mL) was added DIBALH (1.5 M, 2.31 mL) at -70° C. The mixture was stirred at 25° C. for 2 hours. The reaction mixture was quenched by addition MeOH (50 mL) at 0° C., and then diluted with H_2O (100 mL) and extracted with DCM (100 mL×2). The combined organic layer was washed with brine (30 mL), dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~50% Ethylacetate/Petroleum ether gradient @60 mL/min) to give (R)—N-[*(1R)*-6-chloro-4-fluoro-5-methoxy-indan-1-yl]-2-methyl-propane-2-sulfonamide (700 mg, 2.19 mmol, 63.24% yield).

[0978] ^1H NMR (400 MHz, DMSO) δ ppm 7.51 (s, 1H), 5.90 (d, $J=9.2$ Hz, 1H), 4.75 (q, $J=8.4$ Hz, 1H), 3.84 (d, $J=0.8$ Hz, 3H), 2.93 (ddd, $J=2.4, 8.8, 16.0$ Hz, 1H), 2.77-2.67 (m, 1H), 2.43 (td, $J=2.4, 7.8, 12.7$ Hz, 1H), 1.94 (dd, $J=9.2, 12.7$ Hz, 1H), 1.16-1.12 (m, 9H). LC-MS: m/z 320.1 ($\text{M}+\text{H}$)⁺.


Step F (1R)-6-chloro-4-fluoro-5-methoxy-indan-1-amine



[0979] To a solution of (R)—N-[*(1R)*-6-chloro-4-fluoro-5-methoxy-indan-1-yl]-2-methyl-propane-2-sulfonamide (700 mg, 2.19 mmol) in MeOH (8 mL) was added HCl/dioxane (2 M, 4 mL). The mixture was stirred at 25° C. for 2 hours. LC (Petroleum ether: Ethyl acetate=3:1) indicated material was consumed completely and one major new spot formed. The reaction mixture was concentrated under reduced pressure to give (1R)-6-chloro-4-fluoro-5-methoxy-indan-1-amine (500 mg, 1.98 mmol, 90.61% yield, HCl), which was used into the next step without further purification.

[0980] ^1H NMR (400 MHz, DMSO) δ ppm 10.21 (s, 1H), 9.85 (br d, $J=8.2$ Hz, 1H), 8.48 (s, 1H), 7.88 (d, $J=6.8$ Hz, 1H), 7.55 (d, $J=6.8$ Hz, 1H), 7.24-6.98 (m, 2H), 5.97-5.81 (m, 1H), 3.90 (d, $J=1.3$ Hz, 3H), 3.11 (dt, $J=4.4, 8.1$ Hz, 1H), 2.97-2.85 (m, 1H), 2.81-2.70 (m, 1H), 2.20-2.09 (m, 1H).


Step J N-[*(R*)-6-chloro-4-fluoro-5-methoxy-indan-1-yl]-2-(1,3-dioxolan-2-yl)thieno[2,3-c]pyridin-7-amine



[0981] A mixture of (*R*)-6-chloro-4-fluoro-5-methoxy-indan-1-amine (500 mg, 1.98 mmol, HCl), 7-chloro-2-(1,3-dioxolan-2-yl)thieno[2,3-c]pyridine (479.3 mg, 1.98 mmol), Pd(OAc)₂ (44.53 mg, 198.33 μ mol), Cs₂CO₃ (1.29 g, 3.97 mmol) and BINAP (185.08 mg, 297.23 μ mol) in dioxane (10 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 100° C. for 2 hours under N₂ atmosphere. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 40 g SepaFlash® Silica Flash Column, Eluent of 0~50% Ethylacetate/Petroleum ether gradient @60 mL/min) to give N-[*(R*)-6-chloro-4-fluoro-5-methoxy-indan-1-yl]-2-(1,3-dioxolan-2-yl)thieno[2,3-c]pyridin-7-amine (640 mg, 1.52 mmol, 76.67% yield). LC-MS: m/z 386.9 (M+H)⁺.

[0982] ^1H NMR (400 MHz, DMSO) δ ppm 7.96 (d, $J=5.5$ Hz, 1H), 7.49 (s, 1H), 7.22 (d, $J=8.0$ Hz, 1H), 7.13-6.99 (m, 2H), 6.21 (s, 1H), 5.83 (d, $J=7.9$ Hz, 1H), 4.07-4.03 (m, 2H), 4.01 (td, $J=1.9, 5.8$ Hz, 2H), 3.84 (s, 3H), 3.05 (ddd, $J=3.4, 8.8, 16.0$ Hz, 1H), 2.92-2.79 (m, 1H), 2.60-2.53 (m, 1H), 2.14-2.05 (m, 1H).


Step H 7-[[*(R*)-6-chloro-4-fluoro-5-methoxy-indan-1-yl]amino]thieno[2,3-c]pyridine-2-carbaldehyde



[0983] To a solution of N-[*(1R)*-6-chloro-4-fluoro-5-methoxy-indan-1-yl]-2-(1,3-dioxolan-2-yl) thieno[2,3-c]pyridin-7-amine (640 mg, 1.52 mmol) in THF (5 mL) was added aq. HCl (4 M, 4 mL). The mixture was stirred at 25° C. for 2 hours. The reaction mixture was adjusted pH=10 by NaOH solid and then extracted with EtOAc (100 mL*3). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure to give 7-[[*(1R)*-6-chloro-4-fluoro-5-methoxy-indan-1-yl]amino]thieno[2,3-c]pyridine-2-carbaldehyde (490 mg, 1.30 mmol, 85.51% yield), which was used into the next step without further purification.


[0984] ^1H NMR (400 MHz, CDCl₃) δ ppm 10.24 (s, 1H), 8.40 (s, 1H), 8.12 (d, $J=5.6$ Hz, 1H), 7.62 (d, $J=8.0$ Hz, 1H), 7.33 (d, $J=5.6$ Hz, 1H), 7.18 (s, 1H), 5.92 (d, $J=7.7$ Hz, 1H), 3.91 (s, 3H), 3.13 (ddd, $J=3.5, 8.9, 16.1$ Hz, 1H), 3.00-2.87 (m, 1H), 2.68-2.61 (m, 1H), 2.17 (qd, $J=8.3, 12.6$ Hz, 1H). LC-MS: m/z 377.1 (M+H)⁺.

Step I ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-(((R)-6-chloro-4-fluoro-5-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1,4-dihydropyridine-3-carboxylate




[0985] A mixture of 7-[[*(1R)*-6-chloro-4-fluoro-5-methoxy-indan-1-yl]amino]thieno[2,3-c]pyridine-2-carbaldehyde (250 mg, 663.43 μ mol), 5-[4-(4-fluorophenyl)-2-oxo-butyl]-3H-1,3,4-oxadiazol-2-one (166 mg, 663.40 μ mol), tert-butyl (2S)-2-(3-ethoxy-3-oxo-propanoyl)pyrrolidine-1-carboxylate (189 mg, 662.38 μ mol), NH₄OAc (105.3 mg, 1.37 mmol), tris(trifluoromethylsulfonyloxy)ytterbium (43.9 mg, 70.78 μ mol) in EtOH (5 mL) was stirred at 50° C. for 2 hours. The reaction mixture was filtered and concentrated under reduced pressure to give ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-(((R)-6-chloro-4-fluoro-5-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1,4-dihydropyridine-3-carboxylate (580 mg, 662.57 μ mol, 99.87% yield). LC-MS: m/z 875.3 (M+H)⁺.

Step G ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-(((R)-6-chloro-4-fluoro-5-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)nicotinate




[0986] To a solution of ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-(((R)-6-chloro-4-fluoro-5-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1,4-dihydropyridine-3-carboxylate (580 mg, 662.57 μ mol) in CH_3CN (10 mL), H_2O (5 mL) was added CAN (726.6 mg, 1.33 mmol). The mixture was stirred at 25° C. for 2 hours. The reaction mixture was quenched by addition of NaHCO_3 , and then extracted with EtOAc (50 mL * 3). The combined organic layers were washed with brine (25 mL * 2), dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 24 g SepaFlash® Silica Flash Column, Eluent of 0~100% Ethylacetate/Petroleum ether gradient @60 mL/min) to give compound ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-(((R)-6-chloro-4-fluoro-5-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)nicotinate (300 mg, 343.50 μ mol, 51.84% yield). LC-MS: m/z 873.2 ($\text{M}+\text{H}$)⁺.

Step K ethyl 4-(7-(((R)-6-chloro-4-fluoro-5-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-((S)-pyrrolidin-2-yl)nicotinate



[0987] To a solution of ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-4-(7-(((R)-6-chloro-4-fluoro-5-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)nicotinate (300 mg, 343.50 μ mol) in HCl/dioxane (2 M, 12.00 mL, 69.87 eq). The mixture was stirred at 25° C. for 2 hours. The reaction mixture was concentrated under reduced pressure to give crude ethyl 4-(7-(((R)-6-chloro-4-fluoro-5-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)nicotinate (260 mg, 336.24 μ mol, 97.89% yield) was obtained, which was used into the next step without further purification. LC-MS: m/z 773.1 ($\text{M}+\text{H}$)⁺.

Step L 5-((S)-4-(7-(((R)-6-chloro-4-fluoro-5-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one




[0988] To a solution of ethyl 4-(7-(((R)-6-chloro-4-fluoro-5-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-6-(4-fluorophenethyl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-((S)-pyrrolidin-2-yl)nicotinate (260 mg, 336.24 μ mol) in H_2O (3 mL), MeOH (4 mL) was added Na_2CO_3 (356.3 mg, 3.36 mmol). The mixture was stirred at 25° C. for 2 hours. The reaction mixture was diluted with H_2O (30 mL), and then extracted with EtOAc (20 mL * 3). The combined organic layers were washed with brine, dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO®; 20 g SepaFlash® Silica Flash Column, Eluent of 0~100% Ethyl acetate/Petroleum ether gradient @30 mL/min) to give compound 5-((S)-4-(7-(((R)-6-chloro-4-fluoro-5-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (39.8 mg, 16.28% yield).

[0989] ¹H NMR (400 MHz, MeOD-d₄) δ ppm 8.00 (d, J=5.6 Hz, 1H), 7.44 (s, 1H), 7.36 (br d, J=8.0 Hz, 1H), 7.23-7.18 (m, 2H), 7.17-7.11 (m, 2H), 7.07 (t, J=8.8 Hz, 2H), 5.84 (q, J=7.7 Hz, 1H), 4.87 (dd, J=6.3, 10.2 Hz, 1H), 3.85


(s, 3H), 3.57-3.51 (m, 1H), 3.25-3.16 (m, 3H), 3.14-2.96 (m, 4H), 2.89-2.81 (m, 1H), 2.39-2.33 (m, 1H), 2.31-2.23 (m, 2H), 2.09 (dt, $J=3.9, 8.4$ Hz, 1H), 1.48-1.37 (m, 1H). LC-MS: m/z 727.0 ($M+H^+$).

5-((S)-4-(7-(((R)-6-fluoro-5-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 257)



[0990] Compound 257 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.


[0991] 1H NMR (400 MHz, $CDCl_3$) δ =8.08 (d, $J=5.6$ Hz, 1H), 7.39 (s, 1H), 7.16-7.07 (m, 4H), 7.01-6.93 (m, 2H), 6.87 (d, $J=7.6$ Hz, 1H), 5.85-5.73 (m, 1H), 4.82-4.70 (m, 1H), 4.53-4.49 (m, 1H), 3.89 (s, 3H), 3.83-3.71 (m, 1H), 3.48-3.37 (m, 1H), 3.21-2.94 (m, 5H), 2.92-2.81 (m, 1H), 2.79-2.67 (m, 1H), 2.57-2.47 (m, 1H), 2.45-2.32 (m, 2H), 2.06-1.91 (m, 2H), 1.48-1.43 (m, 1H). ^{19}F NMR (376 MHz, $CDCl_3$) δ -116.64 (s, 1F), -137.110 (s, 1F). LC-MS: m/z 693.2 ($M+H^+$). 5-((S)-4-(7-(((R)-6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 258)



[0992] Compound 258 was synthesized using a similar procedure described in Example 39 by using the appropriate materials.

[0993] 1H NMR (400 MHz, $MeOD-d_4$) δ ppm 7.92 (d, $J=5.96$ Hz, 1H), 7.50 (s, 1H), 7.21 (d, $J=5.96$ Hz, 1H), 7.14-7.18 (m, 2H), 6.94-7.02 (m, 2H), 6.65 (q, $J=2.42$ Hz, 1H), 6.63 (s, 1H), 5.74 (br t, $J=7.57$ Hz, 1H), 4.59-4.70 (m, 1H), 3.85 (s, 3H), 3.69 (dt, $J=11.12, 8.33$ Hz, 1H), 3.41-3.49 (m, 1H), 3.25-3.30 (m, 2H), 3.07-3.17 (m, 2H), 2.96-3.05 (m, 1H), 2.67-2.81 (m, 2H), 2.41-2.55 (m, 3H), 2.03-2.10 (m, 1H), 1.43-1.55 (m, 1H). ^{19}F NMR (376 MHz, $METHANOL-d_4$) δ ppm -115.38 (s, 1F), -119.00 (s, 1F). LC-MS: m/z 693.1 ($M+H^+$).


5-((S)-4-(7-(((R)-6,8-difluorochroman-4-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 259)



[0994] Compound 259 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.

[0995] 1H NMR (400 MHz, $DMSO-d_6$): δ 12.70 (br s, 1H), 8.00 (d, $J=5.6$ Hz, 1H), 7.48 (d, $J=7.6$ Hz, 1H), 7.45 (s, 1H), 7.05-7.24 (m, 3H), 7.14 (d, $J=5.6$ Hz, 1H), 7.03-7.09 (m, 2H), 6.86-6.93 (m, 1H), 5.60 (dd, $J=6.0$ Hz, $J=13.2$ Hz, 1H), 4.88 (dd, $J=6.0$ Hz, $J=10.0$ Hz, 1H), 4.24-4.43 (m, 2H), 3.51-3.57 (m, 1H), 3.25-3.29 (m, 1H), 3.19 (t, $J=7.6$ Hz, 2H), 2.95-3.12 (m, 2H), 2.22-2.40 (m, 3H), 2.12-2.21 (m, 2H), 1.40-1.48 (m, 1H). ^{19}F NMR (377 MHz, $DMSO-d_6$): -117.02, -121.77, -132.92. LC-MS: m/z 697.2 ($M+H^+$).


5-((S)-4-(7-(((1S,2R)-2,5-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 260)



[0996] Compound 260 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.

[0997] ^1H NMR (400 MHz, CDCl_3) δ =9.15 (s, 1H), 8.06 (d, $J=5.6$ Hz, 1H), 7.43 (s, 1H), 7.17-7.08 (m, 3H), 7.03-6.91 (m, 4H), 6.11-5.91 (m, 1H), 5.63-5.37 (m, 1H), 5.0-4.90 (m, 1H), 4.82-4.73 (m, 1H), 3.98 (s, 3H), 3.84-3.70 (m, 1H), 3.49-3.26 (m, 2H), 3.23-2.97 (m, 5H), 2.58-2.47 (m, 1H), 2.45-2.32 (m, 2H), 1.47-1.40 (m, 1H). ^{19}F NMR (376 MHz, CCl_3D) δ -116.62, -133.15, -195.27. LC-MS: m/z 711.5 ($\text{M}+\text{H}$) $^+$.


5-((S)-4-(7-(((1S,2S)-2,5-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 261)



[0998] Compound 261 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.

[0999] ^1H NMR (400 MHz, CDCl_3) δ =9.27 (br.s., 1H), 8.06 (d, $J=5.6$ Hz, 1H), 7.44 (s, 1H), 7.17-7.11 (m, 3H), 7.01-6.94 (m, 4H), 6.11-5.93 (m, 1H), 5.61-5.42 (m, 1H), 5.01-4.89 (m, 1H), 4.83-4.72 (m, 1H), 3.99 (s, 3H), 3.84-3.70 (m, 1H), 3.49-3.27 (m, 2H), 3.22-3.05 (m, 5H), 2.58-2.47 (m, 1H), 2.40-2.35 (m, 1H), 2.05-1.97 (m, 1H), 1.48-1.41 (m, 1H). ^{19}F NMR (376 MHz, CHLOROFORM-d) δ -116.63, -133.18. LC-MS: m/z 711.2 ($\text{M}+\text{H}$) $^+$.


(R)-4-(7-(((R)-5-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,10,10a-tetrahydro-5H-pyrido[2',3':3,4]pyrrolo[2,1-c][1,4]oxazin-5-one (Compound 262)



[1000] Compound 262 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.

[1001] ^1H NMR (400 MHz, DMSO-d_6) δ 7.98 (d, $J=5.6$ Hz, 1H), 7.42 (s, 1H), 7.17-7.25 (m, 3H), 7.07-7.10 (m, 3H), 6.97-7.04 (m, 1H), 6.91-6.96 (m, 1H), 5.81-5.90 (m, 1H), 4.77-4.84 (m, 1H), 4.45-4.51 (m, 1H), 4.02-4.10 (m, 1H), 3.92-3.98 (m, 1H), 3.88 (d, $J=1.2$ Hz, 3H), 3.22-3.27 (m, 2H), 3.16-3.20 (m, 3H), 2.99-3.09 (m, 3H), 2.81-2.89 (m, 1H), 2.53-2.57 (m, 1H), 2.02-2.13 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d_6): -117.08, -135.37. LC-MS: m/z 709.3 ($\text{M}+\text{H}$) $^+$.


(R)-4-(7-(((R)-5-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,10,10a-tetrahydro-5H-pyrido[2',3':3,4]pyrrolo[2,1-c][1,4]oxazin-5-one
(Compound 263)



[1002] Compound 263 was synthesized using a similar procedure described in Example 20 by using the appropriate materials.

[1003] ^1H NMR (400 MHz, DMSO- d_6): δ 7.35 (s, 1H), 7.15-7.22 (m, 3H), 6.97-7.10 (m, 3H), 6.90-6.96 (m, 2H), 5.85 (q, $J=8.0$ Hz, 1H), 4.81 (dd, $J=4.8$ Hz, $J=10.0$ Hz, 1H), 4.47 (dd, $J=4.0$ Hz, $J=10.4$ Hz, 1H), 4.06 (d, $J=10.0$ Hz, 1H), 3.95 (d, $J=6.8$ Hz, 1H), 3.87 (d, $J=1.2$ Hz, 3H), 3.24-3.27 (m, 2H), 3.16-3.23 (m, 3H), 2.98-3.10 (m, 3H), 2.80-2.90 (m, 1H), 2.54-2.57 (m, 1H), 2.40 (s, 3H), 2.02-2.12 (m, 1H). ^{19}F NMR (377 MHz, DMSO- d_6): -117.02, -135.41. LC-MS: m/z 723.3 ($\text{M}+\text{H}$) $^+$.


(R)-5-(2-(4-fluorophenethyl)-4-(7-((1-methoxy-6,7-dihydro-5H-cyclopenta[c]pyridin-5-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 264)



[1004] Compound 264 was synthesized using a similar procedure described in Example 39 by using the appropriate materials.

[1005] ^1H NMR (400 MHz, DMSO- d_6): δ 12.71 (br s, 1H), 7.99 (d, $J=5.6$ Hz, 1H), 7.94 (d, $J=5.2$ Hz, 1H), 7.43 (s, 1H), 7.31 (d, $J=8.4$ Hz, 1H), 7.17-7.26 (m, 2H), 7.01-7.10 (m, 3H), 6.89 (d, $J=4.8$ Hz, 1H), 5.90 (q, $J=7.6$ Hz, 1H), 3.89 (s, 3H), 3.56 (s, 2H), 3.15-3.24 (m, 3H), 3.01-3.08 (m, 2H), 2.88-2.95 (m, 1H), 2.72-2.78 (m, 1H), 2.63-2.67 (m, 2H), 2.57-2.59 (m, 1H), 2.01-2.09 (m, 1H), 1.71-1.78 (m, 2H). ^{19}F NMR (377 MHz, DMSO- d_6): -117.02. LC-MS: m/z 688.4 ($\text{M}+\text{H}$) $^+$.


(R)-5-(4-(7-((4-chloro-6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 265)



[1006] Compound 265 was synthesized using a similar procedure described in Example 39 by using the appropriate materials.

[1007] ^1H NMR (400 MHz, DMSO- d_6): δ 12.68 (br s, 1H), 8.44 (d, $J=4.4$ Hz, 2H), 7.30-7.34 (m, 2H), 7.18-7.4 (m, 2H), 7.03-7.11 (m, 2H), 6.96 (s, 1H), 5.95-6.00 (m, 1H), 3.56 (s, 2H), 3.15-3.21 (m, 3H), 3.08-3.13 (m, 1H), 3.00-3.04 (m, 2H), 2.90-2.98 (m, 1H), 2.62-2.66 (m, 2H), 2.54-2.60 (m, 1H), 2.43 (s, 3H), 2.06-2.17 (m, 1H), 1.71-1.77 (m, 2H). ^{19}F NMR (377 MHz, DMSO- d_6): -117.05. LC-MS: m/z 706.2 ($\text{M}+\text{H}$) $^+$.


(R)-5-(4-(7-((3-chloro-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 266)



[1008] Compound 266 was synthesized using a similar procedure described in Example 39 by using the appropriate materials.

[1009] ^1H NMR (400 MHz, DMSO- d_6) δ 12.72 (br s, 1H), 8.37 (s, 1H), 7.93 (d, $J=5.6$ Hz, 1H), 7.82 (s, 1H), 7.41 (s, 1H), 7.19-7.27 (m, 3H), 7.03-7.11 (m, 3H), 5.85 (dd, $J=16.0$ Hz, $J=8.4$ Hz 1H), 3.54-3.59 (m, 2H), 3.16-3.23 (m, 3H), 2.96-3.07 (m, 3H), 2.85-2.93 (m, 1H), 2.62-2.67 (m, 2H), 2.58-2.60 (m, 1H), 2.05-2.15 (m, 1H), 1.72-1.78 (m, 2H). ^{19}F NMR (377 MHz, DMSO- d_6): -117.01. LC-MS: m/z 691.7 ($\text{M}+\text{H}^+$).

(R)-5-(4-(7-((5-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)benzo[d]thiazol-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 267)




[1010] Compound 267 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.

[1011] ^1H NMR (400 MHz, DMSO- d_6) δ 12.61 (br s, 1H), 7.38 (t, $J=8.0$ Hz, 1H), 7.31 (d, $J=8.0$ Hz, 1H), 7.20-7.26 (m,

2H), 7.01-7.10 (m, 3H), 6.96-6.98 (m, 1H), 6.89 (d, $J=7.6$ Hz, 1H), 6.29-6.34 (m, 1H), 5.14-5.25 (m, 1H), 3.89 (d, $J=1.2$ Hz, 3H), 3.58 (s, 2H), 3.19-3.26 (m, 3H), 3.01-3.09 (m, 3H), 2.81-2.91 (m, 1H), 2.64-2.69 (m, 2H), 2.55-2.61 (m, 1H), 2.00-2.10 (m, 1H), 1.77-1.79 (m, 2H). ^{19}F NMR (377 MHz, DMSO- d_6): -117.01, -134.94. LC-MS: m/z 705.3 ($\text{M}+\text{H}^+$).


(R)-5-(4-(4-((5-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[3,2-d]pyrimidin-6-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 268)



[1012] Compound 268 was synthesized using a similar procedure described in the Example 10 by using the appropriate materials.

[1013] ^1H NMR (400 MHz, DMSO- d_6) δ 12.74 (br s, 1H), 8.35-8.76 (m, 2H), 7.42-7.47 (m, 1H), 7.18-7.26 (m, 2H), 7.01-7.11 (m, 3H), 6.93-6.99 (m, 1H), 5.87-5.97 (m, 1H), 3.89 (d, $J=1.2$ Hz, 3H), 3.57 (s, 2H), 3.18-3.21 (m, 2H), 3.00-3.07 (m, 3H), 2.86-2.94 (m, 1H), 2.64-2.67 (m, 3H), 2.57-2.59 (m, 1H), 2.04-2.15 (m, 1H), 1.74-1.76 (m, 2H). ^{19}F NMR (377 MHz, DMSO- d_6): -117.00, -134.64. LC-MS: m/z 706.3 ($\text{M}+\text{H}^+$).

(R)-5-(4-(4-((5-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[3,2-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 269)





[1014] Compound 269 was synthesized using a similar procedure described in the Example 10 by using the appropriate materials.

[1015] ^1H NMR (400 MHz, DMSO-d₆): δ 7.90-7.93 (m, 2H), 7.48 (d, J=7.6 Hz, 1H), 7.15-7.24 (m, 3H), 6.99-7.10 (m, 3H), 6.93-6.98 (m, 1H), 5.81 (q, J=7.6 Hz, 1H), 3.88 (d, J=1.2 Hz, 3H), 3.55 (s, 2H), 3.12-3.21 (m, 3H), 2.98-3.11 (m, 3H), 2.81-2.91 (m, 1H), 2.61-2.66 (m, 2H), 2.54-2.57 (m, 1H), 1.98-2.07 (m, 1H), 1.69-1.73 (m, 2H). ^{19}F NMR (377 MHz, DMSO-d₆): -117.06, -135.23. LC-MS: m/z 705.3 (M+H)⁺.

(R)-5-(4-((5-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-d]pyrimidin-6-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 270)

(R)-5-(4-((5-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[3,2-b]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 271)




[1016] Compound 270 was synthesized using a similar procedure described in the Example 10 by using the appropriate materials.

[1017] ^1H NMR (400 MHz, DMSO-d₆): δ 12.73 (br s, 1H), 8.42 (s, 1H), 8.38 (d, J=8.0 Hz, 1H), 7.80 (s, 1H), 7.19-7.24 (m, 2H), 7.03-7.09 (m, 3H), 6.96-7.00 (m, 1H), 5.83-5.91 (m, 1H), 3.89 (d, J=0.8 Hz, 3H), 3.55 (s, 2H), 3.12-3.21 (m, 3H), 3.05-3.10 (m, 1H), 2.97-3.01 (m, 2H), 2.87-2.91 (m, 1H), 2.62-2.64 (m, 2H), 2.55-2.57 (m, 1H), 2.01-2.09 (m, 1H), 1.66-1.75 (m, 2H). ^{19}F NMR (377 MHz, DMSO-d₆): δ -117.11, -134.66. LC-MS: m/z 706.2 (M+H)⁺.

[1018] Compound 271 was synthesized using a similar procedure described in the Example 10 by using the appropriate materials.

[1019] ^1H NMR (400 MHz, DMSO-d₆): δ 12.71 (br s, 1H), 8.26 (d, J=5.2 Hz, 1H), 7.40 (s, 1H), 7.19-7.26 (m, 2H), 7.02-7.14 (m, 4H), 6.91-6.96 (m, 1H), 6.73 (d, J=5.6 Hz, 1H), 5.29 (q, J=7.2 Hz, 1H), 3.88 (d, J=1.2 Hz, 3H), 3.57 (s, 2H), 3.11-3.21 (m, 3H), 3.00-3.06 (m, 3H), 2.81-2.92 (m, 1H), 2.62-2.67 (m, 2H), 2.54-2.60 (m, 1H), 2.03-2.14 (m, 1H), 1.71-1.79 (m, 2H). ^{19}F NMR (377 MHz, DMSO-d₆): -117.03, -134.70. LC-MS: m/z 705.3 (M+H)⁺.


(R)-5-(4-((4-fluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 272)



[1020] Compound 272 was synthesized using a similar procedure described in Example 10 by using the appropriate materials. (8.30 mg, 0.012 mmol, 16.52%)

[1021] ^1H NMR (400 MHz, DMSO-d₆): δ 12.71 (br s, 1H), 7.98 (d, J=5.2 Hz, 1H), 7.42 (s, 1H), 7.31 (d, J=8.4 Hz, 1H), 7.15-7.25 (m, 3H), 6.99-7.12 (m, 5H), 5.93 (q, J=8.0 Hz, 1H), 3.56 (s, 2H), 3.16-3.23 (m, 3H), 3.00-3.09 (m, 3H), 2.79-2.89 (m, 1H), 2.63-2.66 (m, 2H), 2.55-2.59 (m, 1H), 2.03-2.15 (m, 1H), 1.74 (d, J=4.0 Hz, 2H). ^{19}F NMR (377 MHz, DMSO-d₆): -117.01, -119.17. LC-MS: m/z 675.3 (M+H)⁺.


(R)-5-(4-(7-((5-chloro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 273)



[1022] Compound 273 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.

[1023] ^1H NMR (400 MHz, DMSO-d₆) δ 12.71 (br s, 1H), 7.98 (d, J=6.0 Hz, 1H), 7.42 (s, 1H), 7.33 (s, 1H), 7.16-7.29 (m, 5H), 7.03-7.11 (m, 3H), 5.85 (q, J=8.0 Hz, 1H), 3.56 (s, 2H), 3.16-3.23 (m, 3H), 2.99-3.06 (m, 3H), 2.81-2.89 (m, 1H), 2.62-2.66 (m, 2H), 2.54-2.57 (m, 1H), 2.01-2.17 (m, 1H), 1.70-1.79 (m, 2H). ^{19}F NMR (377 MHz, DMSO-d₆): -117.02. LC-MS: m/z 691.2 (M+H)⁺.


(R)-5-(4-(7-((6-chloro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 274)



[1024] Compound 274 was synthesized using a similar procedure described in Example 10 by using the appropriate materials. (4.19 mg, 3.33%)

[1025] ^1H NMR (400 MHz, DMSO-d₆): δ 12.71 (br s, 1H), 7.99 (d, J=5.6 Hz, 1H), 7.44 (s, 1H), 7.34 (d, J=8.4 Hz, 1H), 7.26-7.30 (m, 2H), 7.20-7.24 (m, 3H), 7.05-7.12 (m, 3H), 5.86 (q, J=8.0 Hz, 1H), 3.57 (s, 2H), 3.16-3.23 (m, 3H), 2.95-3.06 (m, 3H), 2.81-2.86 (m, 1H), 2.63-2.67 (m, 2H), 2.56-2.58 (m, 1H), 2.01-2.10 (m, 1H), 1.71-1.80 (m, 2H). ^{19}F NMR (377 MHz, DMSO-d₆): δ -117.01. LC-MS: m/z 691.2 (M+H)⁺.

(R)-5-(4-(7-((5-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(3-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 275)





[1026] Compound 275 was synthesized using a similar procedure described in Example 10 by using the appropriate materials. (3.86 mg, 3.39%)

[1027] ^1H NMR (400 MHz, DMSO-d₆): δ 12.61 (br s, 1H), 7.97 (d, J=5.2 Hz, 1H), 7.40 (s, 1H), 7.30 (dd, J=14.0 Hz, J=8.0 Hz, 1H), 7.22 (d, J=8.0 Hz, 1H), 7.08 (d, J=5.6 Hz, 1H), 6.98-7.06 (m, 4H), 6.90-6.94 (m, 1H), 5.81-5.87 (m, 1H), 3.88 (s, 3H), 3.56 (s, 2H), 3.17-3.23 (m, 3H), 3.02-3.10 (m, 3H), 2.82-2.86 (m, 1H), 2.61-2.67 (m, 2H), 2.56-2.59 (m, 1H), 2.03-2.11 (m, 1H), 1.70-1.79 (m, 2H). ^{19}F NMR (377 MHz, DMSO-d₆): δ -113.58, -135.37. LC-MS: m/z 705.2 (M+H)⁺.

(R)-5-(4-(7-((5-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(2-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 276)

(R)-5-(2-(3-chlorophenethyl)-4-(7-((5-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 277)




[1028] Compound 276 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.

[1029] ^1H NMR (400 MHz, DMSO-d₆): δ 12.72 (s, 1H), 7.98 (d, J=5.6 Hz, 1H), 7.42 (s, 1H), 7.20-7.30 (m, 3H), 7.06-7.13 (m, 3H), 6.98-7.05 (m, 1H), 6.91-6.96 (m, 1H), 5.84 (q, J=8.0 Hz, 1H), 3.88 (d, J=1.2 Hz, 3H), 3.56 (s, 2H), 3.16-3.22 (m, 3H), 3.01-3.09 (m, 3H), 2.79-2.90 (m, 1H), 2.62-2.65 (m, 2H), 2.56-2.58 (m, 1H), 2.03-2.12 (m, 1H), 1.70-1.78 (m, 2H). ^{19}F NMR (377 MHz, DMSO-d₆): -119.24, -135.35. LC-MS: m/z 705.3 (M+H)⁺.

[1030] Compound 277 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.

[1031] ^1H NMR (400 MHz, DMSO-d₆): δ 12.71 (br s, 1H), 7.98 (d, J=5.6 Hz, 1H), 7.41 (s, 1H), 7.22-7.32 (m, 4H), 7.17 (d, J=8.0 Hz, 1H), 7.09 (d, J=5.6 Hz, 1H), 7.97-7.05 (m, 1H), 6.90-6.96 (m, 1H), 5.84 (q, J=8.0 Hz, 1H), 3.88 (s, 3H), 3.56 (s, 2H), 3.17-3.27 (m, 3H), 3.03-3.11 (m, 3H), 2.80-2.87 (m, 1H), 2.62-2.66 (m, 2H), 2.54-2.57 (m, 1H), 2.01-2.12 (m, 1H), 1.69-1.79 (m, 2H). ^{19}F NMR (377 MHz, DMSO-d₆): -135.35. LC-MS: m/z 721.2 (M+H)⁺.

(R)-5-(2-(2-chlorophenethyl)-4-(7-((5-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 278)




[1032] Compound 278 was synthesized using a similar procedure described in Example 10 by using the appropriate materials. (2.77 mg, 0.004 mmol, 5.48%)

[1033] ^1H NMR (400 MHz, DMSO-d₆): δ 12.75 (br s, 1H), 7.93 (d, J=6.0 Hz, 1H), 7.50-7.59 (m, 1H), 7.36-7.40 (m, 1H), 7.20-7.32 (m, 4H), 6.99-7.12 (m, 2H), 5.62-5.75 (m, 1H), 3.89 (d, J=1.2 Hz, 3H), 3.56 (s, 2H), 3.18-3.27 (m, 3H), 3.04-3.16 (m, 3H), 2.83-2.94 (m, 1H), 2.63-2.67 (m, 2H), 2.57-2.62 (m, 1H), 2.05-2.18 (m, 1H), 1.74 (d, J=4.0 Hz, 2H). ^{19}F NMR (377 MHz, DMSO-d₆): -135.67. LC-MS: m/z 721.2 (M+H)⁺.

(R)-5-(4-(7-((4,6-difluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-5,7,8,9-tetrahydro-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 279)


(R)-5-(4-(7-((5-fluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-5,7,8,9-tetrahydro-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one
(Compound 280)



[1036] Compound 280 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.


[1037] ^1H NMR (400 MHz, MeOD-d₄) δ 7.79 (d, J=6.8 Hz, 1H), 7.66 (s, 1H), 7.35-7.48 (m, 2H), 7.09-7.20 (m, 3H), 6.92-7.06 (m, 3H), 5.47-5.57 (m, 1H), 3.66-3.71 (m, 2H), 3.34-3.36 (m, 1H), 3.28-3.32 (m, 2H), 3.10-3.23 (m, 3H), 2.98-3.09 (m, 1H), 2.75-2.86 (m, 3H), 2.18-2.31 (m, 1H), 1.83 (m, 2H). ^{19}F NMR (376 MHz, MeOD-d₄) δ -115.90, -118.94. LC-MS: m/z 675.2 (M+H)⁺.

(S)-5-(4-(7-((2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-5,7,8,9-tetrahydro-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 281)



[1034] Compound 279 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.

[1035] ^1H NMR (400 MHz, CDCl₃) δ 7.98 (d, J=6 Hz, 1H), 7.29 (s, 1H), 7.00-7.09 (m, 3H), 6.93 (s, 1H), 6.56-6.64 (m, 1H), 5.75-5.87 (m, 1H), 4.33-4.59 (m, 1H), 3.58 (s, 2H), 3.16-3.21 (m, 1H), 3.08-3.14 (m, 2H), 2.94-3.06 (m, 3H), 2.71-2.83 (m, 2H), 2.64-2.69 (m, 2H), 1.86-1.94 (m, 1H), 1.69-1.73 (m, 2H). ^{19}F NMR (376 MHz, CDCl₃) δ -112.23 (s, 1F), -114.64 (s, 1F), -116.65 (s, 1F). LC-MS: m/z 693.1 (M+H)⁺.





[1038] Compound 281 was synthesized using a similar procedure described in Example 22 by using the appropriate materials.

[1039] ^1H NMR (400 MHz, MeOD-d₄) δ 7.98 (d, J=5.6 Hz, 1H), 7.47 (s, 1H), 7.26-7.30 (m, 1H), 7.13-7.22 (m, 3H), 6.89-7.03 (m, 4H), 6.19-6.33 (m, 1H), 3.87 (s, 3H), 3.68 (s, 2H), 3.37-3.53 (m, 2H), 3.21-3.30 (m, 3H), 3.06-3.16 (m, 2H), 2.73-2.85 (m, 2H), 1.75-1.86 (m, 2H). ^{19}F NMR (376 MHz, MeOD-d₄) δ ppm -102.28 (d, J=230.86, 1F) -109.85 (d, J=230.86 Hz, 1F), -118.99 (s, 1F). LC-MS: m/z 723.1 (M+H)⁺.

5-((S)-2-(4-fluorophenethyl)-5-oxo-4-(7-(((S)-2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 282)

(S)-5-(2-(4-fluorophenethyl)-5-oxo-4-(7-((2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5,7,8,9-tetrahydro-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 283)




[1040] Compound 282 was synthesized using a similar procedure described in Example 22 by using the appropriate materials.

[1041] ^1H NMR (400 MHz, MeOD-d₄) δ 7.99 (d, J=5.2 Hz, 1H), 7.47 (s, 1H), 7.13-7.23 (m, 3H), 7.07-7.12 (m, 1H), 6.95-7.04 (m, 3H), 6.22 (t, J=10.91 Hz, 1H), 4.88 (m, 1H), 3.99 (d, J=2.15 Hz, 3H), 3.69 (dt, J=11.27, 8.31 Hz, 1H), 3.40-3.62 (m, 3H), 3.22-3.30 (m, 2H), 3.02-3.20 (m, 2H), 2.38-2.56 (m, 3H), 1.42-1.55 (m, 1H). ^{19}F NMR (376 MHz, MeOD-d₄) δ -102.08 (d, J=246 Hz, 1F), -109.84 (d, J=246 Hz, 1F), -119.02 (s, 1F), -133.84 (s, 1F). LC-MS: m/z 729.1 (M+H)⁺.

[1042] Compound 283 was synthesized using a similar procedure described in Example 22 by using the appropriate materials.

[1043] ^1H NMR (400 MHz, MeOD-d₄) δ 7.88 (d, J=6.8 Hz, 1H), 7.68 (s, 1H), 7.52 (d, J=6.4 Hz, 1H), 7.12-7.25 (m, 4H), 6.93-7.02 (m, 2H), 5.79-5.88 (m, 1H), 3.98-4.06 (m, 3H), 3.69 (s, 2H), 3.52-3.67 (m, 2H), 3.35 (s, 1H), 3.27-3.32 (m, 2H), 3.09-3.17 (m, 2H), 2.76-2.85 (m, 2H), 1.83 (d, J=5.72 Hz, 2H). ^{19}F NMR (376 MHz, MeOD-d₄) δ -100.75 (d, J=233.37 Hz, 1F), -109.62 (d, J=233.37 Hz, 1F), -118.94 (s, 1F), -131.60 (s, 1F). LC-MS: m/z 741.1 (M+H)⁺.

(R)-4-(7-(((S)-2,2-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-3-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-7,8,10,10a-tetrahydro-5H-pyrido[2',3':4']pyrrolo[2,1-c][1,4]oxazin-5-one (Compound 284)







[1044] Compound 284 was synthesized using a similar procedure described in Example 22 by using the appropriate materials.


[1045] ^1H NMR (400 MHz, MeOD-d₄) δ 8.00 (d, J=5.72 Hz, 1H), 7.48 (s, 1H), 7.29 (t, J=7.93 Hz, 1H), 7.11-7.22 (m, 3H), 6.88-7.03 (m, 4H), 6.27 (t, J=11.21 Hz, 1H), 4.81 (dd, J=10.43, 4.59 Hz, 1H), 4.63 (dd, J=11.03, 4.59 Hz, 1H), 4.22 (d, J=10.73 Hz, 1H), 4.00-4.09 (m, 1H), 3.88 (s, 3H), 3.35-3.53 (m, 4H), 3.24-3.30 (m, 2H), 3.05-3.24 (m, 3H). ^{19}F NMR (376 MHz, MeOD-d₄) δ -102.23 (d, J=231.12 Hz, 1F), -109.86 (d, J=231.12 Hz, 1F), -119.03 (s, 1F). LC-MS: m/z 727.1 (M+H)⁺.

Example 40

(R)-5-(4-((4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-5,7,8,9-tetrahydro-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 285)



Step A 3-(3-fluoro-2-methoxyphenyl)propanoic acid



[1046] To stirred HCOOH (46.75 g, 973.15 mmol) was added TEA (45.15 mL, 324.38 mmol) dropwise at 0°C. and the mixture was stirred for 15 minutes. After 3-fluoro-2-methoxy-benzaldehyde (50.0 g, 324.38 mmol) and 2,2-dimethyl-1,3-dioxane-4,6-dione (49.09 g, 340.60 mmol) were added and the mixture was stirred at 100°C. for 11.75 hrs. After cooling to 10~20°C., the mixture was added dropwise to saturated Na₂CO₃ aqueous solution (200 mL) under stirring. The mixture was extracted with ethyl acetate (100 mL×2). To the aqueous layer was added HCl (150 mL,

3 M) dropwise under stirring and the mixture was extracted with ethyl acetate (100 mL×3). The combined organic layers were washed with brine (100 mL), dried over Na_2SO_4 , filtered and the filtrate was concentrated under reduced pressure to give 3-(3-fluoro-2-methoxy-phenyl) propanoic acid (64.0 g, 89.59% yield, 90% purity by H NMR).

[1047] ^1H NMR (400 MHz, CDCl_3) δ =7.05-6.88 (m, 3H), 3.98-3.92 (m, 3H), 3.03-2.92 (m, 2H), 2.71-2.62 (m, 2H).

Step B


5-fluoro-4-hydroxy-2,3-dihydro-1H-inden-1-one



[1048] To an ice cooled solution of 3-(3-fluoro-2-methoxyphenyl) propanoic acid (2.0 g, 10.09 mmol) in DCE (20.0 mL) was added trifluoromethanesulfonic acid (15.26 g, 101.71 mmol) and the reaction mixture was stirred at 120° C. for 16 hours. After cooling to room temperature, the reaction mixture was poured onto ice water (100 mL) and extracted with ethyl acetate (100 mL×2). The combined organic layers were washed with brine (100 mL), dried over anhydrous Na_2SO_4 and the filtrate was concentrated under reduced pressure to afford a crude. The crude product was purified by column chromatography (SiO_2 , 30-90% ethyl acetate in petroleum ether) to give the product, which was triturated with DCM (30 mL) at 20-30° C. for 5 minutes to give 5-fluoro-4-hydroxy-2,3-dihydro-1H-inden-1-one (1.27 g, 75.75% yield). LC-MS: m/z 166.9 ($\text{M}+\text{H})^+$.

[1049] ^1H NMR (400 MHz, CDCl_3) δ =7.40-7.30 (m, 1H), 7.21-7.08 (m, 1H), 5.54 (br.s., 1H), 3.13-3.09 (m, 2H), 2.76-2.72 (m, 2H).

Step C 4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-one




[1050] To a mixture of 5-fluoro-4-hydroxy-2,3-dihydro-1H-inden-1-one (1.07 g, 6.44 mmol) in DMF (70.0 mL) and water (10.0 mL) was added sodium sodium;2-chloro-2,2-difluoro-acetate (2.54 g, 16.67 mmol) and cesium carbonate (4.15 g, 12.73 mmol). The mixture was stirred for 15 minutes at 25-30° C. and then heated to 100° C. for 12 hours under nitrogen. After cooling to room temperature, the mixture was diluted with water (100 mL) and extracted with ethyl acetate (100 mL×2). The combined organic layers were washed with brine (200 mL), dried over anhydrous

sodium sulfate, filtered and the filtrate was concentrated to give a crude. The crude was purified by column chromatography (SiO_2 , 23% ethyl acetate in petroleum ether) to give 4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-one (760.0 mg, 54.60% yield). LC-MS: m/z 216.8 ($\text{M}+\text{H})^+$.

[1051] ^1H NMR (400 MHz, CDCl_3) δ =7.75-7.60 (m, 1H), 7.26-7.18 (m, 1H), 6.66 (t, J =73.6 Hz, 1H), 3.23-3.17 (m, 2H), 2.83-2.68 (m, 2H).


Step D (R,Z)—N-(4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide



[1052] To a stirred solution of 4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-one (880.0 mg, 4.07 mmol) in THF (15.0 mL) was added (R)-2-methylpropane-2-sulfonamide (530.0 mg, 4.37 mmol) and Ti(OEt)_4 (2.10 g, 9.19 mmol) under N_2 and the mixture was stirred under N_2 at 80° C. for 12 hours. After cooling to room temperature, the mixture was diluted with cold water (50 mL) and extracted with ethyl acetate (50 mL×3). The combined organic layers were dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated to give a crude. The crude was purified by column chromatography (SiO_2 , 31-38% ethyl acetate in petroleum ether) to give (R,Z)—N-(4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide (490.0 mg, 37.69% yield).

[1053] ^1H NMR (400 MHz, CDCl_3) δ =7.81-7.61 (m, 1H), 7.24-7.14 (m, 1H), 6.63 (t, J =74.0 Hz, 1H), 3.61-3.41 (m, 1H), 3.24-3.06 (m, 3H), 1.33 (s, 9H).


Step E (R)—N—((R)-4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfonamide



[1054] To a stirred solution of (R,Z)—N-(4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide (490.0 mg, 1.53 mmol) in DCM (10.0 mL) was added DIBAL-H (2.30 mL, 1 M) dropwise under N₂ at -65° C. and the mixture was stirred for 1 hour. The reaction mixture was quenched by addition MeOH (20 mL) at -65° C. and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (45% ethyl acetate in petroleum ether) to give (R)—N—((R)-4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfonamide (320.0 mg, 64.90% yield).

[1055] ¹H NMR (400 MHz, CDCl₃) δ=7.54-7.42 (m, 1H), 7.11-7.00 (m, 1H), 6.57 (t, J=74.0 Hz, 1H), 5.00-4.79 (m, 1H), 3.49-3.39 (m, 1H), 3.23-2.96 (m, 1H), 2.93-2.76 (m, 1H), 2.63-2.46 (m, 1H), 2.05-1.91 (m, 1H), 1.24 (s, 9H).


Step F (R)-4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-amine



[1056] To a solution of (R)—N—((R)-4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfonamide (320.0 mg, 995.78 μmol) in DCM (2.0 mL) was added HCl/dioxane (4 mL, 4 M) dropwise at 0° C. and the mixture was stirred at 0-30° C. for 4 hours. The mixture was concentrated under reduced pressure to give (R)-4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-amine (250.0 mg, crude, HCl salt).

[1057] ¹H NMR (400 MHz, DMSO-d₆) δ=8.61 (br.s., 3H), 7.67-7.55 (m, 1H), 7.45-7.30 (m, 1H), 7.19 (t, J=73.2 Hz, 2H), 4.74 (br.s., 1H), 3.17-3.10 (m, 1H), 2.97-2.88 (m, 1H), 2.61-2.53 (m, 1H), 2.15-1.95 (m, 1H).


Step G (R)—N-(4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-yl)-2-(1,3-dioxolan-2-yl)thieno[2,3-c]pyridin-7-amine



[1058] A mixture of (R)-4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-amine (230.0 mg, 906.77 μmol, HCl salt), 7-chloro-2-(1,3-dioxolan-2-yl)thieno[2,3-c]pyridine (230.0 mg, 951.62 μmol), Cs₂CO₃ (920.0 mg, 2.82 mmol), Pd(dba)₂ (60.0 mg, 104.35 μmol) and BINAP (90.0 mg, 144.54 μmol) in dioxane (10.0 mL) was stirred at 100° C. for 12 hours under N₂. The reaction mixture was concentrated to give a crude. The crude was purified by column chromatography (SiO₂, 11.1% ethyl acetate in petroleum ether) to give (R)—N-(4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-yl)-2-(1,3-dioxolan-2-yl)thieno[2,3-c]pyridin-7-amine (310.0 mg, 80.93% yield). LC-MS: m/z 422.9 (M+H)⁺.

[1059] ¹H NMR (400 MHz, CDCl₃) δ=8.08 (d, J=5.6 Hz, 1H), 7.37 (s, 1H), 7.24-7.18 (m, 1H), 7.08 (d, J=5.6 Hz, 1H), 7.05-6.96 (m, 1H), 6.60 (t, J=74.4 Hz, 1H), 6.22 (s, 1H), 5.98-5.85 (m, 1H), 4.71-4.44 (m, 1H), 4.15-4.12 (m, 2H), 4.11-4.07 (m, 2H), 3.24-3.12 (m, 1H), 2.99-2.90 (m, 1H), 2.87-2.77 (m, 1H), 2.03-1.97 (m, 1H).


Step H (R)-7-((4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde




[1060] To a stirred solution of (R)—N-(4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-yl)-2-(1,3-dioxolan-2-yl)thieno[2,3-c]pyridin-7-amine (290.0 mg, 686.52 μmol) in THF (10.0 mL) was added HCl (10.0 mL, 6 M) and the mixture was stirred for 2 hours at 10-15° C. The reaction mixture was concentrated under reduced pressure, neutralized to pH=7 with saturated NaHCO₃ aqueous solution and extracted with ethyl acetate (50 mL×3). The combined organic layers were washed with brine (200 mL), dried over anhydrous Na₂SO₄, filtered and the filtrate was concentrated to give a crude. The crude was purified by column chromatography (SiO₂, 30% ethyl acetate in petroleum ether) to give (R)-7-((4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (240.0 mg, 92.39% yield).

[1061] ¹H NMR (400 MHz, CDCl₃) δ=10.15 (s, 1H), 8.16 (d, J=6.0 Hz, 1H), 8.00 (s, 1H), 7.25-7.18 (m, 2H), 7.07-6.99 (m, 1H), 6.61 (t, J=74.4 Hz, 1H), 6.02-5.82 (m, 1H), 4.84-4.66 (m, 1H), 3.31-3.11 (m, 1H), 3.03-2.91 (m, 1H), 2.88-2.74 (m, 1H), 2.05-1.98 (m, 1H).

Step I5-(4-((R)-4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-1,5,8,9-tetrahydro-4H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one



Step J (R)-5-(4-((4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 285)




[1062] A mixture of (R)-7-((4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (100.0 mg, 264.29 μmol), 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one (80.0 mg, 319.71 μmol), potassium 5-oxo-2,3-dihydro-1H,5H-2,7a-methanopyrrolizin-7-olate (100.0 mg, 264.20 μmol) and NH₄OAc (50.0 mg, 648.66 μmol) in AcOH (5.0 mL) was stirred at 110° C. for 1 hour. After cooling to room temperature, the reaction mixture was added to water (100 mL). The precipitate was collected by filtration and the filter cake was washed with water (100 mL) to afford the desired compound. The desired compound was dissolved in ethyl acetate (100 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated to give a crude. The crude was purified by combi flash (SiO₂, 4-6% methanol in dichloromethane) to afford 5-(4-(7-((R)-4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-1,5,8,9-tetrahydro-4H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (60.0 mg, 30.57% yield). LC-MS: m/z 743.2 (M+H)⁺.

[1063] To a solution of 5-(4-((R)-4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-1,5,8,9-tetrahydro-4H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (50.0 mg, 67.32 μmol) in MeCN (5.0 mL) was added CAN (75.0 mg, 136.81 μmol) at 10-15° C. and the mixture was stirred at 25-30° C. for 1 hour. The reaction mixture was concentrated under reduced pressure, diluted with water (40 mL) and extracted with ethyl acetate (40 mL×2). The combined organic layers were washed with brine (100 mL), dried over anhydrous sodium sulfate, filtered and the filtrate was concentrated to give a crude. The crude was purified by prep-HPLC (column: C₁₈ 150×30 mm; mobile phase: [water (FA)-ACN]; gradient: 30%-60% B over 7 min), concentrated and lyophilized to give (R)-5-(4-((4-(difluoromethoxy)-5-fluoro-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (285) (25.75 mg, 51.64% yield, 100.0% purity).

[1064] ¹H NMR (400 MHz, CDCl₃) δ=8.04 (d, J=5.6 Hz, 1H), 7.36 (s, 1H), 7.23-7.18 (m, 1H), 7.16-7.10 (m, 2H), 7.08 (d, J=5.6 Hz, 1H), 7.02-6.93 (m, 3H), 6.58 (t, J=74.4 Hz, 1H), 5.91-5.77 (m, 1H), 5.06-4.32 (m, 1H), 3.65 (s, 2H), 3.27-3.22 (m, 2H), 3.13-3.04 (m, 3H), 2.96-2.87 (m, 1H), 2.78-2.71 (m, 3H), 2.02-1.97 (m, 1H), 1.80-1.77 (m, 2H). ¹⁹F NMR (400 MHz, CDCl₃) δ=−80.873, −116.668, −131.859. LC-MS: m/z 741.3 (M+H)⁺.


(R)-5-(4-((5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 286)



[1065] Compound 286 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.

[1066] ^1H NMR (400 MHz, DMSO- d_6) δ 7.98 (d, $J=5.2$ Hz, 1H), 7.40 (s, 1H), 7.20-7.27 (m, 3H), 7.04-7.11 (m, 3H), 6.91-6.97 (m, 1H), 5.78-5.85 (m, 1H), 3.94 (d, $J=1.2$ Hz, 3H), 3.55 (s, 2H), 3.13-3.21 (m, 3H), 2.97-3.06 (m, 3H), 2.80-2.89 (m, 1H), 2.62-2.66 (m, 2H), 2.53-2.55 (m, 1H), 2.01-2.11 (m, 1H), 1.73-1.74 (m, 2H). ^{19}F NMR (377 MHz, DMSO- d_6): -117.06, -138.71, -158.73. LC-MS: m/z 723.3 (M+H) $^+$.


(R)-5-(4-(5-(difluoromethyl)-7-((5-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 287)



[1067] Compound 287 was synthesized using a similar procedure described in Example 21 by using the appropriate materials.

[1068] ^1H NMR (400 MHz, DMSO- d_6) δ 12.74 (br s, 1H), 7.64 (d, $J=7.6$ Hz, 1H), 7.53 (s, 1H), 7.39 (s, 1H), 7.19-7.26 (m, 2H), 7.04-7.11 (m, 2H), 6.95-7.02 (m, 2H), 6.68-6.94 (m, 1H), 5.83 (q, $J=8.0$ Hz, 1H), 3.88 (d, $J=1.2$ Hz, 3H), 3.56 (s, 2H), 3.17-3.23 (m, 3H), 3.01-3.09 (m, 3H), 2.84-2.92 (m, 1H), 2.63-2.66 (m, 2H), 2.54-2.56 (m, 1H), 2.07-2.13 (m, 1H), 1.73-1.78 (m, 2H). ^{19}F NMR (377 MHz, DMSO- d_6): -114.68, -117.00, -135.17. LC-MS: m/z 755.3 (M+H) $^+$.


(R)-5-(4-((5,7-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 288)



[1069] Compound 288 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.

[1070] ^1H NMR (400 MHz, DMSO- d_6) δ 12.70 (br s, 1H), 7.98 (d, $J=5.6$ Hz, 1H), 7.41 (s, 1H), 7.32 (d, $J=8.0$ Hz, 1H), 7.17-7.25 (m, 2H), 7.03-7.16 (m, 4H), 5.96-6.05 (m, 1H), 3.85 (s, 3H), 3.56 (s, 2H), 3.16-3.23 (m, 3H), 3.07-3.14 (m, 1H), 3.00-3.06 (m, 2H), 2.83-2.95 (m, 1H), 2.62-2.66 (m, 2H), 2.53-2.58 (m, 1H), 2.01-2.11 (m, 1H), 1.70-1.78 (m, 2H). ^{19}F NMR (377 MHz, DMSO- d_6): -117.02, -120.84, -129.92. LC-MS: m/z 723.2 (M+H) $^+$.


(R)-5-(4-((7-((6-chloro-4-fluoro-5-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-5,7,8,9-tetrahydro-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 289)



[1071] Compound 289 was synthesized using a similar procedure described in Example 39 by using the appropriate materials.

[1072] ^1H NMR (400 MHz, DMSO- d_6) δ 12.96-12.50 (m, 1H), 8.00 (d, $J=5.6$ Hz, 1H), 7.44 (s, 1H), 7.34 (d, $J=8.0$ Hz, 1H), 7.22 (dd, $J=5.6, 8.4$ Hz, 2H), 7.15-7.06 (m, 4H), 5.85 (d, $J=7.6$ Hz, 1H), 3.86 (s, 3H), 3.57 (s, 2H), 3.23-3.18 (m, 3H), 3.08-3.02 (m, 3H), 2.86 (td, $J=8.2, 16.0$ Hz, 1H), 2.65 (br s, 2H), 2.58 (br dd, $J=4.4, 8.4$ Hz, 1H), 2.15-2.04 (m, 1H), 1.75 (br d, $J=4.4$ Hz, 2H). LC-MS: m/z 739.2 ($\text{M}+\text{H}$) $^+$.


5-((S)-2-(4-fluorophenethyl)-5-oxo-4-(7-((R)-2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 290)



[1073] Compound 290 was synthesized using a similar procedure described in Example 22 by using the appropriate materials.

[1074] ^1H NMR (400 MHz, MeOD- d_4) δ 7.99 (d, $J=5.72$ Hz, 1H), 7.47 (s, 1H), 7.13-7.23 (m, 3H), 7.05-7.12 (m, 1H), 6.94-7.04 (m, 3H), 6.22 (t, $J=10.85$ Hz, 1H), 4.87 (s, 1H), 3.99 (d, $J=2.03$ Hz, 3H), 3.61-3.73 (m, 1H), 3.39-3.60 (m, 3H), 3.23-3.29 (m, 2H), 3.04-3.19 (m, 2H), 2.37-2.55 (m, 3H), 1.45-1.50 (m, 1H). ^{19}F NMR (376 MHz, MeOD- d_4) δ -102.41 (d, $J=231.13$ Hz, 1F), -109.86 (d, $J=231.13$ Hz, 1F), -119.00 (s, 1F), -133.82 (s, 1F). LC-MS: m/z 729.1 ($\text{M}+\text{H}$) $^+$.


5-(4-((1S,2R)-2,5-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-5,7,8,9-tetrahydro-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 291)



[1075] Compound 291 was synthesized using a similar procedure described in Example 24 by using the appropriate materials.

[1076] ^1H NMR (400 MHz, CDCl_3) δ 8.06 (d, $J=5.6$ Hz, 1H), 7.41 (s, 1H), 7.18-7.10 (m, 3H), 7.00-6.93 (m, 4H), 6.11-5.93 (m, 1H), 5.60-5.40 (m, 1H), 5.00-4.89 (m, 1H), 4.02-3.94 (m, 3H), 3.67 (s, 2H), 3.42-3.28 (m, 1H), 3.27-3.23 (m, 1H), 3.23-3.05 (m, 5H), 2.79-2.71 (m, 2H), 1.82-1.77 (m, 2H). ^{19}F NMR (376 MHz, CCl_3D) δ -116.69, -133.20, -195.27. LC-MS: m/z 723.4 ($\text{M}+\text{H}$) $^+$.


(R)-5-(2-(4-fluorophenethyl)-5-oxo-4-(7-((2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5,7,8,9-tetrahydro-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 292)



[1077] Compound 292 was synthesized using a similar procedure described in Example 22 by using the appropriate materials.

[1078] ^1H NMR (400 MHz, MeOD-d₄) δ 7.88 (d, J=6.8 Hz, 1H), 7.68 (s, 1H) 7.54 (d, J=10.8 Hz, 1H) 7.13-7.25 (m, 4H) 6.93-7.03 (m, 2H) 5.80-5.91 (m, 1H), 4.00-4.06 (m, 3H), 3.69 (s, 2H), 3.54-3.66 (m, 2H), 3.34-3.36 (m, 1H), 3.28-3.32 (m, 2H), 3.09-3.17 (m, 2H), 2.81 (br s, 2H), 1.83 (dd, J=4.53, 1.31 Hz, 2H). ^{19}F NMR (376 MHz, MeOD-d₄) δ -100.78 (d, J=233.37 Hz, 1F), -109.62 (d, J=233.37 Hz, 1F), -118.93 (s, 1F), -131.62 (s, 1F). LC-MS: m/z 741.1 (M+H)⁺.

(R)-5-(4-(7-((6,8-difluorochroman-4-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 293)




[1079] Compound 293 was synthesized using a similar procedure described in Example 10 by using the appropriate materials.


[1080] ^1H NMR (400 MHz, DMSO-d₆): δ 12.70 (br s, 1H), 8.00 (d, J=5.6 Hz, 1H), 7.45 (d, J=8.0 Hz, 1H), 7.43 (s, 1H), 7.15-7.24 (m, 3H), 7.13 (d, J=5.6 Hz, 1H), 7.05-7.10 (m, 2H), 6.87-6.92 (m, 1H), 5.61 (q, J=6.4 Hz, 1H), 4.27-4.43 (m, 2H), 3.56 (s, 2H), 3.16-3.22 (m, 3H), 2.99-3.06 (m, 2H), 2.61-2.68 (m, 2H), 2.14-2.22 (m, 2H), 1.71-1.77 (m, 2H). ^{19}F NMR (377 MHz, DMSO-d₆): -117.04, -121.79, -132.93. LC-MS: m/z 709.3 (M+H)⁺.

Example 41


(R)-5-(4-(7-((6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-5,7,8,9-tetrahydro-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 294)




-continued



-continued



Step A 2-bromo-4-fluoro-6-methoxybenzaldehyde




Flash® Silica Flash Column, Eluent of 0-30% Ethylacetate/Petroleum ether gradient @25 mL/min to give 2-bromo-4-fluoro-6-methoxybenzaldehyde (2.7 g, 75.18% yield).

[1082] ^1H NMR (400 MHz, CDCl_3) δ ppm 10.27 (s, 1H), 6.94 (dd, $J=7.99, 2.38$ Hz, 1H), 6.62 (dd, $J=10.43, 2.32$ Hz, 1H), 3.85 (s, 3H).

Step B
3-(2-bromo-4-fluoro-6-methoxyphenyl)propanoic acid

[1081] A solution of the 1-bromo-5-fluoro-2-iodo-3-methoxybenzene (5.1 g, 15.41 mmol) in toluene (70 mL) was cooled to a temperature of -30°C . Then, a solution of isopropylmagnesium chloride (2 M, 11.5 mL) was added slowly over 5 min. A clear brown solution was obtained. Stirring was continued for 1 hr. Anhydrous DMF (61.65 mmol, 4.7 mL) was added slowly over 5 min, the temperature of the reaction mixture increased to -19°C . The reaction mixture was warmed to 0°C . over 1 hr. The reaction was quenched into saturated aqueous NH_4Cl (50 mL), and allowed to warm to room temperature. Ethyl acetate (100 mL *2) and water (100 mL) were added and the layers were separated. The organic layer was washed with brine, concentrated by rotary evaporator. The residue was purified by flash silica gel chromatography (Biotage®; 40 g Sep-




[1083] To a solution of formic acid (347.59 mmol, 13 mL) was added TEA (115.86 mmol, 16 mL) drop-wise at 0°C . To the mixture was added 2-bromo-4-fluoro-6-methoxyben-

zaldehyde (2.7 g, 11.59 mmol) and 2,2-dimethyl-1,3-dioxane-4,6-dione (1.67 g, 11.59 mmol). The reaction mixture was warmed to 100° C. and stirred at 100° C. for 16 hrs. The solution was added aqueous NaOH until pH=10~11. The mixture was washed with EtOAc (50 mL*2). The aqueous phase was added HCl until pH=1-2 and extracted with EtOAc (50 mL*3). The combined organic phase was washed with brine (100 mL), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. Compound 3-(2-bromo-4-fluoro-6-methoxyphenyl)propanoic acid (2.05 g, 63.85% yield) was obtained.

[1084] ¹H NMR (400 MHz, CDCl₃) δ ppm 6.84 (dd, J=8.11, 2.50 Hz, 1H), 6.49 (dd, J=10.49, 2.38 Hz, 1H), 3.74 (s, 3H), 2.97-3.10 (m, 2H), 2.39-2.54 (m, 2H).


Step C
6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-one



[1085] To a solution of 3-(2-bromo-4-fluoro-6-methoxyphenyl)propanoic acid (1.55 g, 5.59 mmol) in THF (30 mL) was added a solution of n-BuLi (2.5 M, 4.92 mL) drop-wise at -70° C. under N₂. The reaction mixture was warmed to 0° C. and stirred at 0° C. for 2 hrs. The solution was quenched with aqueous NH₄Cl (40 mL) at 0° C., then extracted with EtOAc (40 mL*2). The organic layer was separated, washed with brine (50 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (Biotage®; 20 g SepaFlash® Silica Flash Column, Eluent of 0~40% Ethyl acetate/Petroleum ether gradient @25 mL/min) to give 6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-one (779 mg, 77.29% yield).

[1086] ¹H NMR (400 MHz, CDCl₃) δ ppm 6.86 (dd, J=7.15, 2.15 Hz, 1H), 6.64 (dd, J=10.49, 2.15 Hz, 1H), 3.77 (s, 3H), 2.86 (td, J=5.66, 1.67 Hz, 2H), 2.55-2.61 (m, 2H).


Step D (R,Z)—N-(6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide



[1087] To a solution of 6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-one (825 mg, 4.58 mmol) in THF (10 mL) was added (R)-2-methylpropane-2-sulfonamide (582.71 mg, 4.81 mmol) and tetraethoxytitanium (9.16 mmol, 1.90 mL). The mixture was stirred at 60° C. for 16 hrs. Ethyl acetate (15 mL) and water (10 mL) were added to the mixture at 25° C.,

and the formed precipitate was removed by filtration. The filtrate was concentrated in vacuo to give a residue. The residue was purified by flash silica gel chromatography (Biotage®; 12 g SepaFlash® Silica Flash Column, Eluent of 0~40% Ethyl acetate/Petroleum ether gradient @18 mL/min) to give (R,Z)—N-(6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide (419 mg, 32.29% yield). LC-MS: m/z 284.4 (M+H)⁺.


Step E (R)—N—((R)-6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfonamide



[1088] To a solution of (R,Z)—N-(6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfonamide (419 mg, 1.48 mmol) in DCM (3 mL) was added dropwise DIBAL-H (1 M, 2.96 mL) at -70° C. After addition, the mixture was stirred at -70° C. for 2 hrs. The reaction mixture was quenched by addition MeOH (5 mL) at 0° C., and then diluted with H₂O (20 mL) and extracted with DCM (20 mL*2). The combined organic layer was washed with brine (20 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (Biotage®; 12 g SepaFlash® Silica Flash Column, Eluent of 0~40% Ethyl acetate/Petroleum ether gradient @18 mL/min) to give (R)—N—((R)-6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfonamide (237 mg, 56.16% yield). LC-MS: m/z 286.0 (M+H)⁺.

[1089] ¹H NMR (400 MHz, CDCl₃) δ ppm 6.83 (dd, J=8.29, 1.97 Hz, 1H), 6.41 (dd, J=10.91, 2.09 Hz, 1H), 4.79 (q, J=6.91 Hz, 1H), 3.74 (s, 3H), 3.39 (d, J=6.56 Hz, 1H), 2.83 (ddd, J=15.85, 8.64, 4.23 Hz, 1H), 2.55-2.66 (m, 1H), 2.37-2.47 (m, 1H), 1.87-1.99 (m, 1H), 1.16 (s, 9H).

Step F (R)-6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-amine




[1090] To a solution of (R)—N—((R)-6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfonamide (237 mg, 830.48 μmol) in HCl/dioxane (2 M, 3 mL). The mixture was stirred at 25° C. for 30 min. The reaction mixture was concentrated under reduced pressure. The reaction was filtered to give Compound (R)-6-fluoro-

4-methoxy-2,3-dihydro-1H-inden-1-amine (151 mg, 83.53% yield, HCl) was obtained.


[1091] ¹H NMR (400 MHz, MeOD-d₄) δ ppm 6.91 (dd, J=8.28, 2.01 Hz, 1H), 6.78 (dd, J=11.17, 2.13 Hz, 1H), 4.76-4.83 (m, 1H), 3.86 (s, 3H), 2.98-3.11 (m, 1H), 2.82-2.91 (m, 1H), 2.59-2.70 (m, 1H), 2.14 (ddt, J=13.99, 8.72, 5.33, 5.33 Hz, 1H).

Step G (R)-2-(1,3-dioxolan-2-yl)-N-(6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)thieno[2,3-c]pyridin-7-amine




[1092] A mixture of (R)-6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-amine (90 mg, 496.67 μmol), 7-chloro-2-(1,3-dioxolan-2-yl)thieno[2,3-c]pyridine (120.04 mg, 496.67 μmol), Pd(OAc)₂ (11.15 mg, 49.67 μmol), BINAP (61.85 mg, 99.33 μmol) and Cs₂CO₃ (485.47 mg, 1.49 mmol) in dioxane (5 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 100° C. for 16 hrs under N₂ atmosphere. The reaction mixture was partitioned between water (20 mL) and EtOAc (20 mL*2). The organic phase was separated, washed with brine (30 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (Biotage®; 12 g SepaFlash® Silica Flash Column, Eluent of 0~50% Ethyl acetate/Petroleum ether gradient @18 mL/min) to give (R)-2-(1,3-dioxolan-2-yl)-N-(6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)thieno[2,3-c]pyridin-7-amine (84 mg, 43.77% yield). LC-MS: m/z 387.1 (M+H)⁺.

Step H (R)-7-((6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde




[1093] To a solution of (R)-2-(1,3-dioxolan-2-yl)-N-(6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)thieno[2,3-c]pyridin-7-amine (84 mg, 217.37 μmol) in THF (2 mL) was added aq. HCl (4 M, 2 mL). The mixture was stirred at 40° C. for 2 hrs. The solution was added saturated aqueous NaHCO₃ until pH=7-8. The mixture was extracted with EtOAc (20 mL*3). The organic layer was washed with brine (30 mL), dried over anhydrous of Na₂SO₄, filtered and concentrated in vacuum. Compound (R)-7-((6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (72 mg, 96.74% yield) was obtained. LC-MS: m/z 343.0 (M+H)⁺.

Step 15-((R)-6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-1,4,5,7,8,9-hexahydro-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one



[1094] A mixture of (R)-7-((6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (62 mg, 181.08 μmol), potassium 5-oxo-1,2,3,5-tetrahydro-2,7a-methanopyrrolizin-7-olate (68.54 mg, 181.08 μmol), 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one (45.31 mg, 181.08 μmol) and NH₄OAc (27.92 mg, 362.16 μmol) in HOAc (3 mL) was degassed and purged with N₂ for 3 times, and then the mixture was stirred at 100° C. for 1 hr under N₂ atmosphere. The reaction mixture was concentrated under reduced pressure to remove HOAc. The residue was diluted with water (5 mL) and extracted with EtOAc (10 mL*2). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (Biotage®; 12 g SepaFlash® Silica Flash Column, Eluent of 0~100% Ethyl acetate/Petroleum ether gradient @18 mL/min) to give 5-(4-((R)-6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-1,4,5,7,8,9-hexahydro-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (79 mg, 61.73% yield). LC-MS: m/z 707.3 (M+H)⁺.


Step J (R)-5-(4-(7-((6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-5,7,8,9-tetrahydro-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one



[1095] To a solution of 5-(4-(7-((R)-6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-1,4,5,7,8,9-hexahydro-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (69 mg, 97.63 μ mol) in ACN (3 mL)/H₂O (0.5 mL) was added CAN (53.52 mg, 97.63 μ mol). The mixture was stirred at 25° C. for 1 hr. The reaction mixture was quenched by addition aqueous NaHCO₃ (5 mL) at 25° C., and extracted with EtOAc (5 mL*2). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Welch Xtimate C18 150*30 mm*5 um; mobile phase: [water(FA)-ACN]; gradient: 30%-60% B over 9 min) to give (R)-5-(4-(7-((6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-5,7,8,9-tetrahydro-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (2.92 mg, 4.15% yield, 97.8% purity).

[1096] ¹H NMR (400 MHz, MeOD-d₄) δ ppm 7.96 (d, J=5.75 Hz, 1H), 7.44 (s, 1H), 7.13-7.20 (m, 3H), 6.94-7.02 (m, 2H), 6.62 (d, J=2.38 Hz, 1H), 6.59 (s, 1H), 5.82 (t, J=8.44 Hz, 1H), 4.61 (s, 2H), 3.84 (s, 3H), 3.69 (s, 2H), 3.26-3.30 (m, 3H), 3.08-3.16 (m, 2H), 2.95-3.04 (m, 1H), 2.79 (d, J=4.50 Hz, 2H), 2.65-2.77 (m, 2H), 2.01-2.07 (m, 1H), 1.82 (dd, J=4.38, 1.50 Hz, 2H). ¹⁹F NMR (376 MHz, MeOD-d₄) δ ppm -115.74 (s, 1F), -119.03 (s, 1F). LC-MS: m/z 705.3 (M+H)⁺.


(R)-5-(4-(7-((6,8-difluorochroman-4-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 295)



[1097] Compound 295 was synthesized using a similar procedure described in Example 20 by using the appropriate materials.

[1098] ¹H NMR (400 MHz, DMSO-d₆): δ 12.44-12.97 (brs, 0.53H), 7.31-7.34 (m, 2H), 7.19-7.23 (m, 2H), 7.14-7.17 (m, 1H), 7.07 (t, J=8.8 Hz, 2H), 6.96 (s, 1H), 6.89 (d, J=8.8 Hz, 1H), 5.61 (dd, J=6.0 Hz/J=19.6 Hz, 1H), 4.29-4.42 (m, 2H), 3.55 (s, 2H), 3.15-3.22 (s, 3H), 3.00-3.04 (m, 2H), 2.60-2.67 (m, 2H), 2.41 (m, 3H), 2.16-2.20 (m, 2H), 1.73 (d, J=3.6 Hz, 2H). ¹⁹F NMR (377 MHz, DMSO-d₆): -117.04, -121.74, -132.93.


(S)-5-(2-(4-fluorophenethyl)-4-(5-methyl-7-((2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 296)



[1099] Compound 296 was synthesized using a similar procedure described in Example 20 by using the appropriate materials.

[1100] ^1H NMR (400 MHz, DMSO-d₆): δ 12.78-12.64 (m, 1H), 7.42 (d, J=8.8 Hz, 1H), 7.35 (s, 1H), 7.23-7.15 (m, 3H), 7.07 (t, J=8.8 Hz, 2H), 7.04-6.99 (m, 2H), 6.27-6.19 (m, 1H), 3.91 (d, J=1.6 Hz, 3H), 3.62-3.58 (m, 1H), 3.56 (s, 2H), 3.30-3.28 (m, 1H), 3.22-3.17 (m, 3H), 3.08-3.01 (m, 2H), 2.68-2.62 (m, 2H), 2.40 (s, 3H), 1.77-1.71 (m, 2H). ^{19}F NMR (377 MHz, DMSO-d₆): -106.16, -106.79, -117.01, -132.46.


(R)-5-(4-(7-((6,8-difluorochroman-4-yl)amino)-5-(difluoromethyl)thieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H,8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 297)



[1101] Compound 297 was synthesized using a similar procedure described in Example 21 by using the appropriate materials. (11.8 mg, 0.015 mmol, 7.69%)

[1102] ^1H NMR (400 MHz, DMSO-d₆): δ 12.72 (br s, 1H), 7.81 (d, J=7.6 Hz, 1H), 7.56 (s, 1H), 7.44 (s, 1H), 7.16-7.25 (m, 3H), 7.07 (t, J=8.8 Hz, 2H), 6.91-6.96 (m, 1H), 6.88 (t, J=15.2 Hz, 1H), 5.57 (q, J=6.8 Hz, 1H), 4.30-4.42 (m, 2H), 3.56 (s, 2H), 3.17-3.24 (m, 3H), 3.00-3.08 (m, 2H), 2.62-2.67 (m, 2H), 2.18-2.23 (m, 2H), 1.71-1.79 (m, 2H). ^{19}F NMR (377 MHz, DMSO-d₆): -114.68, -117.01, -121.62, -132.81. LC-MS: m/z 759.2 (M+H)⁺.


(R)-5-(4-(7-((6-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H,8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 298)



[1103] Compound 298 was synthesized using a similar procedure described in Example 20 by using the appropriate materials.

[1104] ^1H NMR (400 MHz, DMSO-d₆): δ 12.69 (s, 1H), 7.32 (s, 1H), 7.17-7.23 (m, 3H), 7.05-7.09 (m, 2H), 6.93 (s, 1H), 6.72 (dd, J=2.0 Hz/J=11.6 Hz, 1H), 6.61 (dd, J=2.0 Hz/J=8.8 Hz, 1H), 5.87 (q, J=8.0 Hz, 1H), 3.80 (s, 3H), 3.56 (s, 2H), 3.30-3.32 (m, 1H), 3.17-3.21 (m, 3H), 3.01-3.05 (m, 2H), 2.86-2.93 (m, 1H), 2.64-2.68 (m, 3H), 2.41 (s, 3H), 1.96-2.06 (m, 1H), 1.75 (d, J=4.8 Hz, 2H). ^{19}F NMR (377 MHz, DMSO-d₆): -113.77, -117.02. LC-MS: m/z 719.5 (M+H)⁺.


5-((S)-4-(7-((R)-5,6-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 299)



[1105] Compound 299 was synthesized using a similar procedure described in Example 20 by using the appropriate materials. (501.26 mg, 0.681 mmol, 52.46%)

[1106] ^1H NMR (400 MHz, DMSO-d₆): δ 12.70 (br s, 1H), 7.34 (s, 1H), 7.19-7.24 (m, 3H), 7.03-7.10 (m, 2H), 6.91-6.97 (m, 2H), 5.82 (q, J=8.0 Hz, 1H), 4.87 (dd, J=10.0 Hz, J=6.0 Hz, 1H), 3.95 (d, J=1.2 Hz, 3H), 3.50-3.59 (m, 1H), 3.26-3.29 (m, 1H), 3.16-3.22 (m, 2H), 2.96-3.12 (m, 3H), 2.79-2.90 (m, 1H), 2.52-2.56 (m, 1H), 2.41 (s, 3H), 2.34-2.36 (m, 1H), 2.23-2.31 (m, 2H), 1.99-2.10 (m, 1H), 1.37-1.49 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d₆): -117.02, -138.67, -158.73. LC-MS: m/z 723.2 (M+H)⁺.


(R)-5-(4-(7-((5-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(3-fluorophenethyl)-5-oxo-8,9-dihydro-5H,7H-8,9a-methanopyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 300)



[1107] Compound 300 was synthesized using a similar procedure described in Example 20 by using the appropriate materials. (6.24 mg, 6.19%)

[1108] ^1H NMR (400 MHz, DMSO-d₆): δ 12.70 (br s, 1H), 7.27-7.33 (m, 2H), 7.15 (d, J=8.4 Hz, 1H), 6.98-7.07 (m, 4H), 6.90-6.95 (m, 2H), 5.83-5.89 (m, 1H), 3.87 (d, J=1.2 Hz, 3H), 3.56 (s, 2H), 3.19-3.25 (m, 3H), 3.03-3.09 (m, 3H), 2.80-2.91 (m, 1H), 2.62-2.67 (m, 2H), 2.54-2.56 (m, 1H), 2.40 (s, 3H), 2.01-2.12 (m, 1H) 1.71-1.78 (m, 2H). ^{19}F NMR (377 MHz, DMSO-d₆): δ -113.58, -135.42. LC-MS: m/z 719.3 (M+H)⁺.


5-((S)-4-(7-(((1S,2R)-2,5-difluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 301)



[1109] Compound 301 was synthesized using a similar procedure described in Example 20 by using the appropriate materials. (651.68 mg, 67.46%)

[1110] ^1H NMR (400 MHz, DMSO-d₆): δ 12.66 (br s, 1H), 7.35 (s, 1H), 7.18-7.23 (m, 3H), 7.14 (dd, J=12.0 Hz, J=8.0 Hz, 1H), 7.05-7.09 (m, 2H), 6.95-7.02 (m, 2H), 5.86-5.99 (m, 1H), 5.46-5.65 (m, 1H), 4.87 (dd, J=10.0 Hz, J=6.0 Hz, 1H), 3.90 (s, 3H), 3.52-3.59 (m, 1H), 3.37-3.42 (m, 1H), 3.26-3.30 (m, 1H), 3.12-3.23 (m, 3H), 2.96-3.07 (m, 2H), 2.42 (s, 3H), 2.24-2.40 (m, 3H), 1.39-1.48 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d₆): -117.02, -134.32, -191.67. LC-MS: m/z 725.3 (M+H)⁺.

5-(7-cyclopropyl-4-(7-((R)-5-fluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)-5-methylthieno[2,3-c]pyridin-2-yl)-2-(4-fluorophenethyl)-5-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 302)




[1111] Compound 302 was synthesized using a similar procedure described in Example 20 by using the appropriate materials. (8.10 mg, 32.14%)


[1112] ^1H NMR (400 MHz, DMSO-d₆): δ 9.00 (s, 1H), 7.30 (d, J=1.2 Hz, 1H), 7.20-7.24 (m, 2H), 7.14 (d, J=8.4 Hz, 1H), 7.04-7.08 (m, 2H), 6.93-7.02 (m, 2H), 6.92 (s, 1H), 5.83-5.89 (m, 1H), 4.42 (d, J=1.6 Hz, 1H), 3.87 (s, 3H), 3.19 (t, J=7.6 Hz, 2H), 3.01-3.10 (m, 3H), 2.81-2.89 (m, 1H), 2.53-2.55 (m, 1H), 2.40 (s, 3H), 2.02-2.12 (m, 1H), 1.15-1.24 (m, 1H), 0.57-0.67 (m, 2H), 0.36-0.44 (m, 1H), 0.26-0.35 (m, 1H). ^{19}F NMR (377 MHz, DMSO-d₆): -117.15, -135.45. LC-MS: m/z 707.3 (M+H)⁺.

Example 42


5-((S)-2-(4-fluorophenethyl)-4-(5-methyl-7-((S)-2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (Compound 303)



-continued




-continued



Step A (S)-2-(1,3-dioxolan-2-yl)-5-methyl-N-(2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)thieno[2,3-c]pyridin-7-amine

methoxy-2,3-dihydro-1H-inden-1-yl)thieno[2,3-c]pyridin-7-amine (2150 mg, 4.926 mmol, 61.94%). LC-MS: m/z 437.3 ($M+H$)⁺.


Step B (S)-5-methyl-7-((2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde



[1113] To a solution of 7-chloro-2-(1,3-dioxolan-2-yl)-5-methylthieno[2,3-c]pyridine (2033.69 mg, 7.953 mmol) in Toluene (100.0 mL) was added (S)-2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-amine (1727.31 mg, 7.953 mmol), Pd₂(dba)₃ (728.26 mg, 0.795 mmol), XANT PHOS (920.35 mg, 1.591 mmol), Cs₂CO₃ (10364.75 mg, 31.811 mmol), the mixture was stirred at 110° C. overnight under N₂. The mixture was diluted with EA (100 mL) and water (100 mL). The organic layer was separated, washed with brine (100 mL×2), dried over Na₂SO₄ and concentrated in vacuo. The residue was purified using silica gel column chromatography eluting with PE:EA=10:1. The residue was concentrated in vacuo to afford the title compound (S)-2-(1,3-dioxolan-2-yl)-5-methyl-N-(2,2,5-trifluoro-4-


[1114] To a solution of (S)-2-(1,3-dioxolan-2-yl)-5-methyl-N-(2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)thieno[2,3-c]pyridin-7-amine (2100 mg, 4.812 mmol) in THF (30.0 mL), H₂O (30.0 mL) was added HCl in dioxane (30.0 mL, 6 mol/L in dioxane) at 0° C., the mixture was stirred at rt for 3 h under N₂. The mixture was diluted with EA (100 mL) and saturated Na₂CO₃ solution. The organic layer was separated, washed with saturated brine, dried over Na₂SO₄ and concentrated in vacuo to afford the title compound (S)-5-methyl-7-((2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (1850 mg, 4.715 mmol, 97.98%). LC-MS: m/z 393.0 ($M+H$)⁺.

Step C ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(5-methyl-7-(((S)-2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1,4-dihydropyridine-3-carboxylate




[1115] To a solution of (S)-5-methyl-7-((2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridine-2-carbaldehyde (400 mg, 1.019 mmol) in EtOH (8.0 mL) was added tert-butyl (S)-2-(3-ethoxy-3-oxopropyl)pyrrolidine-1-carboxylate (290.87 mg, 1.019 mmol), 5-(4-(4-fluorophenyl)-2-oxobutyl)-1,3,4-oxadiazol-2(3H)-one (255.08 mg, 1.019 mmol), NH₄OAC (235.72 mg, 3.058 mmol), Yb(OTf)₃ (63.20 mg, 0.102 mmol) then the mixture was stirred at 70° C. overnight under N₂. The mixture was concentrated in vacuo to afford the title compound ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(5-methyl-7-(((S)-2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1,4-dihydropyridine-3-carboxylate (908 mg, 1.019 mmol, 99.98%). LC-MS: m/z 891.5 (M+H)⁺.

Step D ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(5-methyl-7-(((S)-2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)nicotinate




[1116] To a solution of ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(5-methyl-7-(((S)-2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-1,4-dihydropyridine-3-carboxylate (908 mg, 1.019 mmol) in EtOH (15.0 mL) was added CAN (1116.97 mg, 2.038 mmol), the mixture was stirred at rt for 1 h under N₂. The mixture was diluted with EA and saturated NaHCO₃ solution. The organic layer was separated, washed with brine, dried over Na₂SO₄ and concentrated in vacuo. The residue was filtered and purified using prep-HPLC (0.1% NH₃·H₂O in the mixture of ACN and water) to afford the title compound ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(5-methyl-7-(((S)-2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)nicotinate (860 mg, 0.967 mmol, 94.93%). LC-MS: m/z 889.5 (M+H)⁺.

Step E ethyl 6-(4-fluorophenethyl)-4-(5-methyl-7-(((S)-2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-((S)-pyrrolidin-2-yl)nicotinate




[1117] To a solution of ethyl 2-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-6-(4-fluorophenethyl)-4-(5-methyl-7-(((S)-2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)nicotinate (800 mg, 0.900 mmol) in H₂SO₄ in FA (60.0 mL, 5.937 mmol) was added H₂O (30.0 mL), the mixture was stirred at rt overnight under N₂. The mixture was diluted with EA and water. The organic layer was separated, washed with saturated brine, dried over Na₂SO₄ and concentrated in vacuo to afford the title compound ethyl 6-(4-fluorophenethyl)-4-(5-methyl-7-(((S)-2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-((S)-pyrrolidin-2-yl)nicotinate (700 mg, 0.887 mmol, 98.61%). LC-MS: m/z 789.5 (M+H)⁺.

Step F 5-(2-(4-fluorophenethyl)-4-(5-methyl-7-((S)-2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one



Step G 5-((S)-2-(4-fluorophenethyl)-4-(5-methyl-7-((S)-2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one



[1118] To a solution of ethyl 6-(4-fluorophenethyl)-4-(5-methyl-7-((S)-2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)-2-((S)-pyrrolidin-2-yl)nicotinate (640 mg, 0.811 mmol) in DCM (30.0 mL) was added TEA (3.382 mL, 24.330 mmol), the mixture was stirred at rt for 3 h under N₂. The mixture was diluted with EA and water. The organic layer was separated, washed with brine, dried over Na₂SO₄ and concentrated in vacuo. The residue was filtered and purified using prep-HPLC (0.10% NH₃·H₂O in the mixture of ACN and water) to afford the title compound 5-(2-(4-fluorophenethyl)-4-(5-methyl-7-((S)-2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (450.0 mg, 74.75%). LC-MS: m/z 743.2

[1119] The product of 5-(2-(4-fluorophenethyl)-4-(5-methyl-7-((S)-2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (450 mg) was separated directly by chiral SFC (column: DAICEL CHIRALCEL OJ (100 mm*3.0 mm, 3.0 um); mobile phase: [CO₂-MeOH (0.1% DEA)]; B %: 80%, isocratic elution mode) to give 5-((S)-2-(4-fluorophenethyl)-4-(5-methyl-7-((S)-2,2,5-trifluoro-4-methoxy-2,3-dihydro-1H-inden-1-yl)amino)thieno[2,3-c]

pyridin-2-yl)-5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizin-3-yl)-1,3,4-oxadiazol-2(3H)-one (338.39 mg, yield: 75.19%). LC-MS: m/z 743.2 (M+H)⁺.

[1120] ¹H NMR (400 MHz, DMSO-d₆): δ 12.70 (s, 1H), 7.45 (d, J=9.2 Hz, 1H), 7.36 (s, 1H), 7.22-7.16 (m, 3H), 7.06 (t, J=8.8 Hz, 2H), 7.06-6.99 (m, 2H), 6.28-6.16 (m, 1H), 4.89-4.85 (m, 1H), 3.91 (d, J=1.2 Hz, 3H), 3.61-3.51 (m, 3H), 3.30-3.26 (m, 2H), 3.19 (t, J=7.6 Hz, 2H), 3.11-2.96 (m, 2H), 2.40 (s, 3H), 2.36-2.28 (m, 1H), 2.27-2.21 (m, 2H), 1.48-1.37 (m, 1H). ¹⁹F NMR (377 MHz, DMSO-d₆): -106.20, -106.81, -117.00, 132.42.

Biological Assay

Amylin Receptor cAMP Assay I

[1121] AMYRs are heterodimers of the class B calcitonin (CT) G-protein-coupled receptor (CTR) and receptor activity-modifying proteins (RAMPs). All three RAMPs can interact with the CTR and form AMY1, AMY2, AMY3 with RAMP1, RAMP2 and RAMP3, respectively. Like other class B1 GPCRs, the CT receptor family is canonically coupled to Gs-mediated cAMP production, and measurement of cAMP accumulation has been the primary assay used to determine peptide selectivity and potency.

[1122] To optimize functional activity directed toward G_s coupling, COS-7 cells were stably transfected with human calcitonin receptor (CTR) and RAMP3, simultaneously. 100× concentration of compound working solutions were prepared (Agilent Technologies Bravo) with 4-fold serial dilution in 384-well Echo LDV plate (Labcyte, Cat #LP-0200). 100 nL/well 100× concentration of compound working solutions were moved to 384-well white low volume plate (Greiner, Cat #784075) using Labcyte ECHO550. 1×10⁵ cells/mL COS-7/CTR or COS-7/AMY3 (HD Biosciences) cell suspensions prepared with assay buffer [DPBS containing 0.5 mM IBMX (Sigma, Cat #I5879) and 0.1% BSA (GENVIEW, Cat #FA016-100 g)], 10 μL cell suspensions were added to each well of previous generated assay plate which already contains 100 nL compound at 100× concentration using ThermoFisher Multidrop Combi (1000 cells/well). Seal the plate and incubate at 37° C. with 5% CO₂ for 30 min.

[1123] After incubation, the cAMP assay signal was generated using cAMP Hi-range Kit (Cisbio). 5 μL cAMP-d2 working solution was added to each well, followed by 5 μL Anti-cAMP antibody-cryptate working solution which was added to each well using ThermoFisher Multidrop Combi. The samples were then incubated at room temperature for 1 hour protected from light. the fluorescence was read at 665 and 615 nm with Reader PerkinElmer EnVision.

$$\% \text{ Activity} = \frac{100\% \times (\text{mean RLU of test sample} - \text{mean RLU of vehicle control})}{(\text{mean RLU of MAX control} - \text{mean RLU of vehicle control})} \times 100$$

Amylin Receptor cAMP Assay II

[1124] AMYRs are heterodimers of the class B calcitonin (CT) G-protein-coupled receptor (CTR) and receptor activity-modifying proteins (RAMPs). All three RAMPs can interact with the CTR and form AMY1, AMY2, AMY3 with RAMP1, RAMP2 and RAMP3, respectively. Like other class B1 GPCRs, the CT receptor family is canonically coupled to Gs-mediated cAMP production, and measurement of cAMP accumulation has been the primary assay used to determine peptide selectivity and potency.

[1125] To optimize functional activity directed toward G_s coupling, COS-7 cells were stably transfected with human calcitonin receptor (CTR) and RAMP3, simultaneously. 100× concentration of compound working solutions were prepared with 4-fold serial dilution in 384-well Echo LDV plate (Labcyte, Cat #LP-0200-BC). 200 nL/well 100× concentration of compound working solutions were moved to 384-well white microplate (Perkin Elmer, Cat #6007680) using Labcyte ECHO550. 1×10⁵ cells/mL COS-7/AMY3 cell suspensions prepared with assay buffer [HBSS containing 20 mM HEPES (Gibco, Cat #15630-080), 0.5 mM IBMX (Sigma, Cat #I5879) and 0.1% Casein (Sigma, Cat #C4765)], 20 μL cell suspensions were added to each well of previous generated assay plate which already contains 200 nL compound at 100× concentration using ThermoFisher Multidrop Combi (2000 cells/well). Seal the plate and incubate at 37° C. with 5% CO₂ for 30 min.

[1126] After incubation, the cAMP assay signal was generated using cAMP dynamic 2 kit (Revvity, Cat #62AM4PEC). 10 μL cAMP-d2 working solution was added to each well, followed by 10 μL Anti-cAMP antibody-cryptate working solution which was added to each well using CERTUS FLEX LIQUID DISPENSER. The samples were then incubated at room temperature for 1 hour protected from light. the fluorescence was read at 665 and 615 nm with Reader PerkinElmer EnVision 2105.

$$\% \text{ Activity} = \frac{100 \times (\text{mean RLU of test sample} - \text{mean RLU of positive control})}{(\text{mean RLU of vehicle control} - \text{mean RLU of positive control})} \times 100$$

Calcitonin Receptor (CTR) cAMP Assay

[1127] The calcitonin receptor (CTR) belongs to the subfamily of GPCRs known as the secretin or 'B' family of GPCRs. Like other class B1 GPCRs, the CT receptor family is canonically coupled to Gs-mediated cAMP production, and measurement of cAMP accumulation has been the primary assay used to determine peptide selectivity and potency.

[1128] To optimize functional activity directed toward G_s coupling, COS-7 cells were stably transfected with human calcitonin receptor (CTR) to create COS7-human CTR Clone #2 stable cell line. 100× concentration of compound working solutions were prepared with 4-fold serial dilution in 384-well Echo LDV plate (Labcyte, Cat #LP-0200-BC). 200 nL/well 100× concentration of compound working solutions were moved to 384-well white microplate (Perkin Elmer, Cat #6007680) using Labcyte ECHO550. 1×10⁵ cells/mL COS7-human CTR Clone #2 cell suspensions prepared with assay buffer [HBSS containing 20 mM HEPES (Gibco, Cat #15630-080), 0.5 mM IBMX (Sigma, Cat #I5879) and 0.1% Casein (Sigma, Cat #C4765)], 20 μL cell suspensions were added to each well of previous generated assay plate which already contains 200 nL compound at 100× concentration using ThermoFisher Multidrop Combi (2000 cells/well). Seal the plate and incubate at 37° C. with 5% CO₂ for 30 min.

[1129] After incubation, the cAMP assay signal was generated using cAMP dynamic 2 kit (Revvity, Cat #62AM4PEC). 10 μL cAMP-d2 working solution was added to each well, followed by 10 μL Anti-cAMP antibody-cryptate working solution which was added to each well using CERTUS FLEX LIQUID DISPENSER. The samples were then incubated at room temperature for 1 hour protected from light. the fluorescence was read at 665 and 615 nm with Reader PerkinElmer EnVision 2105.

% Activity=100-(mean RLU of test sample-mean RLU of positive control)/(mean RLU of vehicle control-mean RLU of positive control)×100

[1130] The activity of the tested compounds is provided in Table 3 below.

TABLE 3

Compound No.	Amylin Receptor cAMP Stimulation Activity: EC ₅₀ (nM)	Calcitonin Receptor cAMP Stimulation Activity: EC ₅₀ (nM)
101	101**	12.9
102	12.2**	0.800
103	273**	21.5
104	25.5**	0.926
107	34.4**	9.03
108	121*	2.42
111	401**	205
113	1120**	271
114	425**	396
115	566**	28.8
116	253**	25.6
117	113**	53.5
120	23.6**	1.24
123	42.9**	1.19
124	18.2**	0.628
125	50.5**	0.711
127	143**	4.36
128	21.9**	1.13
130	38.3**	3.06
133	90.7**	4.42
139	41.5**	2.70
140	19.1**	2.13
141	711**	88.8
146	54.1**	3.18
147	51.9**	2.80
148	288**	18.7
150	25.4**	1.06
151	159**	22
152	5100**	513
153	16.6**	2.58
154	648**	52.8
155	33.5**	1.21
156	55.4**	2.48
157	115**	7.42
158	12.8**	1.19
159	28.7**	1.17
160	12.2**	0.724
161	35.8**	1.82
162	3.71**	0.157
163	11.2**	0.588
164	39.9**	4.28
165	6.73**	0.539
166	1.38**	0.0875
167	4.38**	0.13
168	15.3**	0.341
169	254**	10.2
170	33.1**	1.19
171	71.4**	1.52
172	51.1**	2.06
173	16.9**	0.788
174	31.9**	0.347
175	26.8**	0.741
176	10.7**	0.557
177	1810**	39.4
178	203**	3.19
179	34.2**	1.25
180	12.7**	0.559
181	3.5**	0.105
182	52.9**	7.85
183	4.23**	0.143
184	3.59**	0.247
185	231**	15.2
186	37.2**	0.682
187	0.608**	0.0484
188	6.57**	0.223

TABLE 3-continued


Compound No.	Amylin Receptor cAMP Stimulation Activity: EC ₅₀ (nM)	Calcitonin Receptor cAMP Stimulation Activity: EC ₅₀ (nM)
189	0.213***	0.0262
190	0.184***	0.00786
191	0.318***	0.0127
192	0.8**	0.00532
193	0.226***	0.00749
194	1.96**	0.229
195	0.0995***	0.00616
196	0.196***	0.00979
197	1790**	58.9
198	1002**	19.2
199	300.5**	3.7
200	1310**	8.61
201	1371**	19.3
202	1749**	66.2
203	528.8**	4.69
204	265.6**	5.06
205	342.1**	5.7
206	1594**	26.1
207	11.3**	0.309
208	74.36**	0.331
209	17.16**	0.154
210	467.5**	23
211	434**	3.85
212	11701**	526
213	53.08**	0.786
214	129.3**	1.92
215	7.23**	0.406
216	1338**	152
217	47.8**	0.706
218	89.3**	11.5
219	437.5**	27.4
220	11351**	20.5
221	864.5**	15.5
222	511**	12.8
223	757.5**	27.6
224	50.7**	0.702
225	14.6**	0.836
226	14.3**	1.08
227	33.3**	1.67
228	3028**	25.7
229	48.4**	13.4
230	17.4**	0.51
231	15346**	171
232	11997**	412
233	1817**	36.3
234	48.1**	1.83
235	18.1**	0.236
236	127.9**	177
237	18.5**	0.591
238	75.7**	5.12
239	23.4**	0.975
240	182**	8.9
241	33.5**	1.72
242	18.4**	0.668
243	11.2**	1.18
244	22.7**	1.16
245	19.1**	0.469
246	6.78**	0.219
247	2412**	21.1
248	4201**	102
249	62843**	857
250	102**	4.5
251	82.8**	7.28
252	248**	7.9
253	1.88***	0.0708
254	0.707***	0.0659
255	0.318***	0.0127
256	12.8**	0.33
257	10.2**	0.696

TABLE 3-continued


Compound No.	Amylin Receptor cAMP Stimulation Activity: EC ₅₀ (nM)	Calcitonin Receptor cAMP Stimulation Activity: EC ₅₀ (nM)
258	1.91**	0.171
259	1.52**	0.152
260	1.24**	0.0529
261	6.35**	0.807
262	2.81**	0.0963
263	0.629**	0.0341
264	7.4**	0.247
265	7.342**	0.174
266	182.1**	2.75
267	14.6**	0.738
268	1.07**	0.077
269	1.78**	0.0975
270	1.6**	0.148
271	3.13**	0.178
272	1.45**	0.0666
273	1.79**	0.165
274	4.54**	0.255
275	0.394**	0.0262
276	1.57**	0.0602
277	0.368**	0.0207
278	0.517**	0.0636
279	0.318**	0.051
280	0.935**	0.114
281	0.733**	0.239
282	0.464**	0.0464
283	1.571**	0.0191
284	81.6**	4.23
285	0.208**	0.0136
286	0.175**	0.00668
287	0.35**	0.0178
288	1.59**	0.0436
289	0.54**	0.0645
290	1641**	17.6
291	0.363**	0.0138
292	298.4**	7.36
293	2.68**	0.0485
294	0.562**	0.0435
295	1.21**	0.0289
296	0.272**	0.0164
297	1.07**	0.0413
298	0.747**	0.0212
299	0.363**	0.0172
300	0.362**	0.016
301	0.857**	0.0551
302	3.97**	0.134
303	0.695**	0.0337

1-31. (canceled)


32. A compound selected from the group consisting of:



189



192




193

***Amylin Receptor cAMP Assay I**

**Amylin Receptor cAMP Assay II


-continued

195




-continued


291




196




296



287




299




-continued

301




-continued

192



193




or a pharmaceutically acceptable salt thereof.


33. A pharmaceutical composition comprising a compound of claim **32**, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

34. The compound of claim **32**, wherein the compound is selected from the group consisting of:

189




195




-continued

196




-continued


296




287




299



291




301



-continued

303




35. A pharmaceutical composition comprising a compound of claim 34, and a pharmaceutically acceptable excipient.

36. The compound of claim 32, wherein the compound is:

38. The compound of claim 32, wherein the compound is:

192




or a pharmaceutically acceptable salt thereof.

39. A pharmaceutical composition comprising a compound of claim 38, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

40. The compound of claim 32, wherein the compound is:


189



or a pharmaceutically acceptable salt thereof.

37. A pharmaceutical composition comprising a compound of claim 36, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

193





or a pharmaceutically acceptable salt thereof.

41. A pharmaceutical composition comprising a compound of claim 40, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

42. A compound which is:

46. The compound of claim 32, wherein the compound is:



or a pharmaceutically acceptable salt thereof.



43. A pharmaceutical composition comprising a compound of claim 42, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

44. A compound which is:

or a pharmaceutically acceptable salt thereof.

47. A pharmaceutical composition comprising a compound of claim 46, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

48. The compound of claim 32, wherein the compound is:




or a pharmaceutically acceptable salt thereof.

45. A pharmaceutical composition comprising a compound of claim 44, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

or a pharmaceutically acceptable salt thereof.

49. A pharmaceutical composition comprising a compound of claim 48, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.


50. The compound of claim **32**, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

51. A pharmaceutical composition comprising a compound of claim **50**, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.


52. The compound of claim **32**, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

53. A pharmaceutical composition comprising a compound of claim **52**, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.


54. The compound of claim **32**, wherein the compound is:



or a pharmaceutically acceptable salt thereof.

55. A pharmaceutical composition comprising a compound of claim **54**, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

56. A compound which is:



or a pharmaceutically acceptable salt thereof.

57. A pharmaceutical composition comprising a compound of claim **56**, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

* * * * *